{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "colab_type": "text",
    "id": "gVq-TuylYRDW"
   },
   "source": [
    "## 1. Install "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 646
    },
    "colab_type": "code",
    "id": "aQl0MMrOGIup",
    "outputId": "60e3a287-f696-429e-d65d-492e0eebd031"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collecting transformers\n",
      "  Downloading transformers-2.10.0-py3-none-any.whl (660 kB)\n",
      "\u001b[K     |████████████████████████████████| 660 kB 4.9 MB/s eta 0:00:01\n",
      "\u001b[?25hRequirement already satisfied: filelock in /home/ubuntu/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages (from transformers) (3.0.12)\n",
      "Collecting sacremoses\n",
      "  Downloading sacremoses-0.0.43.tar.gz (883 kB)\n",
      "\u001b[K     |████████████████████████████████| 883 kB 23.9 MB/s eta 0:00:01\n",
      "\u001b[?25hRequirement already satisfied: requests in /home/ubuntu/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages (from transformers) (2.23.0)\n",
      "Requirement already satisfied: numpy in /home/ubuntu/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages (from transformers) (1.18.1)\n",
      "Collecting tokenizers==0.7.0\n",
      "  Downloading tokenizers-0.7.0-cp36-cp36m-manylinux1_x86_64.whl (3.8 MB)\n",
      "\u001b[K     |████████████████████████████████| 3.8 MB 30.7 MB/s eta 0:00:01\n",
      "\u001b[?25hCollecting regex!=2019.12.17\n",
      "  Downloading regex-2020.5.14-cp36-cp36m-manylinux2010_x86_64.whl (675 kB)\n",
      "\u001b[K     |████████████████████████████████| 675 kB 78.1 MB/s eta 0:00:01\n",
      "\u001b[?25hCollecting sentencepiece\n",
      "  Downloading sentencepiece-0.1.91-cp36-cp36m-manylinux1_x86_64.whl (1.1 MB)\n",
      "\u001b[K     |████████████████████████████████| 1.1 MB 107.8 MB/s eta 0:00:01\n",
      "\u001b[?25hRequirement already satisfied: tqdm>=4.27 in /home/ubuntu/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages (from transformers) (4.44.1)\n",
      "Requirement already satisfied: dataclasses; python_version < \"3.7\" in /home/ubuntu/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages (from transformers) (0.6)\n",
      "Requirement already satisfied: six in /home/ubuntu/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages (from sacremoses->transformers) (1.14.0)\n",
      "Requirement already satisfied: click in /home/ubuntu/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages (from sacremoses->transformers) (7.1.1)\n",
      "Requirement already satisfied: joblib in /home/ubuntu/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages (from sacremoses->transformers) (0.14.1)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /home/ubuntu/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages (from requests->transformers) (2020.4.5.1)\n",
      "Requirement already satisfied: urllib3!=1.25.0,!=1.25.1,<1.26,>=1.21.1 in /home/ubuntu/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages (from requests->transformers) (1.25.8)\n",
      "Requirement already satisfied: idna<3,>=2.5 in /home/ubuntu/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages (from requests->transformers) (2.9)\n",
      "Requirement already satisfied: chardet<4,>=3.0.2 in /home/ubuntu/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages (from requests->transformers) (3.0.4)\n",
      "Building wheels for collected packages: sacremoses\n",
      "  Building wheel for sacremoses (setup.py) ... \u001b[?25ldone\n",
      "\u001b[?25h  Created wheel for sacremoses: filename=sacremoses-0.0.43-py3-none-any.whl size=893259 sha256=dfdb3527161ee733bb40f878d8f119e1bf1a94a43d6add973d68e6266397bfaa\n",
      "  Stored in directory: /home/ubuntu/.cache/pip/wheels/49/25/98/cdea9c79b2d9a22ccc59540b1784b67f06b633378e97f58da2\n",
      "Successfully built sacremoses\n",
      "Installing collected packages: regex, sacremoses, tokenizers, sentencepiece, transformers\n",
      "Successfully installed regex-2020.5.14 sacremoses-0.0.43 sentencepiece-0.1.91 tokenizers-0.7.0 transformers-2.10.0\n"
     ]
    }
   ],
   "source": [
    "!pip install transformers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "question=\"What is the best method to combat the hypercoagulable state seen in COVID-19 ?\"\n",
    "file_name=\"sm_df.txt\"\n",
    "non_answer='[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP]'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "4f2d3be919d64ff4b19e5e57ba5ee12c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=443.0, style=ProgressStyle(description_…"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "03dce59a9bc84a778e7108105f6196f3",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=1340675298.0, style=ProgressStyle(descr…"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "8f30e0e0f2904559bc0533fed11b425c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=231508.0, style=ProgressStyle(descripti…"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "#from mrjob.job import MRJob\n",
    "import torch\n",
    "from transformers import BertForQuestionAnswering\n",
    "model = BertForQuestionAnswering.from_pretrained('bert-large-uncased-whole-word-masking-finetuned-squad')\n",
    "from transformers import BertTokenizer\n",
    "tokenizer = BertTokenizer.from_pretrained('bert-large-uncased-whole-word-masking-finetuned-squad')\n",
    "import pandas as pd\n",
    "import json "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    }
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1d7234df1a19a0cf0b4038ceb31e7a97881cdbd7__0_\n",
      "1d7234df1a19a0cf0b4038ceb31e7a97881cdbd7__1_Purpose\n",
      "1d7234df1a19a0cf0b4038ceb31e7a97881cdbd7__2_Description\n",
      "1d7234df1a19a0cf0b4038ceb31e7a97881cdbd7__3_DISCUSSION\n",
      "0ced1f946cce007aa319a0ba38aef2c4b14dab0e__0_Background\n",
      "0ced1f946cce007aa319a0ba38aef2c4b14dab0e__1_Selection of potential HLA-A*0201 binding peptides derived from SARS-CoV/S protein\n",
      "0ced1f946cce007aa319a0ba38aef2c4b14dab0e__2_Ex vivo generation of peptide-specific CD8 + CTLs from healthy human donor PBLs\n",
      "0ced1f946cce007aa319a0ba38aef2c4b14dab0e__3_In vivo induction of peptide-specific CD8 + CTLs in HLA-A2.1/K b transgenic mice\n",
      "0ced1f946cce007aa319a0ba38aef2c4b14dab0e__4_Discussion\n",
      "0ced1f946cce007aa319a0ba38aef2c4b14dab0e__5_Conclusion\n",
      "0ced1f946cce007aa319a0ba38aef2c4b14dab0e__6_Peptides\n",
      "0ced1f946cce007aa319a0ba38aef2c4b14dab0e__7_Cells and Cell Culture\n",
      "0ced1f946cce007aa319a0ba38aef2c4b14dab0e__8_Animals\n",
      "0ced1f946cce007aa319a0ba38aef2c4b14dab0e__9_Generation of CTLs in healthy donors\n",
      "0ced1f946cce007aa319a0ba38aef2c4b14dab0e__10_Generation of CTLs in HLA-A2.1/K b transgenic mice\n",
      "0ced1f946cce007aa319a0ba38aef2c4b14dab0e__11_Cytotoxicity assays\n",
      "0ced1f946cce007aa319a0ba38aef2c4b14dab0e__12_Enzyme-linked immunosorbent spot (ELISPOT) assay\n",
      "2a667552f5924857d6eaf9a8104e5f92e236dde9__0_\n",
      "2a667552f5924857d6eaf9a8104e5f92e236dde9__1_Stages in the Emergence of an Infectious Disease\n",
      "2a667552f5924857d6eaf9a8104e5f92e236dde9__2_Reported EID Outbreaks\n",
      "2a667552f5924857d6eaf9a8104e5f92e236dde9__3_Animal Diseases of Economic and/or Zoonotic Impact\n",
      "2a667552f5924857d6eaf9a8104e5f92e236dde9__4_One Health Program, South Africa\n",
      "2a667552f5924857d6eaf9a8104e5f92e236dde9__5_Rinderpest\n",
      "2a667552f5924857d6eaf9a8104e5f92e236dde9__6_Rift Valley Fever\n",
      "2a667552f5924857d6eaf9a8104e5f92e236dde9__7_Peste de Petits Ruminants (PPR)\n",
      "2a667552f5924857d6eaf9a8104e5f92e236dde9__8_Control of EIDs and Deadly Outbreaks in Humans\n",
      "2a667552f5924857d6eaf9a8104e5f92e236dde9__9_Conclusion\n",
      "2f57fc005f74c28402fe57d88144a855ee09efb2__0_Introduction\n",
      "2f57fc005f74c28402fe57d88144a855ee09efb2__1_IoT and its background for COVID-19 pandemic\n",
      "2f57fc005f74c28402fe57d88144a855ee09efb2__2_Need for the study\n",
      "2f57fc005f74c28402fe57d88144a855ee09efb2__3_Key merits of IoT for COVID-19 Pandemic\n",
      "2f57fc005f74c28402fe57d88144a855ee09efb2__4_Processes involved in IoT for COVID-19\n",
      "2f57fc005f74c28402fe57d88144a855ee09efb2__5_The overall impact of IoT in context to COVID-19 concerns (i.e. contact tracing, cluster identification and compliance of quarantine)\n",
      "2f57fc005f74c28402fe57d88144a855ee09efb2__6_Global technological advancements to resolve COVID-19 cases rapidly\n",
      "2f57fc005f74c28402fe57d88144a855ee09efb2__7_Significant applications of IoT for COVID-19 pandemic\n",
      "2f57fc005f74c28402fe57d88144a855ee09efb2__8_Various Issues and Future Scope of the study\n",
      "2f57fc005f74c28402fe57d88144a855ee09efb2__9_Conclusion\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__0_\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__1_Detection of proliferation and cytokine production in whole-blood cultures in vitro after stimulation with measles antigen.\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__2_T-cell Recognition of Mouse Type-II-Collagen in Mice\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__3_MUCOSAL AND SERUM ANTIBODY RESPONSES TO\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__4_MUCOSAL IgA RESPONSES ARE NOT IMPAIRED IN IL-* KNOCKOUT\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__5_ORAL TOLERANCE IS STIMULATED IN CDS-/-AND IL-4-/-(TH2-/-) MICE.\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__6_IgE ELEVATION IN PLASMODWM CHABAUDI\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__7_EXPRESSION OF THE VERY EARLY ACTIVATION ANTIGEN CD69 ON HgCt-ACnVATED MURINE LYMPHOCYTES.\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__8_Human Thymic Epithelial Cells present superantigens for humane thymocytes and CD4+ T cells.\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__9_STUDY OF THE REGULATORY ACTION OF T-ACTIVIN ON THE FUNCTION OF MONONUCLEAR MONOCYTES IN MICE WITH EXPERIMENTALLY SUPPRESSED ANTIBACTERIAL MACROPHAGE RESISTANCE\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__10_p2-niicroglobulin in human placenta\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__11_BINDING TO WHOLE BLOOD CELLS OF IMMUNE\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__12_COMPARISON OF LOCAL AND SYSTEMIC IMMUNE\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__13_MISMATCH OF CD8 EXPRESSION AND CLASS II-RESTRICriON IN T CELL RECEPTOR TRANSGENIC MICE DEPENDS UPON ENDOGENOUS TCRa CHAINS. Ludvig\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__14_THE PRESENCE OF CARBOHYDRATES ON TYPE 11 COLLAGEN DETERMINES THE MHC-RESTRICTION OF THE T-CELL RESPONSE TOWARDS TYPE II COLLAGEN IN I-A<1 vs I-AP MICE\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__15_CYTOKINE PROFILES OF MICROVASCULAR ENDOTHELIUM FROM THE HUMAN GUT.\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__16_THE STAPHYLOCOCCAL ACCESSORY REGULATOR (SAR) CONTROLS STAPHYLOCOCUS AUREUS VIRULENCE IN A MURINE ARTHRITIS MODEL I-M. Nilsson, T. Bremell. A. Tarkowski; Depts. of Clinical\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__17_Interleukin-2 induces tyrosine phosporylation of STAT3and STAT5-like proteins in human CD4 T cell lines.\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__18_LPadyukov.\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__19_ROLE OF CD4-h T-CELLS AND\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__20_DIFFERENTIAL EXPRESSION OF ADHESION\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__21_MONOCLONAL ANTIBODIES AGAINST SUBUNITS OF CFA/I INHIBIT BINDING TO HUMAN ENTEROCYTES AND PROTECT AGAINST CS4-EXPRESSING ETEC\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__22_AMI-SYNTHETIC PEPTIDE POLYCLONAL ANTIBODIES REACTING WITH\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__23_CORTICOSTEROIDS AMELIORATE\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__24_HUMAN VASCULAR ADHESION PROTElN-1 MEDIATES CARBOHYDRATE-DEPENDENT, SELECTIN-INDEPENDENT BINDING OF LYMPHOCYTES TO ENDOTHELIAL CELLS UNDER SHEAR STRESS\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__25_T CELL RESPONSES TO KERATINS AND STREPTO-\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__26_RELEASE OF SULFIDOLEUKOTRIENES EV VITRO -RELATION TO ROUTINE SKIN TESTS IN THE DIAGNOSIS OF ALLERGY\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__27_NATIVE HUMAN SERUM AMYLOID P COMPONENT IS\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__28_ARTHRITIS.\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__29_Conclusions;\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__30_T CELL RECEPTOR V GENE USAGE BY LUNG AND PERIPHERAL BLOOD T LYMPHOCYTES IN PATIENTS\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__31_CHARACTERIZATION OF J-CHADS EXPRESSION AND QUANTITATION OF J-CHAIN mRNA IN HUMAN B-CELL LINES.\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__32_ANTIGEN-BINDING SITES DOMINATE THE SURFACE\n",
      "238a7184d9d9876b23b92b957489b91c98365c39__33_IN VITRO MODEL OF EPITHELIAL CELL -THYMOCYTE INTERACTION IN HUMAN THYMUS\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__0_Erreger\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__1_Klinische Präsentation\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__2_Diagnostik\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__3_> Bei Erstdiagnose besteht eine Meldepflicht laut § 7\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__4_Therapie\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__5_Prognose\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__6_Prävention\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__7_Hämolytisch-urämisches Syndrom (HUS)\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__8_Epidemiologie\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__9_Diagnose\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__10_Gasbrand\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__11_Varizella zoster Epidemiologie\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__12_CMV-Infektion und HIV.\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__13_Tollwut\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__14_Behandlung\n",
      "7a94eca079f2ff99b0656a0f036c012dece4f58d__15_Infektionen bei hämatoonkologischen Erkrankungen/ Knochenmarkstransplantation\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__0_\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__1_Main Diseases of Interest in the Field\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__2_Definitions and History of Bioterrorism\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__3_Main Infectious Agents in Bioterrorism and New Infections\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__4_Smallpox (Variola)\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__5_Poliomyelitis (Infantile Paralysis)\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__6_Anthrax (Carbuncle)\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__7_Plague (Pestis, Black Death)\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__8_Tularemia\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__9_Tetanus\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__10_Botulism\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__11_Tuberculosis (TBC)\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__12_Severe Acute Respiratory Syndrome (SARS)\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__13_Ebola/Marburg Diseases\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__14_Hantavirus, Lassa Fever, etc\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__15_Zika Virus Disease\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__16_Influenza Virus, with New Strains Continuously Appearing\n",
      "a73b233c9ad198c2f7529b429e6e6c8ded3a9257__17_Conclusions\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__0_\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__1_Monocytes/macrophages and granulocytes:\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__2_Clinical Symptoms of Pneumonias\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__3_Alveolar Pneumonias (Bronchopneumonia and Lobar Pneumonia; Adult and Childhood)\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__4_Gross Morphology\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__5_Variants of Bronchopneumonias (Purulent Pneumonia (PN))\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__6_Diffuse Alveolar Damage (DAD) and Acute Interstitial Pneumonia\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__7_Lymphocytic Interstitial Pneumonia (LIP)\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__8_Immunohistochemistry\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__9_Giant Cell Interstitial Pneumonia (GIP; See Also Under Pneumoconiosis)\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__10_The Infectious Organisms\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__11_HIV Infection and the Lung\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__12_Transplacental Infection Causing Pneumonias in Childhood\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__13_Bronchopulmonary Dysplasia (BPD)\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__14_Aspiration Pneumonia\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__15_HIV Infection\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__16_Introduction\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__17_What Infl uences Granuloma\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__18_Morphologic Spectrum of Epithelioid Cell Granulomas\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__19_The Causes of Epithelioid Cell Granulomas and Their Differential Diagnosis\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__20_Infectious Epithelioid Cell Granulomas\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__21_Mycobacteriosis\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__22_Granulomatous or Tuberculoid Leprosy\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__23_Rare Bacterial Infections\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__24_Mycosis\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__25_Histoplasmosis\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__26_Cryptococcosis (European Blastomycosis)\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__27_Blastomycosis\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__28_Coccidio-and Paracoccidiomycosis\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__29_The Noninfectious Epithelioid Cell Granuloma\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__30_Clinics and Radiology\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__31_Chronic Allergic Metal Disease\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__32_Extrinsic Allergic Alveolitis/ Hypersensitivity Pneumonia (EAA, HP)\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__33_Sarcoid-Like Reaction\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__34_Wegener's Granulomatosis/ Granulomatosis with Polyangiitis (GPA)\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__35_Rheumatoid Arthritis\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__36_Bronchocentric Granulomatosis (BCG)\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__37_Lung Involvement in Chronic Infl ammatory Bowel Disease\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__38_Foreign Body Granuloma\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__39_Methods to Be Used for a Defi nite Diagnosis of Infectious Organisms\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__40_8.3\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__41_Historical Remarks on Interstitial Pneumonia Classifi cation\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__42_Usual Interstitial Pneumonia (UIP)/Idiopathic Pulmonary Fibrosis (IPF)\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__43_Epidemiology and Incidence\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__44_Clinical Presentation and CT\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__45_Pathogenesis and Etiology\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__46_Histology\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__47_Diagnosis in Small Biopsies\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__48_Familial IPF (FIPF)\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__49_Nonspecifi c Interstitial Pneumonia (NSIP)\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__50_Organizing and Cryptogenic\n",
      "d1c2bbf2e5d05e99bce59329cdd7c083b199302d__51_Airway-Centered Interstitial Fibrosis (ACIF)\n",
      "9adc9a119a898bcef955d3a7e616789d3a025fd6__0_\n",
      "9adc9a119a898bcef955d3a7e616789d3a025fd6__1_Epidemiology and risk factors\n",
      "9adc9a119a898bcef955d3a7e616789d3a025fd6__2_Etiologic and pathogenetic considerations\n",
      "9adc9a119a898bcef955d3a7e616789d3a025fd6__3_Clinical and laboratory assessment\n",
      "9adc9a119a898bcef955d3a7e616789d3a025fd6__4_Current management\n",
      "9adc9a119a898bcef955d3a7e616789d3a025fd6__5_Toward the intensive care unit\n",
      "9adc9a119a898bcef955d3a7e616789d3a025fd6__6_Conclusions\n",
      "9adc9a119a898bcef955d3a7e616789d3a025fd6__7_Competing interests\n",
      "451da2eda2039c3d4d8e28a80e08870b07800731__0_\n",
      "451da2eda2039c3d4d8e28a80e08870b07800731__1_Annumptonn\n",
      "451da2eda2039c3d4d8e28a80e08870b07800731__2_Procenn of priority ntatun determinaton for individual patentn\n",
      "451da2eda2039c3d4d8e28a80e08870b07800731__3_Shared Decinion Making and Trannparency\n",
      "451da2eda2039c3d4d8e28a80e08870b07800731__4_Originn of Connennun Statement\n",
      "451da2eda2039c3d4d8e28a80e08870b07800731__5_Final Thought\n",
      "451da2eda2039c3d4d8e28a80e08870b07800731__6_Appendix of Contributng Authorn in alphabetcal order:\n",
      "57b87570af5cf987b34c9b6b66fa02ef95928002__0_\n",
      "8f1032019679c929dbbb1218644d410e4f91e8c8__0_2\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__0_\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__1_Biotic Impoverishment\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__2_Indirect Biotic Depletion\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__3_Degradation of water\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__4_Soil depletion\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__5_Chemical contamination\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__6_Altered biogeochemical cycles\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__7_Global climate change\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__8_Direct Depletion of Nonhuman Life\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__9_Overharvest of renewable resources\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__10_Habitat fragmentation and destruction\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__11_Biotic homogenization\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__12_Genetic engineering\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__13_Direct Degradation of Human Life\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__14_Emerging and reemerging diseases\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__15_Loss of cultural diversity\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__16_Reduced quality of life\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__17_Environmental injustice\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__18_Political instability\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__19_Cumulative effects\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__20_Root Causes of Human Impact\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__21_Fragmented Worldviews, Fragmented Worlds\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__22_Too Many Consuming Too Much\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__23_Measuring Environmental Impacts\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__24_Social System\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__25_General Sustainability Indexes\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__26_Ecological Footprints\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__27_Measuring the State of Living Systems\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__28_Benthic invertebrates Fishes\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__29_Recognizing and Managing Environmental Impacts\n",
      "da2df28b4830c173b44828ec5c9019a5cb16138f__30_Reuniting the Fragments\n",
      "05620ea699e7dcf77f750bbb52911ea18b005d8f__0_DRIVERS OF NHP TO HUMAN CONTACT AND INTERSPECIES PATHOGENS' TRANSMISSION\n",
      "05620ea699e7dcf77f750bbb52911ea18b005d8f__1_NHP MEAT CONSUMPTION\n",
      "05620ea699e7dcf77f750bbb52911ea18b005d8f__2_ILLEGAL IMPORT OF NHP MEAT IN USA AND EUROPE\n",
      "05620ea699e7dcf77f750bbb52911ea18b005d8f__3_LAND CONVERSION FOR HUMAN USE\n",
      "05620ea699e7dcf77f750bbb52911ea18b005d8f__4_NHP ILLEGAL TRADE\n",
      "05620ea699e7dcf77f750bbb52911ea18b005d8f__5_NHP AS MODEL ANIMALS\n",
      "05620ea699e7dcf77f750bbb52911ea18b005d8f__6_TOURISM AND ECOTOURISM\n",
      "05620ea699e7dcf77f750bbb52911ea18b005d8f__7_ARTHROPOD BITE\n",
      "05620ea699e7dcf77f750bbb52911ea18b005d8f__8_\"ONE HEALTH, ONE EARTH\": IMPACT OF EVOLUTIONARY PROCESSES\n",
      "05620ea699e7dcf77f750bbb52911ea18b005d8f__9_DOCUMENTED EVIDENCE OF TRANSMISSION OF PATHOGENS FROM HUMAN TO NHP\n",
      "05620ea699e7dcf77f750bbb52911ea18b005d8f__10_of influenza virus was reported in gibbons\n",
      "05620ea699e7dcf77f750bbb52911ea18b005d8f__11_BACTERIAL AND/OR PARASITE RISKS FOR HUMANS SHARING THE NHP'S ECOSYSTEMS\n",
      "05620ea699e7dcf77f750bbb52911ea18b005d8f__12_VIRAL RISKS FOR HUMANS WHO SHARE ECOSYSTEMS WITH NHP\n",
      "05620ea699e7dcf77f750bbb52911ea18b005d8f__13_DISCUSSION\n",
      "05620ea699e7dcf77f750bbb52911ea18b005d8f__14_AUTHOR CONTRIBUTIONS\n",
      "c5ade8ab23dfdc3d4e565df9a069c4b66492491e__0_Introduction\n",
      "c5ade8ab23dfdc3d4e565df9a069c4b66492491e__1_Clinical Associations with Infections\n",
      "c5ade8ab23dfdc3d4e565df9a069c4b66492491e__2_Experimental Models of Protection by Infection\n",
      "c5ade8ab23dfdc3d4e565df9a069c4b66492491e__3_Vaccination\n",
      "c5ade8ab23dfdc3d4e565df9a069c4b66492491e__4_Experimental Models of Induction by Infection\n",
      "c5ade8ab23dfdc3d4e565df9a069c4b66492491e__5_Experimental Models of Protections by Infection\n",
      "c5ade8ab23dfdc3d4e565df9a069c4b66492491e__6_Experimental models of induction by infection\n",
      "c5ade8ab23dfdc3d4e565df9a069c4b66492491e__7_Antiphospholipid Syndrome\n",
      "c5ade8ab23dfdc3d4e565df9a069c4b66492491e__8_Primary Vasculitis\n",
      "c5ade8ab23dfdc3d4e565df9a069c4b66492491e__9_Myocarditis, Dilated Cardiomyopahty, and Chagas's Disease\n",
      "c5ade8ab23dfdc3d4e565df9a069c4b66492491e__10_Inflammatory Bowel Disease\n",
      "c5ade8ab23dfdc3d4e565df9a069c4b66492491e__11_Rheumatic Fever\n",
      "c5ade8ab23dfdc3d4e565df9a069c4b66492491e__12_Pediatric Autoimmune Neuropsychiatric Disorders\n",
      "c5ade8ab23dfdc3d4e565df9a069c4b66492491e__13_The Global Picture\n",
      "514a5ab6c1549c33d8acf502b929bc0699f5e21c__0_Introduction\n",
      "514a5ab6c1549c33d8acf502b929bc0699f5e21c__1_Specimens\n",
      "514a5ab6c1549c33d8acf502b929bc0699f5e21c__2_Viral RNA extraction\n",
      "514a5ab6c1549c33d8acf502b929bc0699f5e21c__3_Real time RT-PCR (qRT-PCR)\n",
      "514a5ab6c1549c33d8acf502b929bc0699f5e21c__4_One-step RT-PCR\n",
      "514a5ab6c1549c33d8acf502b929bc0699f5e21c__5_Virus amplification using cell culture\n",
      "514a5ab6c1549c33d8acf502b929bc0699f5e21c__6_Sequencing of RT-PCR products and phylogenetic analysis\n",
      "514a5ab6c1549c33d8acf502b929bc0699f5e21c__7_Detection of other respiratory viruses\n",
      "514a5ab6c1549c33d8acf502b929bc0699f5e21c__8_Statistical analysis\n",
      "514a5ab6c1549c33d8acf502b929bc0699f5e21c__9_Real time qRT-PCR and RT-PCR detection\n",
      "514a5ab6c1549c33d8acf502b929bc0699f5e21c__10_Sequence analysis of CoV strains\n",
      "514a5ab6c1549c33d8acf502b929bc0699f5e21c__11_Other respiratory viruses\n",
      "514a5ab6c1549c33d8acf502b929bc0699f5e21c__12_Discussion\n",
      "9b49622e8c16b0e941616d09e9ccdcfbc5d5ff0c__0_Introduction\n",
      "9b49622e8c16b0e941616d09e9ccdcfbc5d5ff0c__1_Patients\n",
      "9b49622e8c16b0e941616d09e9ccdcfbc5d5ff0c__2_Procedures\n",
      "9b49622e8c16b0e941616d09e9ccdcfbc5d5ff0c__3_Hematopoietic SCT\n",
      "9b49622e8c16b0e941616d09e9ccdcfbc5d5ff0c__4_GVHD prophylaxis\n",
      "9b49622e8c16b0e941616d09e9ccdcfbc5d5ff0c__5_Supportive care\n",
      "9b49622e8c16b0e941616d09e9ccdcfbc5d5ff0c__6_Statistical analysis\n",
      "9b49622e8c16b0e941616d09e9ccdcfbc5d5ff0c__7_Patient characteristics\n",
      "9b49622e8c16b0e941616d09e9ccdcfbc5d5ff0c__8_Transplant and engraftment\n",
      "9b49622e8c16b0e941616d09e9ccdcfbc5d5ff0c__9_PFS and OS\n",
      "9b49622e8c16b0e941616d09e9ccdcfbc5d5ff0c__10_Discussion\n",
      "9b49622e8c16b0e941616d09e9ccdcfbc5d5ff0c__11_Conflict of interest\n",
      "54d4994936625fa9ff3220b5579724712f4b5769__0_Introduction\n",
      "54d4994936625fa9ff3220b5579724712f4b5769__1_SIR Model for Two-Strain Viruses\n",
      "54d4994936625fa9ff3220b5579724712f4b5769__2_The objective function:\n",
      "54d4994936625fa9ff3220b5579724712f4b5769__3_Optimal Control of SIR Model\n",
      "54d4994936625fa9ff3220b5579724712f4b5769__4_Structure of Optimal Control\n",
      "54d4994936625fa9ff3220b5579724712f4b5769__5_Lemma 2. For all\n",
      "54d4994936625fa9ff3220b5579724712f4b5769__6_SIS Model with Two Virus Strains\n",
      "54d4994936625fa9ff3220b5579724712f4b5769__7_Proposition 2.\n",
      "54d4994936625fa9ff3220b5579724712f4b5769__8_Numerical Simulation\n",
      "54d4994936625fa9ff3220b5579724712f4b5769__9_Conclusion\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__0_\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__1_Methods Virus\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__2_Antibodies\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__3_Ethics statements\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__4_Animals\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__5_Clinical samples\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__6_Concentration and purification of CHIKV\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__7_Bioinformatic approach to determining molecular mimicry\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__8_Immunoreactivity of serum samples obtained from patients infected with CHIKV to the peptides derived from CHIKV glycoprotein E1\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__9_Detection of CHIKV RNA in the harvested tissues by TaqMan real time PCR\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__10_Histopathological study to evaluate the tissue response to injection of virus and peptides by Haematoxylin and Eosin (H&E) staining\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__11_Results\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__12_Clinical features\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__13_Cross reactivity of serum samples obtained from CHIKV infected patients with peptides\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__14_Histopathological features of the tissues injected with CHIKV and peptides\n",
      "977007f901c5697f613ad1b475532ebaf7baef86__15_Discussion\n",
      "b7aed141810c0294eae2351f9cfbfc6d0d06b96b__0_\n",
      "b7aed141810c0294eae2351f9cfbfc6d0d06b96b__1_Patients\n",
      "b7aed141810c0294eae2351f9cfbfc6d0d06b96b__2_Definition of RSV Respiratory Tract Infection\n",
      "b7aed141810c0294eae2351f9cfbfc6d0d06b96b__3_Virology and Microbiology Procedures\n",
      "b7aed141810c0294eae2351f9cfbfc6d0d06b96b__4_RSV Subtyping by Molecular Methods\n",
      "b7aed141810c0294eae2351f9cfbfc6d0d06b96b__5_RSV Neutralization Assays\n",
      "b7aed141810c0294eae2351f9cfbfc6d0d06b96b__6_Statistical Analysis\n",
      "b7aed141810c0294eae2351f9cfbfc6d0d06b96b__7_RESULTS\n",
      "b7aed141810c0294eae2351f9cfbfc6d0d06b96b__8_Risk Factors for Progression from Upper to Lower Respiratory Tract Infection\n",
      "b7aed141810c0294eae2351f9cfbfc6d0d06b96b__9_Lymphocyte Engraftment Dynamics\n",
      "b7aed141810c0294eae2351f9cfbfc6d0d06b96b__10_RSV infection in patients undergoing HCT can result in respiratory failure and death if LRD develops\n",
      "b7aed141810c0294eae2351f9cfbfc6d0d06b96b__11_Supplementary Data\n",
      "a31d6ea0972f8ce473d289cafcf5fe986346beb9__0_\n",
      "a31d6ea0972f8ce473d289cafcf5fe986346beb9__1_MATERIALS AND METHODS\n",
      "a31d6ea0972f8ce473d289cafcf5fe986346beb9__2_Effects of Con A treatment of TGEV-infected eetls on IENct induction\n",
      "a31d6ea0972f8ce473d289cafcf5fe986346beb9__3_Effects of tunicamycin treatment ofTGEVinfected ceils on lENoL-imluction\n",
      "a31d6ea0972f8ce473d289cafcf5fe986346beb9__4_Effects of virus digestion by glycosidases on IENa induction\n",
      "a31d6ea0972f8ce473d289cafcf5fe986346beb9__5_DISCUSSION\n",
      "a39c9d501d3f2ee4e9fca995bae7a63b0085d4b7__0_Introduction\n",
      "a39c9d501d3f2ee4e9fca995bae7a63b0085d4b7__1_The Conventional vs. Alternate RAS\n",
      "a39c9d501d3f2ee4e9fca995bae7a63b0085d4b7__2_ACE2/Ang-(1-7)/mas axis\n",
      "a39c9d501d3f2ee4e9fca995bae7a63b0085d4b7__3_ACE2 and Cardiac Disease\n",
      "a39c9d501d3f2ee4e9fca995bae7a63b0085d4b7__4_Renoprotective Role of ACE2\n",
      "a39c9d501d3f2ee4e9fca995bae7a63b0085d4b7__5_Novel Therapeutic Advances to Enhance ACE2/Ang-(1-7) axis\n",
      "a39c9d501d3f2ee4e9fca995bae7a63b0085d4b7__6_Conclusion\n",
      "a39c9d501d3f2ee4e9fca995bae7a63b0085d4b7__7_Compliance with Ethics Guidelines\n",
      "a39c9d501d3f2ee4e9fca995bae7a63b0085d4b7__8_References\n",
      "0be03cf7b35ab724826046bb39d83ef67222c402__0_Introduction\n",
      "0be03cf7b35ab724826046bb39d83ef67222c402__1_Materials and methods\n",
      "0be03cf7b35ab724826046bb39d83ef67222c402__2_Discussion\n",
      "92ea1980ea8bd1105a53e6b8cc132d2448199864__0_Introduction\n",
      "92ea1980ea8bd1105a53e6b8cc132d2448199864__1_Methods\n",
      "92ea1980ea8bd1105a53e6b8cc132d2448199864__2_Model Design Compartments\n",
      "92ea1980ea8bd1105a53e6b8cc132d2448199864__3_Interventions\n",
      "92ea1980ea8bd1105a53e6b8cc132d2448199864__4_Transitions and flow of people between compartments\n",
      "92ea1980ea8bd1105a53e6b8cc132d2448199864__5_Migration and influx of infected\n",
      "92ea1980ea8bd1105a53e6b8cc132d2448199864__6_(which was not certified by peer review)\n",
      "92ea1980ea8bd1105a53e6b8cc132d2448199864__7_Model Parameters\n",
      "92ea1980ea8bd1105a53e6b8cc132d2448199864__8_Modelling response of Indian states\n",
      "92ea1980ea8bd1105a53e6b8cc132d2448199864__9_Model characterization\n",
      "92ea1980ea8bd1105a53e6b8cc132d2448199864__10_Effect of influx of infected cohort\n",
      "92ea1980ea8bd1105a53e6b8cc132d2448199864__11_Effects of intervention on influx of infections\n",
      "92ea1980ea8bd1105a53e6b8cc132d2448199864__12_Transitory effects of varying β and c over short time windows\n",
      "92ea1980ea8bd1105a53e6b8cc132d2448199864__13_Heuristics for reconstructing the time varying interventions in real data\n",
      "92ea1980ea8bd1105a53e6b8cc132d2448199864__14_Discussion\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__0_Introduction\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__1_Animals and experimental design\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__2_Gross and microscopic lung lesions\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__3_Viral load determination\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__4_RNA extraction and microarray hybridization\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__5_Microarray data analysis\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__6_Q-PCR\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__7_Clinical and pathological features of HP-PRRSV-infected piglets\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__8_Transcriptome analysis of the virus-host cell interaction in vivo\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__9_Sensing the HP-PRRSV infection by PAMs\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__10_Cytoskeleton and exocytosis organization in PAMs\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__11_Protein degradation and folding in PAMs\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__12_Intracellular calcium and zinc homeostasis in PAMs\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__13_Tissue remolding and inflammation\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__14_Confirmation of differential expression by Q-PCR\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__15_Discussion\n",
      "b39580b3bf3af68ed88977c56efdca4d41816b10__16_Conclusions\n",
      "73e6ef40b39788b8397d68b34dc0c07dd292b5e5__0_INTRODUCTION\n",
      "73e6ef40b39788b8397d68b34dc0c07dd292b5e5__1_Propagation and purification of BEC\n",
      "73e6ef40b39788b8397d68b34dc0c07dd292b5e5__2_Fecal samples\n",
      "73e6ef40b39788b8397d68b34dc0c07dd292b5e5__3_Polyclonal antisera\n",
      "73e6ef40b39788b8397d68b34dc0c07dd292b5e5__4_Monoclonal antibodies (MAb)\n",
      "73e6ef40b39788b8397d68b34dc0c07dd292b5e5__5_Antibody screening tests\n",
      "73e6ef40b39788b8397d68b34dc0c07dd292b5e5__6_Conjugation of antibodies with horseradish peroxidase or biotin\n",
      "73e6ef40b39788b8397d68b34dc0c07dd292b5e5__7_Competition ELISA\n",
      "73e6ef40b39788b8397d68b34dc0c07dd292b5e5__8_SDS-gel electrophoresis and immunoblotting\n",
      "73e6ef40b39788b8397d68b34dc0c07dd292b5e5__9_BEC antigen detection by ELISA\n",
      "73e6ef40b39788b8397d68b34dc0c07dd292b5e5__10_Characterization of polyclonal and monoclonal antibodies\n",
      "73e6ef40b39788b8397d68b34dc0c07dd292b5e5__11_Establishment of an ELISA for antigen detection\n",
      "73e6ef40b39788b8397d68b34dc0c07dd292b5e5__12_Coating\n",
      "f9984cd255bf5b0f95061d99c13ef69f3e843dc6__0_\n",
      "f9984cd255bf5b0f95061d99c13ef69f3e843dc6__1_OUR PATIENTS CANNOT WAIT\n",
      "f9984cd255bf5b0f95061d99c13ef69f3e843dc6__2_PROTECTING PATIENTS AND STAFF\n",
      "f9984cd255bf5b0f95061d99c13ef69f3e843dc6__3_ARTICLE IN PRESS\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__0_Introduction\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__1_Waterborne disease\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__2_Log removal\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__3_Turbidity\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__4_Biofiltration\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__5_Trickling filter\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__6_Slow sand filtration\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__7_Rapid sand filter\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__8_Stormwater biofilter\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__9_Submerged zone\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__10_Removal of pathogenic bacteria in stormwater biofilter\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__11_Filter media\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__12_Amendments of filter media\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__13_Surface modification of filter media\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__14_Biofilm\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__15_Infauna\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__16_Vegetation\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__17_Microbial-earthworm ecofilters\n",
      "5164ce1de0ee4b2ad9e899d990c1ad9c4513a46d__18_Conclusion\n",
      "3949a9e9a8c6c26ed1b9aa4bd9b02291dbeefe4a__0_Introduction\n",
      "3949a9e9a8c6c26ed1b9aa4bd9b02291dbeefe4a__1_Ethics statement\n",
      "3949a9e9a8c6c26ed1b9aa4bd9b02291dbeefe4a__2_Overview of the methodology\n",
      "3949a9e9a8c6c26ed1b9aa4bd9b02291dbeefe4a__3_Data\n",
      "3949a9e9a8c6c26ed1b9aa4bd9b02291dbeefe4a__4_Model\n",
      "3949a9e9a8c6c26ed1b9aa4bd9b02291dbeefe4a__5_Contact patterns at home\n",
      "3949a9e9a8c6c26ed1b9aa4bd9b02291dbeefe4a__6_Non-household contacts\n",
      "3949a9e9a8c6c26ed1b9aa4bd9b02291dbeefe4a__7_Age-specific final epidemic sizes\n",
      "3949a9e9a8c6c26ed1b9aa4bd9b02291dbeefe4a__8_Discussion\n",
      "ec9a51accf3afe859de847c59a0e50bb0be2968e__0_\n",
      "88449101d4c40d01dc551a4a46f259654cbf953a__0_Background\n",
      "88449101d4c40d01dc551a4a46f259654cbf953a__1_Objectives\n",
      "88449101d4c40d01dc551a4a46f259654cbf953a__2_Norovirus Outbreak Epidemic Curves and Effective Reproduction Ratios*\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__0_Introduction\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__1_Study design\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__2_Study subjects identification, criteria for inclusion\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__3_Laboratory procedures\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__4_Data collection\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__5_Influenza vaccination and immunization status\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__6_Vaccine-effectiveness\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__7_Ascertainment of cases and controls\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__8_Hospitalizations related to a viral respiratory infection\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__9_Emergency admission diagnoses\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__10_Influenza-like illness\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__11_Case-control characteristics\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__12_Vaccination status\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__13_Influenza vaccine effectiveness\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__14_Discussion\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__15_How our findings relate to previous knowledge\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__16_Viral match and vaccine effectiveness\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__17_Limitations\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__18_Case-control status ascertainment\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__19_Specimen collection method\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__20_Case-case approach\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__21_Sample size\n",
      "ca5b0374e1226b4e98aa7c06e5f732b1bd7a2659__22_Conclusions\n",
      "3e8f1cce602f86dd1f7227dbfe0c21ac995ff470__0_\n",
      "3e8f1cce602f86dd1f7227dbfe0c21ac995ff470__1_Case Study 1: Vietnam\n",
      "3e8f1cce602f86dd1f7227dbfe0c21ac995ff470__2_Case Study 2: Cameroon\n",
      "3e8f1cce602f86dd1f7227dbfe0c21ac995ff470__3_A Sustainable, Optimal, and Continuous Use Model for PHEOCs for Global Settings\n",
      "3e8f1cce602f86dd1f7227dbfe0c21ac995ff470__4_Acknowledgments\n",
      "25b6f48e9b16f929e827258253ef02b3b7a7ff91__0_Timely estimates of infl uenza A H7N9 infection severity\n",
      "25b6f48e9b16f929e827258253ef02b3b7a7ff91__1_*Cécile Viboud, Lone Simonsen\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__0_\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__1_Bureaucratic Accountability\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__2_Accountability Structure in the Korea Coast Guard (KCG): An Organizational Perspective\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__3_Sustaining Hierarchical Accountability\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__4_Emphasizing Political Accountability\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__5_Weak Professional Accountability\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__6_The Sewol Ferry Accident\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__7_The Korea Coast Guard Reactions to the Sewol Ferry Accident\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__8_Weighing Hierarchical Accountability\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__9_Prioritizing Political Accountability\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__10_Holding Legal Accountability\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__11_Lacking Professional Accountability\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__12_Hierarchical Accountability\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__13_Political Accountability\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__14_Legal Accountability\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__15_Reaction of the Korean Central Government\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__16_Professional Accountability\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__17_2015)\n",
      "d9e5f31a5101ab6d72776a4c782cc2b64c7cede1__18_Conclusion and Discussion\n",
      "82fd8ec8a42a7949848d4aed04c19afd6c0df415__0_Introduction\n",
      "82fd8ec8a42a7949848d4aed04c19afd6c0df415__1_… Are Opportunities\n",
      "82fd8ec8a42a7949848d4aed04c19afd6c0df415__2_Paradigm Shift\n",
      "82fd8ec8a42a7949848d4aed04c19afd6c0df415__3_Towards the Transformation Age\n",
      "82fd8ec8a42a7949848d4aed04c19afd6c0df415__4_The Knowledge Economy\n",
      "c2d27310b7add3827d3765104f57928f4e097a2f__0_Introduction\n",
      "c2d27310b7add3827d3765104f57928f4e097a2f__1_Expression of RVFV glycoproteins on the cell surface\n",
      "c2d27310b7add3827d3765104f57928f4e097a2f__2_RVFV cell-cell fusion using replicon vectors\n",
      "c2d27310b7add3827d3765104f57928f4e097a2f__3_β-galactosidase α-complementation quantification of cell-cell fusion\n",
      "c2d27310b7add3827d3765104f57928f4e097a2f__4_pH and temperature dependence of RVFV glycoprotein-mediated membrane fusion\n",
      "c2d27310b7add3827d3765104f57928f4e097a2f__5_RVFV receptor characterization: trypsin inhibition\n",
      "c2d27310b7add3827d3765104f57928f4e097a2f__6_Discussion\n",
      "c2d27310b7add3827d3765104f57928f4e097a2f__7_Cell lines\n",
      "c2d27310b7add3827d3765104f57928f4e097a2f__8_Plasmids and replicons\n",
      "c2d27310b7add3827d3765104f57928f4e097a2f__9_Expression of RVFV glycoproteins\n",
      "c2d27310b7add3827d3765104f57928f4e097a2f__10_Localization and surface expression of RVFV glycoproteins\n",
      "c2d27310b7add3827d3765104f57928f4e097a2f__11_RVFV syncytia formation fusion assay\n",
      "c2d27310b7add3827d3765104f57928f4e097a2f__12_RVFV β-galactosidase α-complementation quantification\n",
      "c2d27310b7add3827d3765104f57928f4e097a2f__13_Temperature dependence of RVFV-mediated membrane fusion\n",
      "c2d27310b7add3827d3765104f57928f4e097a2f__14_Fusion inhibition by trypsin\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__0_Introduction\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__1_Respiratory Viruses\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__2_Respiratory Syncytial Virus\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__3_Human Rhinovirus\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__4_Adenovirus\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__5_Influenza Virus\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__6_Human Parainfluenza Virus\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__7_Human Metapnuemovirus\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__8_Human Coronavirus\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__9_Human Bocavirus\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__10_Viral Co-infections\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__11_Respiratory Bacteria\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__12_Streptococcus pneumoniae\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__13_Haemophilus influenzae\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__14_Moraxella catarrhalis\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__15_Staphylococcus aureus\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__16_Bacterial Interactions\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__17_8.4\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__18_Historical Context\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__19_Clinical Evidence of Viral-Bacterial Co-infections in Children\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__20_Mechanisms for Viral-Bacterial Interactions\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__21_Decreased Bacterial Clearance\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__22_Increased Bacterial Adherence\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__23_Bacterial Promotion of Secondary Viral Infections\n",
      "cbcd1a019ffc2158d9f6c58e251f8b30d297a6bb__24_Conclusion\n",
      "9306cdc04e064ce1f94afebefa524724bd5e1cfc__0_Introduction\n",
      "9306cdc04e064ce1f94afebefa524724bd5e1cfc__1_General\n",
      "9306cdc04e064ce1f94afebefa524724bd5e1cfc__2_Template genes\n",
      "9306cdc04e064ce1f94afebefa524724bd5e1cfc__3_Construction of DNA template\n",
      "9306cdc04e064ce1f94afebefa524724bd5e1cfc__4_Cell-free protein synthesis\n",
      "9306cdc04e064ce1f94afebefa524724bd5e1cfc__5_Purification using DNA column\n",
      "9306cdc04e064ce1f94afebefa524724bd5e1cfc__6_Preparation of protein microarray using agarose/DNA microplate\n",
      "9306cdc04e064ce1f94afebefa524724bd5e1cfc__7_Detection and inhibition of autophosphorylation activity of the\n",
      "9306cdc04e064ce1f94afebefa524724bd5e1cfc__8_Detection of protease activity on the microplate\n",
      "9306cdc04e064ce1f94afebefa524724bd5e1cfc__9_Detection of protein-protein interaction on the microplate\n",
      "9306cdc04e064ce1f94afebefa524724bd5e1cfc__10_Arabidopsis HY5 (DBtag) strongly binds to commercially\n",
      "9306cdc04e064ce1f94afebefa524724bd5e1cfc__11_Functional analysis of DBtag-human protein kinases on the\n",
      "9306cdc04e064ce1f94afebefa524724bd5e1cfc__12_Specific cleavage of DBtag-fusion proteins on the agarose/\n",
      "9306cdc04e064ce1f94afebefa524724bd5e1cfc__13_Discussion\n",
      "b7bf5fb6998becfe4c9854920e2b3f3b6d5e8976__0_ser-Hitze], \"Hydronosus\" [Wasserkrankheit] und \"Sudoriferus morbus\" [Schweißbringende Krankheit]\n",
      "b7bf5fb6998becfe4c9854920e2b3f3b6d5e8976__1_Die fünf Epidemien des Englischen Schweißes\n",
      "b7bf5fb6998becfe4c9854920e2b3f3b6d5e8976__2_Die Erkrankung\n",
      "b7bf5fb6998becfe4c9854920e2b3f3b6d5e8976__3_Die Prophylaxe\n",
      "209d7a85764f38f4108bbedee5bc4a00a52ccf11__0_TÍTULO:\n",
      "209d7a85764f38f4108bbedee5bc4a00a52ccf11__1_RESUMEN\n",
      "209d7a85764f38f4108bbedee5bc4a00a52ccf11__2_INTRODUCCIÓN\n",
      "209d7a85764f38f4108bbedee5bc4a00a52ccf11__3_MÉTODOS\n",
      "209d7a85764f38f4108bbedee5bc4a00a52ccf11__4_RESULTADOS\n",
      "209d7a85764f38f4108bbedee5bc4a00a52ccf11__5_DISCUSIÓN\n",
      "209d7a85764f38f4108bbedee5bc4a00a52ccf11__6_CONCLUSIONES\n",
      "209d7a85764f38f4108bbedee5bc4a00a52ccf11__7_CONFLICTOS DE INTERÉS Y FINANCIACIÓN\n",
      "209d7a85764f38f4108bbedee5bc4a00a52ccf11__8_1.\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__0_INTRODUCTION\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__1_TYPES OF VACCINE\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__2_VACCINATION OF INDIVIDUAL DOGS\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__3_Revaccination of Adult Dogs\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__4_Passive Immunization\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__5_An Update on New Canine Vaccines\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__6_VACCINATION OF INDIVIDUAL CATS\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__7_Revaccination of Adult Cats\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__8_Sites of Vaccination for Cats\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__9_Serological Testing\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__10_VACCINATION OF DOGS AND CATS IN THE SHELTER ENVIRONMENT\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__11_GENERAL CONSIDERATIONS Comprehensive Individual Care beyond Vaccination\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__12_Medical Record Documentation\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__13_Rabies\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__14_E20\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__15_Table 6. Vaccine Husbandry: Key Points for Veterinary Practitioners\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__16_Seronegative animals\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__17_Adverse Events\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__18_ACKNOWLEDGMENTS\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__19_Mechanisms and Duration of Immunity (DOI)\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__20_Precautions\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__21_Disease Facts\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__22_Types of Vaccines Available Modified Live Virus (MLV) Vaccines:\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__23_Types of Vaccines Available\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__24_E30\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__25_E31\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__26_Inactivated (Killed) Vaccines:\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__27_FREQUENTLY ASKED QUESTIONS (FAQS)\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__28_May I vaccinate a puppy that is at high risk of getting CDV with a human measles vaccine?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__29_Can certain vaccines immunize pups having maternally derived antibody (MDA) against CDV at an earlier age?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__30_I know that maternally derived antibodies (MDA) can prevent active immunization with MLV vaccines -but can they also block immunity to killed vaccines?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__31_For how long can a reconstituted MLV vaccine sit at room temperature without losing activity?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__32_67.\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__33_Should I vaccinate a cat infected with FeLV and/or FIV infection?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__34_Where should I inject vaccine into a cat?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__35_Does severe nutritional deficiency affect the immune response to vaccines?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__36_If a puppy or kitten fails to receive colostrum will it have any passive antibody protection from the dam?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__37_How can these colostrum-deprived young animals be protected from the core diseases?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__38_At what age can one stop vaccinating dogs?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__39_What protocol is recommended for an unvaccinated adult dog?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__40_For an adult dog with an unknown Leptospira vaccination history, what's the recommended vaccination protocol? Is it still two doses 2-4 weeks apart as in puppies?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__41_What protocol is recommended for an unvaccinated adult cat?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__42_Should a cat be vaccinated if it already has signs of upper respiratory disease?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__43_Are serum antibody titres useful in determining vaccine-induced immunity?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__44_How long after CPV-2/CDV vaccination should you wait before measuring protective antibody concentrations using inclinic tests?\n",
      "8b493f9cbb23066c3de9b8f63f331ced04ee03ef__45_Why don't the VGG recommend routine rabies antibody testing?\n",
      "bf30423d4b37babbcfc4a5ec5f86e32a703d97dd__0_\n",
      "bf30423d4b37babbcfc4a5ec5f86e32a703d97dd__1_SIRS model\n",
      "bf30423d4b37babbcfc4a5ec5f86e32a703d97dd__2_Classic CA model\n",
      "bf30423d4b37babbcfc4a5ec5f86e32a703d97dd__3_Geo-entity based CA model\n",
      "bf30423d4b37babbcfc4a5ec5f86e32a703d97dd__4_Computation for correlation factors\n",
      "bf30423d4b37babbcfc4a5ec5f86e32a703d97dd__5_Simulation analysis\n",
      "bf30423d4b37babbcfc4a5ec5f86e32a703d97dd__6_Case study\n",
      "bf30423d4b37babbcfc4a5ec5f86e32a703d97dd__7_Conclusions\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__0_\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__1_Introduction\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__2_Estimating HLA-DRB1 promiscuity level\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__3_Global distribution of promiscuous HLA-DRB1 alleles\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__4_Link between pathogen diversity and HLA-DRB1 promiscuity level\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__5_Evolution of promiscuous HLA alleles\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__6_Fig 3. Promiscuity changes rapidly during evolution and might be a selectable trait. (A)\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__7_Pathogen diversity and HLA class I promiscuity\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__8_Discussion\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__9_Computational prediction of epitope-binding promiscuity\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__10_Calculating epitope-binding promiscuity using in vitro data\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__11_Calculating promiscuity levels of human populations\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__12_Pathogen diversity\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__13_Literature mining of associations between HLA alleles and infectious diseases\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__14_Amino acid distance between DRB1 alleles\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__15_Sequence diversity and promiscuity fragility\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__16_Statistical analysis and graphical representation\n",
      "7e9a78b8f365405455eb60c2645de7bd7359e7a1__17_Supporting information\n",
      "39ee2164fd26eb50a770a31e1fb67c230b4f2ee4__0_\n",
      "39ee2164fd26eb50a770a31e1fb67c230b4f2ee4__1_SARS Case Definition\n",
      "39ee2164fd26eb50a770a31e1fb67c230b4f2ee4__2_Inclusion Criteria\n",
      "39ee2164fd26eb50a770a31e1fb67c230b4f2ee4__3_National Surveillance for SARS\n",
      "39ee2164fd26eb50a770a31e1fb67c230b4f2ee4__4_Laboratory Confirmation of SARS Infection\n",
      "39ee2164fd26eb50a770a31e1fb67c230b4f2ee4__5_Laboratory Testing for Other Respiratory Pathogens\n",
      "39ee2164fd26eb50a770a31e1fb67c230b4f2ee4__6_Results\n",
      "39ee2164fd26eb50a770a31e1fb67c230b4f2ee4__7_Number of Illnesses Reported and Completeness of Surveillance Data\n",
      "39ee2164fd26eb50a770a31e1fb67c230b4f2ee4__8_Surveillance System Sensitivity and Predictive Value\n",
      "39ee2164fd26eb50a770a31e1fb67c230b4f2ee4__9_Flexibility and Timeliness of Surveillance\n",
      "39ee2164fd26eb50a770a31e1fb67c230b4f2ee4__10_Evaluation of Alternative Respiratory Pathogens\n",
      "39ee2164fd26eb50a770a31e1fb67c230b4f2ee4__11_Discussion\n",
      "53280f7c1287689ed55c52e3ff08c27cd6dedf00__0_Introduction\n",
      "53280f7c1287689ed55c52e3ff08c27cd6dedf00__1_Efforts to Avoid the Need for Prioritization\n",
      "53280f7c1287689ed55c52e3ff08c27cd6dedf00__2_Pandemic Response Goals and Principles for Setting Vaccination Priorities\n",
      "53280f7c1287689ed55c52e3ff08c27cd6dedf00__3_US Efforts to Define Pandemic Influenza Vaccination Priorities\n",
      "53280f7c1287689ed55c52e3ff08c27cd6dedf00__4_• Universal susceptibility to the pandemic influenza virus • Clinical and healthcare impacts absent effective mitigation strategies°\n",
      "53280f7c1287689ed55c52e3ff08c27cd6dedf00__5_US Pandemic Vaccine Prioritization\n",
      "53280f7c1287689ed55c52e3ff08c27cd6dedf00__6_Pandemic Vaccine Prioritization in Other Industrialized Countries\n",
      "53280f7c1287689ed55c52e3ff08c27cd6dedf00__7_Future Needs\n",
      "157c17f29b8e3a4dd3fa4da26336d4c5d35a3dd2__0_Infection control and its application to the administration of intravenous medications during gastrointestinal endoscopy\n",
      "157c17f29b8e3a4dd3fa4da26336d4c5d35a3dd2__1_IMPORTANT INFECTION CONTROL PRACTICES AND PROCEDURES Masks, gowns, and gloves\n",
      "157c17f29b8e3a4dd3fa4da26336d4c5d35a3dd2__2_Environmental cleaning\n",
      "157c17f29b8e3a4dd3fa4da26336d4c5d35a3dd2__3_ASEPTIC ADMINISTRATION OF IV MEDICATIONS\n",
      "157c17f29b8e3a4dd3fa4da26336d4c5d35a3dd2__4_Read the label and package insert of each IV medication\n",
      "157c17f29b8e3a4dd3fa4da26336d4c5d35a3dd2__5_CONCLUSIONS\n",
      "6979d40067c7917b6b92917ff8c3db8a440f5f4c__0_INTRODUCTION\n",
      "6979d40067c7917b6b92917ff8c3db8a440f5f4c__1_PROTEOMICS OF HERPESVIRIONS\n",
      "6979d40067c7917b6b92917ff8c3db8a440f5f4c__2_PUTATIVE FUNCTIONS OF HOST PROTEINS ASSOCIATED WITH HERPESVIRIONS\n",
      "6979d40067c7917b6b92917ff8c3db8a440f5f4c__3_IMPLICATIONS OF VIRION-ASSOCIATED HOST PROTEINS FOR HERPESVIRUSES\n",
      "6979d40067c7917b6b92917ff8c3db8a440f5f4c__4_TECHNICAL LIMITATIONS\n",
      "6979d40067c7917b6b92917ff8c3db8a440f5f4c__5_www.frontiersin.org\n",
      "6979d40067c7917b6b92917ff8c3db8a440f5f4c__6_CONCLUDING REMARKS AND FUTURE DIRECTIONS\n",
      "6979d40067c7917b6b92917ff8c3db8a440f5f4c__7_ACKNOWLEDGMENTS\n",
      "6b5d95e684e0f6f772f59c321e1c66f551569af4__0_\n",
      "3ab51821b2402f4d06379d112505fa97f0fafb97__0_Introduction\n",
      "3ab51821b2402f4d06379d112505fa97f0fafb97__1_Virology\n",
      "3ab51821b2402f4d06379d112505fa97f0fafb97__2_Epidemiology\n",
      "3ab51821b2402f4d06379d112505fa97f0fafb97__3_Human Cases\n",
      "3ab51821b2402f4d06379d112505fa97f0fafb97__4_Pathogenesis\n",
      "3ab51821b2402f4d06379d112505fa97f0fafb97__5_Avian\n",
      "3ab51821b2402f4d06379d112505fa97f0fafb97__6_Human\n",
      "3ab51821b2402f4d06379d112505fa97f0fafb97__7_Other mammalian species\n",
      "3ab51821b2402f4d06379d112505fa97f0fafb97__8_Diagnosis\n",
      "3ab51821b2402f4d06379d112505fa97f0fafb97__9_Prevention and Vaccines\n",
      "3ab51821b2402f4d06379d112505fa97f0fafb97__10_Treatment\n",
      "3ab51821b2402f4d06379d112505fa97f0fafb97__11_Conclusions\n",
      "31caba946fefeb876ff3a07e61b628f79a0b9598__0_Background\n",
      "31caba946fefeb876ff3a07e61b628f79a0b9598__1_Outbreak area\n",
      "31caba946fefeb876ff3a07e61b628f79a0b9598__2_Case definition\n",
      "31caba946fefeb876ff3a07e61b628f79a0b9598__3_Clinical and epidemiological investigation\n",
      "31caba946fefeb876ff3a07e61b628f79a0b9598__4_Laboratory investigation\n",
      "31caba946fefeb876ff3a07e61b628f79a0b9598__5_Data collection and analysis\n",
      "31caba946fefeb876ff3a07e61b628f79a0b9598__6_Interventions\n",
      "31caba946fefeb876ff3a07e61b628f79a0b9598__7_Laboratory investigations\n",
      "31caba946fefeb876ff3a07e61b628f79a0b9598__8_Evaluation of interventions\n",
      "31caba946fefeb876ff3a07e61b628f79a0b9598__9_Discussion\n",
      "31caba946fefeb876ff3a07e61b628f79a0b9598__10_Conclusion\n",
      "ab179a2dc1b93e7d39b5b371760a3e59da2f2b7e__0_Background\n",
      "ab179a2dc1b93e7d39b5b371760a3e59da2f2b7e__1_Study participants\n",
      "ab179a2dc1b93e7d39b5b371760a3e59da2f2b7e__2_Clinical procedures\n",
      "ab179a2dc1b93e7d39b5b371760a3e59da2f2b7e__3_Statistical analysis\n",
      "ab179a2dc1b93e7d39b5b371760a3e59da2f2b7e__4_Results\n",
      "ab179a2dc1b93e7d39b5b371760a3e59da2f2b7e__5_Discussion\n",
      "879df084e06fcce1980e3f73c36748068b39f049__0_\n",
      "879df084e06fcce1980e3f73c36748068b39f049__1_METHODS\n",
      "879df084e06fcce1980e3f73c36748068b39f049__2_RESULTS\n",
      "879df084e06fcce1980e3f73c36748068b39f049__3_DISCUSSION\n",
      "879df084e06fcce1980e3f73c36748068b39f049__4_CONCLUSIONS\n",
      "58a3f26fc5d83178e55fc8101691e2d6af9459d2__0_Introduction\n",
      "58a3f26fc5d83178e55fc8101691e2d6af9459d2__1_Case definition\n",
      "58a3f26fc5d83178e55fc8101691e2d6af9459d2__2_Information collection and flow\n",
      "58a3f26fc5d83178e55fc8101691e2d6af9459d2__3_Radiology\n",
      "58a3f26fc5d83178e55fc8101691e2d6af9459d2__4_Community survey\n",
      "58a3f26fc5d83178e55fc8101691e2d6af9459d2__5_Statistical analysis\n",
      "58a3f26fc5d83178e55fc8101691e2d6af9459d2__6_Radiographically confirmed pneumonia\n",
      "58a3f26fc5d83178e55fc8101691e2d6af9459d2__7_442\n",
      "58a3f26fc5d83178e55fc8101691e2d6af9459d2__8_Laboratory findings\n",
      "58a3f26fc5d83178e55fc8101691e2d6af9459d2__9_Recurrent pneumonia\n",
      "58a3f26fc5d83178e55fc8101691e2d6af9459d2__10_Cost\n",
      "58a3f26fc5d83178e55fc8101691e2d6af9459d2__11_Discussion\n",
      "c45ce5ebb4556d328bea24d834472ce2e570b4fd__0_\n",
      "8896df393cbfd2ccde62500c60233cfad6a0d223__0_Introduction\n",
      "8896df393cbfd2ccde62500c60233cfad6a0d223__1_Monocyte-derived-dendritic cells (Mo-DCs) were susceptible to MERS-CoV infection\n",
      "8896df393cbfd2ccde62500c60233cfad6a0d223__2_MERS-CoV infection in Mo-DCs was productive\n",
      "8896df393cbfd2ccde62500c60233cfad6a0d223__3_MERS-CoV triggered stronger cytokine and chemokine response than SARS-CoV in Mo-DCs\n",
      "8896df393cbfd2ccde62500c60233cfad6a0d223__4_MERS-CoV induced higher surface expression of antigen-presentation and co-stimulatory molecules than SARS-CoV in Mo-DCs\n",
      "8896df393cbfd2ccde62500c60233cfad6a0d223__5_Discussion\n",
      "8896df393cbfd2ccde62500c60233cfad6a0d223__6_Preparation of Mo-DCs\n",
      "8896df393cbfd2ccde62500c60233cfad6a0d223__7_Virus Infections\n",
      "8896df393cbfd2ccde62500c60233cfad6a0d223__8_Immunofluorescence staining\n",
      "8896df393cbfd2ccde62500c60233cfad6a0d223__9_Flow cytometry\n",
      "8896df393cbfd2ccde62500c60233cfad6a0d223__10_Statistical analysis\n",
      "8896df393cbfd2ccde62500c60233cfad6a0d223__11_Financial support\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__0_Streptococcus pyogenes;\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__1_Introducción\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__2_Epidemiología\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__3_Clínica\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__4_Complicaciones supurativas\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__5_Complicaciones no supurativas\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__6_Diagnóstico\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__7_Manifestaciones clínicas\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__8_Escalas de predicción\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__9_Métodos microbiológicos\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__10_Diagnóstico recomendado\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__11_Tratamiento Objetivos del tratamiento\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__12_Tratamiento antibiótico\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__13_Tratamiento sintomático\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__14_Derivación\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__15_Derivación urgente\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__16_Faringoamigdalitis aguda\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__17_Complicaciones locorregionales 49\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__18_Complicaciones a distancia\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__19_Derivación diferida\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__20_Amigdalitis de repetición\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__21_Absceso periamigdalino recurrente\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__22_Adenitis cervical recurrente\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__23_Manejo en la farmacia comunitaria\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__24_Tabla 5 Uso de Strep A en la farmacia comunitaria\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__25_Tabla 6\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__26_Criterios claros de derivación\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__27_Conclusiones\n",
      "e18773ecee762195cee18f1b3d83ef02f2db0dc9__28_Conflicto de intereses\n",
      "fb8debd0aa05ec84b8e824394215ce7c9185e139__0_INTRODUCTION\n",
      "fb8debd0aa05ec84b8e824394215ce7c9185e139__1_Study design\n",
      "fb8debd0aa05ec84b8e824394215ce7c9185e139__2_Data collection and definitions\n",
      "fb8debd0aa05ec84b8e824394215ce7c9185e139__3_Outcome\n",
      "fb8debd0aa05ec84b8e824394215ce7c9185e139__4_Statistical analysis\n",
      "fb8debd0aa05ec84b8e824394215ce7c9185e139__5_Clinical characteristics\n",
      "fb8debd0aa05ec84b8e824394215ce7c9185e139__6_Blood analysis parameters in survivors and non-survivors\n",
      "fb8debd0aa05ec84b8e824394215ce7c9185e139__7_(which was not certified by peer review)\n",
      "fb8debd0aa05ec84b8e824394215ce7c9185e139__8_Cellular and humoral immunity in survivors and non-survivors\n",
      "fb8debd0aa05ec84b8e824394215ce7c9185e139__9_ROC curve analyses of mortality\n",
      "fb8debd0aa05ec84b8e824394215ce7c9185e139__10_Dynamic profile of blood parameters after 2 weeks hospitalization in survivors\n",
      "fb8debd0aa05ec84b8e824394215ce7c9185e139__11_DISCUSSION\n",
      "fb8debd0aa05ec84b8e824394215ce7c9185e139__12_Conclusions\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__0_\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__1_Background\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__2_Classification\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__3_Virion Structure\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__4_Genome\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__5_Non-Structural Proteins\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__6_Accessory Proteins\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__7_Life Cycle\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__8_Attachment\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__9_Viral Entry and Uncoating\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__10_Formation of the Replication-Transcription Complex\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__11_Viral RNA Synthesis\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__12_Assembly and Release of Virion\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__13_HCoV-Host Interactions\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__14_Translational Control\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__15_ER Stress Response\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__16_MAP Kinase Pathway\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__17_Autophagy\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__18_Apoptosis\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__19_Pathogenesis\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__20_Epidemiology and Clinical features\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__21_HCoV-229E\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__22_HCoV-OC43\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__23_HCoV-NL63\n",
      "a7b71193936eaf26a9f67fb4af8bc72ad288c558__24_Prevention\n",
      "af471147dddd7e5701bf4919ab4b7aef45a43d7b__0_\n",
      "af471147dddd7e5701bf4919ab4b7aef45a43d7b__1_PATIENTS, MATERIALS, AND METHODS\n",
      "af471147dddd7e5701bf4919ab4b7aef45a43d7b__2_Patient characteristics.\n",
      "af471147dddd7e5701bf4919ab4b7aef45a43d7b__3_Prevalence of respiratory viruses among children with an LRTI.\n",
      "af471147dddd7e5701bf4919ab4b7aef45a43d7b__4_DISCUSSION\n",
      "2e148a87eafa60b12bc5f4216cd476565c9e7d57__0_INTRODUCTION\n",
      "2e148a87eafa60b12bc5f4216cd476565c9e7d57__1_IV. DISCUSSION\n",
      "90a811f37d9971c7eaee26e105085c283808fdb6__0_Introduction\n",
      "90a811f37d9971c7eaee26e105085c283808fdb6__1_Methods\n",
      "90a811f37d9971c7eaee26e105085c283808fdb6__2_Main study characteristics\n",
      "90a811f37d9971c7eaee26e105085c283808fdb6__3_Viral investigations\n",
      "90a811f37d9971c7eaee26e105085c283808fdb6__4_Respiratory symptoms and lung function\n",
      "90a811f37d9971c7eaee26e105085c283808fdb6__5_Outcome and antiviral interventions\n",
      "90a811f37d9971c7eaee26e105085c283808fdb6__6_Graft rejection\n",
      "90a811f37d9971c7eaee26e105085c283808fdb6__7_Figure 1: Odds ratio of (a) respiratory symptoms and (B) acute graft rejection according to the presence or absence of respiratory viral infections in lung transplant recipients.\n",
      "90a811f37d9971c7eaee26e105085c283808fdb6__8_Discussion\n",
      "90a811f37d9971c7eaee26e105085c283808fdb6__9_Respiratory Viruses in Lung Transplant Recipients\n",
      "90a811f37d9971c7eaee26e105085c283808fdb6__10_Supporting Information\n",
      "12c8ef5614d9a35bed3ff95a3b1dc971842514fe__0_Introduction\n",
      "12c8ef5614d9a35bed3ff95a3b1dc971842514fe__1_Results and discussion\n",
      "12c8ef5614d9a35bed3ff95a3b1dc971842514fe__2_Conclusions\n",
      "12c8ef5614d9a35bed3ff95a3b1dc971842514fe__3_Materials and Methods\n",
      "12c8ef5614d9a35bed3ff95a3b1dc971842514fe__4_Reverse transcription, PCR, and 5'-RACE.\n",
      "12c8ef5614d9a35bed3ff95a3b1dc971842514fe__5_Histology and Transmission Electron Microscopy.\n",
      "12c8ef5614d9a35bed3ff95a3b1dc971842514fe__6_Visualization of results.\n",
      "12c8ef5614d9a35bed3ff95a3b1dc971842514fe__7_Figure Legends\n",
      "69ed0332751ba504d01cf6d6c266c9ae499ceb38__0_Introduction\n",
      "69ed0332751ba504d01cf6d6c266c9ae499ceb38__1_Imaging set-up\n",
      "69ed0332751ba504d01cf6d6c266c9ae499ceb38__2_Human volunteers\n",
      "69ed0332751ba504d01cf6d6c266c9ae499ceb38__3_Analysis of recorded images\n",
      "69ed0332751ba504d01cf6d6c266c9ae499ceb38__4_Results\n",
      "69ed0332751ba504d01cf6d6c266c9ae499ceb38__5_Discussion\n",
      "69ed0332751ba504d01cf6d6c266c9ae499ceb38__6_Supporting Information\n",
      "c9f99dd8eaa0fc1baa7d15d075696915319a144c__0_\n",
      "c9f99dd8eaa0fc1baa7d15d075696915319a144c__1_Disease and the Global Commons\n",
      "c9f99dd8eaa0fc1baa7d15d075696915319a144c__2_Contagion and Tipping Points\n",
      "c9f99dd8eaa0fc1baa7d15d075696915319a144c__3_Geographic and Spatial Disease Spread\n",
      "c9f99dd8eaa0fc1baa7d15d075696915319a144c__4_Heterogeneity of Mixing, Cross-immunity, and Coinfection\n",
      "c9f99dd8eaa0fc1baa7d15d075696915319a144c__5_Antibiotic Resistance\n",
      "c9f99dd8eaa0fc1baa7d15d075696915319a144c__6_Mobility\n",
      "c9f99dd8eaa0fc1baa7d15d075696915319a144c__7_A Lagrangian Approach to Modeling Mobility and Infectious Disease Dynamics\n",
      "c9f99dd8eaa0fc1baa7d15d075696915319a144c__8_Behavior, Economic Epidemiology, and Mobility\n",
      "c9f99dd8eaa0fc1baa7d15d075696915319a144c__9_Economic Epidemiology\n",
      "c9f99dd8eaa0fc1baa7d15d075696915319a144c__10_Lagrangian and Economic Epidemiology Models\n",
      "31f2b0f55f9b8bfb75904c0eca57dbb6f79bbf94__0_Introduction\n",
      "31f2b0f55f9b8bfb75904c0eca57dbb6f79bbf94__1_Virus Data Sets\n",
      "31f2b0f55f9b8bfb75904c0eca57dbb6f79bbf94__2_Phylogenetic Analysis\n",
      "31f2b0f55f9b8bfb75904c0eca57dbb6f79bbf94__3_Synthetic Data Sets\n",
      "31f2b0f55f9b8bfb75904c0eca57dbb6f79bbf94__4_Inference of Substitution Rates\n",
      "31f2b0f55f9b8bfb75904c0eca57dbb6f79bbf94__5_Randomization Test\n",
      "31f2b0f55f9b8bfb75904c0eca57dbb6f79bbf94__6_Root-to-Tip Regressions\n",
      "31f2b0f55f9b8bfb75904c0eca57dbb6f79bbf94__7_Synthetic Data\n",
      "31f2b0f55f9b8bfb75904c0eca57dbb6f79bbf94__8_Discussion\n",
      "31f2b0f55f9b8bfb75904c0eca57dbb6f79bbf94__9_VARV\n",
      "31f2b0f55f9b8bfb75904c0eca57dbb6f79bbf94__10_HSV-1\n",
      "31f2b0f55f9b8bfb75904c0eca57dbb6f79bbf94__11_High Rates of Evolution in dsDNA Viruses?\n",
      "31f2b0f55f9b8bfb75904c0eca57dbb6f79bbf94__12_Supplementary Material\n",
      "83f5a54a7daaa9f3e9bbb55d56d975a679d656aa__0_Introduction\n",
      "83f5a54a7daaa9f3e9bbb55d56d975a679d656aa__1_Methods\n",
      "83f5a54a7daaa9f3e9bbb55d56d975a679d656aa__2_Study selection and characteristics\n",
      "83f5a54a7daaa9f3e9bbb55d56d975a679d656aa__3_Observational studies\n",
      "83f5a54a7daaa9f3e9bbb55d56d975a679d656aa__4_Case reports\n",
      "83f5a54a7daaa9f3e9bbb55d56d975a679d656aa__5_Discussion\n",
      "83f5a54a7daaa9f3e9bbb55d56d975a679d656aa__6_Conclusion\n",
      "83f5a54a7daaa9f3e9bbb55d56d975a679d656aa__7_Table 3\n",
      "9abf4b92756906bb2121dbabe54131bd08f31660__0_INTRODUCTION\n",
      "9abf4b92756906bb2121dbabe54131bd08f31660__1_Study design\n",
      "9abf4b92756906bb2121dbabe54131bd08f31660__2_Incidence estimation\n",
      "9abf4b92756906bb2121dbabe54131bd08f31660__3_Duration of hospitalization\n",
      "9abf4b92756906bb2121dbabe54131bd08f31660__4_Probability of ICU admission and mortality\n",
      "9abf4b92756906bb2121dbabe54131bd08f31660__5_Transmission dynamics\n",
      "9abf4b92756906bb2121dbabe54131bd08f31660__6_Ethics approval\n",
      "9abf4b92756906bb2121dbabe54131bd08f31660__7_Role of the funding source\n",
      "9abf4b92756906bb2121dbabe54131bd08f31660__8_Patients\n",
      "9abf4b92756906bb2121dbabe54131bd08f31660__9_Incidence of COVID-19 hospitalization\n",
      "9abf4b92756906bb2121dbabe54131bd08f31660__10_Duration of hospital stay\n",
      "9abf4b92756906bb2121dbabe54131bd08f31660__11_Intensive care requirements and case fatality risk\n",
      "9abf4b92756906bb2121dbabe54131bd08f31660__12_DISCUSSION\n",
      "e58c8d02a519cb271727a06b0b54ea39307cf9f8__0_\n",
      "4bdb53b23deb0bc56d0aa7b26551ab76b1fd082e__0_Background\n",
      "4bdb53b23deb0bc56d0aa7b26551ab76b1fd082e__1_Epidemiological data\n",
      "4bdb53b23deb0bc56d0aa7b26551ab76b1fd082e__2_Statistical model\n",
      "4bdb53b23deb0bc56d0aa7b26551ab76b1fd082e__3_Estimation settings\n",
      "4bdb53b23deb0bc56d0aa7b26551ab76b1fd082e__4_Ethical considerations\n",
      "4bdb53b23deb0bc56d0aa7b26551ab76b1fd082e__5_Availability of supporting data\n",
      "4bdb53b23deb0bc56d0aa7b26551ab76b1fd082e__6_Time dependent risk of MERS death\n",
      "4bdb53b23deb0bc56d0aa7b26551ab76b1fd082e__7_Estimated time from illness onset to death\n",
      "4bdb53b23deb0bc56d0aa7b26551ab76b1fd082e__8_Discussion\n",
      "4bdb53b23deb0bc56d0aa7b26551ab76b1fd082e__9_Conclusion\n",
      "656d51738d99ab844ae143615bf4c4a40b1e1fec__0_\n",
      "656d51738d99ab844ae143615bf4c4a40b1e1fec__1_Materials and methods\n",
      "656d51738d99ab844ae143615bf4c4a40b1e1fec__2_Results\n",
      "656d51738d99ab844ae143615bf4c4a40b1e1fec__3_Discussion\n",
      "e9d01ab9a55093ad1c1277a7845d3254d3ad6fe8__0_Introduction: A Brief Summary of Cystic Fibrosis Today\n",
      "e9d01ab9a55093ad1c1277a7845d3254d3ad6fe8__1_Figure 1.\n",
      "e9d01ab9a55093ad1c1277a7845d3254d3ad6fe8__2_Alternatives to Ad (1995-2008)\n",
      "e9d01ab9a55093ad1c1277a7845d3254d3ad6fe8__3_Adeno-Associated Virus\n",
      "e9d01ab9a55093ad1c1277a7845d3254d3ad6fe8__4_Nonviral Vectors\n",
      "e9d01ab9a55093ad1c1277a7845d3254d3ad6fe8__5_Retroviral and Lentiviral Vectors\n",
      "e9d01ab9a55093ad1c1277a7845d3254d3ad6fe8__6_Addressing Barriers to Gene Transfer\n",
      "e9d01ab9a55093ad1c1277a7845d3254d3ad6fe8__7_New Models for Preclinical Studies (2008-2018)\n",
      "e9d01ab9a55093ad1c1277a7845d3254d3ad6fe8__8_Gene Editing and the Era of Precision Medicine\n",
      "7743c3acb2cb07e744352bd554f7da4cafb54e5f__0_\n",
      "7743c3acb2cb07e744352bd554f7da4cafb54e5f__1_PBMC.\n",
      "7743c3acb2cb07e744352bd554f7da4cafb54e5f__2_MHC\n",
      "7743c3acb2cb07e744352bd554f7da4cafb54e5f__3_mAb.\n",
      "7743c3acb2cb07e744352bd554f7da4cafb54e5f__4_Treatment of PBMC with mAb and complement.\n",
      "7743c3acb2cb07e744352bd554f7da4cafb54e5f__5_IFN induction.\n",
      "7743c3acb2cb07e744352bd554f7da4cafb54e5f__6_IFN blocking experiments with anti-SLA class II mAb.\n",
      "7743c3acb2cb07e744352bd554f7da4cafb54e5f__7_IFN bioassay.\n",
      "7743c3acb2cb07e744352bd554f7da4cafb54e5f__8_1) Effect of antibody and complement treatment of IFNa producer cells.\n",
      "7743c3acb2cb07e744352bd554f7da4cafb54e5f__9_2) Effect of antibody in the absence of complement on IFNa production.\n",
      "7743c3acb2cb07e744352bd554f7da4cafb54e5f__10_DISCUSSION\n",
      "f2a737c4f700ab78c9c3da7db73f690c4a996382__0_INTRODUCTION\n",
      "f2a737c4f700ab78c9c3da7db73f690c4a996382__1_MATERIALS AND METHODS Serum Samples\n",
      "f2a737c4f700ab78c9c3da7db73f690c4a996382__2_Virus and Cell Culture\n",
      "f2a737c4f700ab78c9c3da7db73f690c4a996382__3_Gel Electrophoresis\n",
      "f2a737c4f700ab78c9c3da7db73f690c4a996382__4_Western Blot Analysis for FIV\n",
      "f2a737c4f700ab78c9c3da7db73f690c4a996382__5_RESULTS\n",
      "f2a737c4f700ab78c9c3da7db73f690c4a996382__6_DISCUSSION\n",
      "7b5111143804a15cd9120956dd6f29e4e1dcc439__0_Introduction\n",
      "7b5111143804a15cd9120956dd6f29e4e1dcc439__1_Reference strain\n",
      "7b5111143804a15cd9120956dd6f29e4e1dcc439__2_Collection and processing of samples\n",
      "7b5111143804a15cd9120956dd6f29e4e1dcc439__3_Primer design\n",
      "7b5111143804a15cd9120956dd6f29e4e1dcc439__4_Standardization of LAMP reaction\n",
      "7b5111143804a15cd9120956dd6f29e4e1dcc439__5_LAMP amplification\n",
      "7b5111143804a15cd9120956dd6f29e4e1dcc439__6_Electrophoresis of LAMP products\n",
      "7b5111143804a15cd9120956dd6f29e4e1dcc439__7_Testing the specificity of LAMP for cpa using restriction enzyme\n",
      "7b5111143804a15cd9120956dd6f29e4e1dcc439__8_LAMP amplification of clinical samples\n",
      "7b5111143804a15cd9120956dd6f29e4e1dcc439__9_Screening of clinical samples by PCR\n",
      "7b5111143804a15cd9120956dd6f29e4e1dcc439__10_Comparison of diagnostic sensitivity of LAMP with PCR\n",
      "7b5111143804a15cd9120956dd6f29e4e1dcc439__11_Results and Discussion\n",
      "7b5111143804a15cd9120956dd6f29e4e1dcc439__12_Conclusion\n",
      "ff4c93f99fe849057d9cc1eb1f7858d237491eb6__0_\n",
      "16aa672efa22f7191a6d18e74fa774103bb16cb7__0_INTRODUCTION\n",
      "16aa672efa22f7191a6d18e74fa774103bb16cb7__1_MATERIALS AND METHODS\n",
      "16aa672efa22f7191a6d18e74fa774103bb16cb7__2_Fusion from without assay\n",
      "16aa672efa22f7191a6d18e74fa774103bb16cb7__3_Analysis of the antigenic reactivities of MAbs after exposure of MVE virus to low pH\n",
      "16aa672efa22f7191a6d18e74fa774103bb16cb7__4_A-Sepharose-purified\n",
      "16aa672efa22f7191a6d18e74fa774103bb16cb7__5_Identification of MAb binding site\n",
      "16aa672efa22f7191a6d18e74fa774103bb16cb7__6_RESULTS\n",
      "16aa672efa22f7191a6d18e74fa774103bb16cb7__7_Identification\n",
      "16aa672efa22f7191a6d18e74fa774103bb16cb7__8_DISCUSSION\n",
      "e2abe3677cfae339bf4d58606db52cec54936b98__0_\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__0_INTRODUCTION\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__1_Sphingolipids\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__2_Bioactive Lipids\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__3_Box 1 Metabolomics for the discovery of antiviral targets\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__4_DEFINING THE ROLE OF THE LIPIDOME IN VIRUS-HOST INTERACTIONS\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__5_Reductionist Approaches\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__6_Inferring Metabolomic Changes from Genomic or Proteomic Profiling\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__7_Nuclear Magnetic Resonance Spectroscopy\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__8_Mass Spectrometry\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__9_LIPIDS IN VIRAL REPLICATION AND PATHOGENESIS\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__10_Lipids in Viral Entry\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__11_Membrane Fusion\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__12_Membrane Composition\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__13_Lipids in Viral Genome Replication\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__14_Genome Replication of RNA Viruses\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__15_Perturbation of Lipid Biosynthesis and Trafficking by RNA Viruses\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__16_Box 3 Cholesterol in viral infections\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__17_Lipids in Viral Assembly and Release\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__18_Recruitment of Viral Components to the Site of Assembly\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__19_Mechanisms for Inducing Membrane Curvature in Budding and Scission\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__20_Influenza Virus Assembly, Budding, and Scission\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__21_Lipids in the Inflammatory Response\n",
      "7fc6d08ff822cbeaf6845bae883a7e66d4c98d90__22_CONCLUDING REMARKS: EXPLOITATION OF VIRAL DEPENDENCE ON HOST LIPIDS AS A SELECTIVE ANTIVIRAL STRATEGY\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__0_Introduction\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__1_Crystallization and Structure Determination of an Active nsp16 29-O-MTase\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__2_Author Summary\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__3_Structure of the nsp10/16 Heterodimer\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__4_S-adenosylhomocysteine-and Sinefungin-Binding\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__5_A Mg 2+ Cation is Present in nsp16, Outside the Active Site\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__6_The Putative RNA Binding Site: Mutagenesis and Effect on Activity\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__7_Interface of the Heterodimer\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__8_Mechanism of 29-O-Methyltransfer\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__9_Role of Mg 2+ on MTase Activity\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__10_MTase Activity is Regulated via Protein-Protein Interactions\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__11_Crystallization and Data Collection\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__12_Structure Determination and Refinement\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__13_RNA Cap Structure Modeling\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__14_Plasmids\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__15_Reagents\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__16_Radioactive Methyltransferase Assay\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__17_Supporting Information\n",
      "e65736745475f7a3bab0f310edb593acc50528b7__18_Table S2\n",
      "000affa746a03f1fe4e3b3ef1a62fdfa9b9ac52a__0_Introduction\n",
      "000affa746a03f1fe4e3b3ef1a62fdfa9b9ac52a__1_Hospital setting\n",
      "000affa746a03f1fe4e3b3ef1a62fdfa9b9ac52a__2_Patients with HCAI-MRSA and HCAI-VRE\n",
      "000affa746a03f1fe4e3b3ef1a62fdfa9b9ac52a__3_Antimicrobial agents and consumption\n",
      "000affa746a03f1fe4e3b3ef1a62fdfa9b9ac52a__4_Statistical analysis\n",
      "000affa746a03f1fe4e3b3ef1a62fdfa9b9ac52a__5_Annual antibiotic consumption\n",
      "000affa746a03f1fe4e3b3ef1a62fdfa9b9ac52a__6_Correlation between antibiotic consumption and incidence of HCAI-MRSA and HCAI-VRE\n",
      "000affa746a03f1fe4e3b3ef1a62fdfa9b9ac52a__7_Discussion\n",
      "8a2a859f5920d1a81d0ab2e619f00f729331fedc__0_\n",
      "8a2a859f5920d1a81d0ab2e619f00f729331fedc__1_Effect of MaMIF on the expression of inflammation-associated genes in hamster peripheral blood mononuclear cells (PBMCs).\n",
      "8a2a859f5920d1a81d0ab2e619f00f729331fedc__2_Effect of MaMIF on PBMC migration. Prior approval from the Institutional Animal Ethical Committee\n",
      "8a2a859f5920d1a81d0ab2e619f00f729331fedc__3_Effect of MaMIF on pancreatic tumor growth in vivo. Syrian golden hamsters (3-4 months old; male)\n",
      "8a2a859f5920d1a81d0ab2e619f00f729331fedc__4_Effect of MaMIF on the overall growth of HapT1 cells in vitro.\n",
      "8a2a859f5920d1a81d0ab2e619f00f729331fedc__5_Effect of MaMIF on VEGF expression in HapT1 cells.\n",
      "8a2a859f5920d1a81d0ab2e619f00f729331fedc__6_Knockdown of MaMIF by siRNA transfection. Small interfering RNA (siRNA) oligonucleotides targeting\n",
      "8a2a859f5920d1a81d0ab2e619f00f729331fedc__7_Results\n",
      "8a2a859f5920d1a81d0ab2e619f00f729331fedc__8_Effect of MaMIF on activation and migration of PBMCs. MIF is known as a potent pro-inflammatory\n",
      "8a2a859f5920d1a81d0ab2e619f00f729331fedc__9_Effect of MaMIF on the growth of HapT1 pancreatic tumor in its syngeneic host.\n",
      "8a2a859f5920d1a81d0ab2e619f00f729331fedc__10_Mechanistic aspects of MaMIF-mediated HapT1 tumor growth in its syngeneic host.\n",
      "8a2a859f5920d1a81d0ab2e619f00f729331fedc__11_Function of intracellular MIF on the overall growth of HapT1 cells in-vitro. In the aforementioned\n",
      "8a2a859f5920d1a81d0ab2e619f00f729331fedc__12_Discussion\n",
      "8a2a859f5920d1a81d0ab2e619f00f729331fedc__13_conclusion\n",
      "8b64358b0398f3930ee9d36f459e008f7155840d__0_\n",
      "8b64358b0398f3930ee9d36f459e008f7155840d__1_Methoden\n",
      "8b64358b0398f3930ee9d36f459e008f7155840d__2_Rekrutierung\n",
      "8b64358b0398f3930ee9d36f459e008f7155840d__3_Ergebnisse\n",
      "8b64358b0398f3930ee9d36f459e008f7155840d__4_Fehlende und zeitverzögerte Informationen\n",
      "8b64358b0398f3930ee9d36f459e008f7155840d__5_Arbeitsbelastung\n",
      "8b64358b0398f3930ee9d36f459e008f7155840d__6_Schlüsselwörter\n",
      "8b64358b0398f3930ee9d36f459e008f7155840d__7_Keywords\n",
      "8b64358b0398f3930ee9d36f459e008f7155840d__8_Stärken und Limitationen\n",
      "8b64358b0398f3930ee9d36f459e008f7155840d__9_Aktive Information durch zentrale Stelle\n",
      "8b64358b0398f3930ee9d36f459e008f7155840d__10_Gesicherte Finanzierung ausbruchbedingter Maßnahmen\n",
      "8b64358b0398f3930ee9d36f459e008f7155840d__11_Entlastung der ambulant tätigen Ärzte\n",
      "8b64358b0398f3930ee9d36f459e008f7155840d__12_Praxisorganisation\n",
      "8b64358b0398f3930ee9d36f459e008f7155840d__13_Stärkung der primärärztlichen und koordinierenden Funktion der Hausärzte\n",
      "e623037e2cb61aa0cf502baf0f5be8e3fe07a101__0_\n",
      "e623037e2cb61aa0cf502baf0f5be8e3fe07a101__1_Marco Colonna\n",
      "e623037e2cb61aa0cf502baf0f5be8e3fe07a101__2_Giorgio Trinchieri\n",
      "e623037e2cb61aa0cf502baf0f5be8e3fe07a101__3_Franck Barrat\n",
      "e623037e2cb61aa0cf502baf0f5be8e3fe07a101__4_Michel Gilliet\n",
      "e623037e2cb61aa0cf502baf0f5be8e3fe07a101__5_M.G\n",
      "e623037e2cb61aa0cf502baf0f5be8e3fe07a101__6_B.R\n",
      "e623037e2cb61aa0cf502baf0f5be8e3fe07a101__7_F.B\n",
      "e623037e2cb61aa0cf502baf0f5be8e3fe07a101__8_M.C\n",
      "e623037e2cb61aa0cf502baf0f5be8e3fe07a101__9_What contribution do pDCs make to antigen presentation in vivo and how important are pDCs for T cell differentiation? F.B\n",
      "e623037e2cb61aa0cf502baf0f5be8e3fe07a101__10_G.T\n",
      "e623037e2cb61aa0cf502baf0f5be8e3fe07a101__11_The contributors\n",
      "e623037e2cb61aa0cf502baf0f5be8e3fe07a101__12_pDCs have been reported to promote both pro-inflammatory and tolerogenic immune responses -how are they able to show such dual functions? F.B\n",
      "e623037e2cb61aa0cf502baf0f5be8e3fe07a101__13_So are pDCs likely to be a useful therapeutic target?\n",
      "6fb77f80990c7b26de01f58d7d15ee40748217f1__0_\n",
      "6fb77f80990c7b26de01f58d7d15ee40748217f1__1_Contents lists available at ScienceDirect\n",
      "6fb77f80990c7b26de01f58d7d15ee40748217f1__2_Defining Voluntary Nonremunerated Blood Donation\n",
      "6fb77f80990c7b26de01f58d7d15ee40748217f1__3_Cost Assessment and Recovery\n",
      "6fb77f80990c7b26de01f58d7d15ee40748217f1__4_Hemovigilance and Decision-Making Processes\n",
      "6fb77f80990c7b26de01f58d7d15ee40748217f1__5_Conclusion\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__0_PRETRAVEL VISIT\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__1_Immunizations\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__2_Traveler's Diarrhea\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__3_Insect-Borne Diseases\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__4_Sexual Activity\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__5_Animal Exposure\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__6_SYMPTOMS IN THE RETURNING TRAVELER Traveler's Diarrhea Background\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__7_Epidemiology\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__8_Diagnosis\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__9_Treatment\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__10_SKIN LESIONS IN THE TRAVELER Background\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__11_Infections in Travelers\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__12_CLM\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__13_Leishmaniasis\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__14_Myiasis\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__15_Tungiasis\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__16_THE RETURNING TRAVELER AND FEVER Background\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__17_Epidemiology of Fever in Returning Travelers\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__18_Diagnostic Algorithm of Fever in Returning Travelers\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__19_MALARIA Background\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__20_Classification\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__21_Clinical Presentation\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__22_DENGUE FEVER Background\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__23_Classification and Clinical Presentation\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__24_RICKETTSIAL INFECTIONS Background\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__25_ENTERIC FEVER Background\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__26_Vaccination and Treatment\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__27_RESPIRATORY INFECTION Background\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__28_THE IMMUNOSUPPRESSED TRAVELER Special Considerations in Patients with HIV\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__29_Special Considerations in Solid Organ Transplant Patients\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__30_Special Considerations in Asplenic Patients\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__31_Special Consideration in Patients on Corticosteroids or Tumor Necrosis Factor a\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__32_Special Consideration in Patients on Oncologic Medications\n",
      "699fba12f495095f4e0921375f75b1b127cbb2a0__33_SUMMARY\n",
      "8a1c9aac07eb230a840ec6c81fff6c4318a31f07__0_INTRODUCTION\n",
      "8a1c9aac07eb230a840ec6c81fff6c4318a31f07__1_COMPLEMENTING TRADITIONAL CULTURE-BASED TECHNIQUES\n",
      "8a1c9aac07eb230a840ec6c81fff6c4318a31f07__2_ADJUNCTS TO MICROBIOME ANALYSIS: FUNCTIONAL CHARACTERIZATION\n",
      "8a1c9aac07eb230a840ec6c81fff6c4318a31f07__3_ALTERATIONS OF THE INTESTINAL MICROBIOTA IN NEC\n",
      "8a1c9aac07eb230a840ec6c81fff6c4318a31f07__4_Torrazza & Neu\n",
      "8a1c9aac07eb230a840ec6c81fff6c4318a31f07__5_FACTORS AFFECTING THE INTESTINAL MICROBIOTA Prenatal\n",
      "8a1c9aac07eb230a840ec6c81fff6c4318a31f07__6_Cesarean Section Versus Vaginal Delivery\n",
      "8a1c9aac07eb230a840ec6c81fff6c4318a31f07__7_Human Milk Versus Infant Formula\n",
      "8a1c9aac07eb230a840ec6c81fff6c4318a31f07__8_Antibiotic Exposure\n",
      "8a1c9aac07eb230a840ec6c81fff6c4318a31f07__9_found that\n",
      "8a1c9aac07eb230a840ec6c81fff6c4318a31f07__10_INTESTINAL MICROBIOTA ALTERATION INDUCES INTESTINAL INFLAMMATION AND CYTOKINES\n",
      "8a1c9aac07eb230a840ec6c81fff6c4318a31f07__11_INTESTINAL MICROBIOTA BACTERIAL TRANSLOCATION AND OTHER RISK FACTORS FOR NEC\n",
      "2d4b778f4f655be171f4a633fc6143fbe4a4d2ba__0_\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__0_\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__1_Radiologic Imaging\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__2_Epidemiology\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__3_Bacteria\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__4_Staphylococcus aureus Streptococcus pyogenes Haemophilus influenzae Moraxella catarrhalis\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__5_Chlamydophila pneumoniae\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__6_Pneumonia-Associated Complications\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__7_Pathogens Viruses\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__8_Streptococcus pneumoniae and the Impact of Pneumococcal Conjugate Vaccine\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__9_Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae, and Other Pathogens\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__10_Atypical Bacterial Pathogens\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__11_Viral and Bacterial Coinfections\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__12_Diagnostic Testing for Etiology and Prognosis\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__13_Culture-Based Methods\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__14_Listeria monocytogenes\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__15_Chlamydia trachomatis\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__16_Chlamydia psittaci\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__17_Francisella tularensis\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__18_Yersinia pestis\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__19_Bacillus anthracis\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__20_Leptospira interrogans\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__21_Mycobacterium tuberculosis\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__22_Coccidioides immitis\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__23_Serologic Studies\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__24_Antigen Detection\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__25_Molecular Diagnostics\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__26_Biomarkers\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__27_Other Diagnostic Methods\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__28_Disease Management and National Guidelines\n",
      "2794ce17b4648bed210c57a9a7b51fa255601211__29_Conclusions\n",
      "309d522d234c655ee74403b62d39a9b0897b2f24__0_\n",
      "309d522d234c655ee74403b62d39a9b0897b2f24__1_Materials and Methods\n",
      "309d522d234c655ee74403b62d39a9b0897b2f24__2_Preparation of cRNA Probes\n",
      "309d522d234c655ee74403b62d39a9b0897b2f24__3_In Situ Hybridization\n",
      "309d522d234c655ee74403b62d39a9b0897b2f24__4_In Situ Hybridization and IHC Double Labeling\n",
      "309d522d234c655ee74403b62d39a9b0897b2f24__5_Masson Trichrome Stain\n",
      "309d522d234c655ee74403b62d39a9b0897b2f24__6_Data Analysis\n",
      "309d522d234c655ee74403b62d39a9b0897b2f24__7_Bronchial Epithelium\n",
      "309d522d234c655ee74403b62d39a9b0897b2f24__8_Pneumocytes\n",
      "309d522d234c655ee74403b62d39a9b0897b2f24__9_Leukocytes\n",
      "309d522d234c655ee74403b62d39a9b0897b2f24__10_Vascular Endothelial Cells\n",
      "309d522d234c655ee74403b62d39a9b0897b2f24__11_Fibroblasts\n",
      "309d522d234c655ee74403b62d39a9b0897b2f24__12_Statistical Analysis\n",
      "309d522d234c655ee74403b62d39a9b0897b2f24__13_Discussion\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__0_\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__1_Introduction\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__2_Definitions\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__3_Bacteraemia\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__4_SIRS and its relationships to sepsis\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__5_Relationships between sepsis and bacteraemia\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__6_Risk factors for bacteraemia during sepsis\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__7_Risk factors for severe sepsis among ICU patients\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__8_Risk factors for severe sepsis during bacteraemia\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__9_SIRS, sepsis, and infection\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__10_Sources of infection in septic patients\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__11_Short-term mortality\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__12_Long-term impact of sepsis on outcome\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__13_Selection of patients for inclusion into trials\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__14_Stratification of patients upon inclusion\n",
      "1862da9d213b50e12f2e6eaea5692b84b16dc1ef__15_End-points and efficacy analysis\n",
      "35e2f54d46ff658885f640b42da3d9328d5dd769__0_INTRODUCTION\n",
      "35e2f54d46ff658885f640b42da3d9328d5dd769__1_MATERIALS AND METHODS Viruses\n",
      "35e2f54d46ff658885f640b42da3d9328d5dd769__2_Virus Antigens for ELSA\n",
      "35e2f54d46ff658885f640b42da3d9328d5dd769__3_Serum Samples\n",
      "35e2f54d46ff658885f640b42da3d9328d5dd769__4_ELSA Procedure\n",
      "35e2f54d46ff658885f640b42da3d9328d5dd769__5_Selection of Viruses for ELSA\n",
      "35e2f54d46ff658885f640b42da3d9328d5dd769__6_Determination of Antibodies to HCVs\n",
      "35e2f54d46ff658885f640b42da3d9328d5dd769__7_Correlation of Antibodies to HCV 229E and CV Paris\n",
      "35e2f54d46ff658885f640b42da3d9328d5dd769__8_Antibody in Human Sera from England\n",
      "35e2f54d46ff658885f640b42da3d9328d5dd769__9_DISCUSSION\n",
      "3363cfaec1065daae0bce3b379d61fb30222a624__0_\n",
      "3363cfaec1065daae0bce3b379d61fb30222a624__1_Conflicts of interest:\n",
      "be792e989703defa6ec59983b09fe84fc507c139__0_Introduction\n",
      "be792e989703defa6ec59983b09fe84fc507c139__1_Analysis framework\n",
      "be792e989703defa6ec59983b09fe84fc507c139__2_Short-term dataset\n",
      "be792e989703defa6ec59983b09fe84fc507c139__3_Long-term dataset\n",
      "be792e989703defa6ec59983b09fe84fc507c139__4_Species traits\n",
      "be792e989703defa6ec59983b09fe84fc507c139__5_Statistical procedures\n",
      "be792e989703defa6ec59983b09fe84fc507c139__6_Species recovery following fire\n",
      "be792e989703defa6ec59983b09fe84fc507c139__7_Identification of significant traits\n",
      "be792e989703defa6ec59983b09fe84fc507c139__8_Classification of woody species\n",
      "be792e989703defa6ec59983b09fe84fc507c139__9_Evaluation of functional groups\n",
      "be792e989703defa6ec59983b09fe84fc507c139__10_Discussion\n",
      "be792e989703defa6ec59983b09fe84fc507c139__11_Acknowledgments\n",
      "e611d4bf18a935508a12483b22fae7540b2a7c49__0_\n",
      "db6853e9633caa6340d4399814bf7afc4bbad16b__0_\n",
      "db6853e9633caa6340d4399814bf7afc4bbad16b__1_Theory\n",
      "db6853e9633caa6340d4399814bf7afc4bbad16b__2_Materials and Methods\n",
      "db6853e9633caa6340d4399814bf7afc4bbad16b__3_Results and Discussion\n",
      "db6853e9633caa6340d4399814bf7afc4bbad16b__4_Outcomes of chip based qRT-PCR detection of Influenza A virus.-\n",
      "db6853e9633caa6340d4399814bf7afc4bbad16b__5_Conclusions\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__0_Background\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__1_Study design, settings, and patients\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__2_Data collection\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__3_Randomization\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__4_Pharmacokinetic study\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__5_Bioanalytical methods\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__6_Population pharmacokinetic model\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__7_Other pharmacokinetic calculations\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__8_Monte Carlo simulations\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__9_Statistical analysis\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__10_Enrolment and characteristics of study patients\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__11_Pharmacokinetic data\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__12_Probability of target attainment\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__13_PK/PD in ELF and clinical outcomes\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__14_Discussion\n",
      "f9fb86ef0cd075f4f01c3859574572ae3ce9e13b__15_Conclusions\n",
      "a0b5a3f376d0bf92fe46ee15bfe794fd9046a08a__0_Introduction\n",
      "a0b5a3f376d0bf92fe46ee15bfe794fd9046a08a__1_Patients and Study Design\n",
      "a0b5a3f376d0bf92fe46ee15bfe794fd9046a08a__2_Supplementary Figure 1.\n",
      "a0b5a3f376d0bf92fe46ee15bfe794fd9046a08a__3_Molecular Assays\n",
      "a0b5a3f376d0bf92fe46ee15bfe794fd9046a08a__4_Serological Assays\n",
      "a0b5a3f376d0bf92fe46ee15bfe794fd9046a08a__5_Transmission electron microscopy\n",
      "a0b5a3f376d0bf92fe46ee15bfe794fd9046a08a__6_Data Analysis\n",
      "a0b5a3f376d0bf92fe46ee15bfe794fd9046a08a__7_Cohort Description and Epidemiological Characteristics\n",
      "a0b5a3f376d0bf92fe46ee15bfe794fd9046a08a__8_Clinical features\n",
      "a0b5a3f376d0bf92fe46ee15bfe794fd9046a08a__9_Dynamics of SARS-Cov-2 RNA shedding\n",
      "a0b5a3f376d0bf92fe46ee15bfe794fd9046a08a__10_Coronavirus detection by transmission electron microscopy\n",
      "a0b5a3f376d0bf92fe46ee15bfe794fd9046a08a__11_Risk factors for disease severity\n",
      "a0b5a3f376d0bf92fe46ee15bfe794fd9046a08a__12_Discussions\n",
      "a0b5a3f376d0bf92fe46ee15bfe794fd9046a08a__13_Table 2. Characteristics and duration of SARS-CoV-2 RNA shedding in clinical specimens\n",
      "b53d1e66f0c5ab8f90adc4b62f7dee78836ef479__0_A B S T R A C T\n",
      "b53d1e66f0c5ab8f90adc4b62f7dee78836ef479__1_Introducció n\n",
      "b53d1e66f0c5ab8f90adc4b62f7dee78836ef479__2_Barreras y catalizadores del cambio\n",
      "b53d1e66f0c5ab8f90adc4b62f7dee78836ef479__3_Puntos clave\n",
      "b53d1e66f0c5ab8f90adc4b62f7dee78836ef479__4_Puntos fuertes y dé biles en Españ a\n",
      "b53d1e66f0c5ab8f90adc4b62f7dee78836ef479__5_Conclusiones y propuestas\n",
      "b53d1e66f0c5ab8f90adc4b62f7dee78836ef479__6_Conflicto de intereses\n",
      "b53d1e66f0c5ab8f90adc4b62f7dee78836ef479__7_Agradecimientos\n",
      "129341a52b43ccd59368d094950322d983ebe223__0_\n",
      "129341a52b43ccd59368d094950322d983ebe223__1_Study population and ethics approval\n",
      "129341a52b43ccd59368d094950322d983ebe223__2_Sample collection\n",
      "129341a52b43ccd59368d094950322d983ebe223__3_Enteropathogen analyses\n",
      "129341a52b43ccd59368d094950322d983ebe223__4_Fecal S100A12 analysis\n",
      "129341a52b43ccd59368d094950322d983ebe223__5_Data analysis\n",
      "129341a52b43ccd59368d094950322d983ebe223__6_Study population\n",
      "129341a52b43ccd59368d094950322d983ebe223__7_Study prevalence of selected endoparasites and viral agents\n",
      "129341a52b43ccd59368d094950322d983ebe223__8_Fecal S100A12 concentrations\n",
      "129341a52b43ccd59368d094950322d983ebe223__9_Discussion\n",
      "129341a52b43ccd59368d094950322d983ebe223__10_Conclusions\n",
      "049ea8899e4cd0666b0098adac0fe9d50bf669a4__0_Introduction\n",
      "049ea8899e4cd0666b0098adac0fe9d50bf669a4__1_Animals and farm history\n",
      "049ea8899e4cd0666b0098adac0fe9d50bf669a4__2_Scoring severity of cryptosporidiosis\n",
      "049ea8899e4cd0666b0098adac0fe9d50bf669a4__3_Calf weights\n",
      "049ea8899e4cd0666b0098adac0fe9d50bf669a4__4_Diagnosis and genotyping of Cryptosporidium\n",
      "049ea8899e4cd0666b0098adac0fe9d50bf669a4__5_Statistical analysis\n",
      "049ea8899e4cd0666b0098adac0fe9d50bf669a4__6_Clinical scoring of calves\n",
      "049ea8899e4cd0666b0098adac0fe9d50bf669a4__7_Weight of calves over 6 month period\n",
      "049ea8899e4cd0666b0098adac0fe9d50bf669a4__8_Cryptosporidium diagnosis\n",
      "049ea8899e4cd0666b0098adac0fe9d50bf669a4__9_Discussion\n",
      "049ea8899e4cd0666b0098adac0fe9d50bf669a4__10_Calf ID\n",
      "a1b6c2b3b808e995697f94d9676d5d5c85180177__0_Background\n",
      "a1b6c2b3b808e995697f94d9676d5d5c85180177__1_Is there a problem?\n",
      "a1b6c2b3b808e995697f94d9676d5d5c85180177__2_Do health care professionals have special obligations during infectious disease outbreaks?\n",
      "a1b6c2b3b808e995697f94d9676d5d5c85180177__3_By freely choosing a profession devoted to care of the ill, health care professionals have assumed risk\n",
      "a1b6c2b3b808e995697f94d9676d5d5c85180177__4_The profession is legitimated by social contract and therefore its members should be available in times of emergency\n",
      "a1b6c2b3b808e995697f94d9676d5d5c85180177__5_The role of professional codes of ethics\n",
      "a1b6c2b3b808e995697f94d9676d5d5c85180177__6_Have codes of ethics always been silent on the duty to care?\n",
      "a1b6c2b3b808e995697f94d9676d5d5c85180177__7_How strongly formulated should the duty to care be?\n",
      "a1b6c2b3b808e995697f94d9676d5d5c85180177__8_What next?\n",
      "a1b6c2b3b808e995697f94d9676d5d5c85180177__9_Summary\n",
      "6d53690848c0b900e6d766993d9fefd2c4c27c48__0_INTRODUCTION\n",
      "6d53690848c0b900e6d766993d9fefd2c4c27c48__1_TOOL\n",
      "6d53690848c0b900e6d766993d9fefd2c4c27c48__2_Web server integration\n",
      "6d53690848c0b900e6d766993d9fefd2c4c27c48__3_RESULTS FROM AN APPLICATION EXAMPLE\n",
      "6d53690848c0b900e6d766993d9fefd2c4c27c48__4_CHARACTERIZATION OF THE RECOGNIZED CLASS OF PSEUDOKNOTS\n",
      "6d53690848c0b900e6d766993d9fefd2c4c27c48__5_IMPLEMENTATION\n",
      "6d53690848c0b900e6d766993d9fefd2c4c27c48__6_AVAILABILITY\n",
      "46b1c079eb01c8c21fa6c83160d97b64c1f04d50__0_INTRODUCTION\n",
      "46b1c079eb01c8c21fa6c83160d97b64c1f04d50__1_General\n",
      "46b1c079eb01c8c21fa6c83160d97b64c1f04d50__2_Delivery room\n",
      "46b1c079eb01c8c21fa6c83160d97b64c1f04d50__3_Neonatal unit\n",
      "46b1c079eb01c8c21fa6c83160d97b64c1f04d50__4_Other actions\n",
      "46b1c079eb01c8c21fa6c83160d97b64c1f04d50__5_CONCLUSIONS\n",
      "b5c6a1c48730f12db7c74e51ca05a54fb4a9d202__0_Introduction\n",
      "b5c6a1c48730f12db7c74e51ca05a54fb4a9d202__1_The overseas French territories experience\n",
      "b5c6a1c48730f12db7c74e51ca05a54fb4a9d202__2_The determinants of vulnerability to arbovirus infection\n",
      "b5c6a1c48730f12db7c74e51ca05a54fb4a9d202__3_Arboviral outbreaks: a general framework for EID\n",
      "b5c6a1c48730f12db7c74e51ca05a54fb4a9d202__4_Some lessons for future large-scale infectious disease outbreaks\n",
      "b5c6a1c48730f12db7c74e51ca05a54fb4a9d202__5_Proposed outbreak management strategies\n",
      "c35904249e0946d3e4f2dc0369ffa4274c603478__0_\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__0_\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__1_Respiratory Distress Syndrome and Bronchopulmonary Dysplasia\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__2_Acute Lung Injury and Ventilator-Associated Trauma\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__3_Born Alive or Dead\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__4_Sudden Unexpected Death in Infancy and Sudden Infant Death Syndrome\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__5_Pulmonary Infections\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__6_and 3.5).\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__7_Respiratory Infection Outbreaks\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__8_Interpretation of Suspected Aspiration\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__9_Cancer and Its Physiological Derangements\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__10_Pulmonary Thromboembolism\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__11_Pulmonary Hypertension\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__12_Emphysema and Asthma\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__13_Interstitial Lung Disease\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__14_Contribution of Pulmonary Disease to Systemic Disease Processes\n",
      "407284d8852ff557edc0dc4e838026a033f8ee17__15_Conclusions\n",
      "03fa4232b3fbc44b6029d52c3120f4e82fdc49c0__0_Background\n",
      "03fa4232b3fbc44b6029d52c3120f4e82fdc49c0__1_Results and discussion\n",
      "03fa4232b3fbc44b6029d52c3120f4e82fdc49c0__2_Molecular dynamic simulation of OC43 and 16R\n",
      "03fa4232b3fbc44b6029d52c3120f4e82fdc49c0__3_Conclusion\n",
      "03fa4232b3fbc44b6029d52c3120f4e82fdc49c0__4_Homology modelling of the OC43 3CL pro\n",
      "03fa4232b3fbc44b6029d52c3120f4e82fdc49c0__5_Molecular dynamic simulation of the 3CL pro -16R complex\n",
      "668c0f3335c42682e4c38f0647ab4a90ac2cbd70__0_\n",
      "668c0f3335c42682e4c38f0647ab4a90ac2cbd70__1_Etiology\n",
      "668c0f3335c42682e4c38f0647ab4a90ac2cbd70__2_Early illness\n",
      "668c0f3335c42682e4c38f0647ab4a90ac2cbd70__3_Mild-to-moderate respiratory illness\n",
      "668c0f3335c42682e4c38f0647ab4a90ac2cbd70__4_Severe respiratory illness\n",
      "668c0f3335c42682e4c38f0647ab4a90ac2cbd70__5_Possible exposure to SARS-CoV\n",
      "668c0f3335c42682e4c38f0647ab4a90ac2cbd70__6_Likely exposure to SARS-CoV\n",
      "668c0f3335c42682e4c38f0647ab4a90ac2cbd70__7_General criteria\n",
      "668c0f3335c42682e4c38f0647ab4a90ac2cbd70__8_SARS-CoV disease\n",
      "668c0f3335c42682e4c38f0647ab4a90ac2cbd70__9_Hong Kong pulmonologists that ribavirin alone is not indicated as antiviral therapy against SARS-CoV.\n",
      "668c0f3335c42682e4c38f0647ab4a90ac2cbd70__10_Prevention\n",
      "37a1d1104cd2eda84fe96a314ddf5a4ff5d94275__0_\n",
      "37a1d1104cd2eda84fe96a314ddf5a4ff5d94275__1_Introduction\n",
      "37a1d1104cd2eda84fe96a314ddf5a4ff5d94275__2_Estimation of sample size\n",
      "37a1d1104cd2eda84fe96a314ddf5a4ff5d94275__3_Farms\n",
      "37a1d1104cd2eda84fe96a314ddf5a4ff5d94275__4_Sampling\n",
      "37a1d1104cd2eda84fe96a314ddf5a4ff5d94275__5_Testing of fecal samples\n",
      "37a1d1104cd2eda84fe96a314ddf5a4ff5d94275__6_Questionnaires\n",
      "37a1d1104cd2eda84fe96a314ddf5a4ff5d94275__7_Statistical analysis\n",
      "37a1d1104cd2eda84fe96a314ddf5a4ff5d94275__8_Prevalence of C. parvum\n",
      "37a1d1104cd2eda84fe96a314ddf5a4ff5d94275__9_Passive maternal antibody transfer\n",
      "37a1d1104cd2eda84fe96a314ddf5a4ff5d94275__10_Univariable (unconditional) analysis\n",
      "37a1d1104cd2eda84fe96a314ddf5a4ff5d94275__11_Multivariable (conditional) analysis\n",
      "37a1d1104cd2eda84fe96a314ddf5a4ff5d94275__12_Discussion\n",
      "37a1d1104cd2eda84fe96a314ddf5a4ff5d94275__13_Conclusion\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__0_Preparedness Lessons from Modern Disasters and Wars\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__1_EVENT: CHERNOBYL NUCLEAR DISASTER Summary\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__2_Relevance to Today and Clinical Teaching Points\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__3_Lessons for Critical Care\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__4_EVENT: BHOPAL DISASTER Summary\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__5_EVENT: OKLAHOMA CITY BOMBING Summary\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__6_EVENT: SEPTEMBER 11, 2001 Summary\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__7_Relevance to Today and Clinical Teaching Points Preparedness\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__8_Lateral thinking\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__9_Logistical problems\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__10_EVENT: OUTBREAK OF SEVERE ACUTE RESPIRATORY SYNDROME Summary\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__11_EVENT: HURRICANE KATRINA Summary\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__12_Field hospitals\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__13_Staffing issues\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__14_EVENT: OPERATION IRAQI FREEDOM AND OPERATION ENDURING FREEDOM Summary\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__15_Dara & Farmer\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__16_Preparedness Lessons from Modern Disasters\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__17_SUMMARY\n",
      "3277cfef9b0d5fa59863173798af2b4d8aaa0bab__18_A burgeoning number of non-hospitalized individuals with chronic critical illness.\n",
      "c2489ba99a4247b52130bcce78ee3669a67c21c4__0_Introduction\n",
      "c2489ba99a4247b52130bcce78ee3669a67c21c4__1_Method procedure\n",
      "c2489ba99a4247b52130bcce78ee3669a67c21c4__2_Case setup\n",
      "c2489ba99a4247b52130bcce78ee3669a67c21c4__3_Validation procedure\n",
      "c2489ba99a4247b52130bcce78ee3669a67c21c4__4_Numerical method\n",
      "c2489ba99a4247b52130bcce78ee3669a67c21c4__5_Source localization using the improved PSO-based method\n",
      "c2489ba99a4247b52130bcce78ee3669a67c21c4__6_Comparison of the improved method and previous methods\n",
      "c2489ba99a4247b52130bcce78ee3669a67c21c4__7_Conclusions\n",
      "faa7376827b940434c797c4559223d4002c0683f__0_Introduction\n",
      "faa7376827b940434c797c4559223d4002c0683f__1_Key morphological alterations are determined by caspase substrate cleavage\n",
      "faa7376827b940434c797c4559223d4002c0683f__2_Caspase substrates in signal transduction\n",
      "faa7376827b940434c797c4559223d4002c0683f__3_Some peculiarities of substrate cleavage\n",
      "faa7376827b940434c797c4559223d4002c0683f__4_Substrate cleavage at the balance between necrosis and apoptosis\n",
      "faa7376827b940434c797c4559223d4002c0683f__5_Role of caspase substrates in disease progression\n",
      "faa7376827b940434c797c4559223d4002c0683f__6_Limited substrate cleavage in terminal differentiation and hematopoiesis\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__0_INTRODUCTION\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__1_MAGNITUDE OF THE PROBLEM\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__2_HEALTHCARE COSTS RELATED TO MULTIDRUG-RESISTANT ORGANISMS\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__3_CONSUMPTION OF ANTIMICROBIALS IN ANIMALS AND HUMANS\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__4_ANTIMICROBIAL RESIDUES AND RESISTANCE GENES IN SEWAGE AND FOOD\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__5_CONTROL OF ANTIBIOTIC RESISTANCE ON FARMS\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__6_CONTROL OF ANTIMICROBIALS IN EFFLUENTS OF WASTEWATER OR SEWAGE TREATMENT PLANTS\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__7_CONTROL OF ANTIBIOTIC RESISTANCE IN THE COMMUNITY: CONTROL OF OUTPATIENT USE OF ANTIMICROBIALS\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__8_CONTROL OF ANTIBIOTIC RESISTANCE IN THE COMMUNITY: THE RELEVANCE OF FOOD HYGIENE\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__9_Control of antibiotic resistance in farms and animals\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__10_Control of resistant bacteria in wastewater\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__11_Control of antibiotic resistance in the community\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__12_Control of antibiotic resistance in hospital or healthcare institutions\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__13_Administrative and government support\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__14_CONTROL OF ANTIBIOTIC RESISTANCE IN HOSPITALS OR HEALTHCARE INSTITUTIONS: PROACTIVE SCREENING, INFECTION CONTROL AND PATIENT SELF-PROTECTION\n",
      "3be2b917c48e3dc25a4e6bb3028fd5d32e4f2d9d__15_CONCLUDING REMARKS\n",
      "26401aab640b61b28b31696b3540662e5e1428d8__0_Background\n",
      "26401aab640b61b28b31696b3540662e5e1428d8__1_Zika surveillance data\n",
      "26401aab640b61b28b31696b3540662e5e1428d8__2_Testing of travellers\n",
      "26401aab640b61b28b31696b3540662e5e1428d8__3_Statistical analysis\n",
      "26401aab640b61b28b31696b3540662e5e1428d8__4_Sensitivity analysis\n",
      "26401aab640b61b28b31696b3540662e5e1428d8__5_Zika surveillance and test result data\n",
      "26401aab640b61b28b31696b3540662e5e1428d8__6_Estimation of R 0\n",
      "26401aab640b61b28b31696b3540662e5e1428d8__7_Receiver operating characteristic analysis\n",
      "26401aab640b61b28b31696b3540662e5e1428d8__8_Logistic regression analysis\n",
      "26401aab640b61b28b31696b3540662e5e1428d8__9_Discussion\n",
      "26401aab640b61b28b31696b3540662e5e1428d8__10_Conclusions\n",
      "ad59ccca1b78455532759a24f42526bc15dd68dd__0_\n",
      "ad59ccca1b78455532759a24f42526bc15dd68dd__1_RESULTS AND DISCUSSION\n",
      "ad59ccca1b78455532759a24f42526bc15dd68dd__2_Maintenance of PD-1 expression by brain T RM cells is antigen and inflammation independent\n",
      "ad59ccca1b78455532759a24f42526bc15dd68dd__3_PD-1 on brain CD8 TRM cells is antigen independent\n",
      "ad59ccca1b78455532759a24f42526bc15dd68dd__4_Mice and viruses\n",
      "ad59ccca1b78455532759a24f42526bc15dd68dd__5_Adoptive cell transfer\n",
      "ad59ccca1b78455532759a24f42526bc15dd68dd__6_Quantitation of MuPyV genomes\n",
      "ad59ccca1b78455532759a24f42526bc15dd68dd__7_Epigenetic analysis of PD-1 promoter\n",
      "82ef5d93dc7dd6b35e8411969e33633b402e5acc__0_Introduction\n",
      "82ef5d93dc7dd6b35e8411969e33633b402e5acc__1_Author Summary\n",
      "82ef5d93dc7dd6b35e8411969e33633b402e5acc__2_SARS-Coronavirus Infection Induces Multiple Distinct Membrane Alterations\n",
      "82ef5d93dc7dd6b35e8411969e33633b402e5acc__3_Electron Tomography Reveals a Reticulovesicular Network of Modified ER Membranes in SARS-CoV-Infected Cells\n",
      "82ef5d93dc7dd6b35e8411969e33633b402e5acc__4_SARS-CoV Replicase Subunits Localize Predominantly to Convoluted Membranes\n",
      "82ef5d93dc7dd6b35e8411969e33633b402e5acc__5_The Interior of Coronavirus-Induced DMVs Labels Abundantly for Double-Stranded RNA\n",
      "82ef5d93dc7dd6b35e8411969e33633b402e5acc__6_Hijacking Cellular Membranes to Facilitate Coronavirus RNA Synthesis\n",
      "82ef5d93dc7dd6b35e8411969e33633b402e5acc__7_The Enigma of the Double Membrane\n",
      "82ef5d93dc7dd6b35e8411969e33633b402e5acc__8_Comparison with Other þRNA Virus Replication Complexes\n",
      "82ef5d93dc7dd6b35e8411969e33633b402e5acc__9_Pinpointing the Active Site of SARS-CoV RNA Synthesis\n",
      "82ef5d93dc7dd6b35e8411969e33633b402e5acc__10_Materials and Methods\n",
      "82ef5d93dc7dd6b35e8411969e33633b402e5acc__11_Supporting Information\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__0_Introduction\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__1_Survey instrument\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__2_Recruitment process\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__3_Interviews and analysis\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__4_Subject characteristics\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__5_Description of implementations\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__6_Data storage.\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__7_Cross maps.\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__8_User acceptance.\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__9_Maintenance\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__10_Challenges\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__11_SNOMED CT quality challenges\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__12_Content Coverage.\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__13_Hierarchical relationships.\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__14_Syntactic consistency.\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__15_Implementation challenges\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__16_Post-coordination.\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__17_Subsets.\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__18_Other challenges\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__19_Change resistance.\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__20_Coding granularity.\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__21_3.3.3.3.\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__22_Success factors\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__23_Simplicity\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__24_Clinician involvement\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__25_Expertise and collaboration\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__26_Demonstrate value\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__27_Training\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__28_Benefits of using SNOMED CT\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__29_Direct data entry\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__30_Data reuse\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__31_Content coverage and subset development\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__32_Legibility\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__33_Discussion\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__34_Towards a successful SNOMED CT implementation\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__35_Understand process of SNOMED CT implementation\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__36_Encode local terms to SNOMED CT\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__37_Create extensions\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__38_Compile subsets\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__39_Design intuitive data entry interfaces\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__40_Select a data storage method\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__41_Incorporate cross maps\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__42_Design retrieval functions\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__43_Conduct training sessions\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__44_Develop maintenance policies\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__45_Incremental value of SNOMED CT\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__46_Outstanding issues\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__47_Post-coordination\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__48_Retrieval\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__49_Extensions\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__50_Limitations\n",
      "5e87d99a155e3a0d518695c7806b8e2c1409e207__51_Conclusion\n",
      "0c0d04ca73a9fb6e792fb8e75a7bfd015a9a5d3f__0_Introduction\n",
      "0c0d04ca73a9fb6e792fb8e75a7bfd015a9a5d3f__1_Ethics statement\n",
      "0c0d04ca73a9fb6e792fb8e75a7bfd015a9a5d3f__2_Patients and samples\n",
      "0c0d04ca73a9fb6e792fb8e75a7bfd015a9a5d3f__3_Real-time transcription-PCR (RT-PCR) assay\n",
      "0c0d04ca73a9fb6e792fb8e75a7bfd015a9a5d3f__4_Statistical analysis\n",
      "0c0d04ca73a9fb6e792fb8e75a7bfd015a9a5d3f__5_A(H1N1)pdm09 affects the infection rate of other respiratory viruses\n",
      "0c0d04ca73a9fb6e792fb8e75a7bfd015a9a5d3f__6_The A(H1N1)pdm09 effect on the time of infection with other respiratory viruses\n",
      "0c0d04ca73a9fb6e792fb8e75a7bfd015a9a5d3f__7_(\n",
      "0c0d04ca73a9fb6e792fb8e75a7bfd015a9a5d3f__8_Reduced percentages of co-infections following the emergence of the A(H1N1)pdm09 virus\n",
      "cfd6f06653c31766de27f2b499d1557c82ba1733__0_\n",
      "dfcfeb3b2cf021f0d420b8070ff6d81f05c1cb5f__0_\n",
      "44108a4ae274f5b1b2e29d6f1254be02dd5bd447__0_\n",
      "44108a4ae274f5b1b2e29d6f1254be02dd5bd447__1_RESULTS\n",
      "44108a4ae274f5b1b2e29d6f1254be02dd5bd447__2_AAV particles remain intact upon cathepsin cleavage\n",
      "44108a4ae274f5b1b2e29d6f1254be02dd5bd447__3_DISCUSSION\n",
      "44108a4ae274f5b1b2e29d6f1254be02dd5bd447__4_MATERIALS AND METHODS\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__0_\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__1_Cancer detection and prevalence\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__2_transmissible allograft cancers\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__3_Box 1 | Cancer in captive animals\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__4_Virus-associated tumorigenesis\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__5_Allee effect\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__6_Benthic\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__7_Cetacean\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__8_Cholangioma\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__9_Chromatophoroma\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__10_Mirex\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__11_Pinniped\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__12_Population dynamics\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__13_Sirenian\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__14_environmental effects\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__15_Box 2 | Great Lakes areas of concern\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__16_Nature Reviews | Cancer\n",
      "e04b4e9ed223d40c84e41bb11ddc75b567715f21__17_Conclusion and future directions\n",
      "6dbefdd969e40d443f1728dbf6be0010c4babd4c__0_Introduction\n",
      "6dbefdd969e40d443f1728dbf6be0010c4babd4c__1_Virus strains and clinical specimens\n",
      "6dbefdd969e40d443f1728dbf6be0010c4babd4c__2_Nucleic acid extractions\n",
      "6dbefdd969e40d443f1728dbf6be0010c4babd4c__3_cDNA reaction\n",
      "6dbefdd969e40d443f1728dbf6be0010c4babd4c__4_Polymerase chain reaction\n",
      "6dbefdd969e40d443f1728dbf6be0010c4babd4c__5_Analysis of the ampliJied products\n",
      "6dbefdd969e40d443f1728dbf6be0010c4babd4c__6_Plaque assay\n",
      "6dbefdd969e40d443f1728dbf6be0010c4babd4c__7_Selection of the primers\n",
      "6dbefdd969e40d443f1728dbf6be0010c4babd4c__8_Specljiicity of the primers\n",
      "6dbefdd969e40d443f1728dbf6be0010c4babd4c__9_Sensitivity\n",
      "6dbefdd969e40d443f1728dbf6be0010c4babd4c__10_Candida albicans\n",
      "6dbefdd969e40d443f1728dbf6be0010c4babd4c__11_Clinical specimens\n",
      "6dbefdd969e40d443f1728dbf6be0010c4babd4c__12_Discussion\n",
      "4f287b8d2ba695f4e37333729d138813b2095cb8__0_\n",
      "4f287b8d2ba695f4e37333729d138813b2095cb8__1_PATIENTS AND METHODS\n",
      "4f287b8d2ba695f4e37333729d138813b2095cb8__2_On\n",
      "4f287b8d2ba695f4e37333729d138813b2095cb8__3_DISCUSSION\n",
      "4f287b8d2ba695f4e37333729d138813b2095cb8__4_CONCLUSIONS\n",
      "dec004e1d86c83df7737395a72b77a7551042782__0_\n",
      "dec004e1d86c83df7737395a72b77a7551042782__1_INTRODUCTION\n",
      "dec004e1d86c83df7737395a72b77a7551042782__2_Subjects\n",
      "dec004e1d86c83df7737395a72b77a7551042782__3_Apparatus\n",
      "dec004e1d86c83df7737395a72b77a7551042782__4_Procedure\n",
      "dec004e1d86c83df7737395a72b77a7551042782__5_Analyses\n",
      "dec004e1d86c83df7737395a72b77a7551042782__6_RESULTS\n",
      "dec004e1d86c83df7737395a72b77a7551042782__7_Discomfort\n",
      "dec004e1d86c83df7737395a72b77a7551042782__8_Exertion\n",
      "dec004e1d86c83df7737395a72b77a7551042782__9_DISCUSSION\n",
      "ccfde92cc14959cab65169629c83390d9b9c7794__0_\n",
      "ccfde92cc14959cab65169629c83390d9b9c7794__1_Background\n",
      "ccfde92cc14959cab65169629c83390d9b9c7794__2_Human Medicine in Developed\n",
      "ccfde92cc14959cab65169629c83390d9b9c7794__3_APUA Recommendations\n",
      "ccfde92cc14959cab65169629c83390d9b9c7794__4_Reduce Prescription of Antibacterials for Nonbacterial Infections\n",
      "ccfde92cc14959cab65169629c83390d9b9c7794__5_Encourage Patient Compliance\n",
      "ccfde92cc14959cab65169629c83390d9b9c7794__6_communication between doctor and patient must be\n",
      "ccfde92cc14959cab65169629c83390d9b9c7794__7_Tuberculosis\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__0_\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__1_evOLUTiON OF TYPe iii iFN GeNeS\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__2_exPReSSiON iFN LamBda GeNeS dURiNG viRaL iNFeCTiON\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__3_iFN LamBda ReCePTOR exPReSSiON aNd SiGNaLiNG\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__4_GeNeTiC aSSOCiaTiON OF iFN LamBda LOCUS TO viRaL SUSCePTiBiLiTY\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__5_iFNλ immUNe mOdULaTORY eFFeCTS\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__6_effects of iFN on innate immune Cells\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__7_IFN in Monocytic Cell Populations\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__8_IFN in Neutrophils\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__9_effects of iFNs on adaptive immune Cells\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__10_IFN in T Cells\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__11_ROLe OF TYPe iii iFNs aT THe BBB\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__12_OUTSTaNdiNG QUeSTiONS\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__13_aUTHOR CONTRiBUTiONS\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__14_aCKNOwLedGmeNTS\n",
      "c93e251c48b43dfc3e162039968b8ce59810c410__15_FUNdiNG\n",
      "08e6541bee1b67eab1918bcbbe6f90463ecb651a__0_Introduction\n",
      "08e6541bee1b67eab1918bcbbe6f90463ecb651a__1_Materials and Methods\n",
      "08e6541bee1b67eab1918bcbbe6f90463ecb651a__2_Results\n",
      "08e6541bee1b67eab1918bcbbe6f90463ecb651a__3_Discussion\n",
      "8b799357f515d7b477d54e3cccff7a9caf4bcb88__0_\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__0_Introduction\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__1_Scope of the Problem: Epidemiology\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__2_Risk Factors Associated with Acute Illness in Athletes\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__3_Immune System Changes\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__4_A History of a Recent Acute Illness\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__5_Female Gender\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__6_Body Mass Index\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__7_Training Load\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__8_Nutritional Factors\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__9_Other Extrinsic Risk Factors\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__10_Fever\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__11_Heat Stroke\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__12_Fact Box 2 Complications of fever during exercise\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__13_Reasons for Not Exercising During Infections\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__14_General Recommendations\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__15_Upper Respiratory Tract (URT) Infection\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__16_Fact Box 4 Medical complications and risks associated with exercise training in athletes with an acute URT illness\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__17_The Clinical Neck Check\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__18_Infective Mononucleosis (IM)\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__19_Dermatological Infections\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__20_Gastrointestinal Infections\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__21_General Recommendations to Prevent Acute Infective Illness in Team Sports\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__22_Individual Precautions\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__23_The Role of the Medical Staff\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__24_Management of Combined Stress and Load on the Athlete\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__25_Nutritional Strategies\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__26_Vitamin C\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__27_Vitamin D\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__28_Glutamine\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__29_Cystine and Theanine\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__30_Carbohydrate Ingestion During Exercise\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__31_Probiotics\n",
      "3d330660227097892df55473548d5ec4aa4f2af0__32_Take-Home Message\n",
      "4d24eb08456d9723ba8c90fdf6dc75f5fdfeb4a9__0_Introduction\n",
      "4d24eb08456d9723ba8c90fdf6dc75f5fdfeb4a9__1_DNA techniques and protein expression\n",
      "4d24eb08456d9723ba8c90fdf6dc75f5fdfeb4a9__2_SDS-PAGE and immunoblotting\n",
      "4d24eb08456d9723ba8c90fdf6dc75f5fdfeb4a9__3_Dog serum samples\n",
      "4d24eb08456d9723ba8c90fdf6dc75f5fdfeb4a9__4_Virus neutralization (VN) test\n",
      "4d24eb08456d9723ba8c90fdf6dc75f5fdfeb4a9__5_Western blotting\n",
      "4d24eb08456d9723ba8c90fdf6dc75f5fdfeb4a9__6_ELISA\n",
      "4d24eb08456d9723ba8c90fdf6dc75f5fdfeb4a9__7_Results\n",
      "4d24eb08456d9723ba8c90fdf6dc75f5fdfeb4a9__8_Discussion\n",
      "8ac9fa119b1818e217ab8c1f5b20b0d6a32c74ef__0_\n",
      "8ac9fa119b1818e217ab8c1f5b20b0d6a32c74ef__1_Conclusions\n",
      "8ac9fa119b1818e217ab8c1f5b20b0d6a32c74ef__2_Introduction\n",
      "8ac9fa119b1818e217ab8c1f5b20b0d6a32c74ef__3_Study Design and Participants\n",
      "8ac9fa119b1818e217ab8c1f5b20b0d6a32c74ef__4_Laboratory detection for 2019-nCoV\n",
      "8ac9fa119b1818e217ab8c1f5b20b0d6a32c74ef__5_Data Collection\n",
      "8ac9fa119b1818e217ab8c1f5b20b0d6a32c74ef__6_Statistical Analysis\n",
      "8ac9fa119b1818e217ab8c1f5b20b0d6a32c74ef__7_Characteristics of the Patients\n",
      "8ac9fa119b1818e217ab8c1f5b20b0d6a32c74ef__8_Laboratory Tests Findings and Treatments\n",
      "8ac9fa119b1818e217ab8c1f5b20b0d6a32c74ef__9_Chest CT Images Findings\n",
      "8ac9fa119b1818e217ab8c1f5b20b0d6a32c74ef__10_Discussion\n",
      "8ac9fa119b1818e217ab8c1f5b20b0d6a32c74ef__11_Conclusion\n",
      "8ac9fa119b1818e217ab8c1f5b20b0d6a32c74ef__12_Acknowledgments\n",
      "bbf371f5de8f2df497567a0785a367dba3cf03ba__0_Immunodeficiencies Caused by Infectious Diseases\n",
      "bbf371f5de8f2df497567a0785a367dba3cf03ba__1_VIRAL INFECTIONS CAUSING IMMUNODEFICIENCY Canine Distemper Virus Infection\n",
      "bbf371f5de8f2df497567a0785a367dba3cf03ba__2_Canine Parvovirus 2 and Feline Panleukopenia Virus Infection\n",
      "bbf371f5de8f2df497567a0785a367dba3cf03ba__3_Feline Retroviral Infections\n",
      "bbf371f5de8f2df497567a0785a367dba3cf03ba__4_Feline Leukemia Virus Infection\n",
      "bbf371f5de8f2df497567a0785a367dba3cf03ba__5_Feline Immunodeficiency Virus Infection\n",
      "bbf371f5de8f2df497567a0785a367dba3cf03ba__6_BACTERIAL INFECTIONS CAUSING IMMUNODEFICIENCY\n",
      "bbf371f5de8f2df497567a0785a367dba3cf03ba__7_Ehrlichia canis Infection\n",
      "bbf371f5de8f2df497567a0785a367dba3cf03ba__8_Anaplasma Phagocytophilum Infection\n",
      "bbf371f5de8f2df497567a0785a367dba3cf03ba__9_IMMUNOSUPPRESSION CAUSED BY PROTOZOAL AND FUNGAL PATHOGENS\n",
      "bbf371f5de8f2df497567a0785a367dba3cf03ba__10_SUMMARY\n",
      "9a2277d3ce4877659db6f64c3f15924368a21c04__0_\n",
      "9a2277d3ce4877659db6f64c3f15924368a21c04__1_I. INTRODUCTION\n",
      "9a2277d3ce4877659db6f64c3f15924368a21c04__2_II. MODEL\n",
      "9a2277d3ce4877659db6f64c3f15924368a21c04__3_III. THEORY\n",
      "9a2277d3ce4877659db6f64c3f15924368a21c04__4_052311-3\n",
      "9a2277d3ce4877659db6f64c3f15924368a21c04__5_A. Erdös-Rényi (ER) networks\n",
      "9a2277d3ce4877659db6f64c3f15924368a21c04__6_B. Contagion dynamics on empirical networks\n",
      "9a2277d3ce4877659db6f64c3f15924368a21c04__7_V. DISCUSSION\n",
      "6c7fbe981c99b11e6348d769095014a83cad7daa__0_\n",
      "6c7fbe981c99b11e6348d769095014a83cad7daa__1_Untersuchungen iiber die bronchokonstriktorische Wirkung des fi-Itezeptorblockers\n",
      "fa3f346b887c9fca11cce619060cf37b15e6f618__0_Introduction\n",
      "fa3f346b887c9fca11cce619060cf37b15e6f618__1_Expression of capsid protein VP2 in Sf9 cells\n",
      "fa3f346b887c9fca11cce619060cf37b15e6f618__2_SDS-PAGE and immunoblot\n",
      "fa3f346b887c9fca11cce619060cf37b15e6f618__3_Purification of VLPs\n",
      "fa3f346b887c9fca11cce619060cf37b15e6f618__4_Observation of VLPs by electron microscope\n",
      "fa3f346b887c9fca11cce619060cf37b15e6f618__5_Establishment of ELISA for detection of HBoV IgG\n",
      "fa3f346b887c9fca11cce619060cf37b15e6f618__6_Antibody detection of other agents that can cause acute respiratory infection\n",
      "fa3f346b887c9fca11cce619060cf37b15e6f618__7_Quantitative PCR detection of HBoV genome in nasopharyngeal aspirate samples\n",
      "fa3f346b887c9fca11cce619060cf37b15e6f618__8_Hemagglutination assay\n",
      "fa3f346b887c9fca11cce619060cf37b15e6f618__9_Clinical samples\n",
      "fa3f346b887c9fca11cce619060cf37b15e6f618__10_Expression of HBoV VP2 ORF in Sf9 cells and assembly of VLPs\n",
      "fa3f346b887c9fca11cce619060cf37b15e6f618__11_Establishment of an ELISA for detection of HBoV IgG antibody\n",
      "fa3f346b887c9fca11cce619060cf37b15e6f618__12_Detection of HBoV IgG in serum samples by the HBoV VLPs-ELISA\n",
      "fa3f346b887c9fca11cce619060cf37b15e6f618__13_Discussion\n",
      "53889c98bb5e342ae879f4e67c3b4c6368389716__0_Introduction\n",
      "53889c98bb5e342ae879f4e67c3b4c6368389716__1_Solid-Phase Synthesis of Cyclohexapeptides Using Solution-Phase Cyclization\n",
      "53889c98bb5e342ae879f4e67c3b4c6368389716__2_31-34\n",
      "53889c98bb5e342ae879f4e67c3b4c6368389716__3_Solid-Phase Cyclohexapeptide Synthesis Using On-Resin Cyclization\n",
      "53889c98bb5e342ae879f4e67c3b4c6368389716__4_Conclusions\n",
      "53889c98bb5e342ae879f4e67c3b4c6368389716__5_Conflicts of Interest:\n",
      "53889c98bb5e342ae879f4e67c3b4c6368389716__6_Abbreviations\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__0_\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__1_Wasserimmersionszeit bei Ertrinken\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__2_Strafgesetzbuch (StGB) -Allgemeiner Teil\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__3_Kriminalstatistik und ihre Kritik\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__4_! Wichtig\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__5_Operative Fallanalyse (OFA)\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__6_Zusammenhangstrennung durch Zugspannungseinwirkung\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__7_Definition\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__8_Allgemeine Traumatologie\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__9_Tangentiale Einwirkungen führen zur\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__10_Todesursachen\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__11_Spezielle Traumatologie: Kopf\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__12_Spezielle Traumatologie: Gesicht\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__13_Spezielle Traumatologie: Hals\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__14_Spezielle Traumatologie: Rumpf\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__15_3.33a, b). ä Fallbeispiel\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__16_Kriminalistik\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__17_Schnittverletzungen\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__18_132\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__19_Flintenmunition\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__20_Tödliche Schussverletzungen\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__21_Handlungsfähigkeit\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__22_Stopping power\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__23_Geschossembolie\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__24_Spätfolgen\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__25_Weitere (fakultative) Einschusszeichen\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__26_Ausschuss\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__27_Die\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__28_· Gewaltsame Erstickung\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__29_Forensisch wichtige Erstickungsformen\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__30_Leichenschau und Obduktionsbefunde\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__31_Tod beim Tauchen\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__32_Nichtertrinkungsbedingter, nichtnatürlicher Tod im Wasser\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__33_Besonderheiten von Wasserleichen\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__34_Rechtsmedizinisch relevante Ereignisse mit Brandschäden.\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__35_Flächenausdehnung der Verbrennung\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__36_Vitale Zeichen und Reaktionen\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__37_Lokale Kältewirkung (Erfrierung)\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__38_· Thermische Energie\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__39_Einleitung\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__40_Ätiologie des Abortes\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__41_Rechtsgrundlagen\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__42_Epidemiologie\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__43_Die legale Schwangerschaftsunterbrechung\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__44_3.16\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__45_E. Lignitz\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__46_Unterscheidung vitaler und postmortaler Verletzungen\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__47_Konkurrenz und Koinzidenz von Todesursachen Konkurrenz von Todesursachen\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__48_Koinzidenz von Todesursachen\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__49_Priorität von Verletzungen\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__50_Kombinationen unterschiedlicher Gewalteinwirkung\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__51_Handlungsfähigkeit nach Verletzungen\n",
      "438952be25f1e8ab1711da2ab8f400cfbe3bea8f__52_Verletzungslokalisationen und äußere Befundmuster\n",
      "5ae8a3abce0fb0647d9f164f9ad1716abfb6dd61__0_INTRODUCTION\n",
      "5ae8a3abce0fb0647d9f164f9ad1716abfb6dd61__1_Dogs\n",
      "5ae8a3abce0fb0647d9f164f9ad1716abfb6dd61__2_Marrow Grafts\n",
      "5ae8a3abce0fb0647d9f164f9ad1716abfb6dd61__3_Chimerism Analysis\n",
      "5ae8a3abce0fb0647d9f164f9ad1716abfb6dd61__4_Kidney Transplantation\n",
      "5ae8a3abce0fb0647d9f164f9ad1716abfb6dd61__5_Donor Sensitization and Donor Lymphocyte Infusion (DLI)\n",
      "5ae8a3abce0fb0647d9f164f9ad1716abfb6dd61__6_RESULTS\n",
      "5ae8a3abce0fb0647d9f164f9ad1716abfb6dd61__7_Effect of DLI on Kidney Allografts and Native Trichimeric Kidneys\n",
      "5ae8a3abce0fb0647d9f164f9ad1716abfb6dd61__8_Chimerism\n",
      "5ae8a3abce0fb0647d9f164f9ad1716abfb6dd61__9_GVHD after DLI\n",
      "5ae8a3abce0fb0647d9f164f9ad1716abfb6dd61__10_DISCUSSION\n",
      "d377f33b063b05d9ccac80895475df06e66de8c8__0_\n",
      "d377f33b063b05d9ccac80895475df06e66de8c8__1_Introduction\n",
      "d377f33b063b05d9ccac80895475df06e66de8c8__2_Study design\n",
      "d377f33b063b05d9ccac80895475df06e66de8c8__3_Study population and data collection\n",
      "d377f33b063b05d9ccac80895475df06e66de8c8__4_Laboratory data\n",
      "d377f33b063b05d9ccac80895475df06e66de8c8__5_Statistical analysis\n",
      "d377f33b063b05d9ccac80895475df06e66de8c8__6_Ethics\n",
      "d377f33b063b05d9ccac80895475df06e66de8c8__7_Characteristics of the patients with ILI, and virus distribution\n",
      "d377f33b063b05d9ccac80895475df06e66de8c8__8_Characteristics and outcome of RSV-positive patients\n",
      "d377f33b063b05d9ccac80895475df06e66de8c8__9_RSV-positive patients versus RSV-negative patients and influenza virus-positive patients\n",
      "d377f33b063b05d9ccac80895475df06e66de8c8__10_Discussion\n",
      "d377f33b063b05d9ccac80895475df06e66de8c8__11_Transparency declaration\n",
      "d377f33b063b05d9ccac80895475df06e66de8c8__12_Funding\n",
      "98611d45908963bef1777c46d5d4139096c84504__0_\n",
      "cb4559846cc88a70f82266bfdd80dbac2df8af93__0_Introduction\n",
      "cb4559846cc88a70f82266bfdd80dbac2df8af93__1_ILI definitions\n",
      "cb4559846cc88a70f82266bfdd80dbac2df8af93__2_Systematic reviews of influenza and ILI\n",
      "cb4559846cc88a70f82266bfdd80dbac2df8af93__3_Studies of ILI\n",
      "cb4559846cc88a70f82266bfdd80dbac2df8af93__4_Studies which did not use CDC or WHO ILI definitions 4.4.2.1. Studies which tested for both influenza and other viruses.\n",
      "cb4559846cc88a70f82266bfdd80dbac2df8af93__5_Symptoms assessed in ILI surveys, and ability to discriminate pathogens\n",
      "cb4559846cc88a70f82266bfdd80dbac2df8af93__6_Factors affecting influenza diagnostic test accuracy\n",
      "cb4559846cc88a70f82266bfdd80dbac2df8af93__7_Correlations between ILI community surveys and influenza tracking programmes\n",
      "cb4559846cc88a70f82266bfdd80dbac2df8af93__8_Discussion\n",
      "cb4559846cc88a70f82266bfdd80dbac2df8af93__9_Conclusions\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__0_INTRODUCTION\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__1_Registry\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__2_Steering group\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__3_Stakeholders in the Delphi survey\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__4_Stakeholders in the consensus meeting\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__5_Information Sources\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__6_Consensus Process\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__7_Delphi survey\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__8_Outcome scoring\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__9_Consensus definitions\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__10_Consensus meeting\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__11_Ethics and consent\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__12_RESULTS\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__13_Round 1 of the Delphi survey\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__14_Round 2 of the Delphi survey\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__15_Patients' survey\n",
      "f4636bda5c5ae53ed6c05f5aba349a84cdb862be__16_DISCUSSION\n",
      "d5c3ab7d56a6d04ce4feb57a5dd9d0059abca0a7__0_Background\n",
      "d5c3ab7d56a6d04ce4feb57a5dd9d0059abca0a7__1_Search strategy\n",
      "d5c3ab7d56a6d04ce4feb57a5dd9d0059abca0a7__2_Eligibility criteria\n",
      "d5c3ab7d56a6d04ce4feb57a5dd9d0059abca0a7__3_Data extraction\n",
      "d5c3ab7d56a6d04ce4feb57a5dd9d0059abca0a7__4_Prevalence mapping\n",
      "d5c3ab7d56a6d04ce4feb57a5dd9d0059abca0a7__5_Results\n",
      "d5c3ab7d56a6d04ce4feb57a5dd9d0059abca0a7__6_Discussion\n",
      "d5c3ab7d56a6d04ce4feb57a5dd9d0059abca0a7__7_Conclusion\n",
      "d5c3ab7d56a6d04ce4feb57a5dd9d0059abca0a7__8_Additional file\n",
      "d5c3ab7d56a6d04ce4feb57a5dd9d0059abca0a7__9_Competing interests\n",
      "d5c3ab7d56a6d04ce4feb57a5dd9d0059abca0a7__10_Publisher's Note\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__0_Introduction to Research Methodologies Used in Pharmacy Practice\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__1_Core Quantitative and Qualitative Approaches Used in Pharmacy Practice Research\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__2_Research Question and Selection of Study Design\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__3_Classification of Research Methodologies Used in Pharmacy Practice\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__4_Classification of pharmacoepidemiologic study designs\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__5_Quantitative Research Designs in Pharmacy Practice\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__6_Observational Study Designs\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__7_Case-Control Studies\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__8_Cohort Studies\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__9_Case-Crossover Studies\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__10_Cross-Sectional Studies\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__11_Experimental and Quasi-Experimental Study Designs\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__12_[ ( F i g u r e _ 4 ) T D $ F I G ]\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__13_Other Quantitative Study Designs\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__14_Simulated Client Method\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__15_Discrete Choice Experiments\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__16_Qualitative Research Designs in Pharmacy Practice\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__17_Interpretative Frameworks\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__18_Philosophical Assumptions\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__19_Approaches to Inquiry (Methodology)\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__20_Data Collection and Analysis Methods in Qualitative Research\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__21_Common elements and steps in conducting individual interviews and focus groups\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__22_Quality Perspectives in Qualitative Research\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__23_b. Dependability\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__24_Reflexivity in qualitative research\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__25_Ethical Considerations\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__26_Mixed Methods in Pharmacy Practice Research\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__27_Summary and Take-Home Messages\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__28_Conclusion\n",
      "0cd23874388f6556a8c97e153358ce6e274d3a59__29_Glossary\n",
      "fd8ee38a505cf79732f5ba487e15f11619b84150__0_INTRODUCTION\n",
      "fd8ee38a505cf79732f5ba487e15f11619b84150__1_Methods\n",
      "fd8ee38a505cf79732f5ba487e15f11619b84150__2_Data analysis\n",
      "fd8ee38a505cf79732f5ba487e15f11619b84150__3_Subjects\n",
      "fd8ee38a505cf79732f5ba487e15f11619b84150__4_Demographic characteristics\n",
      "fd8ee38a505cf79732f5ba487e15f11619b84150__5_Temporal characteristics\n",
      "fd8ee38a505cf79732f5ba487e15f11619b84150__6_Risk factor analysis\n",
      "fd8ee38a505cf79732f5ba487e15f11619b84150__7_DISCUSSION\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__0_Introduction\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__1_Field specimens\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__2_Molecular detection of FeMV\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__3_Molecular detection of relevant feline pathogens in cats\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__4_Partial and whole genome sequencing\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__5_Virus isolation\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__6_Phylogeny\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__7_Serological analysis\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__8_Histological examination and immunohistochemistry\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__9_Virus histochemistry\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__10_Prevalence of FeMV is higher in cats from colonies\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__11_Other feline pathogens were detected in qPCR FeMV positive carcasses\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__12_FeMV Sheryl/2018 Italy was isolated on cell culture\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__13_Sequences of this study belongs to FeMV genotype 1\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__14_37 cats were positive for FeMV Abs, mostly middle-aged and old cats\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__15_Association between FeMV and renal lesions and between FeMV and TIN was not evidenced\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__16_FeMV genotype 1 has in vitro tropism for epithelial cells of bronchioles and alveolar macrophages\n",
      "ddbe321178b25ba2cc1f1f9b3a3e87a8724f2380__17_Discussion\n",
      "c54608c457676be2a819a1879a14df08074082d1__0_Human Bocavirus in Febrile Children, the Netherlands\n",
      "871e4ddd35c70372f5277d9da89a82895325883e__0_Introduction\n",
      "871e4ddd35c70372f5277d9da89a82895325883e__1_Electrophoretic buffers.\n",
      "871e4ddd35c70372f5277d9da89a82895325883e__2_All samples are collected in sterile tubes in the clinic and sent\n",
      "871e4ddd35c70372f5277d9da89a82895325883e__3_Isolation of Total RNA\n",
      "871e4ddd35c70372f5277d9da89a82895325883e__4_First-Strand cDNA Synthesis\n",
      "871e4ddd35c70372f5277d9da89a82895325883e__5_Total volume 10 μl\n",
      "871e4ddd35c70372f5277d9da89a82895325883e__6_Pre-mix 2 (for one reaction):\n",
      "871e4ddd35c70372f5277d9da89a82895325883e__7_First Run PCR\n",
      "871e4ddd35c70372f5277d9da89a82895325883e__8_Pre-mix 1 (for one reaction)\n",
      "871e4ddd35c70372f5277d9da89a82895325883e__9_Pre-mix 2 (for one reaction)\n",
      "871e4ddd35c70372f5277d9da89a82895325883e__10_Fig. 2\n",
      "4c457b8394487f135501ce78d1b81bc134828a07__0_\n",
      "0e76160729d01c33942105e505724f59a5db1a44__0_Introduction\n",
      "0e76160729d01c33942105e505724f59a5db1a44__1_Cells and virus\n",
      "0e76160729d01c33942105e505724f59a5db1a44__2_Plasmid construction\n",
      "0e76160729d01c33942105e505724f59a5db1a44__3_Preparation and purification of VLPs\n",
      "0e76160729d01c33942105e505724f59a5db1a44__4_Quantitation of VLP amounts\n",
      "0e76160729d01c33942105e505724f59a5db1a44__5_Western blot analysis\n",
      "0e76160729d01c33942105e505724f59a5db1a44__6_Colloidal Coomassie blue staining\n",
      "0e76160729d01c33942105e505724f59a5db1a44__7_Electron microscopic analysis of chimeric VLP\n",
      "0e76160729d01c33942105e505724f59a5db1a44__8_Animals\n",
      "0e76160729d01c33942105e505724f59a5db1a44__9_Procedures for immunization and SCoV challenge\n",
      "0e76160729d01c33942105e505724f59a5db1a44__10_Titration of SCoV-specific neutralizing antibodies\n",
      "0e76160729d01c33942105e505724f59a5db1a44__11_Collection of lungs, histology, immunohistochemistry, and virus titration\n",
      "0e76160729d01c33942105e505724f59a5db1a44__12_Statistical analysis\n",
      "0e76160729d01c33942105e505724f59a5db1a44__13_Production and characterization of chimeric VLPs\n",
      "0e76160729d01c33942105e505724f59a5db1a44__14_Serum neutralizing antibody titers and lung SCoV titers in the mice immunized once with chimeric VLPs\n",
      "0e76160729d01c33942105e505724f59a5db1a44__15_Effects of chimeric VLP amounts on neutralizing antibody titers and inhibition of challenged SCoV replication in the lungs\n",
      "0e76160729d01c33942105e505724f59a5db1a44__16_Histopathological examination and IHC of the lungs of the immunized mice after SCoV challenge\n",
      "0e76160729d01c33942105e505724f59a5db1a44__17_Discussion\n",
      "051cf89045450e5eff3fc9ba4fdc518fe1d623b8__0_\n",
      "051cf89045450e5eff3fc9ba4fdc518fe1d623b8__1_Introduction\n",
      "051cf89045450e5eff3fc9ba4fdc518fe1d623b8__2_Cloning, expression and purification\n",
      "051cf89045450e5eff3fc9ba4fdc518fe1d623b8__3_Crystallization, data collection and structure determination\n",
      "051cf89045450e5eff3fc9ba4fdc518fe1d623b8__4_Preparation of geranylated flavonoids\n",
      "051cf89045450e5eff3fc9ba4fdc518fe1d623b8__5_Enzymatic inhibitory assay\n",
      "051cf89045450e5eff3fc9ba4fdc518fe1d623b8__6_Homology modelling\n",
      "051cf89045450e5eff3fc9ba4fdc518fe1d623b8__7_Kinetic properties of the natural geranylated Cp-NanI inhibitors\n",
      "051cf89045450e5eff3fc9ba4fdc518fe1d623b8__8_Structure of Cp-NanI in complex with diplacone\n",
      "051cf89045450e5eff3fc9ba4fdc518fe1d623b8__9_Comparison with apo and substrate complex of Cp-NanI\n",
      "051cf89045450e5eff3fc9ba4fdc518fe1d623b8__10_Figure 3\n",
      "051cf89045450e5eff3fc9ba4fdc518fe1d623b8__11_Discussion\n",
      "8e99aa562283c4c1cd9e1c8f4dffba12f6165f81__0_Introduction\n",
      "8e99aa562283c4c1cd9e1c8f4dffba12f6165f81__1_Pathological effects of infection\n",
      "8e99aa562283c4c1cd9e1c8f4dffba12f6165f81__2_Physiochemical effects of infection\n",
      "8e99aa562283c4c1cd9e1c8f4dffba12f6165f81__3_Viruses\n",
      "8e99aa562283c4c1cd9e1c8f4dffba12f6165f81__4_Fungi\n",
      "8e99aa562283c4c1cd9e1c8f4dffba12f6165f81__5_Bacteria\n",
      "8e99aa562283c4c1cd9e1c8f4dffba12f6165f81__6_Parasites\n",
      "8e99aa562283c4c1cd9e1c8f4dffba12f6165f81__7_Conclusions\n",
      "6e0b5bbe1af91b80c9ac2fa22fea4d845c6230c8__0_\n",
      "6e0b5bbe1af91b80c9ac2fa22fea4d845c6230c8__1_BAcKGrOUND\n",
      "6e0b5bbe1af91b80c9ac2fa22fea4d845c6230c8__2_changing the Landscape: clinical and Financial Perspectives\n",
      "6e0b5bbe1af91b80c9ac2fa22fea4d845c6230c8__3_cLiNicAL iMPAct\n",
      "6e0b5bbe1af91b80c9ac2fa22fea4d845c6230c8__4_PUBLic HeALtH iMPAct\n",
      "6e0b5bbe1af91b80c9ac2fa22fea4d845c6230c8__5_iMPAct ON trANsLAtiONAL reseArcH\n",
      "6e0b5bbe1af91b80c9ac2fa22fea4d845c6230c8__6_FrOM vOLUMe tO vALUe: cONsiDerAtiONs FOr cONsOLiDAteD cLiNicAL LABOrAtOrY MODeLs\n",
      "6e0b5bbe1af91b80c9ac2fa22fea4d845c6230c8__7_AUtHOr cONtriBUtiONs\n",
      "bd54d9fb67935b02cbd73f4802c82aab63fbcce5__0_\n",
      "bd54d9fb67935b02cbd73f4802c82aab63fbcce5__1_INTRODUCTION\n",
      "bd54d9fb67935b02cbd73f4802c82aab63fbcce5__2_Tissue Preparation and Histological Stains.\n",
      "bd54d9fb67935b02cbd73f4802c82aab63fbcce5__3_MBP\n",
      "bd54d9fb67935b02cbd73f4802c82aab63fbcce5__4_DISCUSSION\n",
      "ff54e3e961a72eb1d2500166809b3651b2f98cf6__0_Introduction\n",
      "ff54e3e961a72eb1d2500166809b3651b2f98cf6__1_Amino acid sequences used in this study\n",
      "ff54e3e961a72eb1d2500166809b3651b2f98cf6__2_Prediction of drug-target interactions using binding affinity scores\n",
      "ff54e3e961a72eb1d2500166809b3651b2f98cf6__3_Results and Discussion\n",
      "ff54e3e961a72eb1d2500166809b3651b2f98cf6__4_Conclusion\n",
      "cdfa3f7c065622bfb2c811f71fc0dbae5b1a4d3d__0_Introduction\n",
      "cdfa3f7c065622bfb2c811f71fc0dbae5b1a4d3d__1_Tick collection and identification\n",
      "cdfa3f7c065622bfb2c811f71fc0dbae5b1a4d3d__2_Nucleic acid extraction\n",
      "cdfa3f7c065622bfb2c811f71fc0dbae5b1a4d3d__3_cDNA labeling, amplification and sequencing\n",
      "cdfa3f7c065622bfb2c811f71fc0dbae5b1a4d3d__4_Sequence processing and taxonomy assignment\n",
      "cdfa3f7c065622bfb2c811f71fc0dbae5b1a4d3d__5_Confirmation of sequences and recovery of genomic ends\n",
      "cdfa3f7c065622bfb2c811f71fc0dbae5b1a4d3d__6_Phylogenetic analysis\n",
      "cdfa3f7c065622bfb2c811f71fc0dbae5b1a4d3d__7_Results\n",
      "cdfa3f7c065622bfb2c811f71fc0dbae5b1a4d3d__8_Orthomyxoviridae family\n",
      "cdfa3f7c065622bfb2c811f71fc0dbae5b1a4d3d__9_Other viral families\n",
      "cdfa3f7c065622bfb2c811f71fc0dbae5b1a4d3d__10_Discussion\n",
      "cdfa3f7c065622bfb2c811f71fc0dbae5b1a4d3d__11_Data availability statement\n",
      "cdfa3f7c065622bfb2c811f71fc0dbae5b1a4d3d__12_Juliette Hayer\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__0_Introduction\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__1_The Medicinal Plants\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__2_History of Medicinal Plants\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__3_Herbal Remedies for Human Sufferings\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__4_Medicinal Importance of Plants\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__5_Diabetes\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__6_Antioxidant Property\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__7_Organophosphate Exposure\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__8_Anti-carcinogenic Activity\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__9_Meticillin-resistant Staphylococcus aureus (MRSA)\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__10_Candiasis\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__11_Plants Showing Anti-fungal Properties\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__12_Plants Showing Contraceptive Effects\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__13_Regulation: Dietary Supplement and Health Education Act\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__14_Present Status of Herbal Medicines\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__15_Future Prospects and Constraints of Herbal Drug Industry\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__16_Piriformospora indica -Model Symbiotic Fungus\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__17_Phylogenetic Position of P. indica\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__18_Applications and Diverse Functions\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__19_Eco-Functional Identity\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__20_Host Spectrum\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__21_Interaction Between Novel Symbiotic Fungus P. indica and Medicinal Plants\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__22_Spilanthes calva\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__23_Adhatoda vasica\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__24_Withania somnifera\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__25_Safed Musli\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__26_Bacopa monniera\n",
      "9da3d0bb5a6df7b3fc1e318ec2c8dc24e120f016__27_Conclusion\n",
      "ee55aea26f816403476a7cb71816b8ecb1110329__0_Introduction\n",
      "ee55aea26f816403476a7cb71816b8ecb1110329__1_Benchmark Dataset\n",
      "ee55aea26f816403476a7cb71816b8ecb1110329__2_Sample Representation\n",
      "ee55aea26f816403476a7cb71816b8ecb1110329__3_Use 2D Molecular Fingerprints to Represent Drugs\n",
      "ee55aea26f816403476a7cb71816b8ecb1110329__4_Use Pseudo Amino Acid Composition to Represent the Nuclear Receptors\n",
      "ee55aea26f816403476a7cb71816b8ecb1110329__5_Formulate the Pair of Drugs with Nuclear Receptor\n",
      "ee55aea26f816403476a7cb71816b8ecb1110329__6_Operation Engine or Algorithm\n",
      "ee55aea26f816403476a7cb71816b8ecb1110329__7_Metrics for Measuring Prediction Quality\n",
      "ee55aea26f816403476a7cb71816b8ecb1110329__8_Jackknife Test Approach\n",
      "ee55aea26f816403476a7cb71816b8ecb1110329__9_Independent Dataset Test\n",
      "ee55aea26f816403476a7cb71816b8ecb1110329__10_Conclusions\n",
      "ecd4b70b244e71dbfe8a014d5986f9eac6fc13b4__0_\n",
      "ecd4b70b244e71dbfe8a014d5986f9eac6fc13b4__1_Results\n",
      "ecd4b70b244e71dbfe8a014d5986f9eac6fc13b4__2_Discussion\n",
      "ecd4b70b244e71dbfe8a014d5986f9eac6fc13b4__3_Methods\n",
      "15f32645ef27787af4120e37cc67c24ed6c8f305__0_\n",
      "15f32645ef27787af4120e37cc67c24ed6c8f305__1_Phylogenetic analysis\n",
      "15f32645ef27787af4120e37cc67c24ed6c8f305__2_Marking of utilizing capability by SARS-CoV-2\n",
      "15f32645ef27787af4120e37cc67c24ed6c8f305__3_Results and discussion\n",
      "15f32645ef27787af4120e37cc67c24ed6c8f305__4_Declaration of Competing Interest\n",
      "b407a19638e108117f069f8737a053f15c7c3e51__0_\n",
      "b407a19638e108117f069f8737a053f15c7c3e51__1_Study Design and Population\n",
      "b407a19638e108117f069f8737a053f15c7c3e51__2_Clinical Classifications and Laboratory Investigations\n",
      "b407a19638e108117f069f8737a053f15c7c3e51__3_Definitions and Statistical Analyses\n",
      "b407a19638e108117f069f8737a053f15c7c3e51__4_HMPV and RSV Among Children with RTI and Asymptomatic Controls\n",
      "b407a19638e108117f069f8737a053f15c7c3e51__5_Seasonal Trends and Epidemics\n",
      "b407a19638e108117f069f8737a053f15c7c3e51__6_LRTI Hospitalization Rates During 9 Seasons\n",
      "b407a19638e108117f069f8737a053f15c7c3e51__7_Shedding of HMPV\n",
      "b407a19638e108117f069f8737a053f15c7c3e51__8_DISCUSSION\n",
      "b407a19638e108117f069f8737a053f15c7c3e51__9_Supplementary Data\n",
      "d9ecb8e78616bebdb37e3b3b689ad60bafd922e3__0_\n",
      "d9ecb8e78616bebdb37e3b3b689ad60bafd922e3__1_M-nsp13 can unwind both RNA and DNA helices.\n",
      "d9ecb8e78616bebdb37e3b3b689ad60bafd922e3__2_M-nsp13 is a unidirectional helicase. Previous reports have shown that SARS-\n",
      "d9ecb8e78616bebdb37e3b3b689ad60bafd922e3__3_DISCUSSION\n",
      "d9ecb8e78616bebdb37e3b3b689ad60bafd922e3__4_MATERIALS AND METHODS\n",
      "d9ecb8e78616bebdb37e3b3b689ad60bafd922e3__5_SUPPLEMENTAL MATERIAL\n",
      "d9ecb8e78616bebdb37e3b3b689ad60bafd922e3__6_ACKNOWLEDGMENT\n",
      "d9ecb8e78616bebdb37e3b3b689ad60bafd922e3__7_FUNDING INFORMATION\n",
      "615190f165f14eefbbd4d309a15c8bb80ccb84cd__0_Introduction\n",
      "615190f165f14eefbbd4d309a15c8bb80ccb84cd__1_Data\n",
      "615190f165f14eefbbd4d309a15c8bb80ccb84cd__2_The Richards model\n",
      "615190f165f14eefbbd4d309a15c8bb80ccb84cd__3_Test for stationarity (unit root test, ADF)\n",
      "615190f165f14eefbbd4d309a15c8bb80ccb84cd__4_Correlation coefficient, r\n",
      "615190f165f14eefbbd4d309a15c8bb80ccb84cd__5_Granger causality test\n",
      "615190f165f14eefbbd4d309a15c8bb80ccb84cd__6_Results\n",
      "615190f165f14eefbbd4d309a15c8bb80ccb84cd__7_Discussion\n",
      "02beed2dafa4fa3f5d0bb8f91c9ab8a1966e6ed6__0_\n",
      "02beed2dafa4fa3f5d0bb8f91c9ab8a1966e6ed6__1_RESULTS\n",
      "02beed2dafa4fa3f5d0bb8f91c9ab8a1966e6ed6__2_Reduction of virus sanctuaries by virus-specific B cells\n",
      "02beed2dafa4fa3f5d0bb8f91c9ab8a1966e6ed6__3_Activated but exhausted CD8 + T cells in viral sanctuaries\n",
      "02beed2dafa4fa3f5d0bb8f91c9ab8a1966e6ed6__4_Virus persistence at epithelial sites\n",
      "02beed2dafa4fa3f5d0bb8f91c9ab8a1966e6ed6__5_DISCUSSION\n",
      "02beed2dafa4fa3f5d0bb8f91c9ab8a1966e6ed6__6_METHODS\n",
      "61472699f26e3bedce001d84f6e4791ac50652f0__0_\n",
      "61472699f26e3bedce001d84f6e4791ac50652f0__1_Our argument\n",
      "61472699f26e3bedce001d84f6e4791ac50652f0__2_Hospital mortalityvalue in surveillance and impact evaluation\n",
      "61472699f26e3bedce001d84f6e4791ac50652f0__3_Hospital mortality and system failure\n",
      "61472699f26e3bedce001d84f6e4791ac50652f0__4_Hospital mortality as a measure of the quality of care\n",
      "61472699f26e3bedce001d84f6e4791ac50652f0__5_Benchmarking\n",
      "61472699f26e3bedce001d84f6e4791ac50652f0__6_Examining relationships between specific inputs and outcomes\n",
      "61472699f26e3bedce001d84f6e4791ac50652f0__7_Conclusion\n",
      "61472699f26e3bedce001d84f6e4791ac50652f0__8_Consent for publication\n",
      "8d1333505f23680f2134dc59a34754abb3b26d4f__0_\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__0_Background\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__1_Study design and setting\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__2_Participants and sampling\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__3_Interview process, instrumentation and policy documents\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__4_Data analysis\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__5_Results\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__6_Governance and decision-making\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__7_Serious\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__8_Coordination and advice\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__9_Politics, science and policy\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__10_Key infrastructure for PRPI\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__11_Information, education and communication\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__12_Prevention, mitigation and containment\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__13_Discussion\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__14_Limitations\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__15_Conclusion and recommendations\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__16_Ethics and consent\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__17_Funding information\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__18_Paper context\n",
      "b9b2738ea98d39ed9c2080bc308e1f57dcc512d1__19_ORCID\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__0_Introduction\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__1_Viruses and the culture methods\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__2_Sewage and disinfection\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__3_Electropositive filter media particle\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__4_Detection of residual chlorine\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__5_Evaluation of concentration efficiency of f 2 and SARS-CoV from seeded sewage by positively charged filter\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__6_Concentration of SARS-CoV from sewage\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__7_RNA extraction\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__8_Primer design for assay of SARS-CoV nucleic acid\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__9_Primer design for assay of enteroviruses nucleic acid\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__10_Detection of SARS-CoV and enteroviruses by RT-PCR\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__11_Detection of the PCR product\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__12_Nucleotide sequence analysis\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__13_Recoveries of f 2 and SARS-CoV from 100 ml of seeded sewage\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__14_Detection limit of SARS-CoV by RT-PCR\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__15_Concentration and detection of SARS-CoV from sewage before disinfection\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__16_Concentration and detection of SARS-CoV from sewage after disinfection\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__17_Result of nucleotide sequence analysis\n",
      "7a701dd3cb95f84821441fe6da76ba974c179eb3__18_Discussion\n",
      "3a448cd641ab17b2f3f23800569912369d60409f__0_The Need for Antivirals Against Flaviviruses\n",
      "3a448cd641ab17b2f3f23800569912369d60409f__1_Flaviviral Proteases as Drug Targets\n",
      "3a448cd641ab17b2f3f23800569912369d60409f__2_Function and Structure of Flaviviral Proteases\n",
      "3a448cd641ab17b2f3f23800569912369d60409f__3_Inhibitors of Flaviviral Proteases\n",
      "3a448cd641ab17b2f3f23800569912369d60409f__4_Small-Molecular Dengue Virus Protease Inhibitors\n",
      "3a448cd641ab17b2f3f23800569912369d60409f__5_Small-Molecular West Nile Virus Protease Inhibitors\n",
      "3a448cd641ab17b2f3f23800569912369d60409f__6_Small-Molecular Zika Virus Protease Inhibitors\n",
      "3a448cd641ab17b2f3f23800569912369d60409f__7_Peptide-Derived Inhibitors of Dengue, West Nile and Zika Virus Proteases\n",
      "3a448cd641ab17b2f3f23800569912369d60409f__8_Perspectives Towards Zika Virus Protease Inhibitors\n",
      "3a448cd641ab17b2f3f23800569912369d60409f__9_Conclusion\n",
      "3a448cd641ab17b2f3f23800569912369d60409f__10_Note\n",
      "056f35bf25005ec3974c0633a63492b675a17849__0_Introduction\n",
      "056f35bf25005ec3974c0633a63492b675a17849__1_Bioinformatics\n",
      "056f35bf25005ec3974c0633a63492b675a17849__2_Genomic sequencing\n",
      "056f35bf25005ec3974c0633a63492b675a17849__3_Genetics\n",
      "056f35bf25005ec3974c0633a63492b675a17849__4_Clinical informatics\n",
      "056f35bf25005ec3974c0633a63492b675a17849__5_Imaging\n",
      "056f35bf25005ec3974c0633a63492b675a17849__6_Roles for informaticians in the pandemic and beyond\n",
      "056f35bf25005ec3974c0633a63492b675a17849__7_Clinical information systems and learning healthcare systems\n",
      "056f35bf25005ec3974c0633a63492b675a17849__8_Clinical research informatics\n",
      "056f35bf25005ec3974c0633a63492b675a17849__9_Informatics infrastructure\n",
      "056f35bf25005ec3974c0633a63492b675a17849__10_Pharmacovigilance and repurposing existing data for COVID-19 treatments\n",
      "056f35bf25005ec3974c0633a63492b675a17849__11_Data integration\n",
      "056f35bf25005ec3974c0633a63492b675a17849__12_Advanced computational approaches to diagnosis, decision making, and treatment\n",
      "056f35bf25005ec3974c0633a63492b675a17849__13_Consumer health informatics\n",
      "056f35bf25005ec3974c0633a63492b675a17849__14_Patient education and monitoring\n",
      "056f35bf25005ec3974c0633a63492b675a17849__15_Smart devices and sensors\n",
      "056f35bf25005ec3974c0633a63492b675a17849__16_Public health informatics\n",
      "056f35bf25005ec3974c0633a63492b675a17849__17_Information systems for COVID-19 monitoring\n",
      "056f35bf25005ec3974c0633a63492b675a17849__18_Data visualization and analysis systems for rapid assessment of COVID-19 spread\n",
      "056f35bf25005ec3974c0633a63492b675a17849__19_Secondary effects of COVID-19 on public health and well-being\n",
      "056f35bf25005ec3974c0633a63492b675a17849__20_Real-time monitoring via social media\n",
      "056f35bf25005ec3974c0633a63492b675a17849__21_Summary\n",
      "362f9e6b508a42ffebfd1a95d146955d59c7cea0__0_Background\n",
      "362f9e6b508a42ffebfd1a95d146955d59c7cea0__1_SVR model parameter optimization\n",
      "362f9e6b508a42ffebfd1a95d146955d59c7cea0__2_SVRMHC models performed better than linear models in quantitative predictions\n",
      "362f9e6b508a42ffebfd1a95d146955d59c7cea0__3_SVRMHC models out-performed other methods in identifying strong binders\n",
      "362f9e6b508a42ffebfd1a95d146955d59c7cea0__4_Discussion\n",
      "362f9e6b508a42ffebfd1a95d146955d59c7cea0__5_Conclusion\n",
      "362f9e6b508a42ffebfd1a95d146955d59c7cea0__6_Support Vector Machine Regression (SVR) overview\n",
      "362f9e6b508a42ffebfd1a95d146955d59c7cea0__7_Data description\n",
      "362f9e6b508a42ffebfd1a95d146955d59c7cea0__8_Encoding scheme of peptide sequences\n",
      "362f9e6b508a42ffebfd1a95d146955d59c7cea0__9_Outlier determination and exclusion\n",
      "362f9e6b508a42ffebfd1a95d146955d59c7cea0__10_Assessment of model performance\n",
      "e8fa6ff57f5e18b27fa9d70df3d3c90f4633264d__0_Results\n",
      "e8fa6ff57f5e18b27fa9d70df3d3c90f4633264d__1_Discussion\n",
      "e8fa6ff57f5e18b27fa9d70df3d3c90f4633264d__2_Neutralization tests.\n",
      "b7afde848461b9e1f1ca5d926d3e3c5e3ed2b808__0_\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__0_INTRODUCTION\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__1_DESTINATION-SPECIFIC VARIATIONS IN PROPORTIONATE MORBIDITY\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__2_ASSESSMENT OF TRAVEL HISTORY\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__3_CLINICAL PRESENTATION\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__4_Fever and Rash\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__5_Fever and Jaundice\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__6_Fever and Central Nervous System Involvement\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__7_Fever and Eosinophilia\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__8_PEDIATRIC CONSIDERATIONS\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__9_MALARIA\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__10_Fever in the Returning Traveler\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__11_DENGUE FEVER\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__12_ENTERIC FEVER (TYPHOID AND PARATYPHOID)\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__13_RICKETTSIAL INFECTION\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__14_PROTECTION OF CONTACTS AND STAFF\n",
      "0df458e721d5da7ac7cecf688be5f172a348c192__15_SUMMARY\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__0_Background\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__1_Objectives\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__2_Preparation of Aqueous and Hydro-alcoholic A. kellalensis Extracts\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__3_MA-104 cells (Embryonic rhesus monkey kidney cells)\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__4_Cell Toxicity and Viability (Determination of the Maximum Non-toxic Concentration)\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__5_MTT Assay\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__6_Neutral Red Dye Retention Assay\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__7_Crystal Violet Assay\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__8_Trypan Blue Dye Uptake to Assess Viability\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__9_Titration of the Virus\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__10_Antiviral Assays\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__11_Virucidal Assay\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__12_Determination of Antiviral Activity\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__13_Data Analysis\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__14_Results\n",
      "a62951116b1815c48334c0caae599e4d4f06e58f__15_Discussion\n",
      "fc2bdbffdc78de293666821f5f06cd10ece84c2b__0_Introduction\n",
      "fc2bdbffdc78de293666821f5f06cd10ece84c2b__1_Study design and patients\n",
      "fc2bdbffdc78de293666821f5f06cd10ece84c2b__2_Research in context\n",
      "fc2bdbffdc78de293666821f5f06cd10ece84c2b__3_Added value of this study\n",
      "fc2bdbffdc78de293666821f5f06cd10ece84c2b__4_Implications of all the available evidence\n",
      "fc2bdbffdc78de293666821f5f06cd10ece84c2b__5_Procedures\n",
      "fc2bdbffdc78de293666821f5f06cd10ece84c2b__6_Role of the funding source\n",
      "fc2bdbffdc78de293666821f5f06cd10ece84c2b__7_Results\n",
      "fc2bdbffdc78de293666821f5f06cd10ece84c2b__8_Virus detection in other samples\n",
      "fc2bdbffdc78de293666821f5f06cd10ece84c2b__9_Discussion\n",
      "fc2bdbffdc78de293666821f5f06cd10ece84c2b__10_cases in France (A-E)\n",
      "fc2bdbffdc78de293666821f5f06cd10ece84c2b__11_Declaration of interests\n",
      "b68faf9150e22fa304e01614a2efe1ef90f9b96b__0_Introduction\n",
      "b68faf9150e22fa304e01614a2efe1ef90f9b96b__1_Discussion\n",
      "b68faf9150e22fa304e01614a2efe1ef90f9b96b__2_Conclusion\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__0_\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__1_2ED-01-02\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__2_2ED-03-06 Developmental plasticity of the bone marrow derived cells G VASSILOPOULOS Biomedical Research Institute (IIBEAA), Athens, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__3_2ED-03-07 Risk management in transfusion medicine L LOUKOPOULOS NASA Ames Research Centre, Athens, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__4_J JORGENSEN Aarhus University Hospital, Aarhus, Denmark\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__5_2ED-05-14\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__6_RP REBULLA IRCCS Ospedale Maggiore Policlinico, Milano, Italy\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__7_SJ STANWORTH, SJ BRUNSKILL and CJ HYDE National Blood Service, Oxford, UK\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__8_M-PL1-04\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__9_ML LETOWSKA Inst Haematol & Blood Transfusion, Warsaw, Poland\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__10_2: FRESH FROZEN PLASMA\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__11_M-PA-010 Photodynamic inactivation of human hepatitis B virus in plasma as revealed by long-range PCR\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__12_Conclusions:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__13_D STAINSBY, SM KNOWLES, C MILKINS, H JONES and H COHEN Serious Hazards of Transfusion, Manchester, UK\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__14_M-PA-025 Transplanted stem cell apheresis products containing tumor cells and patient survival W GEBAUER and I BARKLAGE DRK Oldenburg, Oldenburg, Germany\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__15_M-PA-026 Large volume vs. standard mononucrear cell (MNC) harvesting for peripheral blood stem cell transplantation M TRKULJIC, B BALINT, G OSTOJIC and L RISTIC Military Medical Academy, Belgrade, Serbia\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__16_A MANIATIS Henry Dunant Hospital, Athens, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__17_M-PA-035 New methods and current trends in donor testing (for infection)\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__18_Methods:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__19_M-PA-039\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__20_M-PA-042\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__21_M-PA-041\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__22_M-PA-043\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__23_Results:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__24_M-PA-044 Lyophilized platelets (Lyo P) used for the detection of HPA antibodies by MAIPA assay D RIGAL EFS Lyon, Lyon, France\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__25_M-PA-045 RHD (201R 223V) allele cluster analysis in different ethnic populations refines RHD phylogeny in humans by identification of RHD (223V) and new aberrant D alleles\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__26_Conclusion:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__27_01: ORGANISATION OF BLOOD TRANSFUSION SERVICES\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__28_Conclusions\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__29_P-006\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__30_P-007\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__31_02: DONORS AND BLOOD DONATION\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__32_P-010\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__33_P-011\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__34_Materials and methods:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__35_P-022\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__36_Methods\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__37_P-032 A study on blood donors with bruises and hematomas following blood donations\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__38_P-040\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__39_P-045\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__40_Aims:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__41_P-047\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__42_MM SHOOSHTARI, A BAHRAMI, M MAGHSUDLLU and M HARIRI Iranian Blood Transfusion Organization, Tehran, Iran\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__43_P-049\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__44_P-052\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__45_P-053\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__46_P-055\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__47_P-061\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__48_SV CHERMNYKH, VK CHAYKA and TN DEMINA Donetsk State Medical University, Donetsk, Ukraine\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__49_P-063\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__50_P-067\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__51_PA-IA -protein A immunoadsorption -method of efficient extracorporeal removal of pathological autoantibodies S RUMMLER and D BARZ University Hospital of Jena, Jena, Germany\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__52_P-076\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__53_P-080\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__54_LA BUST and AR BIRD Western Province Blood Transfusion, Western Cape, South Africa\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__55_I BESSON FAURE, N GONCALVES and C DUMOULIN Hemosystem, Marseille, France\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__56_P-081\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__57_P-082\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__58_F DE GROOF and F HOFMAN Gambro BCT, Zaventem, Belgium\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__59_P-083 A fast and rapid method to determine the ATP content in packed red blood cells A DOESCHER, C VOGT, T HUNDHAUSEN and EK PETERSHOFEN Red Cross Blood Transfusion Service, Oldenburg, Germany\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__60_P-086\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__61_S GOGIC EU Project for Transfusion Service, Belgrade, Serbia\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__62_Aim of study: In 2004 the Project for National Blood transfusion\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__63_P-088\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__64_A MAINUKA and P KATAAHA Uganda Blood Transfusion Services, Fort Portal, Uganda\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__65_P-091\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__66_P-092\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__67_SM MUDAHI-ORENSTEIN, N MANNY, O ZELIG and Y DAKOSTA Hadassah Hebrew University Medical Cent, Jerusalem, Israel\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__68_P-094 Measurement system analysis of counting blood cells for blood components quality control R NEMEC, M STACHELOVA and Z CERMAKOVA Faculty Hospital Ostrava, Ostrava-Poruba, Czech Republic\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__69_P-096\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__70_P-097\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__71_C POLITIS, P KATSEA, L KAVALLIEROU, A MAKRI, M XENIKAKI and V TRIANTAPHYLLOU G. Gennimatas General Hospital, Athens, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__72_P-099\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__73_JS SHUKLA, RK CHAUDHARY, SS DAS and P AGARWAL Sanjay Gandhi Postgrad Institute of Med., Lucknow, India\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__74_P-101\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__75_P-102 Validation of HemoCue Plasma/Low Hb photometer in transfusion medicine T VUK, S MORIC, M BALIJA and I JUKIC Croatian Institute of Transfusion Med., Zagreb, Croatia\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__76_P-103 Determination of haemolysis in RCC's -should all supernatants be filtered before analysis? T VUK, R ANTOLOVIC, M BALIJA and I JUKIC Croatian Institute of Transfusion Med., Zagreb, Croatia\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__77_Management of returned blood products in CITM -analysis 2000-2004 T VUK, M BARIŠIC, M STRAUSS-PATKO, M BALIJA and I JUKIC Croatian Institute of Transfusion Med., Zagreb, Croatia\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__78_P-106 A methodic approach of information management, a solution for process management of hemovigilance JGAH VAN DER WIJST, A VAN DEN BOS and BE DE PAUW University Hospital Nijmegen, St. Radboud, Nijmegen, Netherlands\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__79_Method:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__80_Result:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__81_P-107 Training in transfusion medicine in Bulgaria S BAKALOVA, M KIROVA and A ANDREEV NCHT, Sofia, Bulgaria\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__82_P-109 Education in transfusion medicine -Macedonian experience P BLAGOEVSKA, S KOSTOVSKA, V STEFANOVSKA, T MAKAROVSKA AND R GRUBOVIK National Institute for Transfusion Medic, Skopje, Macedonia\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__83_Macedonia.\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__84_P-110 Experience of postgraduate education on transfusiology for doctors IG DUTKEVICH, AV MALOV, AV MARCHENKO, EA SELIVANOV and EN SUCHOMLINA Medical Academy of Postgraduate Studies, Saint-Petersburg, Russian Federation\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__85_P-111 Experience of organization of special postgraduate education on extracorporal hemocorrection and photohemotherapy IG DUTKEVICH, AV MARCHENKO, EA SELIVANOV and EN SUCHOMLINA Medical Academy of Postgraduate Studies, Saint-Petersburg, Russian Federation\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__86_Change of blood consumption in Turkey N SOLAZ, S KEMAHLI and S CIN Ankara University, Ankara, Turkey\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__87_P-114\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__88_Mannose-binding-lectin (MBL) levels and blood transfusions related to postoperative complications after cardiac surgery Y BILGIN, A ROOS, J LORINSER, A BRAND and M DAHA Leiden University Medical Center, Rotterdam, Netherlands\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__89_P-116 Relationship between leukocyte-depleted erythrocyte concentrates and cytokines in cardiac surgery Y BILGIN*, A BRAND*, LMG WATERING*, J LORINSER* and MHJ VAN OERS † *Leiden University Medical Center, Rotterdam, † Academical Medical Center, Amsterdam, Netherlands\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__90_P-117\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__91_P-118\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__92_Prophylaxis of RHD immunization in Croatia on the threshold of its accession to the European Union G JAKLIN* and B GOLUBIC-CEPULIC † *General Hospital, Varazdin, † Clinical Hospital Center Zagreb, Zagreb, Croatia\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__93_P-120\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__94_RhD alloimmunization in a university hospital C MONTEIRO, F ARAÚJO, A LEITE, C KOCH, R PEREIRA and L CUNHA RIBEIRO Hospital São João, Porto, Portugal\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__95_P-122 The use of blood and blood products in patients who are hospitalized and treat in the internal department in Gevgelija (2000-2004) S ORTAKOVSKA and M BALAMOVSKI Medical Center 'Gevgelija,, Department of Transfusion Medicine, Gevgelija, Macedonia\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__96_P-123 Blood transfusion requirement in femoral neck fracture repair M PAPADOPOULOU, SF SNEZANA FILIPPOVITS, G MOUTSIANOS, A SARIDES and G. PAPAGEORGIOU General Hospital Katerini, Katerini, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__97_P-124\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__98_Aim of study:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__99_P-128\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__100_Material and methods:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__101_P-132 Combined patient based analyses of RCT's comparing buffy-coat depleted RBC transfusions with filtered RBC transfusions LMG VAN DE WATERING, DSE LOOMANS and A BRAND Sanquin Blood Bank South West Region, Leiden, Netherlands\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__102_P-133 Selection of phenotyped blood for pre-menopausal females in the UK and mainland Europe J WHITE, C MILKINS, D BENKHALED and M ROWLEY UK NEQAS (BTLP), Watford, UK\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__103_P-135\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__104_P-139\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__105_P-142 TRALI complication postsurgically in elderly female AK KAPERONI, EK KOUKOU, V KOTSALIS and S KARATAPANIS 'ELPIS' General Hospital, Agia Paraskevi, Athens, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__106_P-149 Post transfusion purpura: a challenging diagnosis E SIGLER, L SHVIDEL, A BERREBI and M SHTALRID Kaplan Medical Center, Rehovot, Israel\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__107_P-150 3 years of transfusion reaction reports -a summary of the Haemovigilance Programme in Singapore S SYED, MB KOH and D TEO\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__108_Introduction:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__109_P-159 Epidemiological and demographic factors of anti-HCV infected blood donors (1992-2002) M HATZITAKI, H DIAMANTI, E BOURONIKOU, N STABOULZIS and N PAPADOULIS General Hospital of Larissa, Larissa, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__110_P-173 Bacterial monitoring of platelets -is the extension of selflife feasible K STAMOULIS, M PETROULA, A SDRAKA, I DRAKOU, H FAITAKI, G DEGGIANAKI, I KATRAMADOS, S VLACHAKOU and E ECONOMOU-PETERSEN NCPBP E.Politis, Nikea, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__111_P-174\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__112_Aim of the study:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__113_P-179\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__114_S AMINI KAFI-ABAD, K ATARODI, ASFH SOLEIMANI-FREEZ-HENDI, SR RAMMAN and AT TALEBIAN Iranian Blood Transfusion Research Cente, Tehran, Iran\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__115_P-180 Delta infection and hepatitis B virus replication in Iranian patients with chronic hepatitis B S AMINI KAFI-ABAD, R SHAME-REEZ, FF FERDOWSIAN and AT TALEBIAN Iranian Blood Transfusion Research Cente, Tehran, Iran\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__116_P-181 Combination hepatitis C virus antigen and antibody immunoassay as a new tool for early diagnosis of infection F ANSALDI, B BRUZZONE, P LAI, C STICCHI, C RICCIO, R GASPARINI, P CROVARI and G ICARDI University of Genoa, Genoa, Italy\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__117_P-182 Prevalence of parvovirus B19 and hepatitis a virus in Portuguese blood donors F ARAUJO, I HENRIQUES, F MONTEIRO, E MEIRELES, A CRUZ and G TAVARES Hospital São João, Porto, Portugal\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__118_Bio-Rad Laboratories, Marnes-La-Coquette, France\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__119_P-204\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__120_P-208\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__121_T MONTAG-LESSING Paul Ehrlich Institute, Langen, Germany\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__122_P-211\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__123_P-212\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__124_V REHACEK and B JILKOVA Charles University Hospital, Hradec Kralove, Czech Republic\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__125_P-220 NAT for parvo B19 -five years experience WK ROTH, A THEMANN, E SEIFRIED and M SCHMIDT German Red Cross, Institute Frankfurt, Frankfurt, Germany\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__126_P-221 Evaluation of an immunoenzymatic assay anti-Treponema pallidum for screening blood donations MCS SARGENTO, C FERREIRA, AM SILVA, I SIMÕES and I FERRAZ Hospitais da Universidade de Coimbra, Coimbra, Portugal\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__127_MCSS SARGENTO, AM SILVA, C FERREIRA, E SILVA, A PINA and C BORGES Hospitais da Universidade de Coimbra, Coimbra, Portugal\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__128_P-224 A new FACS-based method to screen platelet concentrates for bacterial contamination M SCHMIDT*, T MONTAG † , SB NICOL † , HP SPENGLER ‡ , MK HOURFAR*, T TONN*, WK ROTH* and E SEIFRIED* *German Red Cross Institute Frankfurt, Frankfurt, † Paul Ehrlich Institute, Langen, ‡ Becton Dickinson, Erembodegem, Germany\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__129_P-226 Automated versus manual extraction for HCV-RNA detection with the Roche Cobas Ampliscreen HCV-V 2.0 E SERAFI, K STAMOULIS, A LYRAS, X BABOURI, K MARAKI, M PETRIDOU, E KOUTROULAKI, E CHALARI and E ECONOMOU-PETERSEN NCPBP E.Politis, Nikea, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__130_P-229 Low prevalence of HTLV-I/II infection markers: a 6-year retrospective analysis K STAMOULIS*, M AFENTAKI*, S STEPHANAKOU † , V ZEVGOLIS*, H LEKATSA*, G KASTANIOTIS*, K PAPAVASILIOU*, K SOFRONIADOU † and E ECONOMOU-PETERSEN* *NCPBP E. Politis, Nikea, † Blood Transfusion Center, Nikea, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__131_P-230 Toxoplasma antibodies in Iranian blood donors FA TARABADI*, M SHAEIGAN*, A AZIMZADEH*, A TALAEBIAN* and G BABAEE † *Iranian Blood Transf. Research Center, Tehran, † 2-Tarbiat Modares University, Tehran, Iran\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__132_Method and samples:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__133_P-231 Serological blood detection in multitransfused thalassemic patients T TIMOVA, L MANINSKA, R MADZUNKOV and S ORTAKOVSKA Madical Cantre, Strumica, Macedonia\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__134_P-234 Seroepidimiology of transfusion transmitted diseases in the state of Achaia PT TSELIOU, G TALAMPOUKA, A SALTAMAVROS, V KIRIAKOPOULOU, C VERRA, T GOLFINOPOULOU and K ALEXOPOULOS Saint Andrews Hospital, Patras, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__135_DV VIRIJEVIC Blood Transfusion Institute, Nis, Serbia\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__136_P-239\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__137_K WALKER, K SMEH, B FRANCIS, W DIMECH, M KARAKALTSAS and EM DAX National Serology Reference Laboratory, Melbourne, Australia\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__138_P-240 Simultaneous HIV-1 and HCV NAT screening using a single nucleic acid extraction S WESSBERG, P PALOMÄKI, K TUOMI and H LAITINEN Finnish Red Cross, Blood Service, Helsinki, Finland\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__139_P-241\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__140_10: PROMOTING BLOOD DONATION\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__141_Dept of Transfusion Medicine, Umeå, Sweden\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__142_T-PA-057\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__143_Ministry of Health, Sharjah, United Arab Emirates\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__144_T-PA-058 Problems and possibilities: recruitment and retention of young people as blood donors AH MISJE, HE HEIER and V BOSNES Ulleval University Hospital, Oslo, Norway\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__145_T-PA-059 Blood donor magnetic card: a challenge for amplification of both first-time and repeat blood donors and safe blood supply K FARMAKI*, I TSOUMARI*, K FARMAKIS † and M SAVANOS* *General Hospital of Corinth, Corinth, † IT Systems Analyst, MSC LSE, Corinth, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__146_11: EMERGING TECHNOLOGIES IN TRANSFUSION\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__147_JS COSTE Etablissement Français du Sang, Montpellier, France\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__148_12: EVIDENCE BASED BLOOD TRANSFUSION\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__149_13: HEMOTHERAPY IN HEMOGLOBINOPATHIES\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__150_C Politis G. Gennimatas General Hospital, Athens, Hellas\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__151_T-PA-075\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__152_AA AESSOPOS and DF FARMAKIS Athens University Medical School, Athens, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__153_T-PA-077\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__154_D KARAKANTZA, A KOURAKLI, A MOUGIOU, A KOUGELOU, E ARVANITOPOULOU, D LEMPOUSSI, N ZOUMBOS and E THEODORI University Hospital of Patras, Patras, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__155_Study design and methods:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__156_14: DEVELOPMENTS IN THE SAFETY OF PLASMA DERIVED PRODUCTS\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__157_BD FLAN LFB, Courtaboeuf Cedex, France\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__158_T-PA-079 Viral safety of plasma products: current status and consequences T BURNOUF Human Plasma Product Services, Lille, France\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__159_Background:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__160_Conclusions: Extensive in vitro analysis demonstrates that INTER-\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__161_T-PA-081 Application of the European directive 2004/33/EC: quantification of residual RBCs in plasma by flow cytometry M DELAMAIRE, R TARDIVEL, A BEAUPLET, MC LE GOFF and G SEMANA Etablissement Francais du Sang, Rennes, France\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__162_15: NATA SESSION -AUTOLOGOUS TRANSFUSION\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__163_T-PA-086 Modern concepts of autologous hemotherapy V KRETSCHMER and R KARGER University Hospital, Marburg, Germany\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__164_T-PA-087 Hyperoxic hemodilution: a new blood-sparing strategy J MEIER, A PAPE and O HABLER Johann Wolfgang Goethe University, Frankfurt am Main, Germany\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__165_Effects of hyperoxic ventilation in extreme hemodilution:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__166_T-PA-090\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__167_JP PANAGOPOULOS P.G.N.P., Patras, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__168_T-PA-091\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__169_A novel system for storage of pooled buffy coat platelet concentrates (BC PC) in a glucose containing additive solution (PAS-G) S HOLME, JC YU, R GARCEZ and C CHONG Pall Life Sciences, Covina, CA, USA\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__170_T-PA-095\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__171_PF VAN DER MEER, LAE LIEFTING, AH SCHOLTALBERS and RNI PIETERSZ Sanquin Blood Bank North West Region, Amsterdam, Netherlands\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__172_17: RISK OF CONTAMINATION OF BLOOD COMPONENTS\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__173_Inactivation of bacteria ES SEIFRIED and MM MUELLER German Red Cross Blood Donor Service, Frankfurt am Main, Germany\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__174_T-PA-100 Prevention of bacterial contamination of blood components M NESS Johns Hopkins, Baltimore, MD, USA\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__175_MP JANSSEN* and CL VAN DER POEL † *UMCU, Utrecht, † Sanquin BloodSupply Foundation, Amsterdam, Netherlands\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__176_18: THE EXPANDING ROLE OF THE BLOOD CENTRE\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__177_T-PA-109\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__178_Hema-Quebec, Sainte-Foy, Canada\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__179_Héna-Québec, Montréal, Canada\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__180_T-PA-108 Directed cord blood banking for transplantation J SMYTHE, DH PAMPHILON and S WATT National Blood Service, Oxford, UK\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__181_LI GAO*, H-H FAN*, X-X NIE*, Y-C GONG † , Y-M YANG*, K-C QIAN* and F GAO* *Transfusion Institute of Shanghai, Shanghai, † Shanghai Blood Center, Shanghai, China\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__182_TUESDAY PLENARY SESSION 3\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__183_T-PL3-07 Immunomodulatory effects of intravenous immunoglobulin (IVIg) M KAZATCHKINE National Agency on Aids Research (ANRS), Paris, France\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__184_P-249\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__185_P-250\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__186_AO ALAYYADIE and B BAUER Kuwait Central Blood Bank, Kuwait, Kuwait\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__187_Results\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__188_Conclusion: Immunohematology Reference Laboratory in Kuwait\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__189_Frequency of O, A, B, AB and Rh (D) antibody in the region Gevgelija-Valandovo (1989-2004) M BALAMOVSKI and S ORTAKOVSKA Medical Center 'Gevgelija', Gevgelija, Macedonia\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__190_P-256 Retrospective review of alloimmunization frequency in the patients of the Northeastern Greece Z BEZIRGIANNIDOU, G MARTINIS, M THEODORIDIS, V TERZOUDE, S NANOU and K PAGANIARE University Hospital of Alexandroupolis, Alexandroupolis, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__191_P-257\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__192_P CHALKIA, P DIDOUDI, S INTZEPELI, V MPAKALOUDI, E NTINOPOULOU, A XATZITOLIOS and A TSOUKALA AHEPA Hospital, Thssaloniki, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__193_P-258 Differential warm adsorption of alloantibodies to a high frequency antigen P CHALKIA, A TSOUKALA, E KOSTOPOULOU, E NTINOPOULOU and S INTZEPELI AHEPA Hospital, Thssaloniki, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__194_P-259\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__195_P-259a Evaluation of validity of the expired 0.8% red cells in antibody identification gel tests using\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__196_P-262 Weak D and Rh(D) phenotype prevalence in the Rh (D) negative blood donors of the university hospital, Coimbra (Portugal) A ESASUMAGA, C BORGES, D FERREIRA, AZ FONSECA and MP NETO Hospitais Universidade de Coimbra, Coimbra, Portugal\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__197_P-263\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__198_Applicability of identification of Kidd system in voluntary donated RBC units M GAVALAKI, TH ADRAKTAS, G GEORGIOU, E KALFA, E MIRIOKEFALITAKI, K TSOUKALA and A KARAFOULIDOU Laikon General Hospital, Athens, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__199_P-267 Affinity of monoclonal RHD reagents for weak D: risk for anti-D immunization Z HUNDRIC HASPL, J BINGULAC POPOVIC, V DRAZIC, I BOSANAC, M TOMICIC, N JURAKOVIC-LONCAR, I JUKIC and M BALIJA Croatian Institute of Transfusion Med., Zagreb, Croatia\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__200_P-268 Reduction or lack of reactivity of anti-Vel with dithiothreitol (DTT)-treated red cells BE ISRAEL, D FIGUEROA-RODRIGUEZ, TB KAUFMAN, JL OSUCH, KD KITCHEN and S CAGLIOTI Blood Systems Laboratories, Tempe, USA\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__201_P-271 Detection and identification of red cell alloantibodies in cardiac and cardiac surgery patients: a four-year study A KOUSOULAKOU, V KAZAKOU, A APOSTOLOU, P FATSEAS, H GIANNIKOPOULOU, M ALIBERTI, I ANASTASOPOULOU, E KARAPATA and E MELISSARI Onassis Cardiac Surgery Center, Athens, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__202_P-272 Anti-C(RH4) in RHD negative pregnant women E LEE, C PARMENTER and G BURGESS National Blood Service, London, UK\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__203_P-273\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__204_P-274\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__205_P-275 Comparison between two column agglutination tests for red cell antibody detection S MUDAHI-ORENSTEIN, N MANNY, O ZELIG and Y DAKOSTA Hadassah University Medical Center, Jerusalem, Israel\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__206_P-277\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__207_P-278\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__208_P-279\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__209_P-280\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__210_P-282 Erythrocyte autoantiboby formation in sickle cell patients BA RUBIM, GAP GUASTI and SL CASTILHO HEMORIO, Rio de Janeiro, Brazil\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__211_P-283\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__212_P-284\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__213_2000-2004 R SHOOR, O ASHER, E SHINAR and V YAHALOM Magen David Adom Israel, National Blood Services, Tel Hashomer, Israel\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__214_P-286 Distribution of RH and Kell antigens and phenotypes of RBC among patients with homozygous betta-thalassemia in Azerbaijan\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__215_P-287\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__216_P-290 Positive direct antiglobulin test (DAT) in newborns: 7 years experience A XANTHAKI, K GEROMERIATI, H KAFKOULA, G BOLLAS, M XYMITIRI, P KARVOUNIARIS, D DRAKOS and A ZOIDOU Thriasio General Hospital, ELEFSINA, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__217_P-292\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__218_YY ZHOU, W XIONG and CP SHAO Shenzhen Blood Center, Shenzhen, China\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__219_09.2: IMMUNOHEMATOLOGY -GRANULOCYTE IMMUNOLOGY\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__220_P-293\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__221_MM SHOOSHTARI, AA DAVATGAR and M AGHAIPOUR Iranian Blood Transfusion Organization, Tehran, Iran\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__222_P-295\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__223_Hippokrateion of Athens, Papagou -Athens, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__224_P-298\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__225_P-300\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__226_P-301\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__227_P-304\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__228_P-307\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__229_A DOESCHER, FF WAGNER and EK PETERSHOFEN Red Cross Blood Transfusion Service, Oldenburg, Germany\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__230_P-310\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__231_P-311\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__232_P-315 Protection with human anti-D immunoglobulin to a D-patient who was transfuse with D+ blood H KAFKOULA, G BOLLAS, A XANTHAKI, M XYMITIRI, J KOTERMAYER, D DRAKOS, F TSEREMIADOU and A ZOIDOU Thriasio General Hospital, Elefsina, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__233_P-320 Chimeric donor cells transfer MCMV specific immunity in a murine transfusion microchimerism model TH LEE, L WEN, D CHAFETS, L MONTALVO, WF REED and MP BUSCH Blood Systems Research Institute, San Francisco, CA, USA\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__234_Summary and conclusion:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__235_11.1: TRANSFUSION ALTERNATIVES -AUTOLOGOUS TRANSFUSION\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__236_P-323 Preoperative autologous blood donation in a few cases with allo-and auto-antibodies M GAVALAKI, TH ADRAKTAS, G KANELLOPOULOU, A KRINI, P KOTSI and A KARAFOULIDOU Laikon General Hospital, Athens, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__237_P-322\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__238_V DANILATOU, E LYDAKI, I NIKOLOUDI, I BOLONAKI and K FOUNTOULI University Hospital of Heraklion, Heraklion, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__239_P-327\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__240_HT TEIMORI Iranian Blood Transfusion Organization, Tehran, Iran\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__241_P-328\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__242_Department of Dental and Maxil, Napoli, Italy\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__243_P-329\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__244_P-330 Transport validation in extreme temperature conditions M ADAMCOVA and R PACASOVA FN Brno, Brno, Czech Republic\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__245_P-337\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__246_P-350\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__247_A VETLESEN, MR MIRLASHARI, F EZLIGINI and J KJELDSEN-KRAGH Ullevaal University Hospital, Oslo, Norway\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__248_P-351\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__249_P-355\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__250_P-356 Bone marrow and abnormalities of hematopoietic microenvironment N DANESHVAR, N TAKZAREE, HR FOROTAN and A TAKZAREE Tehran Univ. of Medical Sciences, Tehran, Iran\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__251_P-360\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__252_P-368\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__253_19: PLASMA FRACTIONATION\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__254_Inst. of Hematology & Blood Transfusion, Warsaw, Poland\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__255_P-380\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__256_K STAMOULIS, S VLACHAKOU and E ECONOMOU-PETERSEN NCPBP E.Politis, NIKEA, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__257_21: VARIOUS\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__258_P-381 Prevalence of hereditary hemochromatosis in patients with hepatitis B or C F ARAUJO, E MEIRELES, J CRUZ, F MONTEIRO, I HENRIQUES, A CRUZ, G TAVARES and G MACEDO Hospital São João, Porto, Portugal\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__259_P-387 Exosomes secreted by dendritic cells (DCS): a new tumor vaccine H FAN, L GAO, K QIAN and Y ZHU Shanghai Blood Center, Shanghai, China\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__260_P-389\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__261_Comments and conclusions:\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__262_P-393\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__263_P-394\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__264_P-396\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__265_P-400\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__266_P-409 Hypofibronogenaemia B BOSNJAK, M MARKOVIC and B KOS Klinicka bolnica Osijek, Osijek, Croatia\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__267_P-415\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__268_P-412 Specificity and clinic importance of anti-erythrocyte antibodies B NIKOLIC, D VIRIJEVIC, S MILIC and Z STANOJKOVIC Blood Transfusion Institute, NIS, Serbia and Montenegro\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__269_P-413\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__270_P ENGLEZOS TIF, Cyprus, Cyprus\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__271_WEDNESDAY PLENARY SESSION 4\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__272_GS STAMATOYANNOPOULOS\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__273_KJ PASI Barts and The London, London, UK\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__274_19: IMMUNE-MEDIATED HEMATOLOGIC DISORDERS V\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__275_HA PAPADAKI University Hospital of Heraklion, Heraklion Crete, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__276_IK KORSHAVN, AC SCHMIDT-MELBYE and HE HEIER Ullevaal University Hospital, Oslo, Norway\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__277_W-PA-117\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__278_K STAMOULIS, V ZEVGOLIS, A DIONISATOU, A ATHANASIOU, I DRAKOU, A BRAMOU, E STEPHANIDIS, S VLACHAKOU and E ECONOMOU-PETERSEN NCPBP E. Politis, Nikea, Greece\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__279_W-PA-119\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__280_JF CHAPMAN Blood Stocks Management Scheme, London, UK\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__281_W-PA-121\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__282_W-PA-122\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__283_E ZHIBURT, P REIZMAN and A VECHERKO Federal Blood Center, Moscow, Russian Federation\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__284_21: ALTERNATIVES TO ALLOGENEIC TRANSFUSION\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__285_P BERIS Geneva University Hospital, Geneva, Switzerland\n",
      "94397d7d7dbb362b167ba30c155c1cd02cd94d77__286_SM KASPER Klinikum Bremerhaven, Bremerhaven, Germany\n",
      "21cc67d7621201e72ce2fa654581cba5b4d301c9__0_Introduction\n",
      "21cc67d7621201e72ce2fa654581cba5b4d301c9__1_Materials and methods\n",
      "21cc67d7621201e72ce2fa654581cba5b4d301c9__2_In vitro cytotoxicity assay\n",
      "21cc67d7621201e72ce2fa654581cba5b4d301c9__3_Immunofluorescent staining and microscopy\n",
      "21cc67d7621201e72ce2fa654581cba5b4d301c9__4_RNA extraction and real-time PCR\n",
      "21cc67d7621201e72ce2fa654581cba5b4d301c9__5_Statistical analysis\n",
      "21cc67d7621201e72ce2fa654581cba5b4d301c9__6_Results\n",
      "21cc67d7621201e72ce2fa654581cba5b4d301c9__7_Discussion\n",
      "9d2c6b24e096eac147115b77f295e0ddcb5435c6__0_Introduction\n",
      "9d2c6b24e096eac147115b77f295e0ddcb5435c6__1_Characterization of KY/180 in Female Ferrets\n",
      "9d2c6b24e096eac147115b77f295e0ddcb5435c6__2_FDG-PET/CT Imaging of the H1N1pdm-infected Ferrets Show Progressive Inflammation\n",
      "9d2c6b24e096eac147115b77f295e0ddcb5435c6__3_Viral shedding and Replication of the Nasal Turbinates and Lung Tissues\n",
      "9d2c6b24e096eac147115b77f295e0ddcb5435c6__4_Histopathology of H1N1pdm-infected and Mock-infected Ferrets\n",
      "9d2c6b24e096eac147115b77f295e0ddcb5435c6__5_FDG-PET/CT and Histopathology Show Positive Correlation During Infection\n",
      "9d2c6b24e096eac147115b77f295e0ddcb5435c6__6_Discussion\n",
      "9d2c6b24e096eac147115b77f295e0ddcb5435c6__7_Virus and Cells\n",
      "9d2c6b24e096eac147115b77f295e0ddcb5435c6__8_Ferrets\n",
      "9d2c6b24e096eac147115b77f295e0ddcb5435c6__9_CT and PET Imaging\n",
      "9d2c6b24e096eac147115b77f295e0ddcb5435c6__10_Image Processing and Analyses\n",
      "9d2c6b24e096eac147115b77f295e0ddcb5435c6__11_Viral Titers in Swabs and Tissues\n",
      "9d2c6b24e096eac147115b77f295e0ddcb5435c6__12_Hemagglutination Inhibition Assay (HI)\n",
      "9d2c6b24e096eac147115b77f295e0ddcb5435c6__13_Histopathology\n",
      "9d2c6b24e096eac147115b77f295e0ddcb5435c6__14_Statistical Analyses\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__0_Background\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__1_Methods\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__2_Findings\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__3_Interpretation\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__4_Introduction\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__5_Research in context\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__6_Added value of this study\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__7_Implications of all the available evidence\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__8_Epidemiological modelling of COVID-19 outbreak in four cities\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__9_(which was not certified by peer review)\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__10_Scenario design for interventions and the timing of policy action\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__11_School closure\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__12_Reduction in other mobility\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__13_Role of the funding source\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__14_Results\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__15_Figure 4 Avoided infected cases of the five policy interventions (Scenarios A -G in\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__16_Discussion\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__17_Declaration of interests\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__18_Open Access Code and Data sharing\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__19_Population age structure\n",
      "d062a4c0a1e7df6f46a60c0862d2a09748d3601f__20_City\n",
      "545134e3cfab85ced28f13d21a992f82f2b7a73d__0_\n",
      "85850a663c0ae83543e47260d6a42f9a36cf68f0__0_Introduction\n",
      "85850a663c0ae83543e47260d6a42f9a36cf68f0__1_Clinical samples\n",
      "85850a663c0ae83543e47260d6a42f9a36cf68f0__2_RNA extraction and RT-PCR\n",
      "85850a663c0ae83543e47260d6a42f9a36cf68f0__3_Primer\n",
      "85850a663c0ae83543e47260d6a42f9a36cf68f0__4_Analytic restriction digest of Conscoro PCR product\n",
      "85850a663c0ae83543e47260d6a42f9a36cf68f0__5_Cloning and sequencing of PCR products\n",
      "85850a663c0ae83543e47260d6a42f9a36cf68f0__6_Phylogenetic analysis\n",
      "85850a663c0ae83543e47260d6a42f9a36cf68f0__7_GenBank accession numbers\n",
      "85850a663c0ae83543e47260d6a42f9a36cf68f0__8_PCR analysis for CRCoV and CCoV\n",
      "85850a663c0ae83543e47260d6a42f9a36cf68f0__9_Sequence analysis of N gene and M gene PCR products\n",
      "85850a663c0ae83543e47260d6a42f9a36cf68f0__10_Sequence analysis of the 5 end of the spike gene\n",
      "85850a663c0ae83543e47260d6a42f9a36cf68f0__11_Sequence analysis of ORFs 7a and 7b\n",
      "85850a663c0ae83543e47260d6a42f9a36cf68f0__12_Discussion\n",
      "86f2ce979023ce2b61ab1650331e7cdebf8e1aa8__0_\n",
      "86f2ce979023ce2b61ab1650331e7cdebf8e1aa8__1_Specimens\n",
      "86f2ce979023ce2b61ab1650331e7cdebf8e1aa8__2_RNA extraction and RT-PCR\n",
      "86f2ce979023ce2b61ab1650331e7cdebf8e1aa8__3_Virus isolation\n",
      "86f2ce979023ce2b61ab1650331e7cdebf8e1aa8__4_Detection of intracytoplasmic viral inclusion body\n",
      "86f2ce979023ce2b61ab1650331e7cdebf8e1aa8__5_Transmission electron microscopy (TEM)\n",
      "86f2ce979023ce2b61ab1650331e7cdebf8e1aa8__6_Hemagglutination (HA) assay\n",
      "86f2ce979023ce2b61ab1650331e7cdebf8e1aa8__7_DNA sequencing and molecular analysis\n",
      "86f2ce979023ce2b61ab1650331e7cdebf8e1aa8__8_Results\n",
      "86f2ce979023ce2b61ab1650331e7cdebf8e1aa8__9_Discussion\n",
      "29e127bd725d589be1458079521381080cfc2e90__0_\n",
      "29e127bd725d589be1458079521381080cfc2e90__1_METHODS\n",
      "29e127bd725d589be1458079521381080cfc2e90__2_Anti-oxidant Enzyme Activities\n",
      "29e127bd725d589be1458079521381080cfc2e90__3_Changes in Animal Weights following Ozone Exposure\n",
      "29e127bd725d589be1458079521381080cfc2e90__4_Ozne\n",
      "29e127bd725d589be1458079521381080cfc2e90__5_DISCUSSION\n",
      "9d1128280d095834077759a4529827311a6b6708__0_Introduction\n",
      "9d1128280d095834077759a4529827311a6b6708__1_Chemistry\n",
      "9d1128280d095834077759a4529827311a6b6708__2_Anti-HCMV activity\n",
      "9d1128280d095834077759a4529827311a6b6708__3_Anti-VZV activity\n",
      "9d1128280d095834077759a4529827311a6b6708__4_Conclusions\n",
      "9d1128280d095834077759a4529827311a6b6708__5_General\n",
      "9d1128280d095834077759a4529827311a6b6708__6_Compounds 4a, 4b, 4d-k\n",
      "9d1128280d095834077759a4529827311a6b6708__7_1-[5-(3-Bromophenoxy)pentyl]uracil (4c).\n",
      "9d1128280d095834077759a4529827311a6b6708__8_1-[4-[(4-Bromobenzyl)oxy]butyl]uracil (16).\n",
      "9d1128280d095834077759a4529827311a6b6708__9_1-[[2-(4-Bromobenzyloxy)ethoxy]methyl]-uracil (19).\n",
      "9d1128280d095834077759a4529827311a6b6708__10_1-[4-(4-Bromophenoxy)benzyl]uracil (22).\n",
      "9d1128280d095834077759a4529827311a6b6708__11_General procedure for the synthesis of 2-chloro-N-(4substituted phenyl)acetamide 6a-c\n",
      "9d1128280d095834077759a4529827311a6b6708__12_4.2.3.\n",
      "9d1128280d095834077759a4529827311a6b6708__13_Anti-HIV activity assays.\n",
      "9d1128280d095834077759a4529827311a6b6708__14_Cytostatic activity assays.\n",
      "60f0773c8eeace01dd0364c5c63febbfe9dd3a62__0_Introduction\n",
      "60f0773c8eeace01dd0364c5c63febbfe9dd3a62__1_Ethics statement\n",
      "60f0773c8eeace01dd0364c5c63febbfe9dd3a62__2_Animals, vaccination, and experimental challenge with Leishmania chagasi plus Lutzomyia longipalpis saliva\n",
      "60f0773c8eeace01dd0364c5c63febbfe9dd3a62__3_Vaccine preparation\n",
      "60f0773c8eeace01dd0364c5c63febbfe9dd3a62__4_Blood sample collection and PBMCs culture in vitro\n",
      "60f0773c8eeace01dd0364c5c63febbfe9dd3a62__5_Quantification of cytokines\n",
      "60f0773c8eeace01dd0364c5c63febbfe9dd3a62__6_NO production\n",
      "60f0773c8eeace01dd0364c5c63febbfe9dd3a62__7_Spleen samples and parasite load measurement by qPCR\n",
      "60f0773c8eeace01dd0364c5c63febbfe9dd3a62__8_Statistical analysis\n",
      "60f0773c8eeace01dd0364c5c63febbfe9dd3a62__9_Results\n",
      "60f0773c8eeace01dd0364c5c63febbfe9dd3a62__10_Discussion\n",
      "28cfe86a8fa13dacd3f447dcb095ac9a9f99a33a__0_\n",
      "28cfe86a8fa13dacd3f447dcb095ac9a9f99a33a__1_Acknowledgments\n",
      "51340894a896316b58653a60c48da9c16b3ad0e3__0_Results\n",
      "51340894a896316b58653a60c48da9c16b3ad0e3__1_OXY inhibits a Late\n",
      "51340894a896316b58653a60c48da9c16b3ad0e3__2_Salicylanilide anthelmintic drugs restrict HCMV infection.\n",
      "51340894a896316b58653a60c48da9c16b3ad0e3__3_Discussion\n",
      "51340894a896316b58653a60c48da9c16b3ad0e3__4_HAdV-mediated endosome disruption.\n",
      "51340894a896316b58653a60c48da9c16b3ad0e3__5_Virus yield reduction.\n",
      "51340894a896316b58653a60c48da9c16b3ad0e3__6_HCMV infectivity assay by quantitative PCR.\n",
      "d800dfd11a8200915ebe5144b41eae3116adbe5a__0_\n",
      "d800dfd11a8200915ebe5144b41eae3116adbe5a__1_Co-culture of cells\n",
      "d800dfd11a8200915ebe5144b41eae3116adbe5a__2_Infection with adenovirus\n",
      "d800dfd11a8200915ebe5144b41eae3116adbe5a__3_Development of the isolated co-culture cell system\n",
      "d800dfd11a8200915ebe5144b41eae3116adbe5a__4_DISCUSSION\n",
      "eb4e468f68974db552de7a9f4e41d95607b0c461__0_Background\n",
      "eb4e468f68974db552de7a9f4e41d95607b0c461__1_Genomic Organization and Sequence Divergence of FIV Ple\n",
      "eb4e468f68974db552de7a9f4e41d95607b0c461__2_Phylogenetic Analyses of FIV Ple Subtypes\n",
      "eb4e468f68974db552de7a9f4e41d95607b0c461__3_Discordant env phylogeny between FIV Ple subtypes reveals ancestral FIV recombination events in the wild\n",
      "eb4e468f68974db552de7a9f4e41d95607b0c461__4_B. Env (2958 bp) A. Combined All Genes (9391 bp)\n",
      "eb4e468f68974db552de7a9f4e41d95607b0c461__5_Conclusion\n",
      "eb4e468f68974db552de7a9f4e41d95607b0c461__6_Cell Culture of FIV Ple Subtype E Botswana lion Ple-1027\n",
      "eb4e468f68974db552de7a9f4e41d95607b0c461__7_Cell Culture of FIV Ple Subtype B: Serengeti lion Ple-458\n",
      "eb4e468f68974db552de7a9f4e41d95607b0c461__8_DNA extraction, Cloning and Sequencing of FIV Ple Subtypes B and E\n",
      "eb4e468f68974db552de7a9f4e41d95607b0c461__9_FIV\n",
      "63cd7bbd5d2e326dd0b41652646db9725f17d709__0_Introduction\n",
      "63cd7bbd5d2e326dd0b41652646db9725f17d709__1_Ethics guidelines on COVID-19 triage-a synopsis\n",
      "63cd7bbd5d2e326dd0b41652646db9725f17d709__2_Discussion\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__0_Inleiding\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__1_Bloedgroepbepaling\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__2_Bloedgroepsystemen\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__3_Antistofscreening\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__4_Bloedproducten\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__5_J.T.A. Knape\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__6_Vroege transfusiereacties en complicaties van transfusies\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__7_Acute hemolyse, NHTR, TRALI, TA-GVHD\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__8_Bacteriële contaminatie\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__9_Volumeoverbelasting\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__10_Anafylactische transfusiereacties\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__11_Late en subklinische complicaties van transfusiereacties Purpura\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__12_Uitgestelde hemolytische transfusiereacties\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__13_Immunologische effecten\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__14_Posttransfusiehepatitis, hiv of aids\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__15_Indicaties voor erytrocytentransfusie\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__16_Kernpunten\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__17_Transfusie bij aanmaakstoornissen\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__18_4-5-6-regel (UMC Groningen)\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__19_Afbraakstoornissen\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__20_Indicaties bij acute anemie\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__21_Cardiovasculair belaste patiënten\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__22_Cerebraal belaste patiënten\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__23_Pulmonaal belaste patiënten\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__24_Massaal bloedverlies\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__25_Compensatoire fenomenen\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__26_Casus\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__27_Massaal bloedverlies tijdens de graviditeit\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__28_Indicaties voor trombocytentransfusie\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__29_Trombocytopenie\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__30_Trombocytopathie door acetylsalicylzuur en NSAID's\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__31_Trombocytengetal\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__32_Indicaties voor vers plasma\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__33_Deficiënties in de stolling\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__34_Fibrinolytische therapie couperen\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__35_Heparine-effecten met protamine couperen\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__36_Bloedbesparende technieken\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__37_Erytropoëtine\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__38_Factor VIIa\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__39_Weigering bloedtransfusie\n",
      "1a40a631728aaf36e96427131c6c96c23ddf6e4c__40_Hemovigilantie\n",
      "ce4bde08cb7e899ebf6061f3d369e81e94087113__0_\n",
      "ce4bde08cb7e899ebf6061f3d369e81e94087113__1_Origin and Metabolism of Biogenic Fatty Acids\n",
      "ce4bde08cb7e899ebf6061f3d369e81e94087113__2_Involvement of the PLA 2 Family in the Inflammatory Process\n",
      "ce4bde08cb7e899ebf6061f3d369e81e94087113__3_Platelet Activating Factor (PAF)\n",
      "ce4bde08cb7e899ebf6061f3d369e81e94087113__4_Prostaglandins\n",
      "ce4bde08cb7e899ebf6061f3d369e81e94087113__5_Leukotrienes\n",
      "ce4bde08cb7e899ebf6061f3d369e81e94087113__6_Impact of ω-3 Fatty Acid Supplementation on Lipid Mediator Generation\n",
      "ce4bde08cb7e899ebf6061f3d369e81e94087113__7_Conclusions\n",
      "db987742f029e0ff2ef3e88aa7c9b13ea6c3612b__0_\n",
      "db987742f029e0ff2ef3e88aa7c9b13ea6c3612b__1_Acute Rhinitis\n",
      "db987742f029e0ff2ef3e88aa7c9b13ea6c3612b__2_Post-URTI Disorders\n",
      "db987742f029e0ff2ef3e88aa7c9b13ea6c3612b__3_Allergic Rhinitis\n",
      "db987742f029e0ff2ef3e88aa7c9b13ea6c3612b__4_Rhinosinusitis (Acute or Chronic, with or without Polyps)\n",
      "db987742f029e0ff2ef3e88aa7c9b13ea6c3612b__5_Oral Inflammation\n",
      "db987742f029e0ff2ef3e88aa7c9b13ea6c3612b__6_Conflicts of Interest\n",
      "efbdd8ddbea0a0eaa99be1f66e98864592b991d2__0_Introduction\n",
      "efbdd8ddbea0a0eaa99be1f66e98864592b991d2__1_Design concept\n",
      "efbdd8ddbea0a0eaa99be1f66e98864592b991d2__2_Challenges\n",
      "efbdd8ddbea0a0eaa99be1f66e98864592b991d2__3_Conclusion\n",
      "efbdd8ddbea0a0eaa99be1f66e98864592b991d2__4_Compliance with ethical standards\n",
      "a6604f5c880a6a511053e91df3800780cdc3a876__0_\n",
      "a6604f5c880a6a511053e91df3800780cdc3a876__1_Results\n",
      "a6604f5c880a6a511053e91df3800780cdc3a876__2_Water-borne\n",
      "a6604f5c880a6a511053e91df3800780cdc3a876__3_2001-2007\n",
      "a6604f5c880a6a511053e91df3800780cdc3a876__4_Authors Location and year of flood Study design Main results\n",
      "a6604f5c880a6a511053e91df3800780cdc3a876__5_Discussion\n",
      "a6604f5c880a6a511053e91df3800780cdc3a876__6_Risk of bias and quality assessment\n",
      "a6604f5c880a6a511053e91df3800780cdc3a876__7_Conclusions and Further Research\n",
      "a6604f5c880a6a511053e91df3800780cdc3a876__8_Disclosure of Potential Conflicts of Interest\n",
      "a6604f5c880a6a511053e91df3800780cdc3a876__9_Acknowledgments\n",
      "a6604f5c880a6a511053e91df3800780cdc3a876__10_Literature Review Methodology\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__0_Background\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__1_B.\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__2_Infection of U937 cells is acid-independent\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__3_Analysis of reovirus replication in U937 cells differentiated by PMA\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__4_NE can facilitate reovirus infection in U937 cells\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__5_NE-generated subviral particles are infectious and do not require additional proteolytic processing\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__6_NE, an acid-independent serine protease, can promote productive reovirus infection in U937 promonocytes\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__7_Does the serine protease Cat G also play a role in reovirus infection of U937 cells?\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__8_The acid-dependence of reovirus infection is a reflection of the requirements for protease activation\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__9_Does NE mediate uncoating intracellularly or extracellularly in U937 cell cultures?\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__10_Implications for infection in the host\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__11_Measurement of cysteine protease activity\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__12_Immunoblot analysis of NE expression\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__13_Analysis of viral protein expression in infected cells\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__14_Generation of NE subviral particles for infection\n",
      "dff6195f5e24ebfa2fb4060142611b48021f673c__15_Analysis of virus titer after NE treatment of virions\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__0_Take Home message\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__1_(which was not certified by peer review)\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__2_INTRODUCTION\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__3_Data source\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__4_Study design and definitions\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__5_Statistical analysis\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__6_Baseline demographics between case and test negative controls\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__7_Comorbidities associated with diagnosis of COVID-19\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__8_Analysis of subpopulation which excluded high regional outbreak area (DG area)\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__9_Analysis of subpopulation in high regional outbreak area (DG area)\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__10_Baseline demographics between severe and non-severe confirmed COVID-19\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__11_Result of Overall analysis\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__12_DISCUSSION\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__13_CONCLUSION\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__14_Conflict of Interest Disclosures:\n",
      "a9dc8e80b30bb3d4a5ea38c6c5c5a58d6fab12da__15_Funding/Support: This study was supported by grants from the Gachon University Gil\n",
      "405b6caaf6c4d621f41c35217147a073ab87a87c__0_Introduction\n",
      "405b6caaf6c4d621f41c35217147a073ab87a87c__1_Viruses\n",
      "405b6caaf6c4d621f41c35217147a073ab87a87c__2_Virulence test\n",
      "405b6caaf6c4d621f41c35217147a073ab87a87c__3_Nineteen IBV strains isolated between 2008 and 2010 in Sichuan province\n",
      "405b6caaf6c4d621f41c35217147a073ab87a87c__4_Virulence study\n",
      "405b6caaf6c4d621f41c35217147a073ab87a87c__5_Discussion\n",
      "193df1e1948baf738c46f9325a04454f96b19868__0_SARS-PsV and MERS-PsV production and concentration\n",
      "193df1e1948baf738c46f9325a04454f96b19868__1_Mice immunization\n",
      "193df1e1948baf738c46f9325a04454f96b19868__2_Neutralization assay\n",
      "1a718b68d87befef4bc6881add5c832febd5a3a1__0_CORONAVIRUS-LIKE PARTICLES IN DIARRHOEA STOOLS\n",
      "6a4a0de0df03bfd7860d0732ea9d42daeac06b10__0_\n",
      "6a4a0de0df03bfd7860d0732ea9d42daeac06b10__1_Specimen Collection\n",
      "6a4a0de0df03bfd7860d0732ea9d42daeac06b10__2_Cell Culture and Virus Isolation\n",
      "6a4a0de0df03bfd7860d0732ea9d42daeac06b10__3_Neutralization Assays with an Antibody Pool\n",
      "6a4a0de0df03bfd7860d0732ea9d42daeac06b10__4_Extraction of Viral RNA\n",
      "6a4a0de0df03bfd7860d0732ea9d42daeac06b10__5_RT-PCR and Sequencing of DNA\n",
      "6a4a0de0df03bfd7860d0732ea9d42daeac06b10__6_Sequence Analysis\n",
      "6a4a0de0df03bfd7860d0732ea9d42daeac06b10__7_Results\n",
      "6a4a0de0df03bfd7860d0732ea9d42daeac06b10__8_Discussion\n",
      "0b400fadfa150bb8da5700e8dcdfbe069574468b__0_4\n",
      "0b400fadfa150bb8da5700e8dcdfbe069574468b__1_Molecular dynamic simulations guide peptide binder design 91\n",
      "0b400fadfa150bb8da5700e8dcdfbe069574468b__2_SBP1 peptide specifically binds SARS-CoV-2-RBD with low nanomolar affinity 109\n",
      "0b400fadfa150bb8da5700e8dcdfbe069574468b__3_120\n",
      "0b400fadfa150bb8da5700e8dcdfbe069574468b__4_6\n",
      "0b400fadfa150bb8da5700e8dcdfbe069574468b__5_7\n",
      "0b400fadfa150bb8da5700e8dcdfbe069574468b__6_GPU-accelerated molecular dynamic simulation 174\n",
      "0b400fadfa150bb8da5700e8dcdfbe069574468b__7_Peptide cleavage and deprotection 192\n",
      "9ce2121413f1ccb8c09161b73ef0bd66804373c7__0_\n",
      "9ce2121413f1ccb8c09161b73ef0bd66804373c7__1_Side effects of novel cancer immunotherapies\n",
      "9ce2121413f1ccb8c09161b73ef0bd66804373c7__2_Immun-Checkpoint-Signalweg in der zellulären Immunantwort\n",
      "9ce2121413f1ccb8c09161b73ef0bd66804373c7__3_Übergreifende Prinzipien von immunvermittelten Nebenwirkungen\n",
      "9ce2121413f1ccb8c09161b73ef0bd66804373c7__4_Organsystembezogene Diagnostik und Therapie von irAE\n",
      "9ce2121413f1ccb8c09161b73ef0bd66804373c7__5_Hautbefall\n",
      "9ce2121413f1ccb8c09161b73ef0bd66804373c7__6_Gastrointestinale Manifestation\n",
      "9ce2121413f1ccb8c09161b73ef0bd66804373c7__7_Endokrine Manifestation\n",
      "9ce2121413f1ccb8c09161b73ef0bd66804373c7__8_Nierenbeteiligung\n",
      "9ce2121413f1ccb8c09161b73ef0bd66804373c7__9_Entzündlich-rheumatische Nebenwirkungen\n",
      "9ce2121413f1ccb8c09161b73ef0bd66804373c7__10_Leitlinien\n",
      "9ce2121413f1ccb8c09161b73ef0bd66804373c7__11_Fazit für die Praxis\n",
      "30902c33683438d343f4cb8c1858819bb16de596__0_\n",
      "30902c33683438d343f4cb8c1858819bb16de596__1_Introduction\n",
      "30902c33683438d343f4cb8c1858819bb16de596__2_Virus stocks and cell cultures\n",
      "30902c33683438d343f4cb8c1858819bb16de596__3_Assays for viral transcr~~tase activity\n",
      "30902c33683438d343f4cb8c1858819bb16de596__4_Electrophoresis of viral proteins and RNA species\n",
      "30902c33683438d343f4cb8c1858819bb16de596__5_Inhibition of virus yields by papaverine\n",
      "30902c33683438d343f4cb8c1858819bb16de596__6_Effect of papaverine on synthesis of viral proteins\n",
      "30902c33683438d343f4cb8c1858819bb16de596__7_Nucleic acid synthesis in papaverine-treated cells\n",
      "30902c33683438d343f4cb8c1858819bb16de596__8_Drug effect on viral transcription\n",
      "30902c33683438d343f4cb8c1858819bb16de596__9_After Wrus Adsorption\n",
      "30902c33683438d343f4cb8c1858819bb16de596__10_Discussion\n",
      "d0464b088c3c7a939a2f1862f7e910ffd9340eeb__0_Introduction\n",
      "d0464b088c3c7a939a2f1862f7e910ffd9340eeb__1_Study population\n",
      "d0464b088c3c7a939a2f1862f7e910ffd9340eeb__2_Molecular laboratory procedures\n",
      "d0464b088c3c7a939a2f1862f7e910ffd9340eeb__3_Statistical analysis\n",
      "d0464b088c3c7a939a2f1862f7e910ffd9340eeb__4_Distribution of respiratory viruses\n",
      "d0464b088c3c7a939a2f1862f7e910ffd9340eeb__5_Age and sex distribution of detected viruses\n",
      "d0464b088c3c7a939a2f1862f7e910ffd9340eeb__6_Seasonal distribution of detected viruses\n",
      "d0464b088c3c7a939a2f1862f7e910ffd9340eeb__7_Clinical features of respiratory viruses\n",
      "d0464b088c3c7a939a2f1862f7e910ffd9340eeb__8_Characteristic laboratory features of respiratory viruses\n",
      "d0464b088c3c7a939a2f1862f7e910ffd9340eeb__9_Discussion\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__0_Problem description and assumptions\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__1_Objectives and contributions\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__2_Formulation over a finite time interval\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__3_A formula for x ∞\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__4_Bounds on x ∞\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__5_Existence and necessary conditions for an optimal control\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__6_6\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__7_Infinite-time control\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__8_Lemma 4.\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__9_9\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__10_Thus, maximizing x ∞ (T ) is equivalent to maximizing\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__11_Optimal control with L = 0\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__12_Quadratic running cost of control\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__13_Minimizing hospital overflow\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__14_Application to the COVID-19 pandemic\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__15_18\n",
      "60b39342bba3246e04aeb5cd0636e88378c95861__16_Conclusion\n",
      "0bf39c12d7c4576441079e2e758ec1eacfe015d1__0_\n",
      "0bf39c12d7c4576441079e2e758ec1eacfe015d1__1_KSHV particles are trafficked beyond the early endosome for late endosomal escape\n",
      "0bf39c12d7c4576441079e2e758ec1eacfe015d1__2_Immunofluorescence microscopy demonstrates KSHV to localize in EEs and LEs\n",
      "0bf39c12d7c4576441079e2e758ec1eacfe015d1__3_Discussion\n",
      "0bf39c12d7c4576441079e2e758ec1eacfe015d1__4_Conclusions\n",
      "0bf39c12d7c4576441079e2e758ec1eacfe015d1__5_Cells\n",
      "0bf39c12d7c4576441079e2e758ec1eacfe015d1__6_Antibodies\n",
      "0bf39c12d7c4576441079e2e758ec1eacfe015d1__7_Proteins and reagents\n",
      "0bf39c12d7c4576441079e2e758ec1eacfe015d1__8_Sucrose flotation gradient\n",
      "0bf39c12d7c4576441079e2e758ec1eacfe015d1__9_Western blotting and acid phosphatase activity assay\n",
      "0bf39c12d7c4576441079e2e758ec1eacfe015d1__10_Monitoring KSHV levels in gradient fractions by qPCR\n",
      "0bf39c12d7c4576441079e2e758ec1eacfe015d1__11_Immunofluorescence microscopy\n",
      "f38fb37b63f9d5af92c01ea934be0536a92ef5ac__0_\n",
      "9f82db8107ec9ced3f686b30ccc27645cd6f9643__0_\n",
      "9f82db8107ec9ced3f686b30ccc27645cd6f9643__1_Study Population\n",
      "9f82db8107ec9ced3f686b30ccc27645cd6f9643__2_Study Period\n",
      "9f82db8107ec9ced3f686b30ccc27645cd6f9643__3_Laboratory Analysis\n",
      "9f82db8107ec9ced3f686b30ccc27645cd6f9643__4_Statistical Analysis\n",
      "9f82db8107ec9ced3f686b30ccc27645cd6f9643__5_Ethics\n",
      "9f82db8107ec9ced3f686b30ccc27645cd6f9643__6_Enrollment\n",
      "9f82db8107ec9ced3f686b30ccc27645cd6f9643__7_Characteristics of Participants\n",
      "9f82db8107ec9ced3f686b30ccc27645cd6f9643__8_Detected Viruses\n",
      "9f82db8107ec9ced3f686b30ccc27645cd6f9643__9_Characteristics of Participants With Different Types of Detected Viruses\n",
      "9f82db8107ec9ced3f686b30ccc27645cd6f9643__10_Deaths in Participants\n",
      "9f82db8107ec9ced3f686b30ccc27645cd6f9643__11_Healthcare-Associated Infections\n",
      "9f82db8107ec9ced3f686b30ccc27645cd6f9643__12_DISCUSSION\n",
      "9f82db8107ec9ced3f686b30ccc27645cd6f9643__13_Supplementary Material\n",
      "22fedac215550efbec7acb5582b5a205ef2e1672__0_Introduction\n",
      "22fedac215550efbec7acb5582b5a205ef2e1672__1_Humans\n",
      "22fedac215550efbec7acb5582b5a205ef2e1672__2_Animals\n",
      "22fedac215550efbec7acb5582b5a205ef2e1672__3_Virus Propagation\n",
      "22fedac215550efbec7acb5582b5a205ef2e1672__4_Molecular Virology and Protein Expression\n",
      "22fedac215550efbec7acb5582b5a205ef2e1672__5_Evolution\n",
      "22fedac215550efbec7acb5582b5a205ef2e1672__6_Mammalian Astroviruses\n",
      "22fedac215550efbec7acb5582b5a205ef2e1672__7_Avian Astroviruses\n",
      "22fedac215550efbec7acb5582b5a205ef2e1672__8_Immune Response\n",
      "22fedac215550efbec7acb5582b5a205ef2e1672__9_Treatment, Prevention, and Control\n",
      "a7641fd45a605bc6226e08daa05f6fcc9767c825__0_introduction\n",
      "a7641fd45a605bc6226e08daa05f6fcc9767c825__1_model\n",
      "a7641fd45a605bc6226e08daa05f6fcc9767c825__2_Theoretical analysis\n",
      "a7641fd45a605bc6226e08daa05f6fcc9767c825__3_Results\n",
      "a7641fd45a605bc6226e08daa05f6fcc9767c825__4_Conclusion\n",
      "1274bafe9ad51a9de304cac9ac7237811bfe0b43__0_\n",
      "1274bafe9ad51a9de304cac9ac7237811bfe0b43__1_Materials and Methods\n",
      "1274bafe9ad51a9de304cac9ac7237811bfe0b43__2_Methods of diagnosis for viruses.\n",
      "1274bafe9ad51a9de304cac9ac7237811bfe0b43__3_Results\n",
      "1274bafe9ad51a9de304cac9ac7237811bfe0b43__4_Association between thrombocytosis, clinical features and viral infection from the logistic regression analysis.\n",
      "1274bafe9ad51a9de304cac9ac7237811bfe0b43__5_Complication and prognosis of thrombocytosis group.\n",
      "1274bafe9ad51a9de304cac9ac7237811bfe0b43__6_Discussion\n",
      "d0f4b6cbebcae6a0fa9a145e74783391ca8cada9__0_\n",
      "d0f4b6cbebcae6a0fa9a145e74783391ca8cada9__1_Virus stocks and viral culture.\n",
      "d0f4b6cbebcae6a0fa9a145e74783391ca8cada9__2_Sensitivity and specificity.\n",
      "d0f4b6cbebcae6a0fa9a145e74783391ca8cada9__3_DISCUSSION\n",
      "05ab207a64078304b97d725886cc42f595afda00__0_\n",
      "05ab207a64078304b97d725886cc42f595afda00__1_Planning phase\n",
      "05ab207a64078304b97d725886cc42f595afda00__2_Effective intervention measures 7\n",
      "05ab207a64078304b97d725886cc42f595afda00__3_Financial incentive\n",
      "05ab207a64078304b97d725886cc42f595afda00__4_Performance\n",
      "05ab207a64078304b97d725886cc42f595afda00__5_Executive phase\n",
      "05ab207a64078304b97d725886cc42f595afda00__6_Regional development of model hospitals\n",
      "05ab207a64078304b97d725886cc42f595afda00__7_Regional assessment and screening of participating hospitals\n",
      "05ab207a64078304b97d725886cc42f595afda00__8_Policy evaluation phase\n",
      "05ab207a64078304b97d725886cc42f595afda00__9_Challenges of HAI in Taiwan\n",
      "05ab207a64078304b97d725886cc42f595afda00__10_Conflicts of interest\n",
      "a986a6d115df1e271c89a765800aa931ac3f6833__0_Background\n",
      "a986a6d115df1e271c89a765800aa931ac3f6833__1_FETP regional programmes and networks\n",
      "a986a6d115df1e271c89a765800aa931ac3f6833__2_Partners in implementation\n",
      "a986a6d115df1e271c89a765800aa931ac3f6833__3_Methods\n",
      "a986a6d115df1e271c89a765800aa931ac3f6833__4_FETP curricula\n",
      "a986a6d115df1e271c89a765800aa931ac3f6833__5_Collaborating organizations and agencies\n",
      "a986a6d115df1e271c89a765800aa931ac3f6833__6_FETP residents and graduates\n",
      "a986a6d115df1e271c89a765800aa931ac3f6833__7_Some recent FETP activities and accomplishments\n",
      "a986a6d115df1e271c89a765800aa931ac3f6833__8_Quality improvement\n",
      "a986a6d115df1e271c89a765800aa931ac3f6833__9_Discussion\n",
      "a986a6d115df1e271c89a765800aa931ac3f6833__10_Conclusions\n",
      "a986a6d115df1e271c89a765800aa931ac3f6833__11_Competing interests\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__0_Introduction\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__1_Reagents\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__2_Cells and viruses\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__3_Generation of LCMV/vRNP cell line\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__4_Generation of LASV/vRNP cell line\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__5_Expression of NP and L in the LCMV/vRNP cell line\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__6_Expression of NP and L in the LASV/vRNP cell line\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__7_siRNA knockdown of LCMV and LASV L polymerases\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__8_Multiplexed vRNP-cytotoxicity assay\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__9_Compound libraries and qHTS\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__10_Determination of compounds EC 50 and CC 50 in LCMV cell-based infection assay\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__11_Data and statistical analysis\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__12_Determination of production of LCMV infectious progeny\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__13_LCMV MG assay\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__14_LASV MG assay\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__15_Generation and characterization of cell lines expressing functional LCMV and LASV vRNPs\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__16_Assay performance in 1,536-well format\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__17_qHTS and confirmation\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__18_Functional confirmation of vRNPs as targets of selected hits\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__19_Hit validation in the context of LCMV infection\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__20_Discussion\n",
      "84e52da5894b060f5642f40b6eac9d6df16a56c6__21_Conclusion\n",
      "8f98c8621da6438169976931b2bc2cce12959a70__0_Introduction\n",
      "8f98c8621da6438169976931b2bc2cce12959a70__1_Fungal strains and culture conditions\n",
      "8f98c8621da6438169976931b2bc2cce12959a70__2_Frameshifting efficiency\n",
      "8f98c8621da6438169976931b2bc2cce12959a70__3_Deletion of PaYIP3\n",
      "8f98c8621da6438169976931b2bc2cce12959a70__4_Complementation of PaYIP3 and creation of truncated and corrected CDS (coding sequence)\n",
      "8f98c8621da6438169976931b2bc2cce12959a70__5_Plasmid constructions for GFP-tagging\n",
      "8f98c8621da6438169976931b2bc2cce12959a70__6_Western blot analysis\n",
      "8f98c8621da6438169976931b2bc2cce12959a70__7_Microscopy analysis\n",
      "8f98c8621da6438169976931b2bc2cce12959a70__8_Phylogenetic analysis\n",
      "8f98c8621da6438169976931b2bc2cce12959a70__9_Results\n",
      "8f98c8621da6438169976931b2bc2cce12959a70__10_The -1 frameshift of PaYIP3 has been conserved during the evolution of Pezizomycotina\n",
      "8f98c8621da6438169976931b2bc2cce12959a70__11_Complementation of the PaYIP3 D mutant\n",
      "8f98c8621da6438169976931b2bc2cce12959a70__12_Tagging the wild-type, short and long forms of PaYIP3 with GFP\n",
      "8f98c8621da6438169976931b2bc2cce12959a70__13_Quantification of -1 frameshifting efficiency\n",
      "8f98c8621da6438169976931b2bc2cce12959a70__14_Discussion\n",
      "548d91668f76b6b964f7d05624e5883d955988b2__0_\n",
      "548d91668f76b6b964f7d05624e5883d955988b2__1_Results\n",
      "7b78b3f3345bdf445955d1394fe122a84a8c4694__0_Introduction\n",
      "7b78b3f3345bdf445955d1394fe122a84a8c4694__1_Background\n",
      "7b78b3f3345bdf445955d1394fe122a84a8c4694__2_Role as a Surgeon\n",
      "7b78b3f3345bdf445955d1394fe122a84a8c4694__3_Role as a Medical Doctor\n",
      "7b78b3f3345bdf445955d1394fe122a84a8c4694__4_Role as a Teacher\n",
      "7b78b3f3345bdf445955d1394fe122a84a8c4694__5_Role in the Family\n",
      "9721af1b88d60abbff468d841941f85a13731861__0_\n",
      "9721af1b88d60abbff468d841941f85a13731861__1_METHODS Subjects\n",
      "9721af1b88d60abbff468d841941f85a13731861__2_Cough aerosol sampling system (CASS)\n",
      "9721af1b88d60abbff468d841941f85a13731861__3_CASS protocol\n",
      "9721af1b88d60abbff468d841941f85a13731861__4_Clinical parameters Pulmonary function testing\n",
      "9721af1b88d60abbff468d841941f85a13731861__5_Other\n",
      "9721af1b88d60abbff468d841941f85a13731861__6_Room air sampling and air exchange\n",
      "9721af1b88d60abbff468d841941f85a13731861__7_CASS aerosol samples and chamber settle plate\n",
      "9721af1b88d60abbff468d841941f85a13731861__8_Sputum samples, afferent limb cultures and air samples\n",
      "9721af1b88d60abbff468d841941f85a13731861__9_Analysis of data\n",
      "9721af1b88d60abbff468d841941f85a13731861__10_CASS studies\n",
      "9721af1b88d60abbff468d841941f85a13731861__11_Sputum microbiology\n",
      "9721af1b88d60abbff468d841941f85a13731861__12_CASS microbiology\n",
      "9721af1b88d60abbff468d841941f85a13731861__13_Settle plate and air sampling microbiology\n",
      "9721af1b88d60abbff468d841941f85a13731861__14_DISCUSSION\n",
      "d311964341e7e167635e150212eee7d7a70130e8__0_Introduction\n",
      "d311964341e7e167635e150212eee7d7a70130e8__1_Case Report\n",
      "d311964341e7e167635e150212eee7d7a70130e8__2_Discussion\n",
      "68dec1e5e53ca0b9bc7e95a5d7fe67dba19cb690__0_Results\n",
      "68dec1e5e53ca0b9bc7e95a5d7fe67dba19cb690__1_Discussion\n",
      "68dec1e5e53ca0b9bc7e95a5d7fe67dba19cb690__2_Methods\n",
      "78b8eff744fe41ac2145931868e6a5c964d1c68e__0_\n",
      "78b8eff744fe41ac2145931868e6a5c964d1c68e__1_Receptor Binding Inhibition Assay\n",
      "78b8eff744fe41ac2145931868e6a5c964d1c68e__2_Hemagglutination Assay\n",
      "78b8eff744fe41ac2145931868e6a5c964d1c68e__3_Hemagglutination Inhibition Assay\n",
      "78b8eff744fe41ac2145931868e6a5c964d1c68e__4_Plaque Reduction Neutralization Assay (PRNT)\n",
      "901572f1595cb6ea733858d3fc15b8ea46054061__0_Introduction\n",
      "901572f1595cb6ea733858d3fc15b8ea46054061__1_Study Design and Participants\n",
      "901572f1595cb6ea733858d3fc15b8ea46054061__2_Real-Time Reverse Transcription Polymerase Chain Reaction Assay for SARS-CoV-2\n",
      "901572f1595cb6ea733858d3fc15b8ea46054061__3_Flow Cytometry Data Analysis\n",
      "901572f1595cb6ea733858d3fc15b8ea46054061__4_Statistical Analysis\n",
      "901572f1595cb6ea733858d3fc15b8ea46054061__5_Presenting Characteristics\n",
      "901572f1595cb6ea733858d3fc15b8ea46054061__6_Radiologic and Laboratory Parameters in Mild and Severe or Critical Patients\n",
      "901572f1595cb6ea733858d3fc15b8ea46054061__7_Discussion\n",
      "901572f1595cb6ea733858d3fc15b8ea46054061__8_Conclusions\n",
      "901572f1595cb6ea733858d3fc15b8ea46054061__9_Acknowledgment\n",
      "c657dee5652708f18918e1c24b24d2f98cc1c4af__0_\n",
      "c657dee5652708f18918e1c24b24d2f98cc1c4af__1_Introduction\n",
      "c657dee5652708f18918e1c24b24d2f98cc1c4af__2_Methods\n",
      "c657dee5652708f18918e1c24b24d2f98cc1c4af__3_Randomization and intervention\n",
      "c657dee5652708f18918e1c24b24d2f98cc1c4af__4_Primary endpoints\n",
      "c657dee5652708f18918e1c24b24d2f98cc1c4af__5_Eligibility\n",
      "c657dee5652708f18918e1c24b24d2f98cc1c4af__6_Intervention\n",
      "c657dee5652708f18918e1c24b24d2f98cc1c4af__7_Follow-up\n",
      "c657dee5652708f18918e1c24b24d2f98cc1c4af__8_Sample collection and laboratory testing\n",
      "c657dee5652708f18918e1c24b24d2f98cc1c4af__9_Analysis\n",
      "c657dee5652708f18918e1c24b24d2f98cc1c4af__10_Sample size calculation\n",
      "c657dee5652708f18918e1c24b24d2f98cc1c4af__11_Results\n",
      "c657dee5652708f18918e1c24b24d2f98cc1c4af__12_Discussion\n",
      "08d138f10c916bfd41fb359cc523946a62c94982__0_Introduction\n",
      "08d138f10c916bfd41fb359cc523946a62c94982__1_Methods\n",
      "08d138f10c916bfd41fb359cc523946a62c94982__2_P revalence d−21 =\n",
      "08d138f10c916bfd41fb359cc523946a62c94982__3_Italy initially confirmed 3 cases in\n",
      "08d138f10c916bfd41fb359cc523946a62c94982__4_Discussion\n",
      "08d138f10c916bfd41fb359cc523946a62c94982__5_Conclusion\n",
      "08d138f10c916bfd41fb359cc523946a62c94982__6_Limitations\n",
      "08d138f10c916bfd41fb359cc523946a62c94982__7_Acknowledgements\n",
      "08d138f10c916bfd41fb359cc523946a62c94982__8_Supplementary materials\n",
      "738384412cda278edc38daf9fda0a58777eb0548__0_Introduction\n",
      "738384412cda278edc38daf9fda0a58777eb0548__1_Types of Transplant\n",
      "738384412cda278edc38daf9fda0a58777eb0548__2_Overview of the Transplant Process\n",
      "738384412cda278edc38daf9fda0a58777eb0548__3_Complications After Autologous HSCT\n",
      "738384412cda278edc38daf9fda0a58777eb0548__4_Complications of Allogeneic HSCT\n",
      "738384412cda278edc38daf9fda0a58777eb0548__5_Pre-engraftment Complications\n",
      "738384412cda278edc38daf9fda0a58777eb0548__6_Early Post-engraftment Complications\n",
      "738384412cda278edc38daf9fda0a58777eb0548__7_Late Post-engraftment Complications\n",
      "738384412cda278edc38daf9fda0a58777eb0548__8_End of Life Issues in HSCT Patients\n",
      "53f0070769fe2bd7d34e19881cfc20810a2d8121__0_Introduction\n",
      "53f0070769fe2bd7d34e19881cfc20810a2d8121__1_Materials and methods\n",
      "53f0070769fe2bd7d34e19881cfc20810a2d8121__2_Patient 1\n",
      "53f0070769fe2bd7d34e19881cfc20810a2d8121__3_Patient 2\n",
      "53f0070769fe2bd7d34e19881cfc20810a2d8121__4_Patient 3\n",
      "53f0070769fe2bd7d34e19881cfc20810a2d8121__5_Discussion\n",
      "dde8898193c381bb5f2047be20a4d1ee7af765e1__0_\n",
      "dde8898193c381bb5f2047be20a4d1ee7af765e1__1_Financial disclosure\n",
      "dde8898193c381bb5f2047be20a4d1ee7af765e1__2_Conflict of interest\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__0_\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__1_Hydrophobic Metabolome\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__2_Pathogens and Lipids\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__3_Viruses\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__4_Viral entry\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__5_Viral genome replication\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__6_Role of the Lipidome in Host-Pathogen Interactions\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__7_Viral budding\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__8_Innate antiviral response\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__9_Pathogenic Bacteria\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__10_Bacterial invasion\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__11_Bacterial replication\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__12_Bacterial inflammation\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__13_Fungi\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__14_Parasites\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__15_Relevance to Membrane Trafficking\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__16_Conclusions and Outlook\n",
      "96a9f6d5974bbde7b5b92f623ba08004deeb60d8__17_Supporting Information\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__0_Introduction\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__1_MCCN\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__2_Definition 1 (MCCN). A multi-subnet composited complex network is a 4-tuple\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__3_Definition 2 (Adjacency Matrix of MCCN). Given a composited network\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__4_Definition 3 (Degree of a Node According to the Given Relationships).\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__5_Definition 4 (Clustering Coefficient of a Node According to the Given Relationships). C r i r j\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__6_Definition 5 (Strength of the Relationships for the Outer Edge).\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__7_Data source and preprocessing\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__8_Syndrome subnet\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__9_Herb subnet\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__10_Treatment network obtained from the compounding syndrome subnet and herb subnet\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__11_Herb nodes\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__12_Cochin-Chinese Asparagus root (tian men dong)\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__13_Table 5\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__14_Analysis of the six channel subnets by reducing the syndrome subnet\n",
      "8baeff5aad4833fcc6df2ff34ae870f5c8b50b12__15_Conclusions\n",
      "01461449472160d8c79355d213d4b8fa8c8ad761__0_Usefulness of gene expression profiling of bronchoalveolar lavage cells in acute lung allograft rejection\n",
      "01461449472160d8c79355d213d4b8fa8c8ad761__1_Methods\n",
      "01461449472160d8c79355d213d4b8fa8c8ad761__2_Statistical methods\n",
      "01461449472160d8c79355d213d4b8fa8c8ad761__3_Patient characteristics\n",
      "01461449472160d8c79355d213d4b8fa8c8ad761__4_Differential gene expression analyses\n",
      "01461449472160d8c79355d213d4b8fa8c8ad761__5_Functional annotation and pathway enrichment analyses\n",
      "01461449472160d8c79355d213d4b8fa8c8ad761__6_Acute cellular rejection classifier development and performance\n",
      "01461449472160d8c79355d213d4b8fa8c8ad761__7_Discussion\n",
      "01461449472160d8c79355d213d4b8fa8c8ad761__8_Figure 5\n",
      "01461449472160d8c79355d213d4b8fa8c8ad761__9_Disclosure statement\n",
      "241a4dd4d52972e7e0b6ad76225c276bc50d77f8__0_Introduction\n",
      "241a4dd4d52972e7e0b6ad76225c276bc50d77f8__1_Patients and healthy subjects\n",
      "241a4dd4d52972e7e0b6ad76225c276bc50d77f8__2_Laboratory diagnosis\n",
      "241a4dd4d52972e7e0b6ad76225c276bc50d77f8__3_Quantification of serum cytokines\n",
      "241a4dd4d52972e7e0b6ad76225c276bc50d77f8__4_Statistical analysis\n",
      "241a4dd4d52972e7e0b6ad76225c276bc50d77f8__5_Results\n",
      "241a4dd4d52972e7e0b6ad76225c276bc50d77f8__6_Discussion\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__0_\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__1_Historical Perspective\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__2_Hosts' Susceptibility\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__3_Immunological Factors\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__4_Diagnostic Evaluation of Infection\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__5_Pathogens of Interest\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__6_Bacterial Infections\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__7_Principles of Antibiotic Therapy in Neutropenic Patient\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__8_Mycobacterial Infections\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__9_Fungal Infections\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__10_Infections in Patients with Cancer: Overview\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__11_Viral Infections\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__12_Parasitic Infections\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__13_End-Organ Infection\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__14_Pneumonia\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__15_Abdominal Infections\n",
      "26bc8911f95c2f9e44bbec759aa53753327d1685__16_Catheter-Related Infections\n",
      "13f6bc615450f0470c2a265e0a2c8506f0b05048__0_\n",
      "13f6bc615450f0470c2a265e0a2c8506f0b05048__1_EXPOSURE ASSESSMENT: FROM SAMPLING TO ANALYSIS\n",
      "13f6bc615450f0470c2a265e0a2c8506f0b05048__2_PHAGES AS MODELS FOR AIRBORNE VIRUSES\n",
      "13f6bc615450f0470c2a265e0a2c8506f0b05048__3_IN VITRO ASSESSMENT OF MICROBICIDAL AGENTS AND PROCESSES FOR INDOOR AIR DECONTAMINATION\n",
      "13f6bc615450f0470c2a265e0a2c8506f0b05048__4_AIR DECONTAMINATION FOR CONTROL OF INFECTIOUS AGENTS\n",
      "13f6bc615450f0470c2a265e0a2c8506f0b05048__5_Temperature and RH\n",
      "13f6bc615450f0470c2a265e0a2c8506f0b05048__6_Ozone\n",
      "13f6bc615450f0470c2a265e0a2c8506f0b05048__7_Ultraviolet\n",
      "13f6bc615450f0470c2a265e0a2c8506f0b05048__8_Hydrogen peroxide and other microbicides\n",
      "13f6bc615450f0470c2a265e0a2c8506f0b05048__9_Electrostatic precipitation\n",
      "13f6bc615450f0470c2a265e0a2c8506f0b05048__10_CONCLUDING REMARKS\n",
      "210b7878fb4f6c78ceb34874b37c7b71acad0b78__0_\n",
      "210b7878fb4f6c78ceb34874b37c7b71acad0b78__1_Materials and methods\n",
      "210b7878fb4f6c78ceb34874b37c7b71acad0b78__2_Results and discussion\n",
      "ca34ab96806eca903b4245e472559f29f23e4fac__0_Background\n",
      "ca34ab96806eca903b4245e472559f29f23e4fac__1_Design and setting\n",
      "ca34ab96806eca903b4245e472559f29f23e4fac__2_Recruitment and data collection\n",
      "ca34ab96806eca903b4245e472559f29f23e4fac__3_Laboratory methods\n",
      "ca34ab96806eca903b4245e472559f29f23e4fac__4_Data analyses\n",
      "ca34ab96806eca903b4245e472559f29f23e4fac__5_Results\n",
      "ca34ab96806eca903b4245e472559f29f23e4fac__6_Discussion\n",
      "ca34ab96806eca903b4245e472559f29f23e4fac__7_Conclusions\n",
      "ca34ab96806eca903b4245e472559f29f23e4fac__8_Additional file\n",
      "7222e71872a83be2da2e9d07ca439a31603c245d__0_Introduction\n",
      "7222e71872a83be2da2e9d07ca439a31603c245d__1_Foodborne illnesses are linked clearly with the consumption of contaminated foods\n",
      "7222e71872a83be2da2e9d07ca439a31603c245d__2_J o u r n a l P r e -p r o o f\n",
      "7222e71872a83be2da2e9d07ca439a31603c245d__3_Foodborne viruses are detected frequently from foods\n",
      "7222e71872a83be2da2e9d07ca439a31603c245d__4_Foodborne viruses show high stability and resistance towards environmental stress in food systems\n",
      "7222e71872a83be2da2e9d07ca439a31603c245d__5_Conclusions\n",
      "11e29fd44b612542dcb4724e582ed38d68cd93ae__0_Introduction\n",
      "11e29fd44b612542dcb4724e582ed38d68cd93ae__1_Methods\n",
      "11e29fd44b612542dcb4724e582ed38d68cd93ae__2_Mortality\n",
      "11e29fd44b612542dcb4724e582ed38d68cd93ae__3_Risk factors\n",
      "11e29fd44b612542dcb4724e582ed38d68cd93ae__4_Results\n",
      "11e29fd44b612542dcb4724e582ed38d68cd93ae__5_PREVENTING CHRONIC DISEASE\n",
      "11e29fd44b612542dcb4724e582ed38d68cd93ae__6_Discussion\n",
      "60a96220aaf3fbe0cd27e8ad20551712939d2e5e__0_\n",
      "50f9ea2210efc3c98630da060b4254036f83c516__0_Introduction\n",
      "50f9ea2210efc3c98630da060b4254036f83c516__1_Expression of Recombinant NcPROF in Silkworm Larvae and Bm5 Cells\n",
      "50f9ea2210efc3c98630da060b4254036f83c516__2_Purification of bx-PA-NcPROF-GP64TM from Silkworm Larvae\n",
      "50f9ea2210efc3c98630da060b4254036f83c516__3_Ultracentrifugation Analysis of bx-PA-NcPROF-GP64TM, bx-PA-NcPROF, and PA-NcPROF\n",
      "50f9ea2210efc3c98630da060b4254036f83c516__4_Transmission Electron Microscopy Observation of bx-PA-NcPROF-GP64TM\n",
      "50f9ea2210efc3c98630da060b4254036f83c516__5_Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Blotting\n",
      "50f9ea2210efc3c98630da060b4254036f83c516__6_Binding Assay of bx-PA-NcPROF-GP64TM with Mouse TLR11\n",
      "50f9ea2210efc3c98630da060b4254036f83c516__7_Results and Discussion\n",
      "50f9ea2210efc3c98630da060b4254036f83c516__8_Binding Assay of bx-NcPROF-GP64TM with mTLR11\n",
      "50f9ea2210efc3c98630da060b4254036f83c516__9_Morphology of bx-PA-NcPROF-GP64TM Nanoparticles\n",
      "50f9ea2210efc3c98630da060b4254036f83c516__10_Conclusions\n",
      "4815158fd87ae667da39dcab37edd1fc6c3b7d43__0_Introduction\n",
      "4815158fd87ae667da39dcab37edd1fc6c3b7d43__1_Consumer Preferences, Budget Constraints, and Health-Care Use\n",
      "4815158fd87ae667da39dcab37edd1fc6c3b7d43__2_The Unified Model\n",
      "4815158fd87ae667da39dcab37edd1fc6c3b7d43__3_Refinements and Extensions\n",
      "4815158fd87ae667da39dcab37edd1fc6c3b7d43__4_Reduced-Form Demand Models\n",
      "4815158fd87ae667da39dcab37edd1fc6c3b7d43__5_Discrete Choice Health-Care Demands\n",
      "4815158fd87ae667da39dcab37edd1fc6c3b7d43__6_Information Imperfections and the Demand for Health Care\n",
      "4815158fd87ae667da39dcab37edd1fc6c3b7d43__7_Time, Self-Control, and Behavioral Change\n",
      "4815158fd87ae667da39dcab37edd1fc6c3b7d43__8_Conclusion and Perspectives on Future Research\n",
      "0da5d5a5995c1873870835a5be83b387c0503a40__0_\n",
      "ad0b441bc8d80e879335071060bf31ba56ed0062__0_\n",
      "ad0b441bc8d80e879335071060bf31ba56ed0062__1_Compliance with ethical standards\n",
      "b40d86f50a737ede57a34521eb1bc3a0f43ca135__0_INTRODUCTION\n",
      "b40d86f50a737ede57a34521eb1bc3a0f43ca135__1_CONSIDERATIONS OF POLICIES AND PROCESSES\n",
      "b40d86f50a737ede57a34521eb1bc3a0f43ca135__2_General Infection Control Measures\n",
      "b40d86f50a737ede57a34521eb1bc3a0f43ca135__3_Screening of Patients and Visitors\n",
      "b40d86f50a737ede57a34521eb1bc3a0f43ca135__4_Segregation of Risk Groups and Conduct of MPI\n",
      "b40d86f50a737ede57a34521eb1bc3a0f43ca135__5_Segregation of Staff and Service Continuity Plans\n",
      "b40d86f50a737ede57a34521eb1bc3a0f43ca135__6_SUMMARY\n",
      "b40d86f50a737ede57a34521eb1bc3a0f43ca135__7_Disclosures\n",
      "be9ea17af4cabeed0030ea421faf6e8542694cfd__0_Introduction\n",
      "be9ea17af4cabeed0030ea421faf6e8542694cfd__1_Coronaviruses\n",
      "be9ea17af4cabeed0030ea421faf6e8542694cfd__2_Coronaviral spike proteins and receptors\n",
      "be9ea17af4cabeed0030ea421faf6e8542694cfd__3_The SARS coronavirus and its receptor\n",
      "a5642304a80af00417e92adeab9a009fc17a44a5__0_Amar Safdar\n",
      "a5642304a80af00417e92adeab9a009fc17a44a5__1_Faster neutrophil engraftment\n",
      "d8b911e5fd58e3c6eb13568aef318ca9fb9fe7f5__0_\n",
      "d8b911e5fd58e3c6eb13568aef318ca9fb9fe7f5__1_Conflict of interest The authors declare no conflicts of interest\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__0_Introduction\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__1_Enhancement of DNA vaccine potency by different approaches\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__2_Tattooing\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__3_Gene gun\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__4_Ultrasound\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__5_Electroporation\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__6_Laser\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__7_II. Viral and non-viral delivery systems\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__8_Biological gene delivery systems (viral vectors)\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__9_Non-biological gene delivery systems (non-viral vectors)\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__10_Cationic lipids/liposomes\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__11_Polysaccharides and cationic polymers\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__12_VLPs as an efficient delivery system\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__13_Delivery systems in dendritic cell-based vaccines\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__14_Mucosal delivery systems\n",
      "f8abd9e10df6beeffec38bc7dd7083318e0d69ed__15_Conclusion\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__0_Introduction\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__1_Infectious bronchitis\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__2_Infectious bronchitis virus\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__3_Tissue tropism of IBV\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__4_IBV exists as dozens of serotypes\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__5_Failure of serotypes to induce cross-protective immunity\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__6_Vaccination with live-attenuated vaccines\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__7_Duration of respiratory tract immunity following live attenuated vaccination\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__8_Protection against nephritis by live vaccines\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__9_Vaccination with inactivated vaccines\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__10_Passive immunization\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__11_Presence and duration of antibody in the serum, trachea and nasal secretions\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__12_Induction of protection by subviral and vectored vaccines\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__13_Immunization with the S protein\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__14_Immunization with the N protein\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__15_Nature of protective immune responses to IBV\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__16_have shown that cytotoxic T-cell responses in chickens to IBV infection correlated with initial decreases in infection and clinical signs.\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__17_Final comments\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__18_ZUSAMMENFASSUNG\n",
      "7f1d647d43af4ed96625ed113f8bf0ab737e2f0c__19_REVISION\n",
      "5f315243554d53b8a8c652254cbdf0d4ed2e4d46__0_Introduction\n",
      "5f315243554d53b8a8c652254cbdf0d4ed2e4d46__1_Deviation from Exponential growth and Future sketching\n",
      "5f315243554d53b8a8c652254cbdf0d4ed2e4d46__2_Summary and Conclusion\n",
      "ba8a7815eb6ac4e669f420e53e267438f180b478__0_Clinical Background and State-of-the-Art\n",
      "ba8a7815eb6ac4e669f420e53e267438f180b478__1_Scope of the Presented Work\n",
      "ba8a7815eb6ac4e669f420e53e267438f180b478__2_Data Acquisition\n",
      "ba8a7815eb6ac4e669f420e53e267438f180b478__3_Regression Models and Cross-Validation\n",
      "ba8a7815eb6ac4e669f420e53e267438f180b478__4_Performance Metrics\n",
      "ba8a7815eb6ac4e669f420e53e267438f180b478__5_Einthoven Lead Estimation\n",
      "ba8a7815eb6ac4e669f420e53e267438f180b478__6_PEP and LVET Estimation\n",
      "ba8a7815eb6ac4e669f420e53e267438f180b478__7_Electrocardiogram-and Phonocardiogram-Derived Respiration\n",
      "ba8a7815eb6ac4e669f420e53e267438f180b478__8_QRS area (n) =\n",
      "ba8a7815eb6ac4e669f420e53e267438f180b478__9_Discussion\n",
      "ba8a7815eb6ac4e669f420e53e267438f180b478__10_Conclusions\n",
      "ba8a7815eb6ac4e669f420e53e267438f180b478__11_Abbreviations\n",
      "ba8a7815eb6ac4e669f420e53e267438f180b478__12_B2B\n",
      "dfe64ba8bf59ab09b956b293c47a3798df11b31a__0_Background\n",
      "dfe64ba8bf59ab09b956b293c47a3798df11b31a__1_Virus\n",
      "dfe64ba8bf59ab09b956b293c47a3798df11b31a__2_Objectives\n",
      "dfe64ba8bf59ab09b956b293c47a3798df11b31a__3_Patients and microbiological methods\n",
      "dfe64ba8bf59ab09b956b293c47a3798df11b31a__4_RT-PCR for picornaviruses\n",
      "dfe64ba8bf59ab09b956b293c47a3798df11b31a__5_VP1 sequence analysis\n",
      "dfe64ba8bf59ab09b956b293c47a3798df11b31a__6_Nucleotide sequence accession number\n",
      "dfe64ba8bf59ab09b956b293c47a3798df11b31a__7_Clinical characteristics of patients with HRV-C and other picornaviruses detected in fecal samples\n",
      "dfe64ba8bf59ab09b956b293c47a3798df11b31a__8_Discussion\n",
      "dfe64ba8bf59ab09b956b293c47a3798df11b31a__9_Funding\n",
      "7ff45096210eeb392d51f646f5c7fe011079aaf3__0_Introduction\n",
      "7ff45096210eeb392d51f646f5c7fe011079aaf3__1_Salmonella localizes to the Golgi network in epithelial cells\n",
      "7ff45096210eeb392d51f646f5c7fe011079aaf3__2_SseG and an intact Golgi network are required for replication of Salmonella in epithelial cells\n",
      "7ff45096210eeb392d51f646f5c7fe011079aaf3__3_SseG is a Golgi-targeting protein\n",
      "7ff45096210eeb392d51f646f5c7fe011079aaf3__4_TGN46 (\n",
      "7ff45096210eeb392d51f646f5c7fe011079aaf3__5_SCV maturation and association with the Golgi\n",
      "7ff45096210eeb392d51f646f5c7fe011079aaf3__6_Role of SseG in Salmonella virulence\n",
      "7ff45096210eeb392d51f646f5c7fe011079aaf3__7_Materials and methods\n",
      "7ff45096210eeb392d51f646f5c7fe011079aaf3__8_Antibodies and reagents\n",
      "7ff45096210eeb392d51f646f5c7fe011079aaf3__9_Af®nity puri®cation of the anti-SseG antibody\n",
      "7ff45096210eeb392d51f646f5c7fe011079aaf3__10_Bacterial infection of cultured cells and replication assays\n",
      "7ff45096210eeb392d51f646f5c7fe011079aaf3__11_Microscopy\n",
      "7ff45096210eeb392d51f646f5c7fe011079aaf3__12_Transfection of HeLa cells\n",
      "7ff45096210eeb392d51f646f5c7fe011079aaf3__13_Supplementary data\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__0_Introduction\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__1_Protein structure\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__2_Choice of organic compounds\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__3_Molecular electrostatic potential (MEP) analysis\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__4_Bioavailability\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__5_Lipophilicity\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__6_Water solubility\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__7_Docking study\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__8_Designing of new compound\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__9_Toxicity study\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__10_Conclusion\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__11_Methods\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__12_Protein structure modelling\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__13_Bioinformatics\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__14_Molecular docking estimation\n",
      "970ee222f72ae6cfffe492f5f66f38b64074870d__15_Toxicity\n",
      "6f60590d6f700339c1c8c73ebd0a69c2a2fa9744__0_\n",
      "db26c52cd3a2ecf1133a945db24f40943eaba6ad__0_\n",
      "db26c52cd3a2ecf1133a945db24f40943eaba6ad__1_Institution Details\n",
      "db26c52cd3a2ecf1133a945db24f40943eaba6ad__2_Traffic light system integrating with electronic patient records\n",
      "db26c52cd3a2ecf1133a945db24f40943eaba6ad__3_COVID-19 Critical Care Protocols.\n",
      "db26c52cd3a2ecf1133a945db24f40943eaba6ad__4_Data Analyses\n",
      "db26c52cd3a2ecf1133a945db24f40943eaba6ad__5_(which was not certified by peer review)\n",
      "db26c52cd3a2ecf1133a945db24f40943eaba6ad__6_Population demographics\n",
      "db26c52cd3a2ecf1133a945db24f40943eaba6ad__7_Case Fatality rates higher in males.\n",
      "db26c52cd3a2ecf1133a945db24f40943eaba6ad__8_Traffic Lights Real Time Monitoring from Emergency admission\n",
      "db26c52cd3a2ecf1133a945db24f40943eaba6ad__9_Dashboard biomarkers highly abnormal in males, but no association with increasing age\n",
      "db26c52cd3a2ecf1133a945db24f40943eaba6ad__10_DISCUSSION\n",
      "be88b8b8468923d21b61a791fd12381e3e148b7f__0_\n",
      "be88b8b8468923d21b61a791fd12381e3e148b7f__1_Introduction And Background\n",
      "be88b8b8468923d21b61a791fd12381e3e148b7f__2_Literature Search and Selection\n",
      "be88b8b8468923d21b61a791fd12381e3e148b7f__3_Natural History and Clinical Characteristics\n",
      "be88b8b8468923d21b61a791fd12381e3e148b7f__4_Basic Virology\n",
      "be88b8b8468923d21b61a791fd12381e3e148b7f__5_Transmission Dynamics and Protective Measures\n",
      "be88b8b8468923d21b61a791fd12381e3e148b7f__6_Enteric Involvement of Coronavirus\n",
      "be88b8b8468923d21b61a791fd12381e3e148b7f__7_Discussion\n",
      "be88b8b8468923d21b61a791fd12381e3e148b7f__8_Conclusions\n",
      "be88b8b8468923d21b61a791fd12381e3e148b7f__9_Appendices\n",
      "a43bb56b5b1f3c5d5f30023ce701f33d670bc5ce__0_Introduction\n",
      "a43bb56b5b1f3c5d5f30023ce701f33d670bc5ce__1_Blood donors\n",
      "a43bb56b5b1f3c5d5f30023ce701f33d670bc5ce__2_Isolation and purification of PDCs\n",
      "a43bb56b5b1f3c5d5f30023ce701f33d670bc5ce__3_Stimulation of PDCs\n",
      "a43bb56b5b1f3c5d5f30023ce701f33d670bc5ce__4_Flow cytometry staining of PDCs and TLRs\n",
      "a43bb56b5b1f3c5d5f30023ce701f33d670bc5ce__5_Polymerase chain reaction (PCR)\n",
      "a43bb56b5b1f3c5d5f30023ce701f33d670bc5ce__6_Phospho IRF-7 staining\n",
      "a43bb56b5b1f3c5d5f30023ce701f33d670bc5ce__7_Statistical analysis\n",
      "a43bb56b5b1f3c5d5f30023ce701f33d670bc5ce__8_Results\n",
      "a43bb56b5b1f3c5d5f30023ce701f33d670bc5ce__9_Discussion\n",
      "1bc97c8afbc053507a015280443d70217310b89c__0_Social Impact and Economic Burden of Viral Infectious Diseases\n",
      "1bc97c8afbc053507a015280443d70217310b89c__1_Viruses: Types, Current Therapy and Observed Drawbacks\n",
      "1bc97c8afbc053507a015280443d70217310b89c__2_Antiviral Agents Used in Nanotechnology\n",
      "1bc97c8afbc053507a015280443d70217310b89c__3_Biological Barriers Security System\n",
      "1bc97c8afbc053507a015280443d70217310b89c__4_Mucus\n",
      "1bc97c8afbc053507a015280443d70217310b89c__5_Skin\n",
      "1bc97c8afbc053507a015280443d70217310b89c__6_Cell Membrane\n",
      "1bc97c8afbc053507a015280443d70217310b89c__7_Blood-Brain Barrier\n",
      "1bc97c8afbc053507a015280443d70217310b89c__8_Nanotechnology: How Does It Face the Antiviral Therapy?\n",
      "1bc97c8afbc053507a015280443d70217310b89c__9_Current Overview of Nanotechnology Use in Antiviral Therapy: Virus Related\n",
      "1bc97c8afbc053507a015280443d70217310b89c__10_Nano-Based Antiviral Agents against Herpes Viruses\n",
      "1bc97c8afbc053507a015280443d70217310b89c__11_Nanomaterials with Antiviral Intrinsic Activity\n",
      "1bc97c8afbc053507a015280443d70217310b89c__12_Broad-Spectrum Antiviral NPs\n",
      "1bc97c8afbc053507a015280443d70217310b89c__13_Lipid Nanoemulsions Encapsulating Coumestrol as Topical Treatment of Herpes Simplex\n",
      "1bc97c8afbc053507a015280443d70217310b89c__14_Nanomaterials Designed for Antiretroviral Drug Delivery\n",
      "1bc97c8afbc053507a015280443d70217310b89c__15_NRTIs and NNRTIs\n",
      "1bc97c8afbc053507a015280443d70217310b89c__16_PIs\n",
      "1bc97c8afbc053507a015280443d70217310b89c__17_Fusion Inhibitors, Entry Inhibitors and Integrase Inhibitors\n",
      "1bc97c8afbc053507a015280443d70217310b89c__18_Progress in Nanomedicine: Antiviral Nanotherapeutics Approved or under Evaluation\n",
      "1bc97c8afbc053507a015280443d70217310b89c__19_Authors' Perspective to Design Next Generation of Nano-Based Antivirals for Clinical Translation\n",
      "1bc97c8afbc053507a015280443d70217310b89c__20_•\n",
      "1bc97c8afbc053507a015280443d70217310b89c__21_Conclusions\n",
      "3def1027f20e9d0cdec1e04054e1aa2a013c1c61__0_\n",
      "3def1027f20e9d0cdec1e04054e1aa2a013c1c61__1_Nipah Virus and Hendra Virus Stocks\n",
      "3def1027f20e9d0cdec1e04054e1aa2a013c1c61__2_Ethics Approval\n",
      "3def1027f20e9d0cdec1e04054e1aa2a013c1c61__3_Statistics\n",
      "3def1027f20e9d0cdec1e04054e1aa2a013c1c61__4_Infected Ferrets\n",
      "3def1027f20e9d0cdec1e04054e1aa2a013c1c61__5_Measurement of Virus Load\n",
      "3def1027f20e9d0cdec1e04054e1aa2a013c1c61__6_Nipah Virus and Hendra Virus Serum Neutralization Assays\n",
      "3def1027f20e9d0cdec1e04054e1aa2a013c1c61__7_Antibodies\n",
      "3def1027f20e9d0cdec1e04054e1aa2a013c1c61__8_Hematology and Serum Biochemistry\n",
      "3def1027f20e9d0cdec1e04054e1aa2a013c1c61__9_Ferrets\n",
      "3def1027f20e9d0cdec1e04054e1aa2a013c1c61__10_Neutralizing Antibody Titers and Seroconversion of h5B3.1-Treated Ferrets\n",
      "3def1027f20e9d0cdec1e04054e1aa2a013c1c61__11_DISCUSSION\n",
      "3def1027f20e9d0cdec1e04054e1aa2a013c1c61__12_CONCLUSIONS\n",
      "e65d35484d1d0bd50b9b5b7d576cd2731608823e__0_Introduction\n",
      "e65d35484d1d0bd50b9b5b7d576cd2731608823e__1_Methods\n",
      "e65d35484d1d0bd50b9b5b7d576cd2731608823e__2_Results\n",
      "e65d35484d1d0bd50b9b5b7d576cd2731608823e__3_Discussion and conclusions\n",
      "3770ac55babf2fd6c2efdc3e58c8936a99b7a272__0_Introduction\n",
      "3770ac55babf2fd6c2efdc3e58c8936a99b7a272__1_Design of the smFRET experiments\n",
      "3770ac55babf2fd6c2efdc3e58c8936a99b7a272__2_tRNA-tRNA smFRET\n",
      "3770ac55babf2fd6c2efdc3e58c8936a99b7a272__3_L11-tRNA smFRET\n",
      "3770ac55babf2fd6c2efdc3e58c8936a99b7a272__4_L1-tRNA smFRET\n",
      "3770ac55babf2fd6c2efdc3e58c8936a99b7a272__5_2-1-2 vs. 2-3-2 pathway\n",
      "3770ac55babf2fd6c2efdc3e58c8936a99b7a272__6_Ensemble experiments\n",
      "3770ac55babf2fd6c2efdc3e58c8936a99b7a272__7_Discussion\n",
      "3770ac55babf2fd6c2efdc3e58c8936a99b7a272__8_Conclusions\n",
      "3770ac55babf2fd6c2efdc3e58c8936a99b7a272__9_Ribosome preparation\n",
      "3770ac55babf2fd6c2efdc3e58c8936a99b7a272__10_Charged and Labeled tRNA preparation\n",
      "3770ac55babf2fd6c2efdc3e58c8936a99b7a272__11_Acquisition and analysis of smFRET data\n",
      "3770ac55babf2fd6c2efdc3e58c8936a99b7a272__12_Supplementary Material\n",
      "7ba728305beeae3e2857f7e6245184f7ea3c9498__0_\n",
      "7ba728305beeae3e2857f7e6245184f7ea3c9498__1_METHODS\n",
      "7ba728305beeae3e2857f7e6245184f7ea3c9498__2_Endoscopic Findings\n",
      "7ba728305beeae3e2857f7e6245184f7ea3c9498__3_Histopathology\n",
      "7ba728305beeae3e2857f7e6245184f7ea3c9498__4_Blood and Stool Cultures\n",
      "7ba728305beeae3e2857f7e6245184f7ea3c9498__5_Treatment and Clinical Course\n",
      "7ba728305beeae3e2857f7e6245184f7ea3c9498__6_DISCUSSION\n",
      "7ba728305beeae3e2857f7e6245184f7ea3c9498__7_CONCLUSIONS\n",
      "7ba728305beeae3e2857f7e6245184f7ea3c9498__8_Invited Commentary\n",
      "7ba728305beeae3e2857f7e6245184f7ea3c9498__9_The Authors Reply\n",
      "0a4cd3294e9e451b3fb72b290be6222cd0236523__0_Editorial\n",
      "0a4cd3294e9e451b3fb72b290be6222cd0236523__1_The ever present threat of influenza\n",
      "0a4cd3294e9e451b3fb72b290be6222cd0236523__2_Mind the GAP\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__0_Introduction\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__1_Experimental animals\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__2_Infection with feline immunode®ciency virus (FIV)\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__3_Collection of bronchoalveolar lavage (BAL) cells and alveolar macrophages (AM)\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__4_In vitro infection of alveolar macrophages with FIV\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__5_Quantitation of bioactive IL6 and TNFa\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__6_RNA isolation\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__7_Reverse transcription-quantitative competitive PCR (RT-qcPCR) for cytokine mRNA\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__8_Statistical analysis\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__9_FIV infection of SPF cats\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__10_Total BAL cell counts and differentials following FIV infection\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__11_Constitutive cytokine production by AM\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__12_Quantitation of FIV-gag mRNA expression in AM following FIV infection\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__13_FIV status\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__14_Cytokine responses of AM infected with FIV in vitro\n",
      "abd20e33c3e08a2d1beed89375fcae1e510dd99a__15_Discussion\n",
      "9866292cd2d5a8011cc30bf6e5f960bd9c8ce206__0_Introduction\n",
      "9866292cd2d5a8011cc30bf6e5f960bd9c8ce206__1_Materials and methods\n",
      "9866292cd2d5a8011cc30bf6e5f960bd9c8ce206__2_Preparation of the genome and Illumina sequencing\n",
      "9866292cd2d5a8011cc30bf6e5f960bd9c8ce206__3_Genome assembly, RNA folding and recombination analysis\n",
      "9866292cd2d5a8011cc30bf6e5f960bd9c8ce206__4_Genome annotation and single nucleotide polymorphism (SNP) analysis\n",
      "9866292cd2d5a8011cc30bf6e5f960bd9c8ce206__5_Protein secondary structure prediction\n",
      "9866292cd2d5a8011cc30bf6e5f960bd9c8ce206__6_Genome assembly and annotation\n",
      "9866292cd2d5a8011cc30bf6e5f960bd9c8ce206__7_Comparative frequency of mutations in ORFs\n",
      "9866292cd2d5a8011cc30bf6e5f960bd9c8ce206__8_E protein\n",
      "9866292cd2d5a8011cc30bf6e5f960bd9c8ce206__9_N protein\n",
      "9866292cd2d5a8011cc30bf6e5f960bd9c8ce206__10_M protein\n",
      "9866292cd2d5a8011cc30bf6e5f960bd9c8ce206__11_Accessory proteins\n",
      "9866292cd2d5a8011cc30bf6e5f960bd9c8ce206__12_Untranslated regions (UTRs)\n",
      "9866292cd2d5a8011cc30bf6e5f960bd9c8ce206__13_The spike protein\n",
      "9866292cd2d5a8011cc30bf6e5f960bd9c8ce206__14_Conclusions\n",
      "c2732f1806306f0cab041609b3115dbd982ce3a3__0_Introduction\n",
      "c2732f1806306f0cab041609b3115dbd982ce3a3__1_Description of the Fold of Griffithsin\n",
      "c2732f1806306f0cab041609b3115dbd982ce3a3__2_Comparisons with Related Lectins\n",
      "c2732f1806306f0cab041609b3115dbd982ce3a3__3_The Mode of Binding of Carbohydrates\n",
      "c2732f1806306f0cab041609b3115dbd982ce3a3__4_Discussion\n",
      "c2732f1806306f0cab041609b3115dbd982ce3a3__5_Experimental Procedures\n",
      "c2732f1806306f0cab041609b3115dbd982ce3a3__6_Purification of Griffithsin from Nicotiana Tissue\n",
      "c2732f1806306f0cab041609b3115dbd982ce3a3__7_Severe Acute Respiratory Syndrome Virus Assays\n",
      "c2732f1806306f0cab041609b3115dbd982ce3a3__8_Inhibition of Viral Cytopathic Effect\n",
      "c2732f1806306f0cab041609b3115dbd982ce3a3__9_Increase in Neutral Red Dye Uptake\n",
      "c2732f1806306f0cab041609b3115dbd982ce3a3__10_Crystallization of Unliganded Griffithsin\n",
      "c2732f1806306f0cab041609b3115dbd982ce3a3__11_Determination of the Structure of Unliganded Griffithsin\n",
      "c2732f1806306f0cab041609b3115dbd982ce3a3__12_Crystallization and Structure Determination of Carbohydrate Complexes\n",
      "246b2f3f58779c6da0045b7bb0a9560fa3978131__0_Introduction\n",
      "246b2f3f58779c6da0045b7bb0a9560fa3978131__1_Cells, virus, and antiserum\n",
      "246b2f3f58779c6da0045b7bb0a9560fa3978131__2_siRNA transfection and CSFV infection\n",
      "246b2f3f58779c6da0045b7bb0a9560fa3978131__3_Plasmid construction\n",
      "246b2f3f58779c6da0045b7bb0a9560fa3978131__4_siRNA4 expression plasmid construction\n",
      "246b2f3f58779c6da0045b7bb0a9560fa3978131__5_Target site-EGFP fusion reporter plasmid construction\n",
      "246b2f3f58779c6da0045b7bb0a9560fa3978131__6_RNA purification\n",
      "246b2f3f58779c6da0045b7bb0a9560fa3978131__7_Statistical analysis\n",
      "246b2f3f58779c6da0045b7bb0a9560fa3978131__8_Screening for siRNA targeting the NS3 gene\n",
      "246b2f3f58779c6da0045b7bb0a9560fa3978131__9_Effect of multiple siRNA expression\n",
      "246b2f3f58779c6da0045b7bb0a9560fa3978131__10_Examination of the single or multiple siRNA effect by IFA\n",
      "246b2f3f58779c6da0045b7bb0a9560fa3978131__11_Single or multiple siRNA effects by real-time RT-PCR\n",
      "246b2f3f58779c6da0045b7bb0a9560fa3978131__12_Single or multiple siRNA effects by infectious virus assay\n",
      "246b2f3f58779c6da0045b7bb0a9560fa3978131__13_Discussion\n",
      "6ff336c5f099acbe84cf7cfe5f68bd5ba672d6b8__0_\n",
      "6ff336c5f099acbe84cf7cfe5f68bd5ba672d6b8__1_Study population:\n",
      "6ff336c5f099acbe84cf7cfe5f68bd5ba672d6b8__2_RESULTS\n",
      "6ff336c5f099acbe84cf7cfe5f68bd5ba672d6b8__3_DISCUSSION\n",
      "6302e80258b85ac4f27c6db06bcf9e245e981ba9__0_Background\n",
      "6302e80258b85ac4f27c6db06bcf9e245e981ba9__1_Study design, patient enrolment, and data collection\n",
      "6302e80258b85ac4f27c6db06bcf9e245e981ba9__2_Microbiological test\n",
      "6302e80258b85ac4f27c6db06bcf9e245e981ba9__3_Definitions of variables\n",
      "6302e80258b85ac4f27c6db06bcf9e245e981ba9__4_Statistical analysis\n",
      "6302e80258b85ac4f27c6db06bcf9e245e981ba9__5_Ethics\n",
      "6302e80258b85ac4f27c6db06bcf9e245e981ba9__6_Clinical characteristics\n",
      "6302e80258b85ac4f27c6db06bcf9e245e981ba9__7_Detection of viral and bacterial pathogens\n",
      "6302e80258b85ac4f27c6db06bcf9e245e981ba9__8_In-hospital mortality of pneumonia and virus detection\n",
      "6302e80258b85ac4f27c6db06bcf9e245e981ba9__9_Discussion\n",
      "6302e80258b85ac4f27c6db06bcf9e245e981ba9__10_Conclusions\n",
      "f255ff4397c3bcf53e648f5f44a283bd440326cb__0_\n",
      "f255ff4397c3bcf53e648f5f44a283bd440326cb__1_METHODS\n",
      "f255ff4397c3bcf53e648f5f44a283bd440326cb__2_RESULTS\n",
      "f255ff4397c3bcf53e648f5f44a283bd440326cb__3_Hand hygiene knowledge and practices\n",
      "f255ff4397c3bcf53e648f5f44a283bd440326cb__4_Knowledge of isolation categories\n",
      "f255ff4397c3bcf53e648f5f44a283bd440326cb__5_Knowledge of PPE\n",
      "f255ff4397c3bcf53e648f5f44a283bd440326cb__6_Knowledge application\n",
      "f255ff4397c3bcf53e648f5f44a283bd440326cb__7_Infection control training and training needs\n",
      "f255ff4397c3bcf53e648f5f44a283bd440326cb__8_DISCUSSION\n",
      "06294edc6c5ec44fd0e519f6743731033e8a7710__0_\n",
      "5d4e3c42297fade745b12a80ba48accc2e35cbb6__0_Introduction\n",
      "5d4e3c42297fade745b12a80ba48accc2e35cbb6__1_Uvéites et tatouages\n",
      "5d4e3c42297fade745b12a80ba48accc2e35cbb6__2_Symptomatologie clinique\n",
      "5d4e3c42297fade745b12a80ba48accc2e35cbb6__3_Formes étiologiques, ou facteurs déclenchants\n",
      "5d4e3c42297fade745b12a80ba48accc2e35cbb6__4_Évolution Les complications et séquelles\n",
      "5d4e3c42297fade745b12a80ba48accc2e35cbb6__5_Les examens complémentaires\n",
      "5d4e3c42297fade745b12a80ba48accc2e35cbb6__6_Le diagnostic différentiel\n",
      "5d4e3c42297fade745b12a80ba48accc2e35cbb6__7_Le traitement\n",
      "5d4e3c42297fade745b12a80ba48accc2e35cbb6__8_L'uvéite de la maladie de Vogt-Koyanagi-Harada (VKH)\n",
      "5d4e3c42297fade745b12a80ba48accc2e35cbb6__9_ARTICLE IN PRESS\n",
      "5d4e3c42297fade745b12a80ba48accc2e35cbb6__10_Conclusion\n",
      "5d4e3c42297fade745b12a80ba48accc2e35cbb6__11_Déclaration de liens d'intérêts\n",
      "8c9cdb6b0e517ebcca3ba56bec7665d2eedccb8e__0_Letter to the Editor\n",
      "bf0e3ed6e8fa4adbfacbf76e9fa2f5aa1ccdef19__0_Introduction\n",
      "bf0e3ed6e8fa4adbfacbf76e9fa2f5aa1ccdef19__1_Literature Search\n",
      "bf0e3ed6e8fa4adbfacbf76e9fa2f5aa1ccdef19__2_Inclusion and Exclusion Criteria\n",
      "bf0e3ed6e8fa4adbfacbf76e9fa2f5aa1ccdef19__3_Data Extraction\n",
      "bf0e3ed6e8fa4adbfacbf76e9fa2f5aa1ccdef19__4_Statistical Analyses\n",
      "bf0e3ed6e8fa4adbfacbf76e9fa2f5aa1ccdef19__5_Study Characteristics\n",
      "bf0e3ed6e8fa4adbfacbf76e9fa2f5aa1ccdef19__6_Meta-analysis\n",
      "bf0e3ed6e8fa4adbfacbf76e9fa2f5aa1ccdef19__7_Publication Bias\n",
      "bf0e3ed6e8fa4adbfacbf76e9fa2f5aa1ccdef19__8_Sensitivity Analysis\n",
      "bf0e3ed6e8fa4adbfacbf76e9fa2f5aa1ccdef19__9_Discussion\n",
      "c0f5134deae877855c9072a8a712296ae9086c8e__0_\n",
      "c0f5134deae877855c9072a8a712296ae9086c8e__1_A U T O I M M U N I T Y 5\n",
      "c0f5134deae877855c9072a8a712296ae9086c8e__2_A U T O I M M U N I T Y 10\n",
      "c0f5134deae877855c9072a8a712296ae9086c8e__3_Presence of Helicobacter pylori Antibodies in Haemodialysis Patients\n",
      "c0f5134deae877855c9072a8a712296ae9086c8e__4_Supplementation of Vitamin C to Weaner Diets Increases IgM Concentration and Improves the Biological Activity of Vitamin E in Alveolar Macrophages\n",
      "c0f5134deae877855c9072a8a712296ae9086c8e__5_Results:\n",
      "c0f5134deae877855c9072a8a712296ae9086c8e__6_Levels, Complement Activity and Polymorphisms of Mannan-Binding Lectin in Patients of Bronchial Asthma with Allergic Rhinitis\n",
      "c0f5134deae877855c9072a8a712296ae9086c8e__7_Lysine-Dependent Binding of OspE to the C-terminus of Factor H Mediates Complement Resistance in Borrelia burgdorferi\n",
      "c0f5134deae877855c9072a8a712296ae9086c8e__8_Chronic hepatitis B virus (HBV) infection affects about\n",
      "c0f5134deae877855c9072a8a712296ae9086c8e__9_Pattern of Cytokine Responses to Gram-Positive and Gram-Negative Commensal Bacteria is Profoundly Changed when Monocytes Differentiate into Dendritic Cells\n",
      "c0f5134deae877855c9072a8a712296ae9086c8e__10_Rationale:\n",
      "0f8451b64b7aa2e642036d79efc1969125c45873__0_\n",
      "0f8451b64b7aa2e642036d79efc1969125c45873__1_Methods\n",
      "0f8451b64b7aa2e642036d79efc1969125c45873__2_Data sources and searches\n",
      "0f8451b64b7aa2e642036d79efc1969125c45873__3_Study selection and eligibility criteria\n",
      "0f8451b64b7aa2e642036d79efc1969125c45873__4_Data extraction\n",
      "0f8451b64b7aa2e642036d79efc1969125c45873__5_Statistical analysis\n",
      "0f8451b64b7aa2e642036d79efc1969125c45873__6_Study characteristics\n",
      "0f8451b64b7aa2e642036d79efc1969125c45873__7_ACE I/D polymorphism and susceptibility to ALI/ARDS ALI/ARDS patients versus healthy control subjects\n",
      "0f8451b64b7aa2e642036d79efc1969125c45873__8_ALI/ARDS patients versus patients without ALI/ARDS\n",
      "0f8451b64b7aa2e642036d79efc1969125c45873__9_ACE I/D polymorphism and mortality of ALI/ARDS\n",
      "0f8451b64b7aa2e642036d79efc1969125c45873__10_Discussion\n",
      "0f8451b64b7aa2e642036d79efc1969125c45873__11_Conclusions\n",
      "23f71cec67b168779d76b16f771126d98fc6f22e__0_\n",
      "23f71cec67b168779d76b16f771126d98fc6f22e__1_Tropheryma whipplei in Children with Gastroenteritis CME ACTIVITY\n",
      "23f71cec67b168779d76b16f771126d98fc6f22e__2_Learning Objectives\n",
      "23f71cec67b168779d76b16f771126d98fc6f22e__3_Patients\n",
      "23f71cec67b168779d76b16f771126d98fc6f22e__4_Controls\n",
      "23f71cec67b168779d76b16f771126d98fc6f22e__5_Diagnostic Procedures\n",
      "23f71cec67b168779d76b16f771126d98fc6f22e__6_Statistical Analysis\n",
      "23f71cec67b168779d76b16f771126d98fc6f22e__7_Results\n",
      "23f71cec67b168779d76b16f771126d98fc6f22e__8_Discussion\n",
      "93b885af3e32be51e6a885b8af4905e96a6dac8a__0_INTRODUCTION 58\n",
      "5826043d901c0c41492a30b1b1357f32857033da__0_\n",
      "5826043d901c0c41492a30b1b1357f32857033da__1_The garden habitat\n",
      "5826043d901c0c41492a30b1b1357f32857033da__2_The study garden\n",
      "5826043d901c0c41492a30b1b1357f32857033da__3_The sample of hoverflies\n",
      "5826043d901c0c41492a30b1b1357f32857033da__4_Trophic composition of Ihe Malaise (rap sample\n",
      "5826043d901c0c41492a30b1b1357f32857033da__5_Annual variation in the trophic composition of the Malaise trap sample\n",
      "5826043d901c0c41492a30b1b1357f32857033da__6_Seasonal variation in the trophic composition of the [Malaise trap sample\n",
      "5826043d901c0c41492a30b1b1357f32857033da__7_Hoverflies and the garden habitat\n",
      "4d1f8d99b6567e586253b1326d56f559d951be5f__0_Introduction\n",
      "4d1f8d99b6567e586253b1326d56f559d951be5f__1_Docking site exploration\n",
      "4d1f8d99b6567e586253b1326d56f559d951be5f__2_Identification of specific inhibitors of XendoU cleavage activity\n",
      "4d1f8d99b6567e586253b1326d56f559d951be5f__3_Binding-mode analysis of the active hits in XendoU\n",
      "4d1f8d99b6567e586253b1326d56f559d951be5f__4_Investigation of human and viral PP11 inhibition by the active compounds\n",
      "4d1f8d99b6567e586253b1326d56f559d951be5f__5_Discussion\n",
      "4d1f8d99b6567e586253b1326d56f559d951be5f__6_Conclusion\n",
      "4d1f8d99b6567e586253b1326d56f559d951be5f__7_Computational procedures\n",
      "4d1f8d99b6567e586253b1326d56f559d951be5f__8_Biology\n",
      "467240da5b8636371c3eef393595ca39194c9e7c__0_\n",
      "467240da5b8636371c3eef393595ca39194c9e7c__1_Studying Models for Lung-Related Diseases\n",
      "467240da5b8636371c3eef393595ca39194c9e7c__2_Proteomic Studies to Understand the Underlining Mechanisms of Human Diseases\n",
      "467240da5b8636371c3eef393595ca39194c9e7c__3_Genetic Diseases Cystic fibrosis\n",
      "467240da5b8636371c3eef393595ca39194c9e7c__4_Inflammatory and Allergy Diseases Asthma\n",
      "467240da5b8636371c3eef393595ca39194c9e7c__5_Acute respiratory distress syndrome\n",
      "467240da5b8636371c3eef393595ca39194c9e7c__6_Chronic obstructive pulmonary disease\n",
      "467240da5b8636371c3eef393595ca39194c9e7c__7_Air pollutant-induced allergy\n",
      "467240da5b8636371c3eef393595ca39194c9e7c__8_Infectious Diseases SARS\n",
      "467240da5b8636371c3eef393595ca39194c9e7c__9_Tuberculosis (TB) is a disease caused by lower respiratory tract infection of Mycobacterium tuberculosis.\n",
      "467240da5b8636371c3eef393595ca39194c9e7c__10_Lung Cancer\n",
      "467240da5b8636371c3eef393595ca39194c9e7c__11_Conclusion\n",
      "ea2cbf4492c9c9697e5598d5bce032c23cf58736__0_\n",
      "ea2cbf4492c9c9697e5598d5bce032c23cf58736__1_Contributor's Statement\n",
      "ea2cbf4492c9c9697e5598d5bce032c23cf58736__2_Declaration of interests\n",
      "ea2cbf4492c9c9697e5598d5bce032c23cf58736__3_Funding\n",
      "ea2cbf4492c9c9697e5598d5bce032c23cf58736__4_Ethical approval\n",
      "1e0851ed44e0459ff83448af23b81560a41ede72__0_Background\n",
      "1e0851ed44e0459ff83448af23b81560a41ede72__1_Study design and patient recruitment\n",
      "1e0851ed44e0459ff83448af23b81560a41ede72__2_Outcomes\n",
      "1e0851ed44e0459ff83448af23b81560a41ede72__3_Statistical analysis\n",
      "1e0851ed44e0459ff83448af23b81560a41ede72__4_Ethics approval\n",
      "1e0851ed44e0459ff83448af23b81560a41ede72__5_Patients and baseline characteristics\n",
      "1e0851ed44e0459ff83448af23b81560a41ede72__6_Microbiology findings\n",
      "1e0851ed44e0459ff83448af23b81560a41ede72__7_Sensitivity analysis\n",
      "1e0851ed44e0459ff83448af23b81560a41ede72__8_Discussion\n",
      "1e0851ed44e0459ff83448af23b81560a41ede72__9_Conclusions\n",
      "1e0851ed44e0459ff83448af23b81560a41ede72__10_Supplementary information\n",
      "bab6dd24b41528b0a321874ef4827c873846e335__0_Introduction\n",
      "bab6dd24b41528b0a321874ef4827c873846e335__1_Study Design, Setting and Participants\n",
      "bab6dd24b41528b0a321874ef4827c873846e335__2_Sampling Method\n",
      "bab6dd24b41528b0a321874ef4827c873846e335__3_Use of Traditional, Complementary and Alternative Medicine\n",
      "bab6dd24b41528b0a321874ef4827c873846e335__4_Attitudes Towards the Use of T&CM among Ebola Survivors\n",
      "bab6dd24b41528b0a321874ef4827c873846e335__5_Data Collection and Ethical Consideration\n",
      "bab6dd24b41528b0a321874ef4827c873846e335__6_Statistical Analysis\n",
      "bab6dd24b41528b0a321874ef4827c873846e335__7_Results\n",
      "bab6dd24b41528b0a321874ef4827c873846e335__8_Discussion\n",
      "bab6dd24b41528b0a321874ef4827c873846e335__9_Study Limitations\n",
      "bab6dd24b41528b0a321874ef4827c873846e335__10_Conclusions\n",
      "7270ff5e268e22e5d15f9637967f9b006f54af7e__0_\n",
      "7270ff5e268e22e5d15f9637967f9b006f54af7e__1_Introduction\n",
      "7270ff5e268e22e5d15f9637967f9b006f54af7e__2_Options for defining the length of follow-up\n",
      "7270ff5e268e22e5d15f9637967f9b006f54af7e__3_(4) AESI registry and case-control studies\n",
      "7270ff5e268e22e5d15f9637967f9b006f54af7e__4_Conclusion\n",
      "7270ff5e268e22e5d15f9637967f9b006f54af7e__5_Disclaimer\n",
      "136eb8ca0c1420b21582827d1aaf78a8cd7082f4__0_Introduction\n",
      "136eb8ca0c1420b21582827d1aaf78a8cd7082f4__1_Sequence data\n",
      "136eb8ca0c1420b21582827d1aaf78a8cd7082f4__2_Comparative analysis\n",
      "136eb8ca0c1420b21582827d1aaf78a8cd7082f4__3_LM analysis\n",
      "136eb8ca0c1420b21582827d1aaf78a8cd7082f4__4_Phylogenetic analysis\n",
      "136eb8ca0c1420b21582827d1aaf78a8cd7082f4__5_Evaluation of the molecular clock hypothesis\n",
      "136eb8ca0c1420b21582827d1aaf78a8cd7082f4__6_Statistical analysis\n",
      "136eb8ca0c1420b21582827d1aaf78a8cd7082f4__7_Phylogenetic signal using LM\n",
      "136eb8ca0c1420b21582827d1aaf78a8cd7082f4__8_Evolutionary model and rate estimation\n",
      "136eb8ca0c1420b21582827d1aaf78a8cd7082f4__9_Genealogy among different genes\n",
      "136eb8ca0c1420b21582827d1aaf78a8cd7082f4__10_Discussion\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__0_\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__1_INTRODUCTION\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__2_Quantitative Proteomics Identifies Virus Entry-Dependent Receptor Interactions\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__3_SRFBP1 Is Expressed in the Liver and Required for an Early\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__4_SRFBP1 Colocalizes with CD81 without Affecting HCV Receptor Surface Expression\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__5_SRFBP1 Partially Localizes to CD81-Positive Endosomes and Is Further Recruited to CD81 upon HCV Glycoprotein Exposure\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__6_DISCUSSION\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__7_EXPERIMENTAL PROCEDURES SILAC Labeling and HCV Inoculation\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__8_MS Bioinformatics, Hierarchical Clustering, and Hit Scoring\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__9_RNAi Screen for HCV Host Factors and Bioinformatic Analysis\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__10_Primary Human Hepatocytes\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__11_Immunoprecipitation for SILAC\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__12_LC MS/MS Analysis\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__13_MS Bioinformatics\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__14_DAVID/STRING Functional Gene View\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__15_HCVcc Infection and Whole Life Cycle Assay\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__16_Pseudoparticle Infection\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__17_Plasma Membrane Fusion Assay\n",
      "ada83cbdddd07e8faaa3dce238cae69e4b8dc3d2__18_Translational Reporter Assay\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__0_Introduction\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__1_Biochemical and Biophysical Approaches\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__2_Plasmodium falciparum\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__3_Protein Microarrays\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__4_Avidity-Based Extracellular Interaction Screen (AVEXIS).\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__5_Extracellular Protein Microarray Platforms.\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__6_Protein Microarrays for Viral Immunomodulatory Protein\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__7_In Vitro Transcription and Translation-(IVTT-) Based\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__8_Mass Spectrometry-Based and Computational Approaches\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__9_Mass Spectrometry-Based Characterization of Membrane\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__10_Computational Approaches for Characterization of Pathogen-Host Interactions.\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__11_Complementary DNA Libraries and RNA-Interference-Based Approaches.\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__12_CRISPR/Cas9-Based Screening\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__13_Haploid Genetic Screens.\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__14_Population Genomics for Pathogen-Host Interaction\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__15_Phagemic and Transposon Library-Based Screens.\n",
      "47826d4f9693f8859eff729ef432cc24d41cd896__16_Concluding Remarks\n",
      "8427fc0b13e65b500e55da53c7b5cc389f814a22__0_\n",
      "8427fc0b13e65b500e55da53c7b5cc389f814a22__1_Imaging Diagnosis and Outcome\n",
      "8427fc0b13e65b500e55da53c7b5cc389f814a22__2_Discussion\n",
      "631e7c809b71d79f668542b268894ad91f5e89b6__0_Introduction\n",
      "631e7c809b71d79f668542b268894ad91f5e89b6__1_Super-Spreaders in the MERS-CoV Outbreak in South Korea\n",
      "631e7c809b71d79f668542b268894ad91f5e89b6__2_Why Is the Super-Spreader Phenomenon Important?\n",
      "631e7c809b71d79f668542b268894ad91f5e89b6__3_Approaches or Guidelines that Can Proactively Identify Super-Spreaders\n",
      "631e7c809b71d79f668542b268894ad91f5e89b6__4_Additional Approaches to Study Risk Factors behind Super-Spreading\n",
      "631e7c809b71d79f668542b268894ad91f5e89b6__5_Virus and Host\n",
      "631e7c809b71d79f668542b268894ad91f5e89b6__6_Environment\n",
      "631e7c809b71d79f668542b268894ad91f5e89b6__7_Behavior\n",
      "631e7c809b71d79f668542b268894ad91f5e89b6__8_Concluding Remarks\n",
      "fdd420ba12ea83c4db57fccfe77d5aad622db3c6__0_Introduction\n",
      "fdd420ba12ea83c4db57fccfe77d5aad622db3c6__1_Experimental Animals.\n",
      "fdd420ba12ea83c4db57fccfe77d5aad622db3c6__2_PCR Array.\n",
      "fdd420ba12ea83c4db57fccfe77d5aad622db3c6__3_Enzyme-Linked Immunosorbent Assay (ELISA).\n",
      "fdd420ba12ea83c4db57fccfe77d5aad622db3c6__4_Indirect\n",
      "fdd420ba12ea83c4db57fccfe77d5aad622db3c6__5_Statistical Analysis.\n",
      "fdd420ba12ea83c4db57fccfe77d5aad622db3c6__6_Results\n",
      "fdd420ba12ea83c4db57fccfe77d5aad622db3c6__7_Discussion\n",
      "fdd420ba12ea83c4db57fccfe77d5aad622db3c6__8_Conclusion\n",
      "fdd420ba12ea83c4db57fccfe77d5aad622db3c6__9_Conflict of Interests\n",
      "e34641cde765d4db0253328f3dc2f3e175c1c0d4__0_\n",
      "e34641cde765d4db0253328f3dc2f3e175c1c0d4__1_THE E M ERGIN G R HETOR IC OF \"THE COVID -19 GENER ATION \"\n",
      "e34641cde765d4db0253328f3dc2f3e175c1c0d4__2_A RGUIN G AG A INST \"THE COVID -19 GENER ATION \"\n",
      "e34641cde765d4db0253328f3dc2f3e175c1c0d4__3_Issues With Defining \"The COVID-19 Generation\"\n",
      "e34641cde765d4db0253328f3dc2f3e175c1c0d4__4_The Real Dangers With Investigating and Potentially\n",
      "e34641cde765d4db0253328f3dc2f3e175c1c0d4__5_SUG GE STIONS FOR R E S E A RCH BEYOND \"THE COVID -19 GENER ATION \"\n",
      "e34641cde765d4db0253328f3dc2f3e175c1c0d4__6_CON CLUS ION\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__0_Introduction\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__1_Severe Acute Respiratory Syndrome Coronavirus\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__2_The Pathology of Severe Acute Respiratory Syndrome in Man\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__3_Animal Models for Human Severe Acute Respiratory Syndrome\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__4_86\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__5_Comparative Pathology\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__6_The Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus Infection in Man\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__7_Co-morbidity\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__8_Not for H5N1\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__9_Host-specific Factors: (3) Risk Factors\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__10_The Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus Infection in Animal Models\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__11_Influenza A Virus\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__12_The Pathology of Influenza in Man\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__13_Animal Models for Human Influenza\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__14_96\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__15_As in SARS, the pathology of influenza in fatal human cases can be related to factors that have been proven important in influenza virus infection: virus-specific factors and host-specific factors (Tables 3 and 4).\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__16_The Pathogenesis of Influenza Virus Infection in Animal Models\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__17_Comparing the Pathology and Pathogenesis of Severe Acute Respiratory Infection Syndrome and Influenza\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__18_Concluding Remarks\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__19_Recently-emerging Respiratory Viruses\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__20_Future Perspectives\n",
      "a93c74bb95bce91a99f39cb01bbe5b5935f4bbd7__21_Funding\n",
      "c076a6f8e17c0cf7c7d693cc0d25a5a08cd611cf__0_Introduction\n",
      "c076a6f8e17c0cf7c7d693cc0d25a5a08cd611cf__1_Microbiology Virus\n",
      "c076a6f8e17c0cf7c7d693cc0d25a5a08cd611cf__2_Viral-Bacterial Interactions\n",
      "c076a6f8e17c0cf7c7d693cc0d25a5a08cd611cf__3_Bacteriology\n",
      "c076a6f8e17c0cf7c7d693cc0d25a5a08cd611cf__4_Polymicrobial Interactions\n",
      "c076a6f8e17c0cf7c7d693cc0d25a5a08cd611cf__5_Implications of Bacterial Vaccine Efforts for Practice\n",
      "c076a6f8e17c0cf7c7d693cc0d25a5a08cd611cf__6_Bacterial Susceptibility to Antibiotics\n",
      "c076a6f8e17c0cf7c7d693cc0d25a5a08cd611cf__7_Antibiotic Therapy\n",
      "c076a6f8e17c0cf7c7d693cc0d25a5a08cd611cf__8_Initial Antibiotic Treatment Failure\n",
      "c076a6f8e17c0cf7c7d693cc0d25a5a08cd611cf__9_Duration of Therapy\n",
      "c076a6f8e17c0cf7c7d693cc0d25a5a08cd611cf__10_Conclusion\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__0_Introduction\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__1_Tissues, cells, and viruses\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__2_RNA preparation and cDNA synthesis\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__3_Cloning and sequence analysis of canine STING\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__4_Plasmid construction\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__5_Reagents\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__6_Reporter plasmids and luciferase assays\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__7_RNA interference\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__8_Primer\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__9_Western blot analysis\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__10_Statistics\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__11_Cloning and sequence analysis\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__12_Organ-specific expression analysis of canine STING\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__13_Subcellular localization analysis of canine STING\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__14_Overexpression of canine STING leads to activation of the IFN-β promoter via both the NF-κB and IRF3 pathways\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__15_Overexpression of STING inhibits the replication of canine influenza virus H3N2\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__16_Discussion\n",
      "4208e8bddf6d5bf0d1baa10519b9cb2f27821a5f__17_Conflict of interest\n",
      "180b2bd4680762a2cdcafd397a7e9d6748900523__0_27\n",
      "180b2bd4680762a2cdcafd397a7e9d6748900523__1_204\n",
      "180b2bd4680762a2cdcafd397a7e9d6748900523__2_251\n",
      "180b2bd4680762a2cdcafd397a7e9d6748900523__3_278\n",
      "180b2bd4680762a2cdcafd397a7e9d6748900523__4_288\n",
      "180b2bd4680762a2cdcafd397a7e9d6748900523__5_M.myotis_IFITM3\n",
      "38fa4f6737cc35a3fdb6c998b91035e55ac9967a__0_\n",
      "38fa4f6737cc35a3fdb6c998b91035e55ac9967a__1_Respirators\n",
      "38fa4f6737cc35a3fdb6c998b91035e55ac9967a__2_Test respirator coupons\n",
      "38fa4f6737cc35a3fdb6c998b91035e55ac9967a__3_Selection of virus: MS2\n",
      "38fa4f6737cc35a3fdb6c998b91035e55ac9967a__4_MS2 virus aerosol generation and loading on to test respirator coupons\n",
      "38fa4f6737cc35a3fdb6c998b91035e55ac9967a__5_Storage conditions for MS2 loaded respirator coupons\n",
      "38fa4f6737cc35a3fdb6c998b91035e55ac9967a__6_Virus recovery\n",
      "38fa4f6737cc35a3fdb6c998b91035e55ac9967a__7_Plaque assay\n",
      "38fa4f6737cc35a3fdb6c998b91035e55ac9967a__8_Toxicity assay\n",
      "38fa4f6737cc35a3fdb6c998b91035e55ac9967a__9_Data analysis\n",
      "38fa4f6737cc35a3fdb6c998b91035e55ac9967a__10_RESULTS\n",
      "38fa4f6737cc35a3fdb6c998b91035e55ac9967a__11_DISCUSSION\n",
      "38fa4f6737cc35a3fdb6c998b91035e55ac9967a__12_CONCLUSION\n",
      "e630b993a9b1eacba99feec2a3849e8133896b7e__0_Introduction\n",
      "e630b993a9b1eacba99feec2a3849e8133896b7e__1_Material and methods\n",
      "e630b993a9b1eacba99feec2a3849e8133896b7e__2_Results\n",
      "e630b993a9b1eacba99feec2a3849e8133896b7e__3_Discussion\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__0_Introduction\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__1_Background\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__2_Related Work\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__3_Decentralized K -Means\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__4_General P2P K -Means Algorithms and Their Limitations\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__5_Algorithm 1.\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__6_KM-Clustering()\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__7_P2P K -Means with HyperLogLog Counters\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__8_Algorithm 2. Generate HyperLogLog function for k -means at node n i\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__9_Algorithm 3. HyperLogLog update for k -means at node n i\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__10_Adaptive Number of Clusters at Each Node\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__11_Evaluation\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__12_K -Means Clustering Algorithms\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__13_Datasets\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__14_Real-World Datasets:\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__15_Skewed Data and Asynchronous Computations\n",
      "b66fda7dba43eb3ed1bd56e648fdf860eb63addb__16_Conclusion\n",
      "665622d28864a2df5caf4f9fdb8ebe97a0aedd8b__0_INTRODUCTION\n",
      "665622d28864a2df5caf4f9fdb8ebe97a0aedd8b__1_Putative G-Quadruplex Sequences in the M. tuberculosis Genome and Their Evolutionary Conservation\n",
      "665622d28864a2df5caf4f9fdb8ebe97a0aedd8b__2_Evaluation of the Formation of G4 Structures and Their Stability by Employing Circular Dichroism Spectra and Melting Analysis\n",
      "665622d28864a2df5caf4f9fdb8ebe97a0aedd8b__3_Electrophoretic Mobility Shift Assay Indicated the Formation of the Intramolecular G4 by MTB-PGQs\n",
      "665622d28864a2df5caf4f9fdb8ebe97a0aedd8b__4_Exploration of G4 Structure Formation by NMR\n",
      "665622d28864a2df5caf4f9fdb8ebe97a0aedd8b__5_Stabilizing and Energetically Favorable Interaction of the PGQs with the Representative G4 Ligand\n",
      "665622d28864a2df5caf4f9fdb8ebe97a0aedd8b__6_MATERIALS AND METHODS\n",
      "665622d28864a2df5caf4f9fdb8ebe97a0aedd8b__7_Availability\n",
      "665622d28864a2df5caf4f9fdb8ebe97a0aedd8b__8_SUPPLEMENTAL INFORMATION\n",
      "665622d28864a2df5caf4f9fdb8ebe97a0aedd8b__9_CONFLICTS OF INTEREST\n",
      "78f65e28edf36a3504c5ab6e7c15590edfd3feae__0_1.Demographics and characteristics of COVID-19 patients\n",
      "78f65e28edf36a3504c5ab6e7c15590edfd3feae__1_Laboratory indices of COVID-19 patients\n",
      "78f65e28edf36a3504c5ab6e7c15590edfd3feae__2_3.Independent risk factors of severe COVID-19 patients\n",
      "78f65e28edf36a3504c5ab6e7c15590edfd3feae__3_The Predictive factors correlated with severity of COVID-19\n",
      "78f65e28edf36a3504c5ab6e7c15590edfd3feae__4_5.The predictive factors correlated with the severity of lung damage\n",
      "78f65e28edf36a3504c5ab6e7c15590edfd3feae__5_The predictive factors for identification of severe COVID-19 cases\n",
      "78f65e28edf36a3504c5ab6e7c15590edfd3feae__6_Relationship between LDH and inflammation, cardiac and liver injury biomarkers.\n",
      "78f65e28edf36a3504c5ab6e7c15590edfd3feae__7_Discussion\n",
      "78f65e28edf36a3504c5ab6e7c15590edfd3feae__8_Conclusion\n",
      "78f65e28edf36a3504c5ab6e7c15590edfd3feae__9_Data availability\n",
      "78f65e28edf36a3504c5ab6e7c15590edfd3feae__10_Figures\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__0_Introduction\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__1_Plant material\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__2_Alkaloids preparation\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__3_Chemicals\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__4_Animals\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__5_Experimental design\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__6_Serum collection\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__7_Bronchoalveolar lavage fluid(BALF)and cell enumeration\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__8_Lung homogenate\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__9_Lung histopathology\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__10_Statistical analyses\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__11_Observation on general symptom\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__12_Effects of indole alkaloids on inflammatory cell count in BALF\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__13_Effect of indole alkaloids on IL-6 and CRP production in serum\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__14_Effect of indole alkaloids on SOD and MDA activities in serum and lung\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__15_Groups\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__16_Table 4\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__17_Groups Serum Homogenate\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__18_Discussion\n",
      "3fb382f0bd23aaf5f7cf648705119b6f9ad69cfa__19_Conclusions\n",
      "9c309bfc1bf44d4f92176d495c4e7c7ec5080ebd__0_\n",
      "9c309bfc1bf44d4f92176d495c4e7c7ec5080ebd__1_Disclosures\n",
      "9c309bfc1bf44d4f92176d495c4e7c7ec5080ebd__2_Department of Neurosurgery Union Hospital Tongji Medical College Huazhong University of Science and Technology\n",
      "36f9a0846e736e21303f13987d0e0787de742511__0_Introduction\n",
      "36f9a0846e736e21303f13987d0e0787de742511__1_The GAL4/UAS system for in vivo expression of viral transgenes\n",
      "36f9a0846e736e21303f13987d0e0787de742511__2_Studies of human viruses using D. melanogaster\n",
      "36f9a0846e736e21303f13987d0e0787de742511__3_SARS\n",
      "36f9a0846e736e21303f13987d0e0787de742511__4_HIV\n",
      "36f9a0846e736e21303f13987d0e0787de742511__5_Future directions\n",
      "1e4a05b0bb552c2008870b965dad8605710fce2b__0_Introduction\n",
      "1e4a05b0bb552c2008870b965dad8605710fce2b__1_Data sources\n",
      "1e4a05b0bb552c2008870b965dad8605710fce2b__2_High-temperature indices\n",
      "1e4a05b0bb552c2008870b965dad8605710fce2b__3_Statistical analysis\n",
      "1e4a05b0bb552c2008870b965dad8605710fce2b__4_Cumulative relative risk for various high-temperature indices\n",
      "1e4a05b0bb552c2008870b965dad8605710fce2b__5_Discussion\n",
      "1e4a05b0bb552c2008870b965dad8605710fce2b__6_Conclusion\n",
      "ebb91b37009eaa9277f18e46ca1595f1b7223d6f__0_Introduction 29\n",
      "ebb91b37009eaa9277f18e46ca1595f1b7223d6f__1_Patient A 62\n",
      "ebb91b37009eaa9277f18e46ca1595f1b7223d6f__2_Patient B 105\n",
      "a926b146a00f9e82a3f1769039f12aaf4fb3a0cf__0_Introduction\n",
      "a926b146a00f9e82a3f1769039f12aaf4fb3a0cf__1_Results and discussion\n",
      "a926b146a00f9e82a3f1769039f12aaf4fb3a0cf__2_Contents lists available at ScienceDirect\n",
      "a926b146a00f9e82a3f1769039f12aaf4fb3a0cf__3_Conclusion\n",
      "a926b146a00f9e82a3f1769039f12aaf4fb3a0cf__4_General\n",
      "a926b146a00f9e82a3f1769039f12aaf4fb3a0cf__5_(þ)-2-Amino-9-((1R,4S)-4-(2-hydroxyethyl)cyclopent-2-enyl)-\n",
      "ebcbb4241c95ad27eced8844b2efa4e450535931__0_Introduction\n",
      "ebcbb4241c95ad27eced8844b2efa4e450535931__1_Case Report\n",
      "ebcbb4241c95ad27eced8844b2efa4e450535931__2_Infection Control\n",
      "ebcbb4241c95ad27eced8844b2efa4e450535931__3_Discussion\n",
      "ebcbb4241c95ad27eced8844b2efa4e450535931__4_Conclusion\n",
      "1601e9f2bbf89f04f967a4f5f49d7adeca7f0719__0_I. Introduction\n",
      "1601e9f2bbf89f04f967a4f5f49d7adeca7f0719__1_i. Datasets\n",
      "1601e9f2bbf89f04f967a4f5f49d7adeca7f0719__2_ii. Models\n",
      "1601e9f2bbf89f04f967a4f5f49d7adeca7f0719__3_iii. Logistic Regression\n",
      "1601e9f2bbf89f04f967a4f5f49d7adeca7f0719__4_iv. Gradient Boosted Trees\n",
      "1601e9f2bbf89f04f967a4f5f49d7adeca7f0719__5_III. Results and Model Interpretation\n",
      "1601e9f2bbf89f04f967a4f5f49d7adeca7f0719__6_IV. Accessing Models\n",
      "1601e9f2bbf89f04f967a4f5f49d7adeca7f0719__7_V. Conclusions\n",
      "27b2c055e36b8ff22f0b14e23785ccaaef5948ab__0_INTRODUCTION\n",
      "27b2c055e36b8ff22f0b14e23785ccaaef5948ab__1_TERPENOIDS\n",
      "27b2c055e36b8ff22f0b14e23785ccaaef5948ab__2_NUCLEOSIDES\n",
      "27b2c055e36b8ff22f0b14e23785ccaaef5948ab__3_ALKALOIDS AND OTHER NITROGEN-CONTAINING COMPOUNDS\n",
      "27b2c055e36b8ff22f0b14e23785ccaaef5948ab__4_POLYSACCHARIDES\n",
      "27b2c055e36b8ff22f0b14e23785ccaaef5948ab__5_MISCELLANEOUS COMPOUNDS\n",
      "27b2c055e36b8ff22f0b14e23785ccaaef5948ab__6_CRUDE EXTRACTS SHOWING ANTIVIRAL ACTIVITY\n",
      "27b2c055e36b8ff22f0b14e23785ccaaef5948ab__7_CONCLUDING REMARKS\n",
      "27b2c055e36b8ff22f0b14e23785ccaaef5948ab__8_ACKNOWLEDGMENTS\n",
      "6bc8969058239852857384c5a87a7e75f41193b6__0_\n",
      "6bc8969058239852857384c5a87a7e75f41193b6__1_Rats\n",
      "6bc8969058239852857384c5a87a7e75f41193b6__2_Radiation\n",
      "6bc8969058239852857384c5a87a7e75f41193b6__3_Other Preparative Regimens\n",
      "6bc8969058239852857384c5a87a7e75f41193b6__4_Bone Marrow Transplantation\n",
      "6bc8969058239852857384c5a87a7e75f41193b6__5_Antibiotics\n",
      "6bc8969058239852857384c5a87a7e75f41193b6__6_Cyclosporine\n",
      "6bc8969058239852857384c5a87a7e75f41193b6__7_FISCHER ET AL . 1033\n",
      "6bc8969058239852857384c5a87a7e75f41193b6__8_Monoclonal Antibodies\n",
      "6bc8969058239852857384c5a87a7e75f41193b6__9_Cell Separation\n",
      "6bc8969058239852857384c5a87a7e75f41193b6__10_Results\n",
      "6bc8969058239852857384c5a87a7e75f41193b6__11_Discussion\n",
      "6bc8969058239852857384c5a87a7e75f41193b6__12_Summary\n",
      "a13f9ec4f4f4819b5800f85d9075ed5476357918__0_VIRUS LIFE CYCLE\n",
      "a13f9ec4f4f4819b5800f85d9075ed5476357918__1_Definition of virus receptors\n",
      "a13f9ec4f4f4819b5800f85d9075ed5476357918__2_Cellular receptors for virus attachment\n",
      "a13f9ec4f4f4819b5800f85d9075ed5476357918__3_Cellular receptors for virus entry\n",
      "a13f9ec4f4f4819b5800f85d9075ed5476357918__4_Virus receptors on epithelial cells\n",
      "a13f9ec4f4f4819b5800f85d9075ed5476357918__5_Polarity of virus entry\n",
      "a13f9ec4f4f4819b5800f85d9075ed5476357918__6_Accessory factors affecting virus entry into epithelial cells\n",
      "a13f9ec4f4f4819b5800f85d9075ed5476357918__7_Virus assembly at the plasma membrane\n",
      "a13f9ec4f4f4819b5800f85d9075ed5476357918__8_Virus assembly at intracellular membranes\n",
      "a13f9ec4f4f4819b5800f85d9075ed5476357918__9_Nonenveloped viruses\n",
      "a13f9ec4f4f4819b5800f85d9075ed5476357918__10_POLARIZED ENTRY AND RELEASE AS DETERMINANTS OF VIRAL PATHOGENESIS\n",
      "a13f9ec4f4f4819b5800f85d9075ed5476357918__11_Gastrointestinal tract\n",
      "a13f9ec4f4f4819b5800f85d9075ed5476357918__12_Respiratory tract\n",
      "a13f9ec4f4f4819b5800f85d9075ed5476357918__13_IMPLICATIONS FOR EFFECTIVE VACCINES\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__0_\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__1_Diagnosis\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__2_Risk Factors\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__3_Prognosis and Therapy\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__4_Epstein-Barr Virus\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__5_Epidemiology and Prevalence\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__6_Clinical Manifestations\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__7_Varicella-Zoster Virus\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__8_Prevention\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__9_Primary HHV-6 Infection\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__10_Kaposi Sarcoma\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__11_Classic Kaposi Sarcoma in Immunocompetent Subjects\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__12_Endemic Kaposi Sarcoma in Sub-Saharan Africa\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__13_Epidemic Kaposi Sarcoma in HIV-Infected Persons\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__14_Kaposi Sarcoma in Solid Organ Transplant Recipients\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__15_Primary Effusion Lymphoma\n",
      "26efe2480c96d93ed23f8adf49ace5671c55d6d1__16_Multicentric Castleman Disease\n",
      "0e105b6e9745e61af820c835c386a079f69a717d__0_Introduction: nidoviruses as a distinct group of ssRNA+ viruses\n",
      "0e105b6e9745e61af820c835c386a079f69a717d__1_Nidovirus genome diversity and a common genetic plan\n",
      "0e105b6e9745e61af820c835c386a079f69a717d__2_Replicase machinery: the conserved nidovirus backbone\n",
      "0e105b6e9745e61af820c835c386a079f69a717d__3_Replicase machinery: group-specific domains\n",
      "0e105b6e9745e61af820c835c386a079f69a717d__4_Family specific virion morphology and major virion components\n",
      "0e105b6e9745e61af820c835c386a079f69a717d__5_Virus-specific accessory genes: fast adaptability to a new niche?\n",
      "0e105b6e9745e61af820c835c386a079f69a717d__6_RNA synthesis in Nidovirales: what makes it special?\n",
      "0e105b6e9745e61af820c835c386a079f69a717d__7_Mechanisms of evolution: mutations and recombination\n",
      "0e105b6e9745e61af820c835c386a079f69a717d__8_Origins of the Nidovirales and nidovirus families\n",
      "0e105b6e9745e61af820c835c386a079f69a717d__9_Concluding remarks\n",
      "1dc818a92b31dc871d7020ec659faaeb38e519c6__0_Introduction\n",
      "1dc818a92b31dc871d7020ec659faaeb38e519c6__1_Incidence of influenza and respiratory syncytial virus infections in children, and vaccines currently available to protect against these respiratory viruses\n",
      "1dc818a92b31dc871d7020ec659faaeb38e519c6__2_Influenza virus vaccines for infants\n",
      "1dc818a92b31dc871d7020ec659faaeb38e519c6__3_RSV vaccines for infants\n",
      "1dc818a92b31dc871d7020ec659faaeb38e519c6__4_Pre-clinical and clinical trial needs for respiratory virus vaccines\n",
      "1dc818a92b31dc871d7020ec659faaeb38e519c6__5_Safety and efficacy of influenza and RSV vaccines in infants\n",
      "1dc818a92b31dc871d7020ec659faaeb38e519c6__6_Impact of immunologic immaturity and maternal antibodies on infant responses to vaccines\n",
      "1dc818a92b31dc871d7020ec659faaeb38e519c6__7_Designing vaccines against respiratory viruses for infants\n",
      "1dc818a92b31dc871d7020ec659faaeb38e519c6__8_Conclusion\n",
      "04002eb2da9febbca9ac7f6d35c02f5ca32c91f4__0_INTRODUCTION\n",
      "04002eb2da9febbca9ac7f6d35c02f5ca32c91f4__1_Patient diagnosis and inclusion criteria\n",
      "04002eb2da9febbca9ac7f6d35c02f5ca32c91f4__2_Statistical analysis\n",
      "04002eb2da9febbca9ac7f6d35c02f5ca32c91f4__3_Patient characteristics\n",
      "04002eb2da9febbca9ac7f6d35c02f5ca32c91f4__4_Delayed viral clearance among patients with digestive symptoms\n",
      "04002eb2da9febbca9ac7f6d35c02f5ca32c91f4__5_Results of stool testing for COVID-19 viral RNA\n",
      "04002eb2da9febbca9ac7f6d35c02f5ca32c91f4__6_DISCUSSION\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__0_Modifications\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__1_Addition of the SCVMC IRB\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__2_Signature page\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__3_____________________________________\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__4_Schematic\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__5_Background information\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__6_Description of the study agents(s)/intervention(s)\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__7_Summary of previous pre-clinical studies\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__8_Summary of relevant clinical studies\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__9_Summary of epidemiological data\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__10_Rationale\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__11_Immediate risks\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__12_Long range risks\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__13_Rationale for the necessity of such risks\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__14_Why alternative procedures may not be feasible\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__15_Why the value of the information to be gained outweighs the risks involved\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__16_Potential benefits\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__17_STUDY OBJECTIVES\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__18_A. Within the cohort study:\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__19_B. Within the intervention:\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__20_Description of the study design\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__21_Primary endpoint\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__22_Secondary endpoints\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__23_Description of the study population\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__24_Participant inclusion criteria\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__25_Participant exclusion criteria\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__26_Co-enrollment guidelines\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__27_5.1.2.2.\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__28_Strategies for recruitment and retention\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__29_Study agent acquisition\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__30_Formulation, packaging and labeling\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__31_Study agent storage and stability\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__32_Preparation, administration and dosage of study agent(s)/interventions(s)\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__33_Study product accountability procedures\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__34_Assessment of participant compliance with study agent(s)/intervention(s)\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__35_Concomitant medications and procedures\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__36_Precautionary and prohibited medications and procedures\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__37_Prophylactic medications and procedures\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__38_Rescue medications\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__39_Study procedures/evaluations\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__40_Evaluations\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__41_Procedures\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__42_. Special assays or procedures\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__43_ LPS -TBD\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__44_Blood\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__45_Stool\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__46_Urine\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__47_Saliva\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__48_Skin swabs\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__49_Dust swabs\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__50_Kitchen countertop swabs\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__51_STUDY SCHEDULE\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__52_Screening\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__53_Enrollment/baseline\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__54_Follow-up\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__55_At delivery:\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__56_After delivery:\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__57_B. Monthly\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__58_C. Every four months\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__59_D. Every 6 months\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__60_E. Annually\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__61_Final study visit\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__62_Early termination visit\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__63_Definition of an adverse event (AE)\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__64_Definition of a serious adverse event (SAE)\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__65_Specific serious adverse event requirements\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__66_Reporting of pregnancy\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__67_Procedures to be followed in the event of abnormal laboratory test values or abnormal clinical findings\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__68_Type and duration of the follow-up of participants after adverse events\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__69_Halting rules for the protocol\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__70_Premature withdrawal of a participant\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__71_Replacement of a participant who discontinues study treatment\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__72_Site monitoring plan\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__73_Safety monitoring plan\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__74_Overview and study objectives\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__75_Secondary analyses for the intervention include:\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__76_Exploratory analyses encompass a wide range of topics, with several examples listed below.\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__77_Analysis plan\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__78_Cohort\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__79_Intervention\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__80_Maintenance of trial treatment randomization codes\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__81_QUALITY CONTROL AND QUALITY ASSURANCE\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__82_Declaration of Helsinki\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__83_Participant confidentiality\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__84_Institutional review board/medical ethics committee\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__85_Assent or informed consent process (in case of a minor)\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__86_Exclusion of women, minorities and children (special populations)\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__87_Informed consent process\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__88_Study discontinuation\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__89_Future use of stored specimens\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__90_DATA HANDLING AND RECORD KEEPING\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__91_Data management responsibilities\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__92_Data capture methods\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__93_Types of data\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__94_Source documents and access to source data/documents\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__95_Timing/reports\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__96_Study records retention\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__97_Protocol deviations\n",
      "95bd6a3d04bd47a4a7683ea948e6de05125a34c6__98_PUBLICATION POLICY\n",
      "72fc688d0a9aa57f9ca59d40f1eaa4ea89d68285__0_Summary.\n",
      "c983fff3f9370585cf6f9b870b3e0c7f3fca7b52__0_\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__0_\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__1_The threat posed by viral hemorrhagic fever viruses\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__2_Virology and pathology\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__3_The Bunyaviridae\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__4_Bunyavirus genus\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__5_Phlebovirus genus\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__6_Nairovirus genus\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__7_Hantavirus genus\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__8_The Filoviridae\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__9_Human pathology\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__10_The Flaviviridae\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__11_Mosquito-borne flavivirus hemorrhagic fevers\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__12_Dengue virus\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__13_Yellow fever virus\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__14_Clinical presentations and management\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__15_The Arenaviridae\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__16_Guanarito virus: Venezuelan hemorrhagic fever\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__17_Sabia virus: Sabia virus hemorrhagic fever\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__18_Junin virus: Argentine hemorrhagic fever\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__19_Machupo virus: Bolivian hemorrhagic fever\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__20_Whitewater Arroyo virus: Whitewater Arroyo virus hemorrhagic fever\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__21_New therapeutic modalities for Arenaviridae and other RNA viruses\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__22_Phlebovirus genus: Rift Valley fever\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__23_Nairovirus genus: Congo-Crimean hemorrhagic fever\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__24_Convalescent phase\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__25_Marburg virus: Marburg hemorrhagic fever\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__26_Yellow fever\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__27_Kyasanur Forest disease virus and hemorrhagic fever\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__28_Omsk hemorrhagic fever virus and disease\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__29_Alkhumra virus and hemorrhagic fever\n",
      "96b147c0943daa7c3a50a5d395b7e850a8f5c0cc__30_Summary\n",
      "e9301e36ee50ce5038f05536e9038500b2ceba89__0_\n",
      "ebf9a1d5d582496180bfde6dfd42c25006f8780c__0_INTRODUCTION\n",
      "ebf9a1d5d582496180bfde6dfd42c25006f8780c__1_Prebiotics\n",
      "ebf9a1d5d582496180bfde6dfd42c25006f8780c__2_Antineoplastic drugs\n",
      "ebf9a1d5d582496180bfde6dfd42c25006f8780c__3_Antimicrobials\n",
      "ebf9a1d5d582496180bfde6dfd42c25006f8780c__4_Antimalarial agent\n",
      "ebf9a1d5d582496180bfde6dfd42c25006f8780c__5_Isoprenoids\n",
      "ebf9a1d5d582496180bfde6dfd42c25006f8780c__6_Proteins\n",
      "ebf9a1d5d582496180bfde6dfd42c25006f8780c__7_Fatty acids and lipids\n",
      "ebf9a1d5d582496180bfde6dfd42c25006f8780c__8_Vitamins\n",
      "ebf9a1d5d582496180bfde6dfd42c25006f8780c__9_Alcohols\n",
      "ebf9a1d5d582496180bfde6dfd42c25006f8780c__10_Additional compounds\n",
      "ebf9a1d5d582496180bfde6dfd42c25006f8780c__11_Biofuels\n",
      "ebf9a1d5d582496180bfde6dfd42c25006f8780c__12_Echinocandins\n",
      "ebf9a1d5d582496180bfde6dfd42c25006f8780c__13_CONCLUDING REMARKS\n",
      "3168aa9b909bc05f8140726c27e331b6da5abff8__0_INTRODUCTION\n",
      "3168aa9b909bc05f8140726c27e331b6da5abff8__1_Material\n",
      "3168aa9b909bc05f8140726c27e331b6da5abff8__2_SSAKE algorithm\n",
      "3168aa9b909bc05f8140726c27e331b6da5abff8__3_RESULTS\n",
      "3168aa9b909bc05f8140726c27e331b6da5abff8__4_CONCLUSION\n",
      "772285d546fe099226c617ea6ad9e8ad4163f2e7__0_Abstract\n",
      "772285d546fe099226c617ea6ad9e8ad4163f2e7__1_Methods\n",
      "772285d546fe099226c617ea6ad9e8ad4163f2e7__2_Conclusions\n",
      "eec1b65d2870e77c6b20afb7872f3a5fb16e28c1__0_\n",
      "eec1b65d2870e77c6b20afb7872f3a5fb16e28c1__1_Manuscript word count: 711 words\n",
      "eec1b65d2870e77c6b20afb7872f3a5fb16e28c1__2_(which was not certified by peer review)\n",
      "043aa68f2c784899f71225e8eb233150760a6a54__0_\n",
      "043aa68f2c784899f71225e8eb233150760a6a54__1_Data collection\n",
      "043aa68f2c784899f71225e8eb233150760a6a54__2_Analyses of temporal and spatial distribution\n",
      "043aa68f2c784899f71225e8eb233150760a6a54__3_Statistical analysis of risk factors\n",
      "043aa68f2c784899f71225e8eb233150760a6a54__4_RESULTS\n",
      "043aa68f2c784899f71225e8eb233150760a6a54__5_DISCUSSION\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__0_INTRODUCTION\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__1_Generation of a SARS-CoV ORFeome\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__2_Y2H screen of the individual SARS-CoV ORFs and confirmation by CoIP\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__3_Interactions of non-structural proteins\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__4_Interactions of structural proteins\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__5_Interactions of accessory proteins\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__6_Deletion of ORF9b from SARS-CoV\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__7_Bioinformatical analysis Comparison of SARS-CoV and herpesvirus intraviral protein interaction screens\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__8_SARS-CoV-host interaction network\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__9_Immunofluorescence localization of SARS-CoV ORFs\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__10_DISCUSSION\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__11_MATERIALS AND METHODS\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__12_Strategy for Recombinatorial Cloning of the SARS-CoV ORFs\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__13_Yeast-two-hybrid screen\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__14_Co-immunoprecipitation\n",
      "60081af7cc91d270d05e6cb45285578f86c918fb__15_Recombinant virus\n",
      "0c0cd8209801b5fa59796f6a8a06571eabf2ac88__0_INTRODUCTION\n",
      "0c0cd8209801b5fa59796f6a8a06571eabf2ac88__1_Incidence\n",
      "0c0cd8209801b5fa59796f6a8a06571eabf2ac88__2_Presence of SARS-CoV-2 in ocular secretion\n",
      "0c0cd8209801b5fa59796f6a8a06571eabf2ac88__3_Hints from other coronavirus: SARS-CoV\n",
      "0c0cd8209801b5fa59796f6a8a06571eabf2ac88__4_Hints from coronaviruses in animals\n",
      "0c0cd8209801b5fa59796f6a8a06571eabf2ac88__5_COMPARISON OF CONJUNCTIVITIS ASSOCIATED WITH SARS-COV-2, SARS-COV, AND ADENOVIRUS INFECTIONS\n",
      "9e7a93b167e9c3ffc970caf4a644d63439410cc5__0_Background\n",
      "9e7a93b167e9c3ffc970caf4a644d63439410cc5__1_Ethical issues\n",
      "9e7a93b167e9c3ffc970caf4a644d63439410cc5__2_Sources of cases\n",
      "9e7a93b167e9c3ffc970caf4a644d63439410cc5__3_Sources of healthy controls\n",
      "9e7a93b167e9c3ffc970caf4a644d63439410cc5__4_Estimation of sample size\n",
      "9e7a93b167e9c3ffc970caf4a644d63439410cc5__5_Information and sample collection\n",
      "9e7a93b167e9c3ffc970caf4a644d63439410cc5__6_Genotyping\n",
      "9e7a93b167e9c3ffc970caf4a644d63439410cc5__7_Statistical analysis\n",
      "9e7a93b167e9c3ffc970caf4a644d63439410cc5__8_Results\n",
      "9e7a93b167e9c3ffc970caf4a644d63439410cc5__9_Discussion\n",
      "9e7a93b167e9c3ffc970caf4a644d63439410cc5__10_Conclusion\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__0_\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__1_How are standard precautions defined?\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__2_How are transmission-based precautions defined and classified?\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__3_TRANSMISSION-BASED PRECAUTIONS Droplet Precautions\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__4_What materials are required?\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__5_What is the indication to start droplet precautions?\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__6_Meningitis (N meningitidis)\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__7_Box 4 Duration of precautions by pathogen\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__8_Airborne Precautions\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__9_What is the indication to start airborne precautions?\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__10_When can airborne precautions be discontinued for tuberculosis?\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__11_What is the efficacy in preventing disease spread for tuberculosis?\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__12_Contact Precautions\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__13_Vancomycin-resistant Enterococcus\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__14_Carbapenem-resistant Enterobacteriaceae\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__15_What is the efficacy in preventing disease spread?\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__16_What is the cost associated with the use of isolation precautions (and screening)?\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__17_What is the environmental impact associated with the use of isolation precautions?\n",
      "b785a877182ada741a4127aed50a746a1a1b1dea__18_What is the impact of a hospital-based infection control program?\n",
      "2aada329a0cde26b24265c3cdc4d55d2ca72abd1__0_Introduction\n",
      "2aada329a0cde26b24265c3cdc4d55d2ca72abd1__1_Study design and patient recruitment\n",
      "2aada329a0cde26b24265c3cdc4d55d2ca72abd1__2_Clinical assessments\n",
      "2aada329a0cde26b24265c3cdc4d55d2ca72abd1__3_Laboratory assessment\n",
      "2aada329a0cde26b24265c3cdc4d55d2ca72abd1__4_Outcomes\n",
      "2aada329a0cde26b24265c3cdc4d55d2ca72abd1__5_Statistical methods\n",
      "2aada329a0cde26b24265c3cdc4d55d2ca72abd1__6_Patients\n",
      "2aada329a0cde26b24265c3cdc4d55d2ca72abd1__7_Etiology and symptoms\n",
      "2aada329a0cde26b24265c3cdc4d55d2ca72abd1__8_Acute rejection\n",
      "2aada329a0cde26b24265c3cdc4d55d2ca72abd1__9_Lung function\n",
      "2aada329a0cde26b24265c3cdc4d55d2ca72abd1__10_Other adverse events\n",
      "2aada329a0cde26b24265c3cdc4d55d2ca72abd1__11_Discussion\n",
      "dd3e4d4c9b2f290570d93d972973f46b29d9262e__0_\n",
      "dd3e4d4c9b2f290570d93d972973f46b29d9262e__1_CARDIOVASCULAR DISEASE\n",
      "dd3e4d4c9b2f290570d93d972973f46b29d9262e__2_ARTHRITIS/DEGENERATIVE JOINT DISEASE\n",
      "dd3e4d4c9b2f290570d93d972973f46b29d9262e__3_DENTAL DISEASE\n",
      "dd3e4d4c9b2f290570d93d972973f46b29d9262e__4_SPLAY LEG\n",
      "dd3e4d4c9b2f290570d93d972973f46b29d9262e__5_MUSCLE WASTING\n",
      "dd3e4d4c9b2f290570d93d972973f46b29d9262e__6_OCULAR LESIONS\n",
      "dd3e4d4c9b2f290570d93d972973f46b29d9262e__7_CHRONIC OTITIS\n",
      "dd3e4d4c9b2f290570d93d972973f46b29d9262e__8_ULCERATIVE PODODERMATITIS AND PERINEAL DERMATITIS\n",
      "dd3e4d4c9b2f290570d93d972973f46b29d9262e__9_NEOPLASIA\n",
      "dd3e4d4c9b2f290570d93d972973f46b29d9262e__10_MODIFICATION OF THERAPEUTICS IN GERIATRIC RABBITS\n",
      "dd3e4d4c9b2f290570d93d972973f46b29d9262e__11_SEDATION AND ANESTHESIA FOR THE GERIATRIC RABBIT\n",
      "dd3e4d4c9b2f290570d93d972973f46b29d9262e__12_HOSPICE AND END-OF-LIFE ISSUES\n",
      "dd3e4d4c9b2f290570d93d972973f46b29d9262e__13_TECHNIQUES FOR EUTHANASIA\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__0_Introduction\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__1_Occurrence, location, and structure\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__2_Isolation and chemistry\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__3_Assembly and morphogenesis\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__4_Assembly in vitro\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__5_Reassembly in solution\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__6_Reassembly at interfaces\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__7_Genetics, domains, and biosynthesis\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__8_Functional aspects\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__9_Cell shape determination\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__10_Surface properties and protective coats\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__11_S-Layers related to pathogenicity\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__12_S-Layers as molecular sieves and antifouling coating\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__13_S-Layers as adhesion zone for exoenzymes\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__14_S-Layers as template for fine-grain mineralization and bioremediation\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__15_Applications Isoporous ultrafiltration membranes\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__16_S-Layers as matrix for functional molecules and nanoparticles\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__17_S-Layers for vaccine development\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__18_S-layer supported functional lipid membranes\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__19_S-layer protein-lipid interaction\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__20_Planar lipid membranes\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__21_S-layer (glyco)proteins\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__22_S-layer coated liposomes and emulsomes\n",
      "73706c27f129eddf80395baf777ba70dd9432e8e__23_Conclusions and perspectives\n",
      "d2db8695909872104b66c22d6dd84e8e1bee6fc8__0_Introduction\n",
      "d2db8695909872104b66c22d6dd84e8e1bee6fc8__1_Patients\n",
      "d2db8695909872104b66c22d6dd84e8e1bee6fc8__2_Real-time PCR\n",
      "d2db8695909872104b66c22d6dd84e8e1bee6fc8__3_Multiple-reverse transcription PCR\n",
      "d2db8695909872104b66c22d6dd84e8e1bee6fc8__4_Bacterial cultures\n",
      "d2db8695909872104b66c22d6dd84e8e1bee6fc8__5_Serological test\n",
      "d2db8695909872104b66c22d6dd84e8e1bee6fc8__6_Clinical criteria to begin antimicrobial chemotherapy\n",
      "d2db8695909872104b66c22d6dd84e8e1bee6fc8__7_Criteria for selection of antimicrobial agent and treatment period\n",
      "d2db8695909872104b66c22d6dd84e8e1bee6fc8__8_Statistical analysis\n",
      "d2db8695909872104b66c22d6dd84e8e1bee6fc8__9_Bacterial pathogens\n",
      "d2db8695909872104b66c22d6dd84e8e1bee6fc8__10_Evaluation of antimicrobial agents selected empirically\n",
      "d2db8695909872104b66c22d6dd84e8e1bee6fc8__11_Discussion\n",
      "9ae1200763366eaba32a6dc12d7958a1dd08f107__0_\n",
      "9ae1200763366eaba32a6dc12d7958a1dd08f107__1_Class I viral fusion proteins\n",
      "9ae1200763366eaba32a6dc12d7958a1dd08f107__2_Core trimers of class I viral fusion proteins\n",
      "9ae1200763366eaba32a6dc12d7958a1dd08f107__3_Fusion triggering\n",
      "9ae1200763366eaba32a6dc12d7958a1dd08f107__4_Protein refolding and membrane fusion\n",
      "9ae1200763366eaba32a6dc12d7958a1dd08f107__5_Paramyxovirus fusion: capture of intermediates of fusion\n",
      "9ae1200763366eaba32a6dc12d7958a1dd08f107__6_A model for paramyxovirus-mediated fusion\n",
      "9ae1200763366eaba32a6dc12d7958a1dd08f107__7_Atomic structure of HN and the role(s) of HN in fusion activation\n",
      "9ae1200763366eaba32a6dc12d7958a1dd08f107__8_Conclusions\n",
      "ed99ea6c7af5c77db2bf336d263db55646686098__0_\n",
      "ed99ea6c7af5c77db2bf336d263db55646686098__1_WHO: Novel coronavirus epidemic for outbreak a pandemic Novel\n",
      "ed99ea6c7af5c77db2bf336d263db55646686098__2_The ability to recognize the virus infecting: Basic infection number (R0)\n",
      "ed99ea6c7af5c77db2bf336d263db55646686098__3_Epidemiological dynamics is a basis to establish the healthcare system capacity to meet the needs of the epidemic\n",
      "ed99ea6c7af5c77db2bf336d263db55646686098__4_\"Herd Immunity\" is not suitable for prevention and control strategies in outbreak of infectious diseases\n",
      "ed99ea6c7af5c77db2bf336d263db55646686098__5_TCM advantages in treatment of SARS-CoV-2 infection\n",
      "ed99ea6c7af5c77db2bf336d263db55646686098__6_Effective prescription for treatment of COVID-19 pneumonia 4.1.1. Hospital preparations\n",
      "ed99ea6c7af5c77db2bf336d263db55646686098__7_Qingfei Paidu Decoction\n",
      "ed99ea6c7af5c77db2bf336d263db55646686098__8_Pneumonia No.1 Formula\n",
      "ed99ea6c7af5c77db2bf336d263db55646686098__9_Shufeng Jiedu Capsule\n",
      "ed99ea6c7af5c77db2bf336d263db55646686098__10_Basic research on compatibility of traditional Chinese medicine was expounded by using the synergetic effect of multi-targets\n",
      "ed99ea6c7af5c77db2bf336d263db55646686098__11_Fig. 5. Structures of polyphenols in tea\n",
      "ed99ea6c7af5c77db2bf336d263db55646686098__12_Summary\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__0_Background\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__1_TB control in China\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__2_Integration of TB services: from the CDC model to the integrated model\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__3_Methods\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__4_Research sites\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__5_Data collection\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__6_Data analysis\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__7_Validity and reliability of the study\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__8_Results\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__9_Historical context\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__10_Clinical capacity\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__11_Motivation for integration\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__12_Resource allocation\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__13_Incentives and staffing\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__14_Management coordination\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__15_Technical exchange\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__16_Summary of findings\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__17_Policy implications\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__18_Limitations\n",
      "31f33e2c73a467477e3a4a72e6ee128703946fe5__19_Conclusion\n",
      "384c7676eb08fb530ec399208932513c0fa0c4e3__0_Introduction\n",
      "384c7676eb08fb530ec399208932513c0fa0c4e3__1_Specimen collection\n",
      "384c7676eb08fb530ec399208932513c0fa0c4e3__2_Primers\n",
      "384c7676eb08fb530ec399208932513c0fa0c4e3__3_PCRs\n",
      "384c7676eb08fb530ec399208932513c0fa0c4e3__4_Epidemiology and clinical characteristics in children with viral respiratory infections\n",
      "384c7676eb08fb530ec399208932513c0fa0c4e3__5_Discussion\n",
      "384c7676eb08fb530ec399208932513c0fa0c4e3__6_Conclusion\n",
      "086edc5aa469bdeedcc50010957975af5986f181__0_Introduction\n",
      "086edc5aa469bdeedcc50010957975af5986f181__1_What human factors are important at virtual meetings?\n",
      "086edc5aa469bdeedcc50010957975af5986f181__2_Taking breaks\n",
      "086edc5aa469bdeedcc50010957975af5986f181__3_Distraction and Multitasking\n",
      "086edc5aa469bdeedcc50010957975af5986f181__4_Interruptions including noise\n",
      "086edc5aa469bdeedcc50010957975af5986f181__5_Team Building, Authority Gradient & Group Think\n",
      "086edc5aa469bdeedcc50010957975af5986f181__6_Review\n",
      "086edc5aa469bdeedcc50010957975af5986f181__7_Adequate preparation beforehand\n",
      "086edc5aa469bdeedcc50010957975af5986f181__8_Conclusion\n",
      "086edc5aa469bdeedcc50010957975af5986f181__9_Conflict of interest\n",
      "086edc5aa469bdeedcc50010957975af5986f181__10_Ethics statement/confirmation of patient permission\n",
      "727465b992c231e3659ac53a05cfc41e8a7a4109__0_Introduction\n",
      "727465b992c231e3659ac53a05cfc41e8a7a4109__1_Participants and inclusion/exclusion criteria\n",
      "727465b992c231e3659ac53a05cfc41e8a7a4109__2_Data sources\n",
      "727465b992c231e3659ac53a05cfc41e8a7a4109__3_Variables and definitions\n",
      "727465b992c231e3659ac53a05cfc41e8a7a4109__4_Statistical analysis\n",
      "727465b992c231e3659ac53a05cfc41e8a7a4109__5_Results\n",
      "727465b992c231e3659ac53a05cfc41e8a7a4109__6_Demographics\n",
      "727465b992c231e3659ac53a05cfc41e8a7a4109__7_Covid-19 clinical features\n",
      "727465b992c231e3659ac53a05cfc41e8a7a4109__8_Clinical evolution\n",
      "727465b992c231e3659ac53a05cfc41e8a7a4109__9_Discussion\n",
      "727465b992c231e3659ac53a05cfc41e8a7a4109__10_Conclusion\n",
      "727465b992c231e3659ac53a05cfc41e8a7a4109__11_Data availability\n",
      "575faff450d20d0f359d000ebc8b66b638094613__0_INTRODUCTION\n",
      "575faff450d20d0f359d000ebc8b66b638094613__1_Ethics Statement\n",
      "575faff450d20d0f359d000ebc8b66b638094613__2_Viruses\n",
      "575faff450d20d0f359d000ebc8b66b638094613__3_Inoculation of Mice\n",
      "575faff450d20d0f359d000ebc8b66b638094613__4_Immunofluorescence Microscopy\n",
      "575faff450d20d0f359d000ebc8b66b638094613__5_Isolation of Oligodendrocyte-Precursor Cells (OPCs) from Neonatal Mouse Brain\n",
      "575faff450d20d0f359d000ebc8b66b638094613__6_Differentiation of Oligodendrocytes\n",
      "575faff450d20d0f359d000ebc8b66b638094613__7_Infection of Primary OPCs and Differentiated Oligodendrocytes (DOs) with RSA59 and RSMHV2\n",
      "575faff450d20d0f359d000ebc8b66b638094613__8_Quantification of Infected Oligodendrocytes In vivo and In vitro by RSA59 and RSMHV2\n",
      "575faff450d20d0f359d000ebc8b66b638094613__9_RSA59 (DM) and RSMHV2 (NDM) Differ in Their Selective Tropism for Oligodendrocytes in Gray and White Matter\n",
      "575faff450d20d0f359d000ebc8b66b638094613__10_RSA59 and RSMHV2 Differ in Their Ability to Infect Oligodendrocyte Precursors (OPCs) and Differentiated Oligodendrocytes (DOs) In vitro\n",
      "575faff450d20d0f359d000ebc8b66b638094613__11_Both RSA59 and RSMHV2 are Unable to Infect Astrocytes in the Spinal Cord\n",
      "575faff450d20d0f359d000ebc8b66b638094613__12_RSA59 but not RSMHV2 Can Spread to the Myelin Sheath\n",
      "575faff450d20d0f359d000ebc8b66b638094613__13_RSA59 Viral Antigen Axonal Spread to Spinal Cord White Matter\n",
      "575faff450d20d0f359d000ebc8b66b638094613__14_Quantification of Virally Infected Oligodendrocytes In vivo and In vitro\n",
      "575faff450d20d0f359d000ebc8b66b638094613__15_DISCUSSION\n",
      "575faff450d20d0f359d000ebc8b66b638094613__16_AUTHOR CONTRIBUTIONS\n",
      "19543f1c6c501e70297919f68504d1957e459c63__0_Illumina Miseq Procedures\n",
      "19543f1c6c501e70297919f68504d1957e459c63__1_Initial Bioinformatics analysis\n",
      "19543f1c6c501e70297919f68504d1957e459c63__2_Phylogenetic analysis\n",
      "19543f1c6c501e70297919f68504d1957e459c63__3_Structural mapping\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__0_a b s t r a c t\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__1_Introduction\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__2_Materials and methods\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__3_Animals\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__4_Experimental design\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__5_Measurements and analyses\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__6_Statistical analyses\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__7_Feeding regimes\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__8_Water, concentrates, milk and dry matter intake within the observation period\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__9_Milk, water, fluid and dry matter intake during diarrhea\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__10_Fig. 2.\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__11_Electrolyte and energy supply during diarrhea\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__12_Diarrhea and weight gain\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__13_Discussion\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__14_Conclusions\n",
      "86aa49fbf316ed40cb899e8a5896198868efc834__15_Conflict of interest\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__0_\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__1_Monoclonal Antibodies for Therapy\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__2_Nomenclature\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__3_Monoclonal Antibodies Approved for Therapy\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__4_Immune Reactions to Monoclonal Antibodies\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__5_Omalizumab\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__6_Cetuximab\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__7_Infl iximab\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__8_Adalimumab\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__9_Rituximab\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__10_The Next Generation of Monoclonal Antibodies\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__11_Etanercept\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__12_Interferons\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__13_Interleukin 2\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__14_Denileukin Diftitox and Afl ibercept\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__15_Anakinra\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__16_Anti-thymocyte Globulin\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__17_Epoetins\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__18_Human Insulin\n",
      "88104b5c02a2ed0cc56356e3878f90b08a2edeb4__19_Summary\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__0_Background\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__1_DIC and DIT in hemostasis and sepsis\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__2_The central role of the endothelium\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__3_Endothelial heterogeneity and organotropism\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__4_Molecular pathogenesis based on \"two-activation theory of the endothelium\"\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__5_Mechanism of sepsis-associated coagulopathy\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__6_Sepsis-associated clinical syndromes\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__7_Consumptive thrombocytopenia in critically ill patients (TCIP)\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__8_TTP-like syndrome\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__9_Multiorgan dysfunction syndrome (MODS)\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__10_Septic shock due to adrenal insufficiency\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__11_Systemic inflammatory response syndrome (SIRS)\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__12_Combined micro-macrothrombotic syndrome\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__13_Therapeutic approaches for sepsis-induced endothelial pathogenesis\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__14_Therapeutic plasma exchange\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__15_Anti-complement therapy\n",
      "879b563cbe739c7ec914ce9eef39d9a85d6d3801__16_Conclusion\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__0_Introduction\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__1_Sinus maxillaire\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__2_Sinus sphénoïdal\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__3_Sinus frontal\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__4_Flore des cavités nasosinusiennes de l'enfant\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__5_Problèmes de définition\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__6_Les rhinosinusopharyngites aiguës\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__7_Les infections rhinosinusiennes aiguës\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__8_L'ethmoïdite aiguë extériorisée\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__9_La rhinosinusite aiguë\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__10_La rhinosinusopharyngite aiguë\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__11_L'allergie\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__12_L'asthme\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__13_Les déficits immunitaires\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__14_La carence martiale\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__15_Les infections virales\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__16_Le reflux gastro-oesophagien\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__17_La mucoviscidose\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__18_Les dyskinésies ciliaires\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__19_Le diabète insulinodépendant\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__20_La collectivité\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__21_Le tabagisme passif\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__22_La pollution atmosphérique\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__23_Si l'enfant a plus de trois ans [1]\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__24_Faisabilité\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__25_Renseignements apportés\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__26_Indications\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__27_Matériel\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__28_Technique\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__29_Synthèse des indications des examens endonasaux\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__30_Examens microbiologiques\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__31_Prélèvement au méat moyen\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__32_Ponction de sinus maxillaire\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__33_Transport\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__34_Analyse microbiologique\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__35_Hémoculture\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__36_Ponction d'abcès sous-cutané\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__37_Synthèse des indications des prélèvements microbiologiques\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__38_Transillumination\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__39_Échographie\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__40_Radiographie standard\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__41_Examen tomodensitométrique\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__42_Conditions d'examen\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__43_Risque\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__44_Résultats\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__45_Coût\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__46_Synthèse des indications des examens radiologiques\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__47_Examens sanguins\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__48_Le dosage pondéral des immunoglobulines\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__49_Exploration allergologique\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__50_pHmétrie oesophagienne\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__51_Test de la sueur\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__52_Formes compliquées\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__53_Complications méningoencéphaliques, septicémie\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__54_Complications orbitaires\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__55_Traitement\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__56_Traitement antibiotique\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__57_Choix de l'antibiotique\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__58_Les résistances aux antibiotiques\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__59_Conclusion : la recommandation de l'Afssaps (2005) [1]\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__60_Traitements non antibiotiques\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__61_Antipyrétiques\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__62_Antalgiques\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__63_Antiseptiques locaux : antiseptiques (produits soufrés)\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__64_Immunomodulateurs locaux et généraux\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__65_Anti-inflammatoires non stéroïdiens (AINS)\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__66_Mucolytiques, mucorégulateurs (locaux et généraux)\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__67_Vasoconstricteurs locaux\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__68_Les traitements homéopathiques\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__69_Les antibiotiques locaux\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__70_Corticoïdes locaux et généraux\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__71_Mouchage\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__72_Le mouche-bébé\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__73_La kinésithérapie nasale\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__74_Manoeuvres instrumentales : drainage, ponction\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__75_Éducation et formation\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__76_Place des vaccins\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__77_Changement de traitement\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__78_Un traitement symptomatique est en cours\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__79_Conclusion\n",
      "7cfb62ed5ed8e055d690187e98ba38d3b8d42a03__80_Références\n",
      "0d7ece1007cbcb91497b40e276c7c5cac15663e0__0_\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__0_Introduction\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__1_Mice, cells and virus\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__2_Production of recombinant RVFV strains\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__3_Author Summary\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__4_Virus titration by plaque assay\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__5_hRLuc expression analysis in vitro\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__6_GFP and viral expression analysis in vitro\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__7_Infection of mice and monitoring\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__8_In vivo bioluminescence imaging\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__9_Ex vivo bioluminescence imaging\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__10_RNA extraction and quantitative RT-PCR\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__11_Histopathological analysis\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__12_Flow cytometric analysis\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__13_Liposome treatment\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__14_Statistical analysis\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__15_Production and characterization of recombinant Rift Valley fever viruses\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__16_Bioluminescence imaging for Rift Valley fever virus infection\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__17_Identification of hematopoietic target cells by immunohistochemistry and flow cytometry\n",
      "f18afbc0a4621e7f13dcfbc67c85bf8dfe3b30ea__18_Discussion\n",
      "e84b07d4bd208aa18f867d8cb843796a65edfe9e__0_\n",
      "e84b07d4bd208aa18f867d8cb843796a65edfe9e__1_Contents lists available at ScienceDirect\n",
      "e84b07d4bd208aa18f867d8cb843796a65edfe9e__2_Background information: coronavirus disease in China\n",
      "e84b07d4bd208aa18f867d8cb843796a65edfe9e__3_Decline in economic activity and energy consumption\n",
      "e84b07d4bd208aa18f867d8cb843796a65edfe9e__4_Changes in environmental indicator -nitrogen dioxide emissions\n",
      "e84b07d4bd208aa18f867d8cb843796a65edfe9e__5_Nitrogen dioxide measurement\n",
      "e84b07d4bd208aa18f867d8cb843796a65edfe9e__6_Precise monitoring of satellite. The National Aeronautics and\n",
      "e84b07d4bd208aa18f867d8cb843796a65edfe9e__7_Nitrogen dioxide over China\n",
      "e84b07d4bd208aa18f867d8cb843796a65edfe9e__8_Nitrogen dioxide emissions in Wuhan, Nanjing, Shanghai\n",
      "e84b07d4bd208aa18f867d8cb843796a65edfe9e__9_Changes in other key air pollutant\n",
      "e84b07d4bd208aa18f867d8cb843796a65edfe9e__10_Conclusion\n",
      "e84b07d4bd208aa18f867d8cb843796a65edfe9e__11_Declaration of competing interest\n",
      "7881c6e393df08e51ecffa5a85df95187acdc7a1__0_INTRODUCTION\n",
      "7881c6e393df08e51ecffa5a85df95187acdc7a1__1_CASE REPORT\n",
      "7881c6e393df08e51ecffa5a85df95187acdc7a1__2_DISCUSSION\n",
      "e9f49e2685338d697a7405e7ad6424385fd129b6__0_Introduction\n",
      "e9f49e2685338d697a7405e7ad6424385fd129b6__1_Traditional uses of H. cordata\n",
      "e9f49e2685338d697a7405e7ad6424385fd129b6__2_Potential role of H. cordata against inflammation\n",
      "e9f49e2685338d697a7405e7ad6424385fd129b6__3_Role of H. cordata in inflammation-related molecular mechanism in vivo\n",
      "e9f49e2685338d697a7405e7ad6424385fd129b6__4_Potential role of H. cordata against oxidative stress\n",
      "e9f49e2685338d697a7405e7ad6424385fd129b6__5_Role of H. cordata in oxidative stress-related molecular mechanism in vitro\n",
      "e9f49e2685338d697a7405e7ad6424385fd129b6__6_Role of H. cordata in oxidative stress-related molecular mechanism in vivo\n",
      "e9f49e2685338d697a7405e7ad6424385fd129b6__7_Toxicity of H. cordata\n",
      "e9f49e2685338d697a7405e7ad6424385fd129b6__8_Conclusion and future perspectives\n",
      "421838e663f2a0247293270c60d87c535c961068__0_Background\n",
      "421838e663f2a0247293270c60d87c535c961068__1_Study design\n",
      "421838e663f2a0247293270c60d87c535c961068__2_Literature search strategies\n",
      "421838e663f2a0247293270c60d87c535c961068__3_Identification and selection of relevant studies\n",
      "421838e663f2a0247293270c60d87c535c961068__4_Data extraction from the included studies\n",
      "421838e663f2a0247293270c60d87c535c961068__5_Summarizing the findings\n",
      "421838e663f2a0247293270c60d87c535c961068__6_Characteristics of published studies\n",
      "421838e663f2a0247293270c60d87c535c961068__7_Research domains Epidemiology\n",
      "421838e663f2a0247293270c60d87c535c961068__8_Causes\n",
      "421838e663f2a0247293270c60d87c535c961068__9_Clinical manifestation and diagnosis\n",
      "421838e663f2a0247293270c60d87c535c961068__10_Prevention and control\n",
      "421838e663f2a0247293270c60d87c535c961068__11_Strengths and limitations of the study\n",
      "421838e663f2a0247293270c60d87c535c961068__12_Conclusions\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__0_INTRODUCTION\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__1_RESULTS\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__2_Evaluation of a lower-dose intravenous P007-PMO dosing protocol to optimize dystrophin correction\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__3_Investigation of toxicity following treatment with the P007-PMO conjugates\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__4_DISCUSSION\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__5_Animals\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__6_PMO and PMO-peptide conjugates\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__7_RNA extraction and nested RT-PCR analysis\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__8_Intramuscular and systemic injection of PMO-peptide conjugates\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__9_Immunohistochemistry and histology\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__10_Protein extraction and western blot\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__11_Functional grip strength analysis\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__12_Serum creatinine kinase measurements and other biochemical tests\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__13_Statistical analysis\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__14_SUPPLEMENTARY MATERIAL\n",
      "cf4267556daa18262b0f7727f325b94a53b2f2b1__15_FUNDING\n",
      "2c5bb8fe8177ac02f1ea7672949eadf65676cee7__0_Introduction\n",
      "2c5bb8fe8177ac02f1ea7672949eadf65676cee7__1_The occurrence of the animal coronavirus in pets\n",
      "2c5bb8fe8177ac02f1ea7672949eadf65676cee7__2_Cross-reactivity and immune system mobilization\n",
      "2c5bb8fe8177ac02f1ea7672949eadf65676cee7__3_Conclusions:\n",
      "2c5bb8fe8177ac02f1ea7672949eadf65676cee7__4_2.\n",
      "e3228da3354500784e67a619c41329d4544102d9__0_Baculovirus as versatile vectors for protein expression in insect and mammalian cells Thomas A Kost 1 , J Patrick Condreay 1 & Donald L Jarvis 2\n",
      "e3228da3354500784e67a619c41329d4544102d9__1_Isolation and quantification of recombinant baculoviruses\n",
      "e3228da3354500784e67a619c41329d4544102d9__2_Protein glycosylation in the baculovirus-insect cell system\n",
      "e3228da3354500784e67a619c41329d4544102d9__3_Mammalian cells Baculodisplay\n",
      "e3228da3354500784e67a619c41329d4544102d9__4_Enhancing protein expression in insect cells\n",
      "e3228da3354500784e67a619c41329d4544102d9__5_Production of virus-like particles (VLPs) and protein complexes\n",
      "e3228da3354500784e67a619c41329d4544102d9__6_Baculovirus display\n",
      "e3228da3354500784e67a619c41329d4544102d9__7_Recombinant protein production in insect larvae\n",
      "e3228da3354500784e67a619c41329d4544102d9__8_Baculovirus-mediated gene delivery in mammalian cells\n",
      "e3228da3354500784e67a619c41329d4544102d9__9_Host cells and transduction parameters.\n",
      "e3228da3354500784e67a619c41329d4544102d9__10_Baculoviruses as immunizing reagents\n",
      "e3228da3354500784e67a619c41329d4544102d9__11_Conclusions and future developments\n",
      "5be5d9505613508634f87e49357649c9cad7981f__0_Introduction\n",
      "5be5d9505613508634f87e49357649c9cad7981f__1_Model\n",
      "5be5d9505613508634f87e49357649c9cad7981f__2_Packet delivery process\n",
      "5be5d9505613508634f87e49357649c9cad7981f__3_Epidemic spreading process\n",
      "5be5d9505613508634f87e49357649c9cad7981f__4_Results\n",
      "5be5d9505613508634f87e49357649c9cad7981f__5_Evolution of our model\n",
      "5be5d9505613508634f87e49357649c9cad7981f__6_Impacts of α\n",
      "5be5d9505613508634f87e49357649c9cad7981f__7_Impacts of ρ\n",
      "5be5d9505613508634f87e49357649c9cad7981f__8_Impacts of network structure\n",
      "5be5d9505613508634f87e49357649c9cad7981f__9_Impacts of traffic congestion\n",
      "5be5d9505613508634f87e49357649c9cad7981f__10_Impacts of routing protocols\n",
      "5be5d9505613508634f87e49357649c9cad7981f__11_Conclusion\n",
      "ec48ae032c1cfe0d222d36e4e640efa5b21e78bd__0_Introduction\n",
      "ec48ae032c1cfe0d222d36e4e640efa5b21e78bd__1_Immunoglobulin new antigen receptor (IgNAR)\n",
      "ec48ae032c1cfe0d222d36e4e640efa5b21e78bd__2_Diversification of the IgNAR repertoire\n",
      "ec48ae032c1cfe0d222d36e4e640efa5b21e78bd__3_Isolation of target-specific VNAR\n",
      "ec48ae032c1cfe0d222d36e4e640efa5b21e78bd__4_Applications of VNAR\n",
      "ec48ae032c1cfe0d222d36e4e640efa5b21e78bd__5_VNAR in immunodiagnostic applications\n",
      "ec48ae032c1cfe0d222d36e4e640efa5b21e78bd__6_VNAR in immunotherapeutic applications\n",
      "ec48ae032c1cfe0d222d36e4e640efa5b21e78bd__7_Formatting and humanization of VNAR\n",
      "ec48ae032c1cfe0d222d36e4e640efa5b21e78bd__8_Conclusion\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__0_Aims of the conference\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__1_Global need for vaccines\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__2_Vaccines for developing countries\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__3_Old vaccines\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__4_New vaccines\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__5_Need for higher education, training and technology transfer\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__6_International policies\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__7_EU efforts for new vaccine development\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__8_Developing new promising candidate vaccines, drugs and microbicides\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__9_Establishing clinical trial programmes\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__10_Strategies for new vaccines: dissecting the mechanisms of pathogen-host interaction\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__11_Host interaction with pathogen: defence mechanisms\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__12_Pathogen interaction with host: escape mechanisms\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__13_Strategies for new vaccines: mucosal immunisation\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__14_The mucosal immune system: tolerance versus immunity\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__15_Mucosal antigen vectors\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__16_Mucosal adjuvants\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__17_Routes of immunisation versus routes of infection\n",
      "d98ae703c83275a4f9df7f62cc707629949ae87b__18_Conclusions\n",
      "d3aee39816e64957bf5d940e787330f152e71efe__0_Introduction, methods, and results\n",
      "d3aee39816e64957bf5d940e787330f152e71efe__1_Table 1 Fecal consistency scores and fecal PEDV RNA shedding titers in original US PEDV-, S-INDEL PEDV-, and mock (control)-inoculated piglets post inoculation and after challenge with the original US PEDV virus\n",
      "d3aee39816e64957bf5d940e787330f152e71efe__2_Mean fecal consistency scores (SD)\n",
      "d3aee39816e64957bf5d940e787330f152e71efe__3_Discussion\n",
      "35c9282c1b7a5918691efe6f35ca60111bfd590c__0_\n",
      "35c9282c1b7a5918691efe6f35ca60111bfd590c__1_MERS-CoV M localizes in the trans-Golgi network\n",
      "35c9282c1b7a5918691efe6f35ca60111bfd590c__2_The last 20 residues of the C-terminal domain of the MERS-CoV M protein are important for the MERS-CoV M intracellular trafficking\n",
      "35c9282c1b7a5918691efe6f35ca60111bfd590c__3_MERS-CoV M protein TGN localization\n",
      "35c9282c1b7a5918691efe6f35ca60111bfd590c__4_DxE is a functional ER export signal for MERS-CoV M\n",
      "35c9282c1b7a5918691efe6f35ca60111bfd590c__5_Four residues in the C-terminal domain mediate MERS-CoV M localization to the TGN\n",
      "35c9282c1b7a5918691efe6f35ca60111bfd590c__6_KxGxYR is a not an internalization signal and is not involved in M oligomerization\n",
      "35c9282c1b7a5918691efe6f35ca60111bfd590c__7_IBV C-terminal domain is involved in its ERGIC localization\n",
      "35c9282c1b7a5918691efe6f35ca60111bfd590c__8_Discussion\n",
      "35c9282c1b7a5918691efe6f35ca60111bfd590c__9_Plasmids\n",
      "35c9282c1b7a5918691efe6f35ca60111bfd590c__10_Cell culture and transfection\n",
      "35c9282c1b7a5918691efe6f35ca60111bfd590c__11_Immunofluorescence and confocal microscopy\n",
      "315e0d41fc6ddcf3631799cc98556edcb7f4ce4e__0_\n",
      "315e0d41fc6ddcf3631799cc98556edcb7f4ce4e__1_A Delicate Balance\n",
      "315e0d41fc6ddcf3631799cc98556edcb7f4ce4e__2_Influenza\n",
      "315e0d41fc6ddcf3631799cc98556edcb7f4ce4e__3_Figure 2. Possible Mode of H5N1 Avian Influenza Virus Transmission among Migratory Birds, Domestic Poultry, and Humans\n",
      "315e0d41fc6ddcf3631799cc98556edcb7f4ce4e__4_A Multifaceted Response\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__0_Introduction\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__1_CypA inhibitors suppress EV71 multiplication\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__2_Author Summary\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__3_Resistance to compound HL051001P2 maps to the VP1 protein\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__4_CypA interacts with the H-I loop of VP1 in the EV71 capsid\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__5_Discussion\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__6_Cell lines, viruses and antibodies\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__7_Inhibitors and reagents\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__8_Generating the EV71 infectious virus and EV71 subgenomic replicon\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__9_Virus titration\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__10_RNA analysis\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__11_A quantitative RT-PCR (qRT-PCR)-based infection assay\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__12_Selecting CypA inhibitor-resistant viruses\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__13_Generating stable knockdown cell lines\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__14_Recombinant protein production\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__15_Immunoblotting and pull-down assays\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__16_Time-of-addition assay\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__17_A binding assay of the virus to the host cells\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__18_Purifying wt-EV71 by ultracentrifugation\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__19_Supporting Information\n",
      "97229e8af52b75aa9ac0f0eb530bf89f7f5ec134__20_(DOC)\n",
      "6bd9cef4e428744cd56e07599beb2bd8c1e66831__0_Introduction\n",
      "6bd9cef4e428744cd56e07599beb2bd8c1e66831__1_LC-LC\n",
      "6bd9cef4e428744cd56e07599beb2bd8c1e66831__2_CE-CE\n",
      "6bd9cef4e428744cd56e07599beb2bd8c1e66831__3_Multidimensional separation modes for traditional Chinese medicine\n",
      "6bd9cef4e428744cd56e07599beb2bd8c1e66831__4_Concluding remarks\n",
      "77cd45ecb2219deb6da525c81e3f055aabddff41__0_\n",
      "77cd45ecb2219deb6da525c81e3f055aabddff41__1_Clinical Characteristics\n",
      "77cd45ecb2219deb6da525c81e3f055aabddff41__2_Diagnosis\n",
      "77cd45ecb2219deb6da525c81e3f055aabddff41__3_Treatment Options\n",
      "77cd45ecb2219deb6da525c81e3f055aabddff41__4_Epidemiology\n",
      "77cd45ecb2219deb6da525c81e3f055aabddff41__5_Bocavirus\n",
      "77cd45ecb2219deb6da525c81e3f055aabddff41__6_Future Directions and Unmet Needs\n",
      "9f14604a20b4a86b19cf41701f4762005b0ab9eb__0_\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__0_\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__1_Changes in the Pathogenic Spectrum of Community Acquired Infections\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__2_Nosocomial Infections\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__3_Predominant Pathogenic Bacteria\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__4_Gram-Positive Cocci\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__5_Gram-Negative Bacilli\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__6_Anaerobes\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__7_Fungi\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__8_Viruses\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__9_Primary Pathogenic Factors\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__10_Exotoxins and Invasive Enzymes\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__11_Endotoxins\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__12_Post-Surgery-and Post-Trauma-Related Wound Infections\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__13_Etiology and Pathogenesis of Wound Infections\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__14_Prevention and Treatment of Wound Infections\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__15_Wound Infection Prevention\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__16_Treatment of Wound Infections\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__17_Intra-Abdominal Infections Associated with Surgery and Trauma\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__18_Acute Peritonitis Resulting from Surgery and Trauma\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__19_Intra-Abdominal Abscesses after Surgery and Trauma\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__20_Enterogenic Infections Associated with Post-Surgery and Trauma\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__21_Intestinal Barrier Function\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__22_Structural Basis of the Intestinal Barrier\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__23_Mechanical barrier. This barrier consists of intestinal epithelial cells, tight junctions and plaque. The intestinal mechanical barrier is effective in preventing deep penetration of bacteria into mucosal tissues and establishes the physical architecture of the intestinal barrier. The intestinal epithelium consists of cells associated with gut absorption, goblet cells, Paneth cells and some endocrine cells.\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__24_Intestinal Barrier Dysfunction\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__25_Intestinal Barrier Function and Bacterial Translocation\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__26_Clinical Manifestations of Enterogenic Infections\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__27_The Sub-Clinical Infection Stage\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__28_Septic Stage\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__29_Bacteremic Stage\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__30_SIRS or MODS Stage\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__31_Prevention and Treatment of Enterogenic Infections\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__32_Prevention and Prognosis of Surgical and Traumatic Infections\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__33_Prevention of Post-Surgical and Post-Traumatic Infections\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__34_Improvement of Pre-Surgery Prophylaxis\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__35_Prophylactic Antibiotic Therapies\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__36_Conventional Treatments Associated with Surgery and Wound Infections\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__37_Antibiotic Therapies\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__38_Controlling the Infection Source\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__39_Complications of Severe Surgical and Wound Infections Prevention and Treatment of Sepsis and MOF\n",
      "a9da7f526eb7ebc732a62b487647fe1b1cc8f643__40_Future Directions\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__0_Introduction\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__1_RNA synthesis\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__2_RNA vector self-amplification and protein expression\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__3_Animal studies\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__4_Virus neutralization assay\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__5_Intracellular cytokine staining (ICS)\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__6_Influenza virus challenge\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__7_Lung influenza viral load\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__8_Lung processing and characterization of T cells\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__9_Ethics statement\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__10_Statistical analysis\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__11_Generation and characterization of SAM encoding influenza NP and M1 antigens\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__12_Immunogenicity of SAM(NP) and SAM(M1) vaccines\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__13_Induction of cytotoxic T cells by SAM(NP) vaccine\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__14_Protective efficacy in mice against challenge with homologous and heterosubtypic influenza viruses\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__15_Effect of SAM vaccines on lung T-cell responses after influenza virus challenge\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__16_Co-administration of the SAM(M1-NP) vaccine with monovalent inactivated influenza vaccine\n",
      "d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba__17_Discussion\n",
      "6f8d74d92fc89a82d674ee6c72669f921832ecdf__0_Introduction\n",
      "6f8d74d92fc89a82d674ee6c72669f921832ecdf__1_Search for Disordered Patterns Consisting of Two Types of Amino Acid Residues\n",
      "6f8d74d92fc89a82d674ee6c72669f921832ecdf__2_Occurrence of Patterns Consisting of Two Amino Acids in the Clustered PDB\n",
      "6f8d74d92fc89a82d674ee6c72669f921832ecdf__3_DisResClustered DataBase\n",
      "6f8d74d92fc89a82d674ee6c72669f921832ecdf__4_Implementation: Disordered Patterns from the Clustered PDB\n",
      "6f8d74d92fc89a82d674ee6c72669f921832ecdf__5_Occurrence of Disordered Patterns in the Proteomes\n",
      "6f8d74d92fc89a82d674ee6c72669f921832ecdf__6_Construction of Clustered Protein Data Bank\n",
      "6f8d74d92fc89a82d674ee6c72669f921832ecdf__7_Statistical Analysis of Disordered Residues\n",
      "6f8d74d92fc89a82d674ee6c72669f921832ecdf__8_Patterns Consisting of Two Types of Amino Acids\n",
      "6f8d74d92fc89a82d674ee6c72669f921832ecdf__9_Unique Disordered Patterns\n",
      "6f8d74d92fc89a82d674ee6c72669f921832ecdf__10_Real and Random Proteomes\n",
      "6f8d74d92fc89a82d674ee6c72669f921832ecdf__11_Conclusions\n",
      "6f8d74d92fc89a82d674ee6c72669f921832ecdf__12_Conflicts of Interest:\n",
      "8913ef3c6de95c2bacf8e0c9af842f9238c7f344__0_\n",
      "1aac69cac6978a63701ef3261ddfc7523ffc99ad__0_Introduction\n",
      "1aac69cac6978a63701ef3261ddfc7523ffc99ad__1_Importance of Human Movements in Disease Transmission\n",
      "1aac69cac6978a63701ef3261ddfc7523ffc99ad__2_Geographic Considerations in Human Movement\n",
      "1aac69cac6978a63701ef3261ddfc7523ffc99ad__3_Linking the Global to the Local Through Mobility\n",
      "560590f81ed992c9c07ac3cff15e464ca4219f14__0_Introduction\n",
      "560590f81ed992c9c07ac3cff15e464ca4219f14__1_Animal\n",
      "560590f81ed992c9c07ac3cff15e464ca4219f14__2_Procedures\n",
      "560590f81ed992c9c07ac3cff15e464ca4219f14__3_Sample collection\n",
      "560590f81ed992c9c07ac3cff15e464ca4219f14__4_DNA isolation\n",
      "560590f81ed992c9c07ac3cff15e464ca4219f14__5_PCR amplification\n",
      "560590f81ed992c9c07ac3cff15e464ca4219f14__6_Results\n",
      "560590f81ed992c9c07ac3cff15e464ca4219f14__7_Discussion\n",
      "560590f81ed992c9c07ac3cff15e464ca4219f14__8_Conclusion\n",
      "1fe6777710bd340802122284b0c016a9c1c281fa__0_Introduction\n",
      "1fe6777710bd340802122284b0c016a9c1c281fa__1_Viruses and cells\n",
      "1fe6777710bd340802122284b0c016a9c1c281fa__2_Generation of recombinant vaccinia virus\n",
      "1fe6777710bd340802122284b0c016a9c1c281fa__3_Western blotting\n",
      "1fe6777710bd340802122284b0c016a9c1c281fa__4_Immunofluorescence analysis\n",
      "1fe6777710bd340802122284b0c016a9c1c281fa__5_Immunization of rabbits\n",
      "1fe6777710bd340802122284b0c016a9c1c281fa__6_ELISA\n",
      "1fe6777710bd340802122284b0c016a9c1c281fa__7_In vitro NT assay for SARS-CoV\n",
      "1fe6777710bd340802122284b0c016a9c1c281fa__8_In vitro NT assay for VV\n",
      "1fe6777710bd340802122284b0c016a9c1c281fa__9_Statistical analysis\n",
      "1fe6777710bd340802122284b0c016a9c1c281fa__10_Generation and characterization of RVV-S\n",
      "1fe6777710bd340802122284b0c016a9c1c281fa__11_Induction of binding antibodies against spike protein in RVV-S-immunized rabbits\n",
      "1fe6777710bd340802122284b0c016a9c1c281fa__12_Induction of NT antibodies against SARS-CoV in RVV-S-immunized rabbits\n",
      "1fe6777710bd340802122284b0c016a9c1c281fa__13_RVV-S induces NT antibodies against SARS-CoV in the presence of NT antibodies against VV\n",
      "1fe6777710bd340802122284b0c016a9c1c281fa__14_Discussion\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__0_\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__1_Sub-anesthetic Slow Infusion of Ketamine for Treatment of Depression Produces Rare but Currently Unpredictable and Potentially Serious Psychosomatic Effects\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__2_Effects of Calcium Channel Blocker Poisoning Interventions: A Systematic Review\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__3_Conclusions:\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__4_Neurotoxicity from Sidewinder Rattlesnake Envenomation in Arizona\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__5_Clinical Presentations with Different Glyphosate-Containing Herbicides\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__6_Medical Toxicology Education in Medical Schools in the USA\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__7_Qsymia Induced Bilateral Acute Angle-Closure Glaucoma\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__8_Fentanyl Patch Ingestion in an Infant with Endoscopic Retrieval\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__9_Wide Variation in Naloxone Dosing Recommendations for Acute Opioid Toxicity\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__10_Food-Borne Poisonings and Infectious Diseases from Survivor Program Copycat Behaviors\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__11_Succimer Chelation Therapy Safely Used for Lead Poisoning in Pregnancy\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__12_Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__13_Prevention of Neonatal Abstinence Syndrome in the Setting of Intrauterine Baclofen Exposure\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__14_Baclofen Distribution into Breast Milk-A Potential for Toxicity?\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__15_Trends in Opioid Prescribing Based on Provider Specialty in US Ambulatory Clinics\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__16_Severe Bark Scorpion Envenomation in Adults\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__17_Non-APAP Containing Xenobiotics\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__18_Neuropsychiatric Events\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__19_A Comparative Study of Acetaminophen Exposures in ToxIC Registry with Texas Poison Center Data\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__20_An Atypical Presentation of a Tricyclic Antidepressant Overdose Due to a Bezoar\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__21_Ability of Senior Medical Students to Identify Common Serotonergic Agents When Treating Serotonin Syndrome\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__22_Methamphetamine-Related Deaths Before and After Prescription Pseudoephedrine Legislation\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__23_Conclusion:\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__24_Methemoglobinemia as a Complication of Topical Dapsone\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__25_ST Elevation Myocardial Infarction Presenting as a Complication of Crotalus horridus Envenomation\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__26_Inverse Takotsubo Cardiomyopathy after Methamphetamine Use\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__27_Is It PrimeTime for FaceTime? VideoTelephone App Use in Toxicology Consultations\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__28_Stress-Induced Cardiomyopathy Resulting from Abstinent Opioid Withdrawal\n",
      "24386f9c79437e7030e7b99220638acb6b5ff34b__29_Successful Physostigmine Treatment of Delirium Induced by Clozapine Adulterated Street Drugs\n",
      "ffde9cabfcf179f96cea996cb19e2a807615c479__0_Abstract\n",
      "ffde9cabfcf179f96cea996cb19e2a807615c479__1_Résumé\n",
      "ffde9cabfcf179f96cea996cb19e2a807615c479__2_Introduction\n",
      "ffde9cabfcf179f96cea996cb19e2a807615c479__3_Results and discussion\n",
      "ffde9cabfcf179f96cea996cb19e2a807615c479__4_Importance of the interaction between the bacteria and the semiconductor (TiO 2 )\n",
      "ffde9cabfcf179f96cea996cb19e2a807615c479__5_Efficiency of photocatalysis to remove avian influenza virus (A/H5N2) in air\n",
      "ffde9cabfcf179f96cea996cb19e2a807615c479__6_Photocatalytic disinfection versus photocatalytic removal of organic pollutants: are the problematic issues similar?\n",
      "ffde9cabfcf179f96cea996cb19e2a807615c479__7_Photoreactor and light sources for water disinfection\n",
      "ffde9cabfcf179f96cea996cb19e2a807615c479__8_Photocatalysts\n",
      "ffde9cabfcf179f96cea996cb19e2a807615c479__9_Bacterial strain and growth media\n",
      "ffde9cabfcf179f96cea996cb19e2a807615c479__10_Analytical determinations\n",
      "ffde9cabfcf179f96cea996cb19e2a807615c479__11_Photoreactor for air disinfection\n",
      "ffde9cabfcf179f96cea996cb19e2a807615c479__12_Conclusion\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__0_Introduction\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__1_The Effect of CFTR Mutations on Membrane Channel Abundance and Activity\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__2_CF Treatment Options\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__3_The Use of Murine Models in the Study of CF\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__4_Respiratory Tract Disease-Related Changes.\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__5_Development of Intestinal Disease in CF Murine\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__6_Pancreatic Disease in the CF Mouse Model.\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__7_Hepatobiliary Disease Development in Murine Models of CF.\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__8_Fertility and Reproductive Problems in the CF Mouse.\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__9_The Use of the CF Murine Model for Evaluating New Treatment\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__10_The Use of Pig Models to Study CF Pathology\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__11_Respiratory Tract Disease-Related Changes in the Porcine\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__12_Intestinal Disease Development in the CF Pig\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__13_Pancreatic Disease in the CF Pig\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__14_Hepatobiliary Disease in the Pig\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__15_The Potential Use of the CF Pig Model for Development of Novel Therapeutics.\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__16_Disease Phenotype of the CF Ferret\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__17_Respiratory Tract Disease-Specific Changes in the Ferret\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__18_Intestinal Disease Studied in the CF Ferret Model.\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__19_Pancreatic and Hepatobiliary Disease and Fertility.\n",
      "b061aea11013896c5d3a9c7c0c4f884397ad38d9__20_Concluding Remarks\n",
      "2af91bbb625d983d5ad3aadb9e5f1d82268a0f1f__0_Introduction\n",
      "2af91bbb625d983d5ad3aadb9e5f1d82268a0f1f__1_Analysis of Public datasets\n",
      "2af91bbb625d983d5ad3aadb9e5f1d82268a0f1f__2_Collections of clinical data\n",
      "2af91bbb625d983d5ad3aadb9e5f1d82268a0f1f__3_Results\n",
      "2af91bbb625d983d5ad3aadb9e5f1d82268a0f1f__4_SARS-CoV-2 infection is a very serious public health issue. It caused a nationwide\n",
      "72af637abdc92f045426ef76b39818510cd5053a__0_Introduction\n",
      "72af637abdc92f045426ef76b39818510cd5053a__1_Mechanical ventilation Physiology\n",
      "72af637abdc92f045426ef76b39818510cd5053a__2_High-frequency oscillatory ventilation\n",
      "72af637abdc92f045426ef76b39818510cd5053a__3_Side effects of mechanical ventilation\n",
      "72af637abdc92f045426ef76b39818510cd5053a__4_Sedation\n",
      "72af637abdc92f045426ef76b39818510cd5053a__5_Prone positioning\n",
      "72af637abdc92f045426ef76b39818510cd5053a__6_Infection Pneumonia\n",
      "72af637abdc92f045426ef76b39818510cd5053a__7_Sepsis\n",
      "72af637abdc92f045426ef76b39818510cd5053a__8_Monitoring\n",
      "72af637abdc92f045426ef76b39818510cd5053a__9_Pulmonary artery catheters\n",
      "72af637abdc92f045426ef76b39818510cd5053a__10_Pulse oxymetry\n",
      "72af637abdc92f045426ef76b39818510cd5053a__11_Education Training\n",
      "72af637abdc92f045426ef76b39818510cd5053a__12_Health outcomes\n",
      "72af637abdc92f045426ef76b39818510cd5053a__13_Competing interests\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__0_Background\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__1_Aetiology and Genome Characteristics. Avian infectious bronchitis virus (IBV), together with Turkey coronavirus and\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__2_Spike\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__3_The Nonstructural\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__4_Matrix\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__5_Nucleocapsid\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__6_Serotypes and Strain Variations.\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__7_Passive Immunity.\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__8_Innate Immune Responses.\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__9_Humoral Response.\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__10_Cell-Mediated Immune\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__11_Mucosal Immune Response.\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__12_Live Attenuated Vaccines.\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__13_Inactivated or Killed\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__14_Viral Vector-Based\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__15_Subunit and Peptide-Based\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__16_Plasmid DNA Vaccines.\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__17_Reverse Genetic Vaccines.\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__18_Vaccine Expression System.\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__19_Delivery\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__20_Conclusion\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__21_CTL:\n",
      "ddbf31002935c6a62e177e3085670455ec4121ec__22_Conflict of Interests\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__0_Introduction\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__1_Biosecurity\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__2_Preparedness is the Key to Biosecurity\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__3_Biosecurity Measures to Limit Infectious Disease Spread\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__4_Equine Herpesvirus-1 Neurological Disease\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__5_Neurological Signs\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__6_Immunology\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__7_Therapy\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__8_Prognosis\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__9_Prevention\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__10_Regulations\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__11_Clinical Outcomes\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__12_Diagnostic Testing\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__13_Management of Outbreaks of Neurological Disease Associated with EHV-1\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__14_Methicillin-Resistant Staphylococcus aureus\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__15_Control of Methicillin-Resistant Staphylococcus aureus\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__16_Strangles in Horses\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__17_Epidemiology\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__18_Pathogenesis\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__19_Clinical Signs\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__20_Diagnosis\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__21_Treatment\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__22_Complications\n",
      "517d6ba56f368e0776596fa6d9d9bed5b5c2d7bb__23_Control During an Outbreak\n",
      "ddec10d6dd3bc15ddd37db380e934c5a8ce9056d__0_Introduction\n",
      "ddec10d6dd3bc15ddd37db380e934c5a8ce9056d__1_Clinical material\n",
      "ddec10d6dd3bc15ddd37db380e934c5a8ce9056d__2_Pathological examination and histochemical staining\n",
      "ddec10d6dd3bc15ddd37db380e934c5a8ce9056d__3_Transmission electron microscopy\n",
      "ddec10d6dd3bc15ddd37db380e934c5a8ce9056d__4_Clinical features\n",
      "ddec10d6dd3bc15ddd37db380e934c5a8ce9056d__5_Macroscopic examination\n",
      "ddec10d6dd3bc15ddd37db380e934c5a8ce9056d__6_Lungs\n",
      "ddec10d6dd3bc15ddd37db380e934c5a8ce9056d__7_Heart\n",
      "ddec10d6dd3bc15ddd37db380e934c5a8ce9056d__8_Spleen and lymph nodes\n",
      "ddec10d6dd3bc15ddd37db380e934c5a8ce9056d__9_Liver\n",
      "ddec10d6dd3bc15ddd37db380e934c5a8ce9056d__10_Kidney and adrenal glands\n",
      "ddec10d6dd3bc15ddd37db380e934c5a8ce9056d__11_Brain and muscle\n",
      "ddec10d6dd3bc15ddd37db380e934c5a8ce9056d__12_Bone marrow\n",
      "ddec10d6dd3bc15ddd37db380e934c5a8ce9056d__13_Discussion\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__0_I. INTRODUCTION\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__1_A. Genomic data\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__2_B. Partially-observed transmission network\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__3_C. Population distribution and driving distances\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__4_D. Distance statistics for genetic linkages\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__5_E. Probabilistic spatial models\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__6_F. Maximum likelihood estimates for gravity model parameters\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__7_G. Adaptive model selection\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__8_A. A transmission network links most virus genomes\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__9_B. Transmission distances follow a power law model\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__10_D. Adaptive model selection identifies a change in dynamics\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__11_E. Sensitivity analysis of missing chiefdom data\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__12_ACKNOWLEDGMENTS\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__13_SUPPLEMENTAL INFORMATION\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__14_B. Probability of a stationary linkage\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__15_C. Distribution of linkage durations\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__16_D. Sensitivity of the likelihood ratio to the inclusion of long duration linkages\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__17_F. Power law spatial model for linkage distances\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__18_G. Maximum likelihood and confidence intervals for gravity model\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__19_H. Sensitivity to unknown chiefdom localization\n",
      "4eb170db0dd666fc669649d0e6b15e513b6598d6__20_I. Observed mean chiefdom size\n",
      "99a8275966a6431128927e8c450efa7db8c706b1__0_\n",
      "99a8275966a6431128927e8c450efa7db8c706b1__1_The Second Event: The Golden Era of Clinical Microbiology\n",
      "99a8275966a6431128927e8c450efa7db8c706b1__2_Deemphasis of Clinical Microbiology\n",
      "99a8275966a6431128927e8c450efa7db8c706b1__3_Legionella Urinary Antigen\n",
      "6bdc70a008d3c195b02c9c5d2e115d8e87ea35e9__0_Introduction\n",
      "6bdc70a008d3c195b02c9c5d2e115d8e87ea35e9__1_Participants and definitions\n",
      "6bdc70a008d3c195b02c9c5d2e115d8e87ea35e9__2_Collection of clinical information and specimens\n",
      "6bdc70a008d3c195b02c9c5d2e115d8e87ea35e9__3_Virology studies\n",
      "6bdc70a008d3c195b02c9c5d2e115d8e87ea35e9__4_Statistical analyses\n",
      "6bdc70a008d3c195b02c9c5d2e115d8e87ea35e9__5_Patient characteristics\n",
      "6bdc70a008d3c195b02c9c5d2e115d8e87ea35e9__6_Clinical outcomes\n",
      "6bdc70a008d3c195b02c9c5d2e115d8e87ea35e9__7_Predictors of hospitalization\n",
      "6bdc70a008d3c195b02c9c5d2e115d8e87ea35e9__8_Predictors of clinical disease severity and admission length among inpatients\n",
      "6bdc70a008d3c195b02c9c5d2e115d8e87ea35e9__9_Discussion\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__0_Introduction\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__1_Cross-reactive auto-antihodies\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__2_Cross-reactive and auto-reactive T cells\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__3_Tolerance versus autoimmunity\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__4_B cell and Tcell responses contribute to autoimmune disease\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__5_Investigation of epitope mimicry\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__6_Evidence is needed for epitope mimicry\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__7_Epitope mimicry in parasitic diseases\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__8_Peripheral demyelinating neuropathy\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__9_Epitope mimicry in GBS\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__10_Epitope mimicry in insulin-dependent diabetes mellitis\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__11_Epitope mimicry in rheumatic fever\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__12_Epitope mimicry by bacteria in reactive arthritis and ankylosing spondylitis\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__13_MHC miniicr> and autoimmune pathogenesis\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__14_Epitope mimicry ofthe HLA-DR4 susceptibility locus inR.4\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__15_MHC mimicry and the induction of AIDS\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__16_Considerations for the investigation of epitope mimicry\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__17_Determining the significance of primary sequence similarities\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__18_The likelihood of a linear .sequence ol amino acids being an cpiiope\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__19_Effects of amino acid substitution in T cell epitopes\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__20_Cross-reaetions with non-linear or non-protein epitopes\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__21_B cells as presenters of epitope mimics\n",
      "0ef8953414af2b480b5dec741a4a913ed1380321__22_A model of autoimmune pathogenesis mediated by epitope mimicry\n",
      "cc0b62cf9592001ab3629db667ac8474e612aa1d__0_Introduction\n",
      "cc0b62cf9592001ab3629db667ac8474e612aa1d__1_Mutation choice\n",
      "cc0b62cf9592001ab3629db667ac8474e612aa1d__2_Overall structure\n",
      "cc0b62cf9592001ab3629db667ac8474e612aa1d__3_Active site structure\n",
      "cc0b62cf9592001ab3629db667ac8474e612aa1d__4_Implications for dimerization process\n",
      "cc0b62cf9592001ab3629db667ac8474e612aa1d__5_Implication for dimerization\n",
      "cc0b62cf9592001ab3629db667ac8474e612aa1d__6_Conclusion\n",
      "cc0b62cf9592001ab3629db667ac8474e612aa1d__7_Cloning, expression, purification and gel filtration analysis\n",
      "cc0b62cf9592001ab3629db667ac8474e612aa1d__8_Crystallization and data collection\n",
      "cc0b62cf9592001ab3629db667ac8474e612aa1d__9_Structure determination, refinement and model building\n",
      "cc0b62cf9592001ab3629db667ac8474e612aa1d__10_Data collection\n",
      "4912584f576132be4465364bb4890385aad9b978__0_Introduction\n",
      "4912584f576132be4465364bb4890385aad9b978__1_T Cell Responses in SARS Virus\n",
      "4912584f576132be4465364bb4890385aad9b978__2_T Cell Responses in West Nile Virus\n",
      "4912584f576132be4465364bb4890385aad9b978__3_T Cell Responses in Japanese Encephalitis Virus\n",
      "4912584f576132be4465364bb4890385aad9b978__4_T Cell Responses in Acute Dengue Virus\n",
      "4912584f576132be4465364bb4890385aad9b978__5_T Cell Responses in Viral Hemorrhage Fever\n",
      "4912584f576132be4465364bb4890385aad9b978__6_T Cell Responses in Chronic and Acute Viral Infections\n",
      "4912584f576132be4465364bb4890385aad9b978__7_T Cell Responses in Human Papilloma Virus (HPV)\n",
      "4912584f576132be4465364bb4890385aad9b978__8_T Cell Responses in Hepatitis B Virus\n",
      "4912584f576132be4465364bb4890385aad9b978__9_T Cell Responses in Zika Virus\n",
      "4912584f576132be4465364bb4890385aad9b978__10_Future Perspectives and Conclusions\n",
      "6217c77be15bba46ecbc3568159ff0dabf484043__0_Introduction\n",
      "6217c77be15bba46ecbc3568159ff0dabf484043__1_Cells, viruses and reagents\n",
      "6217c77be15bba46ecbc3568159ff0dabf484043__2_Virus inoculation, CPE and growth curve\n",
      "6217c77be15bba46ecbc3568159ff0dabf484043__3_Indirect immunofluorescence assay (IFA)\n",
      "6217c77be15bba46ecbc3568159ff0dabf484043__4_TCID 50 assay\n",
      "6217c77be15bba46ecbc3568159ff0dabf484043__5_RNA extraction and reverse transcription polymerase chain reaction (RT-PCR)\n",
      "6217c77be15bba46ecbc3568159ff0dabf484043__6_Sub-clonal screening of IPI-2I cells\n",
      "6217c77be15bba46ecbc3568159ff0dabf484043__7_Statistical analysis\n",
      "6217c77be15bba46ecbc3568159ff0dabf484043__8_IPI-2I cells are susceptible to TGEV, PDCoV, and PEAV\n",
      "6217c77be15bba46ecbc3568159ff0dabf484043__9_IPI-2I cells can be infected with PEDV, but with low efficiency\n",
      "6217c77be15bba46ecbc3568159ff0dabf484043__10_IPI-2I-dervied homogeneous IPI-FX cells are highly susceptible to PEDV infection\n",
      "6217c77be15bba46ecbc3568159ff0dabf484043__11_IPI-FX cells are also highly susceptible to TGEV, PDCoV, and PEAV\n",
      "6217c77be15bba46ecbc3568159ff0dabf484043__12_Discussion\n",
      "6217c77be15bba46ecbc3568159ff0dabf484043__13_Conclusion\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__0_\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__1_Facility characteristics\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__2_The outbreak\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__3_Outbreak control measures\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__4_Definitions\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__5_Identification of VRE\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__6_Hospital-wide screening and physical segregation of patients\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__7_Surveillance of risk groups\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__8_Outpatient screening\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__9_Electronic tagging\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__10_Cleaning\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__11_Education and audit\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__12_RESULTS\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__13_Epidemiologic information\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__14_VRE/MRSA co-colonization or co-infection\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__15_End of the outbreak\n",
      "8c267554d529fd6ea03d5ba32aa87e788bd56546__16_DISCUSSION\n",
      "51293df19546aee2ddbfe2c09a128177771458ab__0_Conclusion\n",
      "51293df19546aee2ddbfe2c09a128177771458ab__1_Implications for practice\n",
      "51293df19546aee2ddbfe2c09a128177771458ab__2_Introduction\n",
      "51293df19546aee2ddbfe2c09a128177771458ab__3_Prevention system for radiology department staff\n",
      "51293df19546aee2ddbfe2c09a128177771458ab__4_Radiology service requirements\n",
      "51293df19546aee2ddbfe2c09a128177771458ab__5_Patients case definitions\n",
      "51293df19546aee2ddbfe2c09a128177771458ab__6_Protection levels for healthcare staff\n",
      "51293df19546aee2ddbfe2c09a128177771458ab__7_Cleaning and sanitization of radiology equipment (console and examination rooms)\n",
      "51293df19546aee2ddbfe2c09a128177771458ab__8_Acquisition of chest radiographs in patients with suspected or confirmed COVID-19\n",
      "51293df19546aee2ddbfe2c09a128177771458ab__9_Acquisition of chest CT scan in patients with suspected or proven COVID-19\n",
      "51293df19546aee2ddbfe2c09a128177771458ab__10_CT imaging technique\n",
      "1d05a3a4bca4491b8335840d4a66d2be5811875f__0_\n",
      "1d05a3a4bca4491b8335840d4a66d2be5811875f__1_Figure S4.\n",
      "1d05a3a4bca4491b8335840d4a66d2be5811875f__2_Figure S5.\n",
      "1d05a3a4bca4491b8335840d4a66d2be5811875f__3_Figure S6.\n",
      "1d05a3a4bca4491b8335840d4a66d2be5811875f__4_SUPPLEMENTAL EXPERIMENTAL PROCEDURES\n",
      "1d05a3a4bca4491b8335840d4a66d2be5811875f__5_Choice of display contour\n",
      "1d05a3a4bca4491b8335840d4a66d2be5811875f__6_Structure Factor scaling by Guinier analysis\n",
      "1d05a3a4bca4491b8335840d4a66d2be5811875f__7_Fitting of atomic models\n",
      "b13135e96df9890f29dc09c838c7ee6df4a35253__0_\n",
      "b13135e96df9890f29dc09c838c7ee6df4a35253__1_Funding: None.\n",
      "b13135e96df9890f29dc09c838c7ee6df4a35253__2_Competing interests:\n",
      "93b4a8f3cb0bd52fb52181f0b4c7fa24d4073096__0_I. Introduction\n",
      "93b4a8f3cb0bd52fb52181f0b4c7fa24d4073096__1_A. Gauss model (GM)\n",
      "93b4a8f3cb0bd52fb52181f0b4c7fa24d4073096__2_B. Logarithmic daily fatalities are quadratic\n",
      "93b4a8f3cb0bd52fb52181f0b4c7fa24d4073096__3_C. The fitted parameters\n",
      "93b4a8f3cb0bd52fb52181f0b4c7fa24d4073096__4_D. Additional predictions\n",
      "93b4a8f3cb0bd52fb52181f0b4c7fa24d4073096__5_(which was not peer-reviewed)\n",
      "93b4a8f3cb0bd52fb52181f0b4c7fa24d4073096__6_III. Discussion\n",
      "93b4a8f3cb0bd52fb52181f0b4c7fa24d4073096__7_IV. Conclusion\n",
      "93b4a8f3cb0bd52fb52181f0b4c7fa24d4073096__8_A. Methods\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__0_Introduction\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__1_Materials\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__2_Extracting technology of compound Chinese medicine\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__3_Preparation of the medicine microcapsules\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__4_Finishing process of air filter material\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__5_Preparation of anti-bacteria filter sample\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__6_Anti-bacteria experimental 1) Preparing of bacteria solution\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__7_5) Amount of bacteria tested\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__8_The virus specimen\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__9_Preparation of anti-virus filter sample\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__10_Anti-virus experiment\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__11_5) Measurement of the virus lacuna\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__12_Analysis of the extracting process of compound Chinese medicine\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__13_Preparation of medicine microcapsules and finishing agents\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__14_The anti-bacteria rate of finished filters\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__15_The anti-virus rate of finished filters\n",
      "6b03f46ed66822570602fedcf48f30d382017f02__16_Conclusions\n",
      "56bae3c1f9dd6fcfb763cbd3e004fa1393f01833__0_\n",
      "5486b7ab412145142e6981c4d4c9adf70174d995__0_Synonyms\n",
      "5486b7ab412145142e6981c4d4c9adf70174d995__1_Epidemiology\n",
      "5486b7ab412145142e6981c4d4c9adf70174d995__2_Ultrastructure\n",
      "5486b7ab412145142e6981c4d4c9adf70174d995__3_Immunology\n",
      "5486b7ab412145142e6981c4d4c9adf70174d995__4_Clinical Features\n",
      "5486b7ab412145142e6981c4d4c9adf70174d995__5_Pathologic Changes\n",
      "5486b7ab412145142e6981c4d4c9adf70174d995__6_Diagnosis\n",
      "5486b7ab412145142e6981c4d4c9adf70174d995__7_Differential Diagnosis\n",
      "5486b7ab412145142e6981c4d4c9adf70174d995__8_Prevention\n",
      "5486b7ab412145142e6981c4d4c9adf70174d995__9_Treatment and Outcome\n",
      "5486b7ab412145142e6981c4d4c9adf70174d995__10_Vaccine\n",
      "5486b7ab412145142e6981c4d4c9adf70174d995__11_Clinicopathologic Capsule\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__0_In Brief\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__1_INTRODUCTION\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__2_SARS-CoV-2 Applies the CTD to Interact with hACE2\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__3_Complex Structure between SARS-CoV-2 and hACE2\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__4_The Interaction between SARS-CoV-2-CTD and hACE2\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__5_SARS-CoV-2 Exhibits Distinct Epitope Features in the RBD from SARS-CoV\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__6_DISCUSSION\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__7_STAR+METHODS\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__8_ACKNOWLEDGMENTS\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__9_Flow cytometry\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__10_SPR analysis\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__11_Indirect immunofluorescence analysis and confocal microscopy\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__12_Crystallization\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__13_Data collection and structure determination\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__14_Sequences used in the alignments\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__15_QUANTIFICATION AND STATISTICAL ANALYSIS\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__16_Flow cytometry analysis\n",
      "9b164b51ff883d500f09e5d7c4c070b744e55948__17_DATA AND CODE AVAILABILITY\n",
      "022fbc7bea2e253407b6abea4f56950eea6e802a__0_Correspondence 390\n",
      "022fbc7bea2e253407b6abea4f56950eea6e802a__1_Suicide prevention during the COVID-19 outbreak\n",
      "022fbc7bea2e253407b6abea4f56950eea6e802a__2_Public health messaging and harm reduction in the time of COVID-19\n",
      "022fbc7bea2e253407b6abea4f56950eea6e802a__3_bkanat@idc.ac.il\n",
      "0d9e6240d05cf10e7c2177f7c66f51e4d4e6f63a__0_Influenza virus infection\n",
      "0d9e6240d05cf10e7c2177f7c66f51e4d4e6f63a__1_Incidence and time since transplantation\n",
      "0d9e6240d05cf10e7c2177f7c66f51e4d4e6f63a__2_Treatment\n",
      "0d9e6240d05cf10e7c2177f7c66f51e4d4e6f63a__3_Prevention\n",
      "0d9e6240d05cf10e7c2177f7c66f51e4d4e6f63a__4_Infections by other respiratory viruses\n",
      "0d9e6240d05cf10e7c2177f7c66f51e4d4e6f63a__5_Diagnosis\n",
      "0d9e6240d05cf10e7c2177f7c66f51e4d4e6f63a__6_Prophylaxis and treatment\n",
      "0d9e6240d05cf10e7c2177f7c66f51e4d4e6f63a__7_Erythrovirus B19\n",
      "0d9e6240d05cf10e7c2177f7c66f51e4d4e6f63a__8_Measles virus\n",
      "0d9e6240d05cf10e7c2177f7c66f51e4d4e6f63a__9_BK, JC and other polyomaviruses\n",
      "0d9e6240d05cf10e7c2177f7c66f51e4d4e6f63a__10_JC polyomavirus\n",
      "0d9e6240d05cf10e7c2177f7c66f51e4d4e6f63a__11_BK polyomavirus\n",
      "cf267e85c23bd3786514713fc5ad29a03039d985__0_Introduction\n",
      "cf267e85c23bd3786514713fc5ad29a03039d985__1_Patient\n",
      "cf267e85c23bd3786514713fc5ad29a03039d985__2_Kinetics of immune and inflammatory responses\n",
      "cf267e85c23bd3786514713fc5ad29a03039d985__3_Patient and procedures\n",
      "cf267e85c23bd3786514713fc5ad29a03039d985__4_Virological data\n",
      "cf267e85c23bd3786514713fc5ad29a03039d985__5_Cell phenotyping and quantification of serum analytes\n",
      "cf267e85c23bd3786514713fc5ad29a03039d985__6_5)\n",
      "235b8c401e98224dac5a2522cc1d78770d6ca38c__0_INTRODUCTION\n",
      "235b8c401e98224dac5a2522cc1d78770d6ca38c__1_Animal and Feeding Practices\n",
      "235b8c401e98224dac5a2522cc1d78770d6ca38c__2_Sampling and Laboratory Methods\n",
      "235b8c401e98224dac5a2522cc1d78770d6ca38c__3_Statistical Analysis\n",
      "235b8c401e98224dac5a2522cc1d78770d6ca38c__4_RESULTS AND DISCUSSION\n",
      "235b8c401e98224dac5a2522cc1d78770d6ca38c__5_Apparent Clearance of IgG\n",
      "235b8c401e98224dac5a2522cc1d78770d6ca38c__6_Growth, Feed Efficiency, and Health\n",
      "235b8c401e98224dac5a2522cc1d78770d6ca38c__7_Plasma Urea Nitrogen\n",
      "235b8c401e98224dac5a2522cc1d78770d6ca38c__8_Health\n",
      "235b8c401e98224dac5a2522cc1d78770d6ca38c__9_CONCLUSIONS\n",
      "864c48eacb74def662d0b00a81c5499d7f992988__0_Introduction\n",
      "864c48eacb74def662d0b00a81c5499d7f992988__1_China's Genetic Resources\n",
      "864c48eacb74def662d0b00a81c5499d7f992988__2_Constituents of a Genetic Resource\n",
      "864c48eacb74def662d0b00a81c5499d7f992988__3_Hurdles to Gene Prospecting\n",
      "864c48eacb74def662d0b00a81c5499d7f992988__4_The Most Likely Beneficiary of Gene-Hunting Endeavors\n",
      "864c48eacb74def662d0b00a81c5499d7f992988__5_Oversight, Lapses, Broken Promises, the Reprimand, and Counter-Maneuvering\n",
      "864c48eacb74def662d0b00a81c5499d7f992988__6_The Aftermath\n",
      "864c48eacb74def662d0b00a81c5499d7f992988__7_Science, Nationalism, and Beauty Contest\n",
      "864c48eacb74def662d0b00a81c5499d7f992988__8_Conclusions\n",
      "15689b6bee91a345acab95c382caa8727ff4e629__0_\n",
      "15689b6bee91a345acab95c382caa8727ff4e629__1_Clinical presentation\n",
      "15689b6bee91a345acab95c382caa8727ff4e629__2_Risk factors\n",
      "15689b6bee91a345acab95c382caa8727ff4e629__3_Mortality\n",
      "15689b6bee91a345acab95c382caa8727ff4e629__4_Discussion\n",
      "ca43bc22b370e5b9365883083d42da5b1d264818__0_Introduction\n",
      "ca43bc22b370e5b9365883083d42da5b1d264818__1_Virus and Cells\n",
      "ca43bc22b370e5b9365883083d42da5b1d264818__2_Evaluation of the Antiviral Activity of PVP-I Products against SARS-CoV\n",
      "ca43bc22b370e5b9365883083d42da5b1d264818__3_Inactivation of Infectivity of SARS-CoV-Infected Vero E6 Cells by Chemical Reagents\n",
      "ca43bc22b370e5b9365883083d42da5b1d264818__4_Physical Inactivation of SARS-CoV\n",
      "ca43bc22b370e5b9365883083d42da5b1d264818__5_Fixation of Cells Infected with SARS-CoV by Chemical Reagents\n",
      "ca43bc22b370e5b9365883083d42da5b1d264818__6_Discussion\n",
      "ca43bc22b370e5b9365883083d42da5b1d264818__7_Fig. 2.\n",
      "0c8ac295acf684a385eb45d0b37710affa3a9e85__0_\n",
      "0c8ac295acf684a385eb45d0b37710affa3a9e85__1_Results and Discussion\n",
      "0c8ac295acf684a385eb45d0b37710affa3a9e85__2_Methods\n",
      "0c8ac295acf684a385eb45d0b37710affa3a9e85__3_Molecular dynamic simulation. Molecular dock between HD5 (PDB: 1ZMP\n",
      "e279f4afd8d1def9b69ae41e53746314cee28af1__0_\n",
      "e279f4afd8d1def9b69ae41e53746314cee28af1__1_Introduction\n",
      "e279f4afd8d1def9b69ae41e53746314cee28af1__2_Primary end point\n",
      "e279f4afd8d1def9b69ae41e53746314cee28af1__3_Secondary end points\n",
      "e279f4afd8d1def9b69ae41e53746314cee28af1__4_Study design\n",
      "e279f4afd8d1def9b69ae41e53746314cee28af1__5_Recruitment\n",
      "e279f4afd8d1def9b69ae41e53746314cee28af1__6_Exclusion\n",
      "e279f4afd8d1def9b69ae41e53746314cee28af1__7_Data collection\n",
      "e279f4afd8d1def9b69ae41e53746314cee28af1__8_Specimen collection and testing\n",
      "e279f4afd8d1def9b69ae41e53746314cee28af1__9_Transmission dynamics\n",
      "e279f4afd8d1def9b69ae41e53746314cee28af1__10_Follow up\n",
      "e279f4afd8d1def9b69ae41e53746314cee28af1__11_Data analysis\n",
      "e279f4afd8d1def9b69ae41e53746314cee28af1__12_Sample size calculation\n",
      "e279f4afd8d1def9b69ae41e53746314cee28af1__13_Ethical implication\n",
      "e279f4afd8d1def9b69ae41e53746314cee28af1__14_Discussion\n",
      "93cdc5129212f1f3076f6ee752799fac14b844cf__0_A R T I C L E S\n",
      "93cdc5129212f1f3076f6ee752799fac14b844cf__1_Virus isolation from a child with acute respiratory disease\n",
      "93cdc5129212f1f3076f6ee752799fac14b844cf__2_Detection of HCoV-NL63 in patient specimens\n",
      "93cdc5129212f1f3076f6ee752799fac14b844cf__3_Complete genome analysis of HCoV-NL63\n",
      "93cdc5129212f1f3076f6ee752799fac14b844cf__4_DISCUSSION\n",
      "93cdc5129212f1f3076f6ee752799fac14b844cf__5_VIDISCA method.\n",
      "0d31394c8fe61635556b99a932697f7ba4b40ea1__0_Introduction\n",
      "0d31394c8fe61635556b99a932697f7ba4b40ea1__1_Mefloquine and quinine\n",
      "0d31394c8fe61635556b99a932697f7ba4b40ea1__2_Atovaquone\n",
      "0d31394c8fe61635556b99a932697f7ba4b40ea1__3_Ferroquine\n",
      "0d31394c8fe61635556b99a932697f7ba4b40ea1__4_Formulation\n",
      "0d31394c8fe61635556b99a932697f7ba4b40ea1__5_Metabolism\n",
      "0d31394c8fe61635556b99a932697f7ba4b40ea1__6_Mechanism of action\n",
      "0d31394c8fe61635556b99a932697f7ba4b40ea1__7_Failure to induce resistance\n",
      "0d31394c8fe61635556b99a932697f7ba4b40ea1__8_Conclusion and Outlook\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__0_Introduction\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__1_Samples and purification\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__2_High-throughput sequencing and analysis\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__3_Sequence analysis\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__4_Trial for whole-genome analysis of a parvovirus\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__5_Detection of enteric viruses\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__6_Diagnosis of RSS\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__7_Enteric virus genome sequence analysis\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__8_Astroviridae\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__9_Picornaviridae\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__10_Parvoviridae\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__11_Reoviridae\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__12_Caliciviridae\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__13_Picobirnaviridae\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__14_Detection of enteric viruses in the non-RSS-affected flock using multiplex RT-PCR and PCR\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__15_Discussion\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__16_Conclusions\n",
      "0bd3aaa2f3ee6d82b6b94051755fb751ad66652c__17_Supplementary information\n",
      "12529abfccd90c78970ab201e78b79c50ca26a08__0_Introduction\n",
      "12529abfccd90c78970ab201e78b79c50ca26a08__1_Results\n",
      "12529abfccd90c78970ab201e78b79c50ca26a08__2_Discussion\n",
      "12529abfccd90c78970ab201e78b79c50ca26a08__3_16,000 X\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__0_Introduction\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__1_Topological control\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__2_Extended situation\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__3_Nanomechanical switches\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__4_Supramolecular switches, devices and machines\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__5_Three-component machines\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__6_Four-component switches and machines\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__7_Self-sorting and multi-component machinery\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__8_Catalytic machinery\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__9_Networked catalytic machinery\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__10_Double-NetState nine-component catalytic machinery\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__11_Double-NetState nine-component machinery: rotation and catalysis\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__12_Kinetics in mononuclear copper(I) phenanthroline and diimine complexes\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__13_Topologically controlled switches, devices and machines\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__14_Table 2\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__15_Supramolecular machines\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__16_Conclusions on kinetic data\n",
      "a8be42501c674aba223038efd7483cda5d3450e0__17_Conclusion\n",
      "94546c74b4b56723d63609b80b737afe359c3a7e__0_Introduction\n",
      "94546c74b4b56723d63609b80b737afe359c3a7e__1_Children and COVID-19\n",
      "94546c74b4b56723d63609b80b737afe359c3a7e__2_Surgery during the COVID-19 pandemic\n",
      "94546c74b4b56723d63609b80b737afe359c3a7e__3_Outpatient care for children with urological problems during the COVID-19 pandemic\n",
      "94546c74b4b56723d63609b80b737afe359c3a7e__4_Stage 3:\n",
      "94546c74b4b56723d63609b80b737afe359c3a7e__5_Safety measures and precautions for paediatric urology staff\n",
      "94546c74b4b56723d63609b80b737afe359c3a7e__6_Resumption of surgical care after the COVID-19-pandemic peak\n",
      "080096f4b8a900929edb855fb9e39c6c6565e221__0_Introduction\n",
      "080096f4b8a900929edb855fb9e39c6c6565e221__1_Results\n",
      "080096f4b8a900929edb855fb9e39c6c6565e221__2_Pulmonary TMPRSS2 expression in mice does not differ by sex and is unaffected by potent AR blockade\n",
      "080096f4b8a900929edb855fb9e39c6c6565e221__3_TMPRSS2 and ACE2 mRNA expression increase in current smokers whereas in former smokers, expression returns to levels found in never smokers\n",
      "080096f4b8a900929edb855fb9e39c6c6565e221__4_Discussion\n",
      "080096f4b8a900929edb855fb9e39c6c6565e221__5_Mice, treatments and lung harvest\n",
      "080096f4b8a900929edb855fb9e39c6c6565e221__6_Protein and mRNA expression analysis\n",
      "080096f4b8a900929edb855fb9e39c6c6565e221__7_Tmprss2\n",
      "080096f4b8a900929edb855fb9e39c6c6565e221__8_Rplp0\n",
      "080096f4b8a900929edb855fb9e39c6c6565e221__9_Gene expression in human lung\n",
      "e4c853fc283b97718ad4de0cdfdd8ecb95e933a8__0_INTRODUCTION\n",
      "e4c853fc283b97718ad4de0cdfdd8ecb95e933a8__1_Study Population\n",
      "e4c853fc283b97718ad4de0cdfdd8ecb95e933a8__2_RNA and DNA Extraction\n",
      "e4c853fc283b97718ad4de0cdfdd8ecb95e933a8__3_PCR Assays for Respiratory Viruses\n",
      "e4c853fc283b97718ad4de0cdfdd8ecb95e933a8__4_Statistical Analysis\n",
      "e4c853fc283b97718ad4de0cdfdd8ecb95e933a8__5_Prevalence of Respiratory Viruses Among Children With ARTI\n",
      "e4c853fc283b97718ad4de0cdfdd8ecb95e933a8__6_Seasonal and Age Distribution\n",
      "e4c853fc283b97718ad4de0cdfdd8ecb95e933a8__7_HCoV\n",
      "e4c853fc283b97718ad4de0cdfdd8ecb95e933a8__8_Clinical Features\n",
      "e4c853fc283b97718ad4de0cdfdd8ecb95e933a8__9_DISCUSSION\n",
      "e4c853fc283b97718ad4de0cdfdd8ecb95e933a8__10_ACKNOWLEDGMENTS\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__0_Introduction\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__1_Methods\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__2_A socially structured compartmental model with uncertainty\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__3_Multiple control of structured compartmental model\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__4_(which was not certified by peer review)\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__5_Feedback controlled compartmental models with uncertainty\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__6_5\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__7_Results\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__8_Model calibration\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__9_7\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__10_Estimating actual infection trends with uncertain data\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__11_Relaxing control on the various social activities\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__12_10\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__13_Scenario 1: Relaxing lockdown measures at different times\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__14_Scenario 2: Impact of school and work activities\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__15_Scenario 3: Restarting activities while keeping the curve under control\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__16_15\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__17_16\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__18_Discussion\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__19_17\n",
      "c1682bdf8eaaa48fc129cbaf8c0dacacb6b4a656__20_Conclusions\n",
      "edcd72779c065a19742dc23ada42010e367f8acb__0_Introduction\n",
      "edcd72779c065a19742dc23ada42010e367f8acb__1_Sample collection\n",
      "edcd72779c065a19742dc23ada42010e367f8acb__2_Sequencing library construction\n",
      "edcd72779c065a19742dc23ada42010e367f8acb__3_Deep sequencing and data analysis\n",
      "edcd72779c065a19742dc23ada42010e367f8acb__4_Data overview\n",
      "edcd72779c065a19742dc23ada42010e367f8acb__5_Scientific question\n",
      "edcd72779c065a19742dc23ada42010e367f8acb__6_New findings\n",
      "edcd72779c065a19742dc23ada42010e367f8acb__7_Significance of the study\n",
      "edcd72779c065a19742dc23ada42010e367f8acb__8_Detections of viral sequences\n",
      "edcd72779c065a19742dc23ada42010e367f8acb__9_Diversity and composition of the sequences of biological substances\n",
      "edcd72779c065a19742dc23ada42010e367f8acb__10_Discussion\n",
      "edcd72779c065a19742dc23ada42010e367f8acb__11_Conclusions\n",
      "5fa36c857c0d2d78e7a42e369d0ee241e2087855__0_Introduction\n",
      "5fa36c857c0d2d78e7a42e369d0ee241e2087855__1_Methods\n",
      "5fa36c857c0d2d78e7a42e369d0ee241e2087855__2_Case Description\n",
      "5fa36c857c0d2d78e7a42e369d0ee241e2087855__3_Discussion\n",
      "5fa36c857c0d2d78e7a42e369d0ee241e2087855__4_Update on Pathogenesis of Influenza-Associated CNS Disease\n",
      "5fa36c857c0d2d78e7a42e369d0ee241e2087855__5_Neurologic Syndromes Associated with Influenza\n",
      "5fa36c857c0d2d78e7a42e369d0ee241e2087855__6_Influenza-Associated Encephalopathy\n",
      "5fa36c857c0d2d78e7a42e369d0ee241e2087855__7_Influenza-Associated Acute Necrotizing Encephalopathy\n",
      "5fa36c857c0d2d78e7a42e369d0ee241e2087855__8_Post-Infectious Neurologic Complications of Influenza\n",
      "5fa36c857c0d2d78e7a42e369d0ee241e2087855__9_Conclusion\n",
      "210a190d015bd1886f9add90f8570751f41efb26__0_Introduction\n",
      "210a190d015bd1886f9add90f8570751f41efb26__1_ADP-ribose binding studies\n",
      "210a190d015bd1886f9add90f8570751f41efb26__2_Crystallization and structure determination\n",
      "210a190d015bd1886f9add90f8570751f41efb26__3_Quality of the structural models\n",
      "210a190d015bd1886f9add90f8570751f41efb26__4_Overall structures\n",
      "210a190d015bd1886f9add90f8570751f41efb26__5_Discussion\n",
      "210a190d015bd1886f9add90f8570751f41efb26__6_Materials and Methods\n",
      "210a190d015bd1886f9add90f8570751f41efb26__7_Zone-interference gel electrophoresis\n",
      "210a190d015bd1886f9add90f8570751f41efb26__8_Note added in proof\n",
      "152b8cd89a4c482001600b0699b346ea4f378c75__0_INTRODUCTION\n",
      "152b8cd89a4c482001600b0699b346ea4f378c75__1_MATERIALS AND METHODS\n",
      "152b8cd89a4c482001600b0699b346ea4f378c75__2_RESULTS\n",
      "152b8cd89a4c482001600b0699b346ea4f378c75__3_DISCUSSION\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__0_\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__1_Amoebiasis, extra-intestinale (leveramoebiasis)\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__2_Diagnose\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__3_Therapie\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__4_Brucellose\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__5_Specialistische therapie\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__6_Buiktyfus (febris typhoidea)\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__7_Preventie\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__8_Cholera\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__9_Dengue\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__10_Filariasis bancrofti\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__11_Bestrijding, eliminatie\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__12_Giardiasis\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__13_Larva migrans cutanea\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__14_Leishmaniasis cutane\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__15_Leishmaniasis viscerale (kala-azar)\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__16_Leptospirose\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__17_Lintworminfectie\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__18_Loiasis\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__19_Malaria\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__20_Mijnworminfectie\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__21_Reizigersdiarree\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__22_Rickettsiosen\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__23_Schistosomiasis (bilharziasis)\n",
      "e2e0bcb00f1e345e112915d34331516891aea621__24_Spoelworminfectie\n",
      "5a5aba543db0ffbf31c4646b383c02f5af78f759__0_Introduction\n",
      "5a5aba543db0ffbf31c4646b383c02f5af78f759__1_Contents lists available at ScienceDirect\n",
      "5a5aba543db0ffbf31c4646b383c02f5af78f759__2_Sample collection\n",
      "5a5aba543db0ffbf31c4646b383c02f5af78f759__3_Viral metagenomic analysis\n",
      "5a5aba543db0ffbf31c4646b383c02f5af78f759__4_Genome acquisition of novel picornavirus\n",
      "5a5aba543db0ffbf31c4646b383c02f5af78f759__5_Sequence and phylogenetic analyses\n",
      "5a5aba543db0ffbf31c4646b383c02f5af78f759__6_RNA secondary structure analysis\n",
      "5a5aba543db0ffbf31c4646b383c02f5af78f759__7_Nucleotide sequence accession numbers\n",
      "5a5aba543db0ffbf31c4646b383c02f5af78f759__8_Viral metagenomic analysis of lapine samples\n",
      "5a5aba543db0ffbf31c4646b383c02f5af78f759__9_General genomic features of rabbit picornavirus\n",
      "5a5aba543db0ffbf31c4646b383c02f5af78f759__10_Description of 5′/3′ untranslated regions and cis-acting regulation element (CRE)\n",
      "5a5aba543db0ffbf31c4646b383c02f5af78f759__11_Analysis of the polyprotein coding region\n",
      "5a5aba543db0ffbf31c4646b383c02f5af78f759__12_Detection of rabbit picornavirus in lapine faecal samples\n",
      "5a5aba543db0ffbf31c4646b383c02f5af78f759__13_Discussion\n",
      "e87ef4d720be62c4fbfb53cd02bbf5228f2ecb04__0_Background\n",
      "e87ef4d720be62c4fbfb53cd02bbf5228f2ecb04__1_Passive immunization\n",
      "e87ef4d720be62c4fbfb53cd02bbf5228f2ecb04__2_SARS-CoV-2 immunology\n",
      "e87ef4d720be62c4fbfb53cd02bbf5228f2ecb04__3_Crosstalk of the immune system and the brain\n",
      "e87ef4d720be62c4fbfb53cd02bbf5228f2ecb04__4_Passive immunization for cancer patients and in solid organ transplantation\n",
      "e87ef4d720be62c4fbfb53cd02bbf5228f2ecb04__5_Conclusion\n",
      "2b3e73ad2f395eba2016663de34d90751be15038__0_Introduction\n",
      "2b3e73ad2f395eba2016663de34d90751be15038__1_Chimpanzee adenovirus 3\n",
      "2b3e73ad2f395eba2016663de34d90751be15038__2_Plasmid constructs and adenovirus vectors\n",
      "2b3e73ad2f395eba2016663de34d90751be15038__3_Peptides\n",
      "2b3e73ad2f395eba2016663de34d90751be15038__4_Mice and immunizations\n",
      "2b3e73ad2f395eba2016663de34d90751be15038__5_Antibodies detection and titration\n",
      "2b3e73ad2f395eba2016663de34d90751be15038__6_Cytokine intracellular staining\n",
      "2b3e73ad2f395eba2016663de34d90751be15038__7_Pre-immunity to hAd5 and neutralization studies\n",
      "2b3e73ad2f395eba2016663de34d90751be15038__8_Statistics\n",
      "2b3e73ad2f395eba2016663de34d90751be15038__9_Construction of ChAd3 vectors\n",
      "2b3e73ad2f395eba2016663de34d90751be15038__10_hAd5 and ChAd3 express similar levels of CEA\n",
      "2b3e73ad2f395eba2016663de34d90751be15038__11_Immunogenicity of ChAd3 and hAd5 is comparable\n",
      "2b3e73ad2f395eba2016663de34d90751be15038__12_ChAd3 vaccine overcomes hAd5 pre-existing immunity\n",
      "2b3e73ad2f395eba2016663de34d90751be15038__13_ChAd3 vaccine confers anti-tumor effects in BALB/NeuT mice with anti-hAd5 immunity\n",
      "2b3e73ad2f395eba2016663de34d90751be15038__14_Discussion\n",
      "64b27bf90c3ef7b941f8ca682b0bc23e4f559252__0_\n",
      "64b27bf90c3ef7b941f8ca682b0bc23e4f559252__1_The format\n",
      "64b27bf90c3ef7b941f8ca682b0bc23e4f559252__2_The team\n",
      "64b27bf90c3ef7b941f8ca682b0bc23e4f559252__3_The infrastructure\n",
      "64b27bf90c3ef7b941f8ca682b0bc23e4f559252__4_The program\n",
      "64b27bf90c3ef7b941f8ca682b0bc23e4f559252__5_The Hubs\n",
      "64b27bf90c3ef7b941f8ca682b0bc23e4f559252__6_Map of the POM hubs. Inset: Zoom-in of the hubs across Europe.\n",
      "64b27bf90c3ef7b941f8ca682b0bc23e4f559252__7_The #POM bingo board, made on the fly during the event by the UC-Davis hub (courtesy of Marina Radulaski)\n",
      "64b27bf90c3ef7b941f8ca682b0bc23e4f559252__8_The poster session\n",
      "64b27bf90c3ef7b941f8ca682b0bc23e4f559252__9_Before the day of the conference\n",
      "64b27bf90c3ef7b941f8ca682b0bc23e4f559252__10_During POM\n",
      "64b27bf90c3ef7b941f8ca682b0bc23e4f559252__11_Challenges\n",
      "64b27bf90c3ef7b941f8ca682b0bc23e4f559252__12_POM20: ANALYSIS AND PERSPECTIVES\n",
      "64b27bf90c3ef7b941f8ca682b0bc23e4f559252__13_The vision ahead\n",
      "64b27bf90c3ef7b941f8ca682b0bc23e4f559252__14_Conclusions\n",
      "8edf35c1ee0ae65d00ecd1d87b98f48bcce861ee__0_Background\n",
      "8edf35c1ee0ae65d00ecd1d87b98f48bcce861ee__1_COVID-19 Pathogenesis\n",
      "8edf35c1ee0ae65d00ecd1d87b98f48bcce861ee__2_RAS Activity and COVID-19\n",
      "8edf35c1ee0ae65d00ecd1d87b98f48bcce861ee__3_Research Priorities and Study Considerations\n",
      "8edf35c1ee0ae65d00ecd1d87b98f48bcce861ee__4_Conclusion\n",
      "021291da7cf3769e4182317703a95b6c5f7c76f9__0_\n",
      "64929e24b974a401e62f2af92abda931af8b9342__0_Introduction\n",
      "64929e24b974a401e62f2af92abda931af8b9342__1_Siglecs in Bacterial Infection\n",
      "64929e24b974a401e62f2af92abda931af8b9342__2_Siglecs in Viral Infection\n",
      "64929e24b974a401e62f2af92abda931af8b9342__3_Siglecs in Parasitic and Fungal Infections\n",
      "64929e24b974a401e62f2af92abda931af8b9342__4_Crosstalk Between Siglec and Pattern-Recognition Receptors in Host Defense Mechanism\n",
      "64929e24b974a401e62f2af92abda931af8b9342__5_Future Perspectives\n",
      "a70414b29c5001222dc9e30f29b6de1f624a1221__0_INTRODUCTION\n",
      "a70414b29c5001222dc9e30f29b6de1f624a1221__1_MATERIALS AND METHODS\n",
      "a70414b29c5001222dc9e30f29b6de1f624a1221__2_RESULTS\n",
      "a70414b29c5001222dc9e30f29b6de1f624a1221__3_DISCUSSION\n",
      "15e59ab2f9541e4474afa2bdebe831454cd86ab9__0_\n",
      "15e59ab2f9541e4474afa2bdebe831454cd86ab9__1_Materials and Methods\n",
      "15e59ab2f9541e4474afa2bdebe831454cd86ab9__2_Experimental Procedure\n",
      "15e59ab2f9541e4474afa2bdebe831454cd86ab9__3_Statistical Analyses\n",
      "15e59ab2f9541e4474afa2bdebe831454cd86ab9__4_Results\n",
      "15e59ab2f9541e4474afa2bdebe831454cd86ab9__5_Findings on Postmortem Examination\n",
      "15e59ab2f9541e4474afa2bdebe831454cd86ab9__6_Discussion\n",
      "882feb2a3d59dff3a79579042583884eac023fe2__0_Introduction\n",
      "882feb2a3d59dff3a79579042583884eac023fe2__1_Materials and Methods\n",
      "882feb2a3d59dff3a79579042583884eac023fe2__2_Sampling\n",
      "882feb2a3d59dff3a79579042583884eac023fe2__3_Detection of retroviral infection\n",
      "882feb2a3d59dff3a79579042583884eac023fe2__4_Detection of Toxoplasma and coronavirus infection\n",
      "882feb2a3d59dff3a79579042583884eac023fe2__5_Hemogram and biochemical parameters\n",
      "882feb2a3d59dff3a79579042583884eac023fe2__6_Electrophoretic separation of plasma proteins\n",
      "882feb2a3d59dff3a79579042583884eac023fe2__7_Analysis of CD4/CD8 by flow cytometry\n",
      "882feb2a3d59dff3a79579042583884eac023fe2__8_Statistical analysis\n",
      "882feb2a3d59dff3a79579042583884eac023fe2__9_Results\n",
      "882feb2a3d59dff3a79579042583884eac023fe2__10_206\n",
      "882feb2a3d59dff3a79579042583884eac023fe2__11_Discussion\n",
      "c2beebf42f43944f143b4ece73791fcf766943a9__0_Introduction\n",
      "c2beebf42f43944f143b4ece73791fcf766943a9__1_Results and discussion\n",
      "c2beebf42f43944f143b4ece73791fcf766943a9__2_Scheme 2\n",
      "c2beebf42f43944f143b4ece73791fcf766943a9__3_Antiviral activity and cytotoxic evaluation\n",
      "c2beebf42f43944f143b4ece73791fcf766943a9__4_Evaluation of cytostatic activity\n",
      "c2beebf42f43944f143b4ece73791fcf766943a9__5_Conclusion\n",
      "c2beebf42f43944f143b4ece73791fcf766943a9__6_General procedure for the chlorination and bromination reactions\n",
      "c2beebf42f43944f143b4ece73791fcf766943a9__7_Cytostatic activity assays\n",
      "220174ac0a9a107a0013fc4abde3523f15accdc8__0_Introduction\n",
      "220174ac0a9a107a0013fc4abde3523f15accdc8__1_National and international collaboration\n",
      "220174ac0a9a107a0013fc4abde3523f15accdc8__2_Developments in hospital capacity\n",
      "220174ac0a9a107a0013fc4abde3523f15accdc8__3_Organ Donation from deceased donors\n",
      "220174ac0a9a107a0013fc4abde3523f15accdc8__4_Risks and benefits to transplant recipients\n",
      "220174ac0a9a107a0013fc4abde3523f15accdc8__5_Impact of the pandemic on transplant activity\n",
      "ac02f40071a3fc513d2d834ec0bdb3ce8dd16b51__0_Introduction\n",
      "ac02f40071a3fc513d2d834ec0bdb3ce8dd16b51__1_The underlying model and some key epidemiological quantities\n",
      "ac02f40071a3fc513d2d834ec0bdb3ce8dd16b51__2_Replacing generation times with serial intervals\n",
      "ac02f40071a3fc513d2d834ec0bdb3ce8dd16b51__3_Multiple exposures\n",
      "ac02f40071a3fc513d2d834ec0bdb3ce8dd16b51__4_Counting delayed events\n",
      "ac02f40071a3fc513d2d834ec0bdb3ce8dd16b51__5_Results\n",
      "ac02f40071a3fc513d2d834ec0bdb3ce8dd16b51__6_Looking backwards\n",
      "ac02f40071a3fc513d2d834ec0bdb3ce8dd16b51__7_Serial intervals\n",
      "ac02f40071a3fc513d2d834ec0bdb3ce8dd16b51__8_Case fatality rate example\n",
      "ac02f40071a3fc513d2d834ec0bdb3ce8dd16b51__9_A simulation study\n",
      "ac02f40071a3fc513d2d834ec0bdb3ce8dd16b51__10_Discussion\n",
      "fa75bead7f477b812ea15162fa4c0ab977fa7d03__0_\n",
      "fa75bead7f477b812ea15162fa4c0ab977fa7d03__1_Study Design\n",
      "2e16161005776866dfb999bc0632a796a21e846d__0_Introduction\n",
      "2e16161005776866dfb999bc0632a796a21e846d__1_Chemistry and structural characterization\n",
      "2e16161005776866dfb999bc0632a796a21e846d__2_Antiviral activity\n",
      "2e16161005776866dfb999bc0632a796a21e846d__3_Conclusion\n",
      "2e16161005776866dfb999bc0632a796a21e846d__4_Ethyl 2-benzyl-2-(4-fluorophenylhydrazono)acetate (3)\n",
      "2e16161005776866dfb999bc0632a796a21e846d__5_Ethyl 5-fluoro-3-phenyl-1H-indole-2-carboxylate (4)\n",
      "2e16161005776866dfb999bc0632a796a21e846d__6_5-Fluoro-3-phenyl-1H-indole-2-carbohydrazide (5) 25\n",
      "2e16161005776866dfb999bc0632a796a21e846d__7_Antiviral activity assays\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__0_Introduction\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__1_Locally Prevalent Diseases\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__2_Malaria Epidemiology\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__3_Etiology\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__4_Pathophysiology of Severe Malaria\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__5_Infl ammation\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__6_Interaction Between Malaria Parasites and RBCs\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__7_Sequestration\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__8_Clinical Manifestations\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__9_Cerebral Malaria\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__10_Severe Malarial Anemia\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__11_Laboratory Findings and Diagnosis\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__12_Treatment\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__13_Adjuvant Management\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__14_Dengue Epidemiology\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__15_Pathophysiology\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__16_Disease Classifi cation and Clinical Course\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__17_Febrile Phase\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__18_Critical Phase\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__19_Recovery Phase\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__20_Diagnosis\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__21_Management of Dengue Hemorrhagic Fever Grade 1 and 2 (Without Shock)\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__22_Management of DHF Grades 3 and 4 (Dengue Shock Syndrome)\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__23_Typhoid and Paratyphoid Fever Epidemiology\n",
      "e15936fe19a2b81cd9e508de86738993faeaddba__24_Leptospirosis Epidemiology\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__0_\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__1_SARS-CoV\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__2_Human Coronaviruses (HCoVs)\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__3_Human Metapneumovirus (hMPV)\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__4_Human Bocavirus (HBoV)\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__5_Emerging Viral Hemorrhagic Fevers\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__6_Diagnosis\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__7_Emerging Viral Hepatitides\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__8_Hepatitis Delta Virus (HDV)\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__9_Hepatitis E Virus (HEV)\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__10_Emerging Bacterial Pathogens\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__11_Ehrlichia and Anaplasma Species\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__12_Chlamydophila pneumoniae\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__13_Helicobacter pylori\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__14_Cryptosporidia\n",
      "fa9adf799ac000f5e00055de93c993c68df483c7__15_Future Prospects\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__0_INTRODUCTION\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__1_Study outline\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__2_Figure 1 | Experimental design and measurements of alertness. (A)\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__3_Fluctuation of alertness during single TMS sessions\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__4_Figure S1 | Individual differences in levels of alertness across a single TMS session.\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__5_Fluctuating levels of alertness modulate MEPs\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__6_Figure 2 | Motor evoked potentials (MEPs) shown across different levels of alertness.\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__7_Figure S2 | Individual rate of motor evoked potentials (MEPs) as a function of transcranial magnetic stimulation (TMS) intensity in θ/α-defined awake and drowsy\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__8_Fluctuating alertness modulates TMS-evoked potential (TEP) amplitude\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__9_Figure S4 | Individual transcranial magnetic stimulation-triggered cortical reactivity potentials (TEPs) in θ/α-defined awake and drowsy states.\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__10_Figure S5 | TMS-evoked scalp muscle activity in θ/α-defined awake and drowsy states.\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__11_Single-trial MEP and TEP variability across different levels of alertness\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__12_Figure 4 | Single-trial MEP and TEP amplitudes across different levels of alertness. (A)\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__13_Relationship between single-trial MEP and TEP amplitudes across levels of alertness\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__14_Figure S6 | Correlations between MEP and TEP amplitudes at different levels of alertness.\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__15_DISCUSSION\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__16_Participants\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__17_The experimental protocol was approved by the Medical Research Ethics Committee of The\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__18_Electromyography (EMG)\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__19_Transcranial magnetic stimulation (TMS)\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__20_Electroencephalography (EEG)\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__21_Experimental procedure\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__22_Motor evoked potential (MEP) analyses\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__23_EEG measures of alertness\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__24_Pre-TMS level of alertness\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__25_EEG pre-processing and analysis: TMS-EEG reactivity\n",
      "05709a910b2c8db2945155c7c24d1009e83fc802__26_Statistical analysis\n",
      "8695528795dd02723afd17afba6e768d08372aba__0_INTRODUCTION\n",
      "8695528795dd02723afd17afba6e768d08372aba__1_106\n",
      "8695528795dd02723afd17afba6e768d08372aba__2_219\n",
      "8695528795dd02723afd17afba6e768d08372aba__3_Molecular insights for pathogenesis of SARS-CoV-2 infection\n",
      "8695528795dd02723afd17afba6e768d08372aba__4_629\n",
      "8695528795dd02723afd17afba6e768d08372aba__5_725\n",
      "8695528795dd02723afd17afba6e768d08372aba__6_759\n",
      "8695528795dd02723afd17afba6e768d08372aba__7_836\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__0_Introduction\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__1_50\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__2_Materials and methods\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__3_51\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__4_Subcellular localization prediction and targets' prioritization\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__5_52\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__6_Homology modeling\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__7_Structure validation and active site prediction\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__8_Identification of pathogen-specific pathways\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__9_Identification of non-homologous essential proteins\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__10_Subcellular localization and prediction of drug target prioritization\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__11_55\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__12_Novel targets' identification\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__13_Novel targets in pathogens' unique pathways\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__14_Mondal et al\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__15_Identification of broad-spectrum targets\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__16_57\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__17_Structure validation and energy minimization\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__18_Active site analysis\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__19_Conclusion\n",
      "53f9b02ce4cc149507a9d402dcf9d4c191b3bb29__20_61\n",
      "e30e64e79bd36315d66c721be00264d9553eac6b__0_\n",
      "e30e64e79bd36315d66c721be00264d9553eac6b__1_Webtable 3: Cohort studies of the effect of smoking on COPD and lung-cancer mortality in China\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__0_Introduction\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__1_Arcobacter spp.\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__2_Clostridium difficile\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__3_Escherichia coli\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__4_Non-O157 shiga toxin-producing Escherichia coli\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__5_Mycobacterium paratuberculosis\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__6_Salmonella enterica\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__7_Streptococcus suis\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__8_Antimicrobial-Resistant Strains\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__9_Other Bacteria\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__10_Viruses\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__11_Hepatitis Viruses\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__12_Other Viruses\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__13_Parasites\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__14_Cyclospora cayetanensis\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__15_Cryptosporidium and Giardia\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__16_Toxoplasma gondii\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__17_Other Parasites\n",
      "771a8edc9544e682deefafa55fea14dd2e3f85ba__18_Concluding Remarks\n",
      "9f9ca5a0edfc1a2fd8f5b87bd84f332dc06a20e0__0_\n",
      "9f9ca5a0edfc1a2fd8f5b87bd84f332dc06a20e0__1_INTRODUCTION\n",
      "9f9ca5a0edfc1a2fd8f5b87bd84f332dc06a20e0__2_RESULTS\n",
      "9f9ca5a0edfc1a2fd8f5b87bd84f332dc06a20e0__3_Lessons on RdRp Misincorporation and Mismatch Bypass Learned from Magnetic Tweezers Experiments Performed Using Imbalanced Nucleotide Pools\n",
      "9f9ca5a0edfc1a2fd8f5b87bd84f332dc06a20e0__4_Characterization of a Lethal Mutagen, Obligate Chain\n",
      "9f9ca5a0edfc1a2fd8f5b87bd84f332dc06a20e0__5_Pyrazine-Carboxamide Nucleotide Induces Polymerase Backtracking, Defining a Distinct Mechanistic Class of Antiviral Nucleotide\n",
      "9f9ca5a0edfc1a2fd8f5b87bd84f332dc06a20e0__6_A Unique Mechanism of Action of T-1106 against PV in Cell Culture\n",
      "9f9ca5a0edfc1a2fd8f5b87bd84f332dc06a20e0__7_DISCUSSION\n",
      "9f9ca5a0edfc1a2fd8f5b87bd84f332dc06a20e0__8_EXPERIMENTAL PROCEDURES\n",
      "9f9ca5a0edfc1a2fd8f5b87bd84f332dc06a20e0__9_Magnetic Tweezers Instrumentation\n",
      "9f9ca5a0edfc1a2fd8f5b87bd84f332dc06a20e0__10_Reaction Conditions in the Magnetic Tweezers\n",
      "9f9ca5a0edfc1a2fd8f5b87bd84f332dc06a20e0__11_Determination of Uncertainties in Measured and Fitted Parameter Values\n",
      "9f9ca5a0edfc1a2fd8f5b87bd84f332dc06a20e0__12_PV-RdRp-Catalyzed Single-Nucleotide Incorporation Assays\n",
      "9f9ca5a0edfc1a2fd8f5b87bd84f332dc06a20e0__13_Inhibition of PV Replication by Ribavirin and T-1106\n",
      "9f9ca5a0edfc1a2fd8f5b87bd84f332dc06a20e0__14_Cytotoxicity Assays\n",
      "a633596dc4ee28692afaa88122c65b997d1e4d1f__0_Introduction\n",
      "a633596dc4ee28692afaa88122c65b997d1e4d1f__1_Chemical structure and occurrence of tannins\n",
      "a633596dc4ee28692afaa88122c65b997d1e4d1f__2_Biological activity of tannins\n",
      "a633596dc4ee28692afaa88122c65b997d1e4d1f__3_Antimicrobial property\n",
      "a633596dc4ee28692afaa88122c65b997d1e4d1f__4_Anti-parasitic property\n",
      "a633596dc4ee28692afaa88122c65b997d1e4d1f__5_Antioxidant property\n",
      "a633596dc4ee28692afaa88122c65b997d1e4d1f__6_Anti-inflammatory property\n",
      "a633596dc4ee28692afaa88122c65b997d1e4d1f__7_Anti-virus property\n",
      "a633596dc4ee28692afaa88122c65b997d1e4d1f__8_Use of tannins in ruminants\n",
      "a633596dc4ee28692afaa88122c65b997d1e4d1f__9_Use of tannins in monogastric animals\n",
      "a633596dc4ee28692afaa88122c65b997d1e4d1f__10_Chestnut tannins\n",
      "a633596dc4ee28692afaa88122c65b997d1e4d1f__11_Grape tannins\n",
      "a633596dc4ee28692afaa88122c65b997d1e4d1f__12_Tannic acid\n",
      "a633596dc4ee28692afaa88122c65b997d1e4d1f__13_Other sources of tannins\n",
      "a633596dc4ee28692afaa88122c65b997d1e4d1f__14_Conflict of interest\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__0_\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__1_Site of Infection\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__2_Respiratory Tract\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__3_Pneumocystis jiroveci Pneumonia (PCP)\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__4_Viruses\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__5_Gut\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__6_Cryptosporidium\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__7_Giardia\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__8_Disseminated Infection\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__9_Adenovirus\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__10_Cytomegalovirus\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__11_Epstein Barr Virus\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__12_Human Herpes Virus 6\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__13_Varicella Zoster Virus\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__14_Fungal Infections\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__15_Candidiasis\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__16_Aspergillosis\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__17_Central Venous Catheter Infections\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__18_Febrile Neutropenia\n",
      "d3267c4348d4f0b7ffc70a6dc4e7617044671129__19_Conclusions\n",
      "221adf39ad5e4a3eed686cc72355d462d81c9ac0__0_Introduction\n",
      "221adf39ad5e4a3eed686cc72355d462d81c9ac0__1_Background\n",
      "221adf39ad5e4a3eed686cc72355d462d81c9ac0__2_Built-In Facility Design Features of the USAMRIID Isolation Unit (The \"Slammer\")\n",
      "221adf39ad5e4a3eed686cc72355d462d81c9ac0__3_Special Isolation Unit Schematic by Damien Scogin for Emory University is licensed under a Creative Commons Attribution 4.0 International License\n",
      "221adf39ad5e4a3eed686cc72355d462d81c9ac0__4_Design Features of Containment Units\n",
      "221adf39ad5e4a3eed686cc72355d462d81c9ac0__5_Adapting Design Features for More General Use\n",
      "faa0ed2d0a98f27101df6110e4951618546adab5__0_Understanding spending trends for tuberculosis\n",
      "9d63191505e7cdb2dc1436228923fc97515e2ea1__0_Results\n",
      "9d63191505e7cdb2dc1436228923fc97515e2ea1__1_NIBV infection altered the ileal bacterial microbiome composition in chickens.\n",
      "9d63191505e7cdb2dc1436228923fc97515e2ea1__2_Discussion\n",
      "9d63191505e7cdb2dc1436228923fc97515e2ea1__3_Viral strains. The IBV strain was isolated in Nanchang, China in 2011 and stored by the College of Animal\n",
      "9d63191505e7cdb2dc1436228923fc97515e2ea1__4_Viral load quantification by RT-qPCR.\n",
      "c4970abe88f0048aaf9e1a86e8b7512cde678b46__0_\n",
      "c4970abe88f0048aaf9e1a86e8b7512cde678b46__1_Virus Discoveries\n",
      "68986febd925e135bb10b5d3157e830a728d46d9__0_Abstract:\n",
      "68986febd925e135bb10b5d3157e830a728d46d9__1_INTRODUCTION\n",
      "68986febd925e135bb10b5d3157e830a728d46d9__2_METHODS\n",
      "68986febd925e135bb10b5d3157e830a728d46d9__3_Appendix 1 delineates the list of included studies .\n",
      "68986febd925e135bb10b5d3157e830a728d46d9__4_Exclusion Factors Matrix:\n",
      "68986febd925e135bb10b5d3157e830a728d46d9__5_Adverse outcomes for the most common exclusion criteria: While\n",
      "68986febd925e135bb10b5d3157e830a728d46d9__6_DISCUSSION\n",
      "e8ea66083dbe2dd809d6a3a9c7e9e3848c01691c__0_Introduction\n",
      "e8ea66083dbe2dd809d6a3a9c7e9e3848c01691c__1_Morphology\n",
      "e8ea66083dbe2dd809d6a3a9c7e9e3848c01691c__2_Taxonomy\n",
      "e8ea66083dbe2dd809d6a3a9c7e9e3848c01691c__3_Propagation\n",
      "e8ea66083dbe2dd809d6a3a9c7e9e3848c01691c__4_Host Range\n",
      "e8ea66083dbe2dd809d6a3a9c7e9e3848c01691c__5_Incubation Period\n",
      "e8ea66083dbe2dd809d6a3a9c7e9e3848c01691c__6_Pathology\n",
      "e8ea66083dbe2dd809d6a3a9c7e9e3848c01691c__7_FIP Immune Complex Pathogenesis: A Hypothesis\n",
      "e8ea66083dbe2dd809d6a3a9c7e9e3848c01691c__8_Epizootiology\n",
      "e8ea66083dbe2dd809d6a3a9c7e9e3848c01691c__9_Implications\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__0_INTRODUCTION\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__1_Patients and case definition\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__2_Specimens-swab and serum\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__3_Rapid\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__4_Rapid Test-Anti-adenovirus IgM antibody detection\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__5_Viral culture and identification\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__6_Serotyping of adenoviruses\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__7_Viral serological detection\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__8_Case-control study\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__9_Reference laboratory\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__10_Epidemiology\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__11_Clinical status\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__12_Laboratory test Adenovirus DNA detection\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__13_Anti-adenovirus IgM antibody test\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__14_Morphology of virus\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__15_Paired serum detection\n",
      "4940630ef0d7fedb1071bd36b1290bfa20ad28e7__16_DISCUSSION\n",
      "48cf1bbb3cfc934b4a582052c2a3e77d8b0737dc__0_Introduction\n",
      "48cf1bbb3cfc934b4a582052c2a3e77d8b0737dc__1_Concept introduction take home points\n",
      "48cf1bbb3cfc934b4a582052c2a3e77d8b0737dc__2_Session 1\n",
      "48cf1bbb3cfc934b4a582052c2a3e77d8b0737dc__3_Session 2\n",
      "48cf1bbb3cfc934b4a582052c2a3e77d8b0737dc__4_Concept 2-obstacles and opportunities in pre-clinical development\n",
      "48cf1bbb3cfc934b4a582052c2a3e77d8b0737dc__5_Session 3\n",
      "48cf1bbb3cfc934b4a582052c2a3e77d8b0737dc__6_Session 4\n",
      "48cf1bbb3cfc934b4a582052c2a3e77d8b0737dc__7_Concept 3-moving faster to the clinic\n",
      "48cf1bbb3cfc934b4a582052c2a3e77d8b0737dc__8_Session 5\n",
      "48cf1bbb3cfc934b4a582052c2a3e77d8b0737dc__9_Session 6\n",
      "48cf1bbb3cfc934b4a582052c2a3e77d8b0737dc__10_Session 7\n",
      "48cf1bbb3cfc934b4a582052c2a3e77d8b0737dc__11_Closing group exercise\n",
      "48cf1bbb3cfc934b4a582052c2a3e77d8b0737dc__12_Disclaimer\n",
      "48cf1bbb3cfc934b4a582052c2a3e77d8b0737dc__13_Declaration of Competing Interest\n",
      "f15e87968807693e3f40d6860371641a5f399039__0_Introduction\n",
      "f15e87968807693e3f40d6860371641a5f399039__1_A Constructivist View of (Blood) Risk\n",
      "f15e87968807693e3f40d6860371641a5f399039__2_Methods\n",
      "f15e87968807693e3f40d6860371641a5f399039__3_Total 45\n",
      "f15e87968807693e3f40d6860371641a5f399039__4_Uncertainty as risk: What do we call what just happened?\n",
      "f15e87968807693e3f40d6860371641a5f399039__5_Recall\n",
      "f15e87968807693e3f40d6860371641a5f399039__6_Managing the risk -three conceptions of risk\n",
      "f15e87968807693e3f40d6860371641a5f399039__7_Discussion\n",
      "f15e87968807693e3f40d6860371641a5f399039__8_Conclusions\n",
      "f15e87968807693e3f40d6860371641a5f399039__9_Additional material\n",
      "96a6974fb77fa11673cc35eff659f8ee74151366__0_Pheasants\n",
      "96a6974fb77fa11673cc35eff659f8ee74151366__1_Newcastle disease\n",
      "96a6974fb77fa11673cc35eff659f8ee74151366__2_The disease\n",
      "96a6974fb77fa11673cc35eff659f8ee74151366__3_Vaccination\n",
      "96a6974fb77fa11673cc35eff659f8ee74151366__4_History of Newcastle disease in pheasants\n",
      "96a6974fb77fa11673cc35eff659f8ee74151366__5_Recent outbreaks of Newcastle disease in pheasants\n",
      "96a6974fb77fa11673cc35eff659f8ee74151366__6_Discussion\n",
      "a67712c8a7565893fd5fd1b1fdf91d8c96fa3c72__0_Introduction\n",
      "a67712c8a7565893fd5fd1b1fdf91d8c96fa3c72__1_Materials and methods\n",
      "a67712c8a7565893fd5fd1b1fdf91d8c96fa3c72__2_Experiment I\n",
      "a67712c8a7565893fd5fd1b1fdf91d8c96fa3c72__3_Experiment II\n",
      "a67712c8a7565893fd5fd1b1fdf91d8c96fa3c72__4_Histopathology and immunohistochemistry\n",
      "a67712c8a7565893fd5fd1b1fdf91d8c96fa3c72__5_Bioassays in dogs\n",
      "a67712c8a7565893fd5fd1b1fdf91d8c96fa3c72__6_Coproparasitological examinations\n",
      "a67712c8a7565893fd5fd1b1fdf91d8c96fa3c72__7_Serology\n",
      "a67712c8a7565893fd5fd1b1fdf91d8c96fa3c72__8_DNA extraction and PCR for N. caninum\n",
      "a67712c8a7565893fd5fd1b1fdf91d8c96fa3c72__9_Statistical analysis\n",
      "a67712c8a7565893fd5fd1b1fdf91d8c96fa3c72__10_Experimental infection in poultry\n",
      "a67712c8a7565893fd5fd1b1fdf91d8c96fa3c72__11_Groups\n",
      "a67712c8a7565893fd5fd1b1fdf91d8c96fa3c72__12_Infection in dogs\n",
      "a67712c8a7565893fd5fd1b1fdf91d8c96fa3c72__13_Discussion\n",
      "025ed2caa0ae1ab7f04d3479116e6ed2a334938d__0_\n",
      "025ed2caa0ae1ab7f04d3479116e6ed2a334938d__1_Materials and Methods\n",
      "025ed2caa0ae1ab7f04d3479116e6ed2a334938d__2_Clinical Phenotype\n",
      "025ed2caa0ae1ab7f04d3479116e6ed2a334938d__3_Pathological Phenotype\n",
      "025ed2caa0ae1ab7f04d3479116e6ed2a334938d__4_Genetic Analysis\n",
      "025ed2caa0ae1ab7f04d3479116e6ed2a334938d__5_Discussion\n",
      "4ee48cd8173e2857f9d7ffe80e482619868777d2__0_Hitting the reset button for hospitality research in times of crisis: Covid19 and beyond\n",
      "5bc5b2f9dee2ff454efe226384070d467112e25d__0_Introduction\n",
      "5bc5b2f9dee2ff454efe226384070d467112e25d__1_Proposed 2D graphical representation of DNA sequence\n",
      "5bc5b2f9dee2ff454efe226384070d467112e25d__2_Similarity analysis of DNA sequence\n",
      "5bc5b2f9dee2ff454efe226384070d467112e25d__3_Conclusion\n",
      "76e163b9cca8fa653dc8da3b152e117d4a63bd3f__0_\n",
      "76e163b9cca8fa653dc8da3b152e117d4a63bd3f__1_PREVENTING THE INTERNATIONAL SPREAD OF INFECTIOUS DISEASES\n",
      "76e163b9cca8fa653dc8da3b152e117d4a63bd3f__2_THE USE OF ADVANCED INFORMATION TECHNOLOGY\n",
      "76e163b9cca8fa653dc8da3b152e117d4a63bd3f__3_GLOBAL OUTBREAK ALERT AND RESPONSE: THE SARS EXPERIENCE\n",
      "76e163b9cca8fa653dc8da3b152e117d4a63bd3f__4_GLOBAL INFECTIOUS DISEASE EMERGENCIES: THE FUTURE\n",
      "565f8ca61cbddeac8383aabf4117f8b943348e38__0_Introduction\n",
      "565f8ca61cbddeac8383aabf4117f8b943348e38__1_Importance of timely response\n",
      "565f8ca61cbddeac8383aabf4117f8b943348e38__2_Conclusion\n",
      "1f783a5e029f80516169b19fe6e0dacc1e171f87__0_Abstract: (max 250 words) 26\n",
      "1f783a5e029f80516169b19fe6e0dacc1e171f87__1_Method optimisation to increase proportion of viral reads derived from throat swabs 90\n",
      "1f783a5e029f80516169b19fe6e0dacc1e171f87__2_Consistent retrieval of Hazara virus by Nanopore sequencing 116\n",
      "1f783a5e029f80516169b19fe6e0dacc1e171f87__3_123\n",
      "1f783a5e029f80516169b19fe6e0dacc1e171f87__4_Retrieval and reconstruction of complete influenza genomes from pooled/spiked samples 143\n",
      "1f783a5e029f80516169b19fe6e0dacc1e171f87__5_Detection of Hazara virus internal control 172\n",
      "cb2ac105735bcf360963ae001284f4dd3ed8eff9__0_Introduction\n",
      "cb2ac105735bcf360963ae001284f4dd3ed8eff9__1_RCA in Detection of Micro RNAs (miRNAs)\n",
      "cb2ac105735bcf360963ae001284f4dd3ed8eff9__2_RCA in Detection of Infectious Pathogens\n",
      "cb2ac105735bcf360963ae001284f4dd3ed8eff9__3_RCA in Detection of Single Nucleotide Change in Genes\n",
      "cb2ac105735bcf360963ae001284f4dd3ed8eff9__4_Summary\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__0_Introduction\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__1_Purification of influenza virus\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__2_Proteomic analysis of influenza virions\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__3_Author Summary\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__4_Identification of influenza virus-encoded virion proteins\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__5_Identification of virion-associated cellular proteins\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__6_Confirmation of cellular protein incorporation into influenza virions\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__7_Discussion\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__8_i) Cytoskeletal proteins\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__9_ii) Annexins\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__10_iii) Tetraspanins\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__11_iv) Cyclophilin A\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__12_v) CD59\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__13_vi) Glycolytic enzymes\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__14_Deglycosylation of virion proteins\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__15_Protease treatment of virions\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__16_Protein gel electrophoresis and Immunoblot analysis\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__17_Electron microscopy and Immunogold labeling\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__18_Protein identification from gel slices\n",
      "578d296ec1f6acc01c08cc5a9861bac6d47ddfda__19_MudPIT protein identification\n",
      "0fdbbf54d6dad837566e030e7f3bd211a6ae04f2__0_\n",
      "0fdbbf54d6dad837566e030e7f3bd211a6ae04f2__1_Results\n",
      "0fdbbf54d6dad837566e030e7f3bd211a6ae04f2__2_RH does not inflict systemic and local adverse effects.\n",
      "0fdbbf54d6dad837566e030e7f3bd211a6ae04f2__3_RH works in diverse target organs.\n",
      "0fdbbf54d6dad837566e030e7f3bd211a6ae04f2__4_Discussion\n",
      "0fdbbf54d6dad837566e030e7f3bd211a6ae04f2__5_Methods\n",
      "fb6fa4188f29540516deb7512a960cd8e111e79d__0_Physiologie und Funktion der Thrombozyten\n",
      "fb6fa4188f29540516deb7512a960cd8e111e79d__1_» Auch bei normalen\n",
      "fb6fa4188f29540516deb7512a960cd8e111e79d__2_Ursachen und spezifische Therapieansätze\n",
      "fb6fa4188f29540516deb7512a960cd8e111e79d__3_Verminderte Thrombozytenbildung\n",
      "fb6fa4188f29540516deb7512a960cd8e111e79d__4_Heparininduzierte Thrombopenie\n",
      "fb6fa4188f29540516deb7512a960cd8e111e79d__5_Schlüsselwörter\n",
      "fb6fa4188f29540516deb7512a960cd8e111e79d__6_Keywords\n",
      "c2523638fa7a00218325de3d9839d333a699a4d0__0_\n",
      "c2523638fa7a00218325de3d9839d333a699a4d0__1_Direct approach for molecular detection of SARS-CoV-2\n",
      "c2523638fa7a00218325de3d9839d333a699a4d0__2_Discussion\n",
      "c2523638fa7a00218325de3d9839d333a699a4d0__3_(which was not certified by peer review)\n",
      "c2523638fa7a00218325de3d9839d333a699a4d0__4_Ethical statement\n",
      "fee7feaf68010a92153aaf87123be05375ebd33c__0_Introduction\n",
      "fee7feaf68010a92153aaf87123be05375ebd33c__1_Literature review\n",
      "fee7feaf68010a92153aaf87123be05375ebd33c__2_Proposed model\n",
      "fee7feaf68010a92153aaf87123be05375ebd33c__3_Convolutional neural networks\n",
      "fee7feaf68010a92153aaf87123be05375ebd33c__4_Multi-objective fitness function\n",
      "fee7feaf68010a92153aaf87123be05375ebd33c__5_Multi-objective differential evolution\n",
      "fee7feaf68010a92153aaf87123be05375ebd33c__6_A. Mutation operation\n",
      "fee7feaf68010a92153aaf87123be05375ebd33c__7_C. Selection operation\n",
      "fee7feaf68010a92153aaf87123be05375ebd33c__8_Performance analysis\n",
      "fee7feaf68010a92153aaf87123be05375ebd33c__9_COVID-19 chest CT images dataset\n",
      "fee7feaf68010a92153aaf87123be05375ebd33c__10_Quantitative analysis\n",
      "fee7feaf68010a92153aaf87123be05375ebd33c__11_Conclusion\n",
      "fee7feaf68010a92153aaf87123be05375ebd33c__12_Compliance with ethical standards\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__0_Introduction\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__1_ANDV N forms cytoplasmic inclusions and localizes to intracellular vesicular membranes\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__2_ANDV N colocalizes with Rabs of the recycling endosome\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__3_ANDV N colocalizes with endogenous Rab8 and Rab11 during infection\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__4_Dominant negative and constitutively active forms of Rab11 have altered levels of colocalization with ANDV N during infection\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__5_siRNA-mediated downregulation of Rab8 and Rab11 block ANDV secretion\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__6_Discussion\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__7_Reagents and antibodies\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__8_ANDV infection\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__9_Immuno-electron microscopy\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__10_Immune TCID 50 assay\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__11_Plasmids\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__12_DNA transfections\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__13_Immunofluorescence confocal microscopy\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__14_Volocity quantitation of confocal microscopy\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__15_Small interfering RNA transfection\n",
      "1f2490dbadb8402fc324520f92c4868bc4f53f3a__16_SDS-PAGE and western blotting\n",
      "92a8c04a0201a6d46875ff3b312dd72c9e12a7d1__0_Introduction to vanadium: a general overview\n",
      "92a8c04a0201a6d46875ff3b312dd72c9e12a7d1__1_Obtainment and industrial applications of vanadium\n",
      "92a8c04a0201a6d46875ff3b312dd72c9e12a7d1__2_Chemical speciation with (non)essential aminoacids\n",
      "92a8c04a0201a6d46875ff3b312dd72c9e12a7d1__3_Table 2\n",
      "92a8c04a0201a6d46875ff3b312dd72c9e12a7d1__4_Table 4\n",
      "92a8c04a0201a6d46875ff3b312dd72c9e12a7d1__5_Complex\n",
      "92a8c04a0201a6d46875ff3b312dd72c9e12a7d1__6_Bioinorganic implication and application of vanadium complexes\n",
      "92a8c04a0201a6d46875ff3b312dd72c9e12a7d1__7_Perspectives and conclusions\n",
      "92a8c04a0201a6d46875ff3b312dd72c9e12a7d1__8_Dedicatory\n",
      "506764ffd8140a103b330aa1dbb12d4b921ffda2__0_Background\n",
      "506764ffd8140a103b330aa1dbb12d4b921ffda2__1_Establishment of singleplex xMAP detection for ILTV and IBV\n",
      "506764ffd8140a103b330aa1dbb12d4b921ffda2__2_Establishment of duplex xMAP for simultaneous detection of ILTV and IBV\n",
      "506764ffd8140a103b330aa1dbb12d4b921ffda2__3_Determination of threshold\n",
      "506764ffd8140a103b330aa1dbb12d4b921ffda2__4_Specificity of xMAP assay for ILTV and IBV\n",
      "506764ffd8140a103b330aa1dbb12d4b921ffda2__5_Repeatability of xMAP assay for ILTV and IBV\n",
      "506764ffd8140a103b330aa1dbb12d4b921ffda2__6_Discussion\n",
      "506764ffd8140a103b330aa1dbb12d4b921ffda2__7_Conclusions\n",
      "506764ffd8140a103b330aa1dbb12d4b921ffda2__8_Antigens and sera\n",
      "506764ffd8140a103b330aa1dbb12d4b921ffda2__9_Coupling of proteins to fluorescent microspheres\n",
      "506764ffd8140a103b330aa1dbb12d4b921ffda2__10_Methods for bead-based xMAP technology\n",
      "506764ffd8140a103b330aa1dbb12d4b921ffda2__11_ELISA used for comparison\n",
      "b26c952513bff2bb745a0852f03a9cf4354e9138__0_INTRODUCTION\n",
      "b26c952513bff2bb745a0852f03a9cf4354e9138__1_Cells and transfection\n",
      "b26c952513bff2bb745a0852f03a9cf4354e9138__2_Electrophysiology\n",
      "b26c952513bff2bb745a0852f03a9cf4354e9138__3_Virus release assay\n",
      "b26c952513bff2bb745a0852f03a9cf4354e9138__4_RESULTS AND DISCUSSION\n",
      "b26c952513bff2bb745a0852f03a9cf4354e9138__5_CONCLUSIONS\n",
      "b26c952513bff2bb745a0852f03a9cf4354e9138__6_SUPPORTING MATERIAL\n",
      "6fffd29da38651e79d21fe3d018164d10d336653__0_Introduction\n",
      "6fffd29da38651e79d21fe3d018164d10d336653__1_Methods\n",
      "6fffd29da38651e79d21fe3d018164d10d336653__2_Results\n",
      "6fffd29da38651e79d21fe3d018164d10d336653__3_Discussion\n",
      "6fffd29da38651e79d21fe3d018164d10d336653__4_Conclusions\n",
      "6fffd29da38651e79d21fe3d018164d10d336653__5_All authors have completed the Unified Competing Interest form (available on request\n",
      "6fffd29da38651e79d21fe3d018164d10d336653__6_CONTRIBUTORSHIP\n",
      "6fffd29da38651e79d21fe3d018164d10d336653__7_DATA SHARING STATEMENT\n",
      "498c5814ddb98bb877b80e1b0ba51015f4fcb270__0_Introduction\n",
      "498c5814ddb98bb877b80e1b0ba51015f4fcb270__1_HSR impacts on tourism: An overview\n",
      "498c5814ddb98bb877b80e1b0ba51015f4fcb270__2_Tourism in China and Spain\n",
      "498c5814ddb98bb877b80e1b0ba51015f4fcb270__3_The model applied to the Spanish case study\n",
      "498c5814ddb98bb877b80e1b0ba51015f4fcb270__4_Study at the local level: Madrid-Toledo\n",
      "498c5814ddb98bb877b80e1b0ba51015f4fcb270__5_Conclusions\n",
      "2891c813ce4dd156d5f56736db5a10a2065c9167__0_INTRODUCTION\n",
      "2891c813ce4dd156d5f56736db5a10a2065c9167__1_ACTIVE TARGETING STRATEGIES\n",
      "2891c813ce4dd156d5f56736db5a10a2065c9167__2_Nanoparticles\n",
      "2891c813ce4dd156d5f56736db5a10a2065c9167__3_Dendrimers\n",
      "2891c813ce4dd156d5f56736db5a10a2065c9167__4_Carbon Nanotubes\n",
      "2891c813ce4dd156d5f56736db5a10a2065c9167__5_CHALLENGES AND FUTURE DEVELOPMENTS\n",
      "2891c813ce4dd156d5f56736db5a10a2065c9167__6_CONCLUSION\n",
      "2891c813ce4dd156d5f56736db5a10a2065c9167__7_CONFLICT OF INTEREST\n",
      "77ec85bda85ecd0454f90ee851186d8f4396a2da__0_\n",
      "77ec85bda85ecd0454f90ee851186d8f4396a2da__1_Training/Education Pathway\n",
      "77ec85bda85ecd0454f90ee851186d8f4396a2da__2_The Diverse Practice Settings of ID Specialists\n",
      "77ec85bda85ecd0454f90ee851186d8f4396a2da__3_Preventing and Treating Infectious Diseases in the Community\n",
      "77ec85bda85ecd0454f90ee851186d8f4396a2da__4_Infection Prevention and Control in Healthcare Settings\n",
      "77ec85bda85ecd0454f90ee851186d8f4396a2da__5_Antimicrobial Stewardship\n",
      "77ec85bda85ecd0454f90ee851186d8f4396a2da__6_Emergency Preparedness and Response\n",
      "77ec85bda85ecd0454f90ee851186d8f4396a2da__7_ID PHYSICIANS AS LEADERS IN GLOBAL HEALTH\n",
      "77ec85bda85ecd0454f90ee851186d8f4396a2da__8_WORKING TOWARD APPROPRIATE COMPENSATION FOR ID PHYSICIANS\n",
      "77ec85bda85ecd0454f90ee851186d8f4396a2da__9_RECOMMENDATIONS\n",
      "79394af107ef431da927578153a14ce7d29d22e1__0_Introduction\n",
      "79394af107ef431da927578153a14ce7d29d22e1__1_Patients and methods\n",
      "79394af107ef431da927578153a14ce7d29d22e1__2_Results and discussion\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__0_Introduction\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__1_Heterologous Immunity\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__2_Cytokine-induced activation of Tm cells. TCR engages antigen of previously encountered pathogens\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__3_Cellular/humoral cross-reactivity\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__4_Heterologous immunity between respiratory viruses Coronaviruses (CoV)\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__5_In uenza virus (IV)\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__6_Respiratory syncytial virus (RSV)\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__7_Rhinovirus (RV)\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__8_Heterologous immunity between respiratory and other viruses Epstein-Barr virus (EBV)\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__9_Hepatitis C virus (HCV)\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__10_Human immunode ciency virus (HIV)\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__11_Human papilloma viruses (HPV)\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__12_Autoimmunity\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__13_Guillain-Barré syndrome (GBS)\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__14_GBS [106] and this is best described for Campylobacter jejuni.\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__15_Narcolepsy\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__16_Other neurologic/neuropsychiatric disorders\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__17_Celiac disease (CD)\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__18_Myocarditis\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__19_Sjögren's syndrome (SS)\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__20_Type 1 diabetes mellitus (T1DM)\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__21_Asthma/allergy\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__22_Conclusions and Outlook\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__23_Glossary Acute disseminated encephalomyelitis (ADEM):\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__24_Celiac disease (CD):\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__25_Guillain-Barré syndrome (GBS):\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__26_Fig. 2:\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__27_Influenza\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__28_Heterologous immunity (HI):\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__29_Myocarditis:\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__30_Type 1 diabetes mellitus (T1DM):\n",
      "86b03081a859409f85e82252c419fd7a4dc7d5f3__31_Chrysanthi Skevaki, MD PhD\n",
      "08b8071e86c9e39314fad083588214ce40b33ee7__0_Background\n",
      "08b8071e86c9e39314fad083588214ce40b33ee7__1_Patients\n",
      "08b8071e86c9e39314fad083588214ce40b33ee7__2_Data collection\n",
      "08b8071e86c9e39314fad083588214ce40b33ee7__3_Statistical analysis\n",
      "08b8071e86c9e39314fad083588214ce40b33ee7__4_Clinical characteristics of COVID-19 patients\n",
      "08b8071e86c9e39314fad083588214ce40b33ee7__5_Baseline characteristics of laboratory tests in COVID-19 patients\n",
      "08b8071e86c9e39314fad083588214ce40b33ee7__6_Non-respiratory system injury with COVID-19\n",
      "08b8071e86c9e39314fad083588214ce40b33ee7__7_Typical CT images\n",
      "08b8071e86c9e39314fad083588214ce40b33ee7__8_Main treatment measures of COVID-19 patients during hospitalization\n",
      "08b8071e86c9e39314fad083588214ce40b33ee7__9_Discussion\n",
      "b8e9fcc34571f9c29e04f9feb34197250556cb9a__0_Background\n",
      "b8e9fcc34571f9c29e04f9feb34197250556cb9a__1_Vaccines\n",
      "b8e9fcc34571f9c29e04f9feb34197250556cb9a__2_Immunizations\n",
      "b8e9fcc34571f9c29e04f9feb34197250556cb9a__3_ELISA\n",
      "b8e9fcc34571f9c29e04f9feb34197250556cb9a__4_Cell culture\n",
      "b8e9fcc34571f9c29e04f9feb34197250556cb9a__5_Flow cytometry\n",
      "b8e9fcc34571f9c29e04f9feb34197250556cb9a__6_Confocal microscopy\n",
      "b8e9fcc34571f9c29e04f9feb34197250556cb9a__7_Electron microscopy\n",
      "b8e9fcc34571f9c29e04f9feb34197250556cb9a__8_Complement analysis\n",
      "b8e9fcc34571f9c29e04f9feb34197250556cb9a__9_Immunofluorescence assay\n",
      "b8e9fcc34571f9c29e04f9feb34197250556cb9a__10_Results\n",
      "b8e9fcc34571f9c29e04f9feb34197250556cb9a__11_Protective adaptive immunity may be the result of delayed antigen processing and presentation of SAPN to CD8+ T-lymphocytes\n",
      "b8e9fcc34571f9c29e04f9feb34197250556cb9a__12_Discussion\n",
      "bba3e6c3357196e852779f67aafcf9169f86f96a__0_Introduction\n",
      "bba3e6c3357196e852779f67aafcf9169f86f96a__1_Cells and virus\n",
      "bba3e6c3357196e852779f67aafcf9169f86f96a__2_Focus formation assay (FFA)\n",
      "bba3e6c3357196e852779f67aafcf9169f86f96a__3_Plaque assay\n",
      "bba3e6c3357196e852779f67aafcf9169f86f96a__4_FFA and plaque assay of field-collected specimens\n",
      "bba3e6c3357196e852779f67aafcf9169f86f96a__5_Statistical analysis\n",
      "bba3e6c3357196e852779f67aafcf9169f86f96a__6_Immunostaining of cells infected with PEDV\n",
      "bba3e6c3357196e852779f67aafcf9169f86f96a__7_Correlation of dilution and virus titer in FFA\n",
      "bba3e6c3357196e852779f67aafcf9169f86f96a__8_Titration of KPEDV-9 by FFA and plaque assay\n",
      "bba3e6c3357196e852779f67aafcf9169f86f96a__9_FFA versus plaque assay of cell adapted and PEDV specimens collected in the field\n",
      "bba3e6c3357196e852779f67aafcf9169f86f96a__10_Discussion\n",
      "092193fe026d59729062786d8f576b553e11a97d__0_Background\n",
      "092193fe026d59729062786d8f576b553e11a97d__1_Results\n",
      "092193fe026d59729062786d8f576b553e11a97d__2_Discussion\n",
      "092193fe026d59729062786d8f576b553e11a97d__3_Figure 14 Log fold changes of the expression level (y axis) of the MERS-CoV infected genes (x axis) corresponding to Mock in different time points.\n",
      "092193fe026d59729062786d8f576b553e11a97d__4_Personalised medicine: guidelines for predicting comorbidities\n",
      "092193fe026d59729062786d8f576b553e11a97d__5_Conclusion\n",
      "092193fe026d59729062786d8f576b553e11a97d__6_Data\n",
      "092193fe026d59729062786d8f576b553e11a97d__7_Methods\n",
      "d4ea57e72c426571255c1c45861db4c6b46b95d5__0_Introduction\n",
      "d4ea57e72c426571255c1c45861db4c6b46b95d5__1_Animals\n",
      "d4ea57e72c426571255c1c45861db4c6b46b95d5__2_In vivo treatment protocol\n",
      "d4ea57e72c426571255c1c45861db4c6b46b95d5__3_Histopathological, biochemical and immunohistochemical analyses\n",
      "d4ea57e72c426571255c1c45861db4c6b46b95d5__4_RNA isolation and RT-qPCR\n",
      "d4ea57e72c426571255c1c45861db4c6b46b95d5__5_Statistical analysis\n",
      "d4ea57e72c426571255c1c45861db4c6b46b95d5__6_Poly(I:C) administration induced acute liver injury in mice with expression of IL-33 in liver\n",
      "d4ea57e72c426571255c1c45861db4c6b46b95d5__7_NKT cells deficiency protected mice against Poly(I:C)induced liver injury but up-regulated hepatocytespecific IL-33 expression\n",
      "d4ea57e72c426571255c1c45861db4c6b46b95d5__8_MHV3 infection in mice up-regulated pro-inflammatory cytokine expression in liver\n",
      "d4ea57e72c426571255c1c45861db4c6b46b95d5__9_Discussion\n",
      "0eecd976f6ef739bc946d14dd40ea94676055f45__0_\n",
      "0eecd976f6ef739bc946d14dd40ea94676055f45__1_3) Drugs for patients with cardiovascular disease could interfere\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__0_Introduction\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__1_Dimerization of SARS-CoV 3CL pro\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__2_Structure of SARS-CoV 3CL pro\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__3_Inhibitors of SARS-CoV 3CL pro\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__4_From High-Throughput Screening\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__5_AG7088 Analogues\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__6_Anilides\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__7_Keto-Glutamine Analogues\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__8_Glutaminyl Fluoromethyl Ketones\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__9_Aziridinyl Peptide\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__10_Aza-peptide Epoxide\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__11_Miscellaneous\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__12_Isatin\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__13_Metal-Conjugated Inhibitors\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__14_Aryl Boronic Compounds\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__15_Etacrynic Acid\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__16_Benzotriazoles\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__17_Glycopeptides\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__18_Phenylsulfonyl Pyridine\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__19_Oxadiazol-imidazole\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__20_N-phenyl-2-(pyrimidinylthio)acetamide\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__21_Cinanserin\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__22_Calamidazolium Compound\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__23_5-Benzylidene-4-oxo-1,3-thiazolidin Analogues\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__24_Engineering of SARS-CoV 3CL pro\n",
      "6e2b653fd92d873f33a2d7ac6523068d0c8d54c2__25_Conclusions\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__0_Introduction\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__1_Study area\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__2_Cases and controls\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__3_Interviews\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__4_Questionnaire\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__5_Faecal specimen collection\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__6_For non-hospitalized cases\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__7_Microbiological analysis\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__8_Parasitology\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__9_Virology\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__10_Drinking water quality evaluation of private wells\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__11_Indicator organisms in drinking water\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__12_Bacterial pathogens in drinking water\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__13_Water distribution systems\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__14_Livestock density\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__15_Statistical analysis\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__16_Ethics\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__17_Results\n",
      "2cb83e2e65791dcf1d5bfb9ca54ce05c4b356970__18_Discussion\n",
      "1e211bc0033ee7ea3f43bffa37f1b930c76ac188__0_\n",
      "1e211bc0033ee7ea3f43bffa37f1b930c76ac188__1_It's not the virus\n",
      "1e211bc0033ee7ea3f43bffa37f1b930c76ac188__2_Novel therapeutics\n",
      "1e211bc0033ee7ea3f43bffa37f1b930c76ac188__3_What can be done now?\n",
      "1e211bc0033ee7ea3f43bffa37f1b930c76ac188__4_Looking to the future\n",
      "f55d65e01d6305f413482de04d3a269287fe6591__0_Professional Autonomy of the Resident Doctor:\n",
      "de27cd796018157d05dcccbc3dd5362cfca9f48b__0_\n",
      "de27cd796018157d05dcccbc3dd5362cfca9f48b__1_Challenges of Interdisciplinary Literature Search and the Vertical Search Engine LIVIVO\n",
      "de27cd796018157d05dcccbc3dd5362cfca9f48b__2_LIVIVO's Service Oriented Architecture Provides Semantic Content\n",
      "de27cd796018157d05dcccbc3dd5362cfca9f48b__3_The Web Interface and Portal Software of LIVIVO\n",
      "de27cd796018157d05dcccbc3dd5362cfca9f48b__4_AUTHOR:(zoonoses AND (virus OR bacteria)) bf2\n",
      "de27cd796018157d05dcccbc3dd5362cfca9f48b__5_Using LIVIVO as a Provider for Search Services of Third Parties\n",
      "de27cd796018157d05dcccbc3dd5362cfca9f48b__6_The ZB MED Knowledge Environment (KE)\n",
      "de27cd796018157d05dcccbc3dd5362cfca9f48b__7_Mapping of Life Science Ontologies\n",
      "de27cd796018157d05dcccbc3dd5362cfca9f48b__8_Natural Language Processing in LIVIVO\n",
      "de27cd796018157d05dcccbc3dd5362cfca9f48b__9_Conclusion and Outlook\n",
      "c67241e8bd631e1c675b7afcc2dafd85289455a1__0_\n",
      "c67241e8bd631e1c675b7afcc2dafd85289455a1__1_Compliance with ethical standards\n",
      "5f7416cf9facc4058b178a28ba01a6c148597243__0_1.\n",
      "5f7416cf9facc4058b178a28ba01a6c148597243__1_2.\n",
      "5f7416cf9facc4058b178a28ba01a6c148597243__2_3.\n",
      "5f7416cf9facc4058b178a28ba01a6c148597243__3_Conflicts of interest\n",
      "8be9fb2ea6f60cdc3b913295e1157ba1bafe3a64__0_\n",
      "8be9fb2ea6f60cdc3b913295e1157ba1bafe3a64__1_MATERIALS AND METHODS\n",
      "8be9fb2ea6f60cdc3b913295e1157ba1bafe3a64__2_N-Terminal 20 Amino Acids of P45O(M1) Are Sufficient\n",
      "8be9fb2ea6f60cdc3b913295e1157ba1bafe3a64__3_Sec/Ml Sec/Ml-Sec/Ml\n",
      "8be9fb2ea6f60cdc3b913295e1157ba1bafe3a64__4_DISCUSSION\n",
      "57a9f125e6ba8abd8f6daacd6b015cc07eed3ad6__0_Introduction\n",
      "57a9f125e6ba8abd8f6daacd6b015cc07eed3ad6__1_Ensure the supply of medicines and resolve medication shortages\n",
      "57a9f125e6ba8abd8f6daacd6b015cc07eed3ad6__2_Ensure pharmacy operation efficiency through adjusting pharmacist workflow\n",
      "57a9f125e6ba8abd8f6daacd6b015cc07eed3ad6__3_Provide direct pharmaceutical care at cabin hospitals\n",
      "57a9f125e6ba8abd8f6daacd6b015cc07eed3ad6__4_Conclusion\n",
      "408f6a3a417abfbb2fb12e593bd84eca24d9dc35__0_\n",
      "408f6a3a417abfbb2fb12e593bd84eca24d9dc35__1_Limited transcription starts\n",
      "5c7e499584fc1b7710c086393cf9cfd1b5aa0f9a__0_\n",
      "5c7e499584fc1b7710c086393cf9cfd1b5aa0f9a__1_Introduction\n",
      "5c7e499584fc1b7710c086393cf9cfd1b5aa0f9a__2_Microbiology and follow-up\n",
      "5c7e499584fc1b7710c086393cf9cfd1b5aa0f9a__3_Statistical analysis\n",
      "5c7e499584fc1b7710c086393cf9cfd1b5aa0f9a__4_Results\n",
      "5c7e499584fc1b7710c086393cf9cfd1b5aa0f9a__5_Discussion\n",
      "dd06d652faa377823b5ed012cdeea68dbdbb7794__0_Introduction\n",
      "dd06d652faa377823b5ed012cdeea68dbdbb7794__1_Prawn samples\n",
      "dd06d652faa377823b5ed012cdeea68dbdbb7794__2_RNA isolation\n",
      "dd06d652faa377823b5ed012cdeea68dbdbb7794__3_Primers\n",
      "dd06d652faa377823b5ed012cdeea68dbdbb7794__4_RT-PCR\n",
      "dd06d652faa377823b5ed012cdeea68dbdbb7794__5_Differential nested PCRs\n",
      "dd06d652faa377823b5ed012cdeea68dbdbb7794__6_Sequencing\n",
      "dd06d652faa377823b5ed012cdeea68dbdbb7794__7_Selection of generic and specific GAV and YHV primers\n",
      "dd06d652faa377823b5ed012cdeea68dbdbb7794__8_RT-PCR to detect GAV or YHV\n",
      "dd06d652faa377823b5ed012cdeea68dbdbb7794__9_Nested PCRs to differentiate GAV from YHV\n",
      "dd06d652faa377823b5ed012cdeea68dbdbb7794__10_Sensitivity of the RT-nested PCR\n",
      "dd06d652faa377823b5ed012cdeea68dbdbb7794__11_RT-nested PCR differentiation of field samples of GAV and YHV\n",
      "dd06d652faa377823b5ed012cdeea68dbdbb7794__12_PCR co-detection of GAV and YHV RNA mixed at various ratios\n",
      "dd06d652faa377823b5ed012cdeea68dbdbb7794__13_Sequence differences among GAV and YHV RNA samples\n",
      "dd06d652faa377823b5ed012cdeea68dbdbb7794__14_Discussion\n",
      "7f0a661112f0919b1aacfd6e08ccbe0e029551ab__0_Introduction\n",
      "7f0a661112f0919b1aacfd6e08ccbe0e029551ab__1_Animals, light entrainment\n",
      "7f0a661112f0919b1aacfd6e08ccbe0e029551ab__2_Food measurement\n",
      "7f0a661112f0919b1aacfd6e08ccbe0e029551ab__3_Morphology and histometrics\n",
      "7f0a661112f0919b1aacfd6e08ccbe0e029551ab__4_Enzyme assays\n",
      "7f0a661112f0919b1aacfd6e08ccbe0e029551ab__5_Lingual lipase assay\n",
      "7f0a661112f0919b1aacfd6e08ccbe0e029551ab__6_Amylase assay\n",
      "7f0a661112f0919b1aacfd6e08ccbe0e029551ab__7_Chemicals\n",
      "7f0a661112f0919b1aacfd6e08ccbe0e029551ab__8_Statistics\n",
      "7f0a661112f0919b1aacfd6e08ccbe0e029551ab__9_Histometric measurement\n",
      "7f0a661112f0919b1aacfd6e08ccbe0e029551ab__10_Morphology\n",
      "7f0a661112f0919b1aacfd6e08ccbe0e029551ab__11_Discussion\n",
      "4ce793c46f46daca43110c4606571db12d3e5de5__0_INTRODUCTION\n",
      "4ce793c46f46daca43110c4606571db12d3e5de5__1_DEVELOPING A RESEARCH RESPONSE\n",
      "4ce793c46f46daca43110c4606571db12d3e5de5__2_CLINICAL RESEARCH AND THERAPEUTICS\n",
      "4ce793c46f46daca43110c4606571db12d3e5de5__3_DIAGNOSTICS\n",
      "4ce793c46f46daca43110c4606571db12d3e5de5__4_IMMUNE RESPONSES AND VACCINES\n",
      "4ce793c46f46daca43110c4606571db12d3e5de5__5_ECOLOGY AND EPIDEMIOLOGY\n",
      "4ce793c46f46daca43110c4606571db12d3e5de5__6_THE FUTURE\n",
      "4ce793c46f46daca43110c4606571db12d3e5de5__7_RESEARCH DIRECTIONS\n",
      "14171388b33b3d1a296b94fee10c535c54f8c510__0_\n",
      "14171388b33b3d1a296b94fee10c535c54f8c510__1_Raw materials\n",
      "14171388b33b3d1a296b94fee10c535c54f8c510__2_Preparation of immunoglobulins\n",
      "14171388b33b3d1a296b94fee10c535c54f8c510__3_Analytical assay\n",
      "14171388b33b3d1a296b94fee10c535c54f8c510__4_Analysis of SARS convalescent plasma\n",
      "14171388b33b3d1a296b94fee10c535c54f8c510__5_Process development\n",
      "14171388b33b3d1a296b94fee10c535c54f8c510__6_Preparation of SARS hyperimmune globulins\n",
      "14171388b33b3d1a296b94fee10c535c54f8c510__7_DISCUSSION\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__0_Introduction\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__1_MHV infection of CXCL9 −/− and RAG1 −/− mice\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__2_Construction and characterization of recombinant viruses\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__3_Intracerebral inoculation of RAG1 −/− mice with recombinant viruses\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__4_NK cells are protective in response to MHV infection of the liver\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__5_Infection of either CXCL9+/+ or CXCL9−/− mice with MHV-CXCL9 results in protection from disease\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__6_Discussion\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__7_Viruses and cells\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__8_Mice\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__9_Plasmid constructs\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__10_RNA synthesis and viral recombination\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__11_Screening and analysis of putative recombinants\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__12_Mononuclear cell isolation and flow cytometry\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__13_NK cell depletion\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__14_Pathology and immunohistochemistry\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__15_ELISA\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__16_Statistical Analysis\n",
      "d226ac5e0d89df824c61ed9680bfac9927be7680__17_Figure 5. NK cell infiltration into brains and livers\n",
      "121d6115779d455aa909ca67331aa248b6ebf7f9__0_INTRODUCTION\n",
      "121d6115779d455aa909ca67331aa248b6ebf7f9__1_MATERIALS AND METHODS\n",
      "121d6115779d455aa909ca67331aa248b6ebf7f9__2_PCR and Direct sequencing of the PCR products\n",
      "121d6115779d455aa909ca67331aa248b6ebf7f9__3_Insertion of the transcription consensus sequence at different locations in an MHV DI RNA\n",
      "121d6115779d455aa909ca67331aa248b6ebf7f9__4_DISCUSSION\n",
      "ae8c759fe82750edd66adb5e87e2ee44cb73c419__0_Background\n",
      "ae8c759fe82750edd66adb5e87e2ee44cb73c419__1_Results and discussion\n",
      "ae8c759fe82750edd66adb5e87e2ee44cb73c419__2_Conclusions\n",
      "20b7fbbaba87245badca7f04313eacf8fb07f698__0_\n",
      "629b679c1372ac0d4e24c5213edbebe94d5ab877__0_\n",
      "2481c46ab43d983df5cac4bcccf258e14f6e148a__0_Introduction\n",
      "2481c46ab43d983df5cac4bcccf258e14f6e148a__1_Study system\n",
      "2481c46ab43d983df5cac4bcccf258e14f6e148a__2_Pollen sampling and identification\n",
      "2481c46ab43d983df5cac4bcccf258e14f6e148a__3_Bumble bee sampling and identification\n",
      "2481c46ab43d983df5cac4bcccf258e14f6e148a__4_B. terrestris pathogen screening\n",
      "2481c46ab43d983df5cac4bcccf258e14f6e148a__5_Statistical analyses\n",
      "2481c46ab43d983df5cac4bcccf258e14f6e148a__6_Permeability of strawberry cropping systems\n",
      "2481c46ab43d983df5cac4bcccf258e14f6e148a__7_Pathogen prevalence in commercial hives\n",
      "2481c46ab43d983df5cac4bcccf258e14f6e148a__8_Trends across sites in pathogen prevalence\n",
      "2481c46ab43d983df5cac4bcccf258e14f6e148a__9_Trends across individuals in probability of infection\n",
      "2481c46ab43d983df5cac4bcccf258e14f6e148a__10_Discussion\n",
      "2481c46ab43d983df5cac4bcccf258e14f6e148a__11_Pathogen spillover in Bombus\n",
      "2481c46ab43d983df5cac4bcccf258e14f6e148a__12_Within-host multiparasitic interactions\n",
      "2481c46ab43d983df5cac4bcccf258e14f6e148a__13_Study limitations\n",
      "2481c46ab43d983df5cac4bcccf258e14f6e148a__14_Recommendations for commercial bumble bee management and policy\n",
      "2f228723f51b8f2f4c33b8dd11866e435da5f5c9__0_INTRODUCTION\n",
      "2f228723f51b8f2f4c33b8dd11866e435da5f5c9__1_MATERIALS AND METHODS\n",
      "2f228723f51b8f2f4c33b8dd11866e435da5f5c9__2_The HCoV-229E nsp3-Associated X Domain Is a Phosphatase That Converts\n",
      "2f228723f51b8f2f4c33b8dd11866e435da5f5c9__3_Appr-1\"-pase Activity of the SARS-CoV X Domain\n",
      "a4f480324c28ace49dc741533215d1b100af0c74__0_Neue und seltene pneumotrope Viren\n",
      "a4f480324c28ace49dc741533215d1b100af0c74__1_Humanes Metapneumovirus\n",
      "a4f480324c28ace49dc741533215d1b100af0c74__2_Neue humane Polyomaviren\n",
      "a4f480324c28ace49dc741533215d1b100af0c74__3_New and rare pneumotropic viruses Abstract\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__0_INTRODUCTION\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__1_An Augmented Compartment Model to Estimate Epidemic Dynamics Incorporating Testing Bias\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__2_(which was not certified by peer review)\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__3_Testing Bias Strongly Affects the Direct Estimation of Infection Rate\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__4_Testing Bias Influence True Fatality Rates and Case Fatality Rates in Time-Dependent Manner\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__5_Randomized Unbiased Serological Sampling of Widely Infected Population is Necessary to Determine True Fatality Rates\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__6_Continuous Sampling of a Selected Cohort can Provide Useful Dynamics on Acquirement of Immunity\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__7_DISCUSSION\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__8_SIRD model with disease stratification into high and low symptomatic populations\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__9_Augmented SIRD model with testing\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__10_2.\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__11_3.\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__12_4.\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__13_Estimates of infection and death rates\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__14_Calculating the variance of estimates for unbiased random sampling\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__15_DECLARATION\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__16_Biography of First Author\n",
      "4a035741d71bf5dd8457f2e69c574fd9e4441134__17_Figure 2. Influence of testing (sampling) bias for symptomatic patients is high for estimation of infection rate measured by active-viral tests, but mitigated in serological tests for acquired immunity. (A)\n",
      "5dc3d55d6a714ced0f04b70fa1f0e0c9483b82b6__0_\n",
      "a5697db5f79b287fc317eee1ab84f5100e68ecdb__0_\n",
      "a5697db5f79b287fc317eee1ab84f5100e68ecdb__1_CONCLUSIONS:\n",
      "a5697db5f79b287fc317eee1ab84f5100e68ecdb__2_INTRODUCTION\n",
      "a5697db5f79b287fc317eee1ab84f5100e68ecdb__3_METHODS\n",
      "a5697db5f79b287fc317eee1ab84f5100e68ecdb__4_Eligible data\n",
      "a5697db5f79b287fc317eee1ab84f5100e68ecdb__5_Death with age stratification\n",
      "a5697db5f79b287fc317eee1ab84f5100e68ecdb__6_Relative risk of dying with COVID-19 for individuals <65 years old versus older individuals\n",
      "a5697db5f79b287fc317eee1ab84f5100e68ecdb__7_Absolute risk of death with COVID-19 at the population level\n",
      "a5697db5f79b287fc317eee1ab84f5100e68ecdb__8_COVID-19 deaths in individuals <65 years old without underlying conditions\n",
      "a5697db5f79b287fc317eee1ab84f5100e68ecdb__9_The evaluation of data from 8 countries and 4 US locations that are epicenters of the COVID-19\n",
      "a5697db5f79b287fc317eee1ab84f5100e68ecdb__10_Acknowledgments:\n",
      "a5697db5f79b287fc317eee1ab84f5100e68ecdb__11_Conflicts of interest: none\n",
      "ab26f03fd219a3da07426f56fecfcc0a20cb0a4e__0_Stranded whole transcriptome library preparation and sequencing of IFN samples\n",
      "ab26f03fd219a3da07426f56fecfcc0a20cb0a4e__1_Alignments of reads to the mouse reference genome.\n",
      "ab26f03fd219a3da07426f56fecfcc0a20cb0a4e__2_Alignments of reads to viral genome\n",
      "ab26f03fd219a3da07426f56fecfcc0a20cb0a4e__3_MONOCLdb modules functional description\n",
      "8fce6a2e125c3310b80fa368957aa43648e76235__0_\n",
      "8fce6a2e125c3310b80fa368957aa43648e76235__1_Cmss pathology and minubtolog\n",
      "8fce6a2e125c3310b80fa368957aa43648e76235__2_t listopa fhology and immunohistochemistp\n",
      "8fce6a2e125c3310b80fa368957aa43648e76235__3_7iansmission rlrctmn mimscopy (1 t:M)\n",
      "8fce6a2e125c3310b80fa368957aa43648e76235__4_Clinical q n s\n",
      "8fce6a2e125c3310b80fa368957aa43648e76235__5_Cmss patholog and nrzmbiohg\n",
      "8fce6a2e125c3310b80fa368957aa43648e76235__6_Cu!fno.\n",
      "8fce6a2e125c3310b80fa368957aa43648e76235__7_TI:M\n",
      "8fce6a2e125c3310b80fa368957aa43648e76235__8_Discussion\n",
      "0c83fb7b5413cd36d8ca958f15e7640636c8e730__0_Introduction\n",
      "0c83fb7b5413cd36d8ca958f15e7640636c8e730__1_Materials and Methods\n",
      "0c83fb7b5413cd36d8ca958f15e7640636c8e730__2_Samples\n",
      "0c83fb7b5413cd36d8ca958f15e7640636c8e730__3_Virus isolation and titration\n",
      "0c83fb7b5413cd36d8ca958f15e7640636c8e730__4_Immunofluorescence assay\n",
      "0c83fb7b5413cd36d8ca958f15e7640636c8e730__5_Reverse transcription-polymerase chain reaction\n",
      "0c83fb7b5413cd36d8ca958f15e7640636c8e730__6_Rapid kit\n",
      "0c83fb7b5413cd36d8ca958f15e7640636c8e730__7_Electron microscopy\n",
      "0c83fb7b5413cd36d8ca958f15e7640636c8e730__8_Cloning and sequencing\n",
      "0c83fb7b5413cd36d8ca958f15e7640636c8e730__9_Phylogenetic analysis\n",
      "0c83fb7b5413cd36d8ca958f15e7640636c8e730__10_Pathogenicity of the QIAP1401 strain\n",
      "0c83fb7b5413cd36d8ca958f15e7640636c8e730__11_Virus isolation\n",
      "0c83fb7b5413cd36d8ca958f15e7640636c8e730__12_Genetics analysis\n",
      "0c83fb7b5413cd36d8ca958f15e7640636c8e730__13_Pathogenicity of QIAP1401\n",
      "0c83fb7b5413cd36d8ca958f15e7640636c8e730__14_Discussion\n",
      "1d00afb878598fac3a431da9b6b45a794de3eaa7__0_\n",
      "1d00afb878598fac3a431da9b6b45a794de3eaa7__1_Preparation of viral antigens\n",
      "1d00afb878598fac3a431da9b6b45a794de3eaa7__2_Enzyme-linked immunosorbent assay\n",
      "1d00afb878598fac3a431da9b6b45a794de3eaa7__3_Study population\n",
      "1d00afb878598fac3a431da9b6b45a794de3eaa7__4_Age-specific antibody titers to coronauiruses\n",
      "1d00afb878598fac3a431da9b6b45a794de3eaa7__5_Antibody rises in relation to age\n",
      "1d00afb878598fac3a431da9b6b45a794de3eaa7__6_Temporal patterns of antibody rises\n",
      "1d00afb878598fac3a431da9b6b45a794de3eaa7__7_Concurrent antibody rises\n",
      "1d00afb878598fac3a431da9b6b45a794de3eaa7__8_Reinfection with human coronaviruses\n",
      "1d00afb878598fac3a431da9b6b45a794de3eaa7__9_Antibody rises in relation to illness\n",
      "1d00afb878598fac3a431da9b6b45a794de3eaa7__10_DISCUSSION\n",
      "3ae24898796b7972372f6ed11be3d07c44e8cfd5__0_Introduction\n",
      "3ae24898796b7972372f6ed11be3d07c44e8cfd5__1_Cells\n",
      "3ae24898796b7972372f6ed11be3d07c44e8cfd5__2_Viruses\n",
      "3ae24898796b7972372f6ed11be3d07c44e8cfd5__3_Plaque Assa)\n",
      "3ae24898796b7972372f6ed11be3d07c44e8cfd5__4_Determination of physical decay of the viral aerosols\n",
      "3ae24898796b7972372f6ed11be3d07c44e8cfd5__5_Determirwtion\n",
      "3ae24898796b7972372f6ed11be3d07c44e8cfd5__6_Results\n",
      "3ae24898796b7972372f6ed11be3d07c44e8cfd5__7_Effect of the process of nebulizat~on on the viab~l~ry of the virtues\n",
      "3ae24898796b7972372f6ed11be3d07c44e8cfd5__8_Effect of neb~~i~ation on the concentrafion of the dye in the spray fluid\n",
      "3ae24898796b7972372f6ed11be3d07c44e8cfd5__9_Suitability of uranine as a physical tracer\n",
      "3ae24898796b7972372f6ed11be3d07c44e8cfd5__10_Determination of the extent of virus inactivation during the period of aerosol stabilization\n",
      "3ae24898796b7972372f6ed11be3d07c44e8cfd5__11_Determination of the particle size distribution of viral aerosols produced by the collison nebulizer and held at the 3 RH levels (20 + 1°C)\n",
      "3ae24898796b7972372f6ed11be3d07c44e8cfd5__12_Comparison of the surv~~~al of airborne human rotav~rus and poliovirus 1 (cabins\n",
      "3ae24898796b7972372f6ed11be3d07c44e8cfd5__13_Discussion\n",
      "ac45f663ed3b7143b944a5385b5d82754087a6af__0_\n",
      "ac45f663ed3b7143b944a5385b5d82754087a6af__1_Introduction\n",
      "ac45f663ed3b7143b944a5385b5d82754087a6af__2_Virus isolation and subtyping\n",
      "ac45f663ed3b7143b944a5385b5d82754087a6af__3_RT-PCR and nucleotide sequencing of M-gene\n",
      "ac45f663ed3b7143b944a5385b5d82754087a6af__4_Phylogenetic analysis\n",
      "ac45f663ed3b7143b944a5385b5d82754087a6af__5_Antiviral resistance\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-6-00dfb5c4a4bc>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m     37\u001b[0m             \u001b[0;31m# Run our example question through the model.\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     38\u001b[0m             start_scores, end_scores = model(torch.tensor([input_ids]), # The tokens representing our input text.\n\u001b[0;32m---> 39\u001b[0;31m                                             token_type_ids=torch.tensor([segment_ids])) # The segment IDs to differentiate question from answer_text\n\u001b[0m\u001b[1;32m     40\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     41\u001b[0m             \u001b[0;31m# ======== Reconstruct Answer ========\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages/torch/nn/modules/module.py\u001b[0m in \u001b[0;36m__call__\u001b[0;34m(self, *input, **kwargs)\u001b[0m\n\u001b[1;32m    530\u001b[0m             \u001b[0mresult\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_slow_forward\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    531\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 532\u001b[0;31m             \u001b[0mresult\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mforward\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    533\u001b[0m         \u001b[0;32mfor\u001b[0m \u001b[0mhook\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_forward_hooks\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvalues\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    534\u001b[0m             \u001b[0mhook_result\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mhook\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mresult\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages/transformers/modeling_bert.py\u001b[0m in \u001b[0;36mforward\u001b[0;34m(self, input_ids, attention_mask, token_type_ids, position_ids, head_mask, inputs_embeds, start_positions, end_positions)\u001b[0m\n\u001b[1;32m   1444\u001b[0m             \u001b[0mposition_ids\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mposition_ids\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1445\u001b[0m             \u001b[0mhead_mask\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mhead_mask\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1446\u001b[0;31m             \u001b[0minputs_embeds\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0minputs_embeds\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1447\u001b[0m         )\n\u001b[1;32m   1448\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages/torch/nn/modules/module.py\u001b[0m in \u001b[0;36m__call__\u001b[0;34m(self, *input, **kwargs)\u001b[0m\n\u001b[1;32m    530\u001b[0m             \u001b[0mresult\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_slow_forward\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    531\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 532\u001b[0;31m             \u001b[0mresult\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mforward\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    533\u001b[0m         \u001b[0;32mfor\u001b[0m \u001b[0mhook\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_forward_hooks\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvalues\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    534\u001b[0m             \u001b[0mhook_result\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mhook\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mresult\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages/transformers/modeling_bert.py\u001b[0m in \u001b[0;36mforward\u001b[0;34m(self, input_ids, attention_mask, token_type_ids, position_ids, head_mask, inputs_embeds, encoder_hidden_states, encoder_attention_mask)\u001b[0m\n\u001b[1;32m    732\u001b[0m             \u001b[0mhead_mask\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mhead_mask\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    733\u001b[0m             \u001b[0mencoder_hidden_states\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mencoder_hidden_states\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 734\u001b[0;31m             \u001b[0mencoder_attention_mask\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mencoder_extended_attention_mask\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    735\u001b[0m         )\n\u001b[1;32m    736\u001b[0m         \u001b[0msequence_output\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mencoder_outputs\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages/torch/nn/modules/module.py\u001b[0m in \u001b[0;36m__call__\u001b[0;34m(self, *input, **kwargs)\u001b[0m\n\u001b[1;32m    530\u001b[0m             \u001b[0mresult\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_slow_forward\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    531\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 532\u001b[0;31m             \u001b[0mresult\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mforward\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    533\u001b[0m         \u001b[0;32mfor\u001b[0m \u001b[0mhook\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_forward_hooks\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvalues\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    534\u001b[0m             \u001b[0mhook_result\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mhook\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mresult\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages/transformers/modeling_bert.py\u001b[0m in \u001b[0;36mforward\u001b[0;34m(self, hidden_states, attention_mask, head_mask, encoder_hidden_states, encoder_attention_mask)\u001b[0m\n\u001b[1;32m    405\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    406\u001b[0m             layer_outputs = layer_module(\n\u001b[0;32m--> 407\u001b[0;31m                 \u001b[0mhidden_states\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mattention_mask\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mhead_mask\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mi\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mencoder_hidden_states\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mencoder_attention_mask\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    408\u001b[0m             )\n\u001b[1;32m    409\u001b[0m             \u001b[0mhidden_states\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mlayer_outputs\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages/torch/nn/modules/module.py\u001b[0m in \u001b[0;36m__call__\u001b[0;34m(self, *input, **kwargs)\u001b[0m\n\u001b[1;32m    530\u001b[0m             \u001b[0mresult\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_slow_forward\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    531\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 532\u001b[0;31m             \u001b[0mresult\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mforward\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    533\u001b[0m         \u001b[0;32mfor\u001b[0m \u001b[0mhook\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_forward_hooks\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvalues\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    534\u001b[0m             \u001b[0mhook_result\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mhook\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mresult\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages/transformers/modeling_bert.py\u001b[0m in \u001b[0;36mforward\u001b[0;34m(self, hidden_states, attention_mask, head_mask, encoder_hidden_states, encoder_attention_mask)\u001b[0m\n\u001b[1;32m    377\u001b[0m             \u001b[0moutputs\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0moutputs\u001b[0m \u001b[0;34m+\u001b[0m \u001b[0mcross_attention_outputs\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m]\u001b[0m  \u001b[0;31m# add cross attentions if we output attention weights\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    378\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 379\u001b[0;31m         \u001b[0mintermediate_output\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mintermediate\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mattention_output\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    380\u001b[0m         \u001b[0mlayer_output\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0moutput\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mintermediate_output\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mattention_output\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    381\u001b[0m         \u001b[0moutputs\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m(\u001b[0m\u001b[0mlayer_output\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;34m+\u001b[0m \u001b[0moutputs\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages/torch/nn/modules/module.py\u001b[0m in \u001b[0;36m__call__\u001b[0;34m(self, *input, **kwargs)\u001b[0m\n\u001b[1;32m    530\u001b[0m             \u001b[0mresult\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_slow_forward\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    531\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 532\u001b[0;31m             \u001b[0mresult\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mforward\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    533\u001b[0m         \u001b[0;32mfor\u001b[0m \u001b[0mhook\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_forward_hooks\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvalues\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    534\u001b[0m             \u001b[0mhook_result\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mhook\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mresult\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages/transformers/modeling_bert.py\u001b[0m in \u001b[0;36mforward\u001b[0;34m(self, hidden_states)\u001b[0m\n\u001b[1;32m    329\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    330\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0mforward\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mhidden_states\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 331\u001b[0;31m         \u001b[0mhidden_states\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdense\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mhidden_states\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    332\u001b[0m         \u001b[0mhidden_states\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mintermediate_act_fn\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mhidden_states\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    333\u001b[0m         \u001b[0;32mreturn\u001b[0m \u001b[0mhidden_states\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages/torch/nn/modules/module.py\u001b[0m in \u001b[0;36m__call__\u001b[0;34m(self, *input, **kwargs)\u001b[0m\n\u001b[1;32m    530\u001b[0m             \u001b[0mresult\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_slow_forward\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    531\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 532\u001b[0;31m             \u001b[0mresult\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mforward\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    533\u001b[0m         \u001b[0;32mfor\u001b[0m \u001b[0mhook\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_forward_hooks\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvalues\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    534\u001b[0m             \u001b[0mhook_result\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mhook\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mresult\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages/torch/nn/modules/linear.py\u001b[0m in \u001b[0;36mforward\u001b[0;34m(self, input)\u001b[0m\n\u001b[1;32m     85\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     86\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0mforward\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0minput\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 87\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0mF\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mlinear\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mweight\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mbias\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     88\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     89\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0mextra_repr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/pytorch_p36/lib/python3.6/site-packages/torch/nn/functional.py\u001b[0m in \u001b[0;36mlinear\u001b[0;34m(input, weight, bias)\u001b[0m\n\u001b[1;32m   1370\u001b[0m         \u001b[0mret\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mtorch\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0maddmm\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mbias\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0minput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mweight\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mt\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1371\u001b[0m     \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1372\u001b[0;31m         \u001b[0moutput\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0minput\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mmatmul\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mweight\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mt\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1373\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mbias\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1374\u001b[0m             \u001b[0moutput\u001b[0m \u001b[0;34m+=\u001b[0m \u001b[0mbias\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "data_output=[]\n",
    "with open(file_name, 'r') as f:\n",
    "    for line in f:\n",
    "        #if len(data_output)>3:\n",
    "        #    break\n",
    "        con=json.loads(line)\n",
    "        paper_id=con[\"paper_id\"]\n",
    "        text_dict=con[\"text_dict\"]\n",
    "        for key in text_dict.keys():\n",
    "            content = text_dict[key]\n",
    "            com_id=str(paper_id)+\"__\"+str(key)\n",
    "\n",
    "            answer_text=str(content)        \n",
    "\n",
    "            input_ids = tokenizer.encode(question, answer_text,max_length=500)\n",
    "\n",
    "            # Report how long the input sequence is.\n",
    "            #print('Query has {:,} tokens.\\n'.format(len(input_ids)))\n",
    "\n",
    "            # ======== Set Segment IDs ========\n",
    "            # Search the input_ids for the first instance of the `[SEP]` token.\n",
    "            sep_index = input_ids.index(tokenizer.sep_token_id)\n",
    "\n",
    "            # The number of segment A tokens includes the [SEP] token istelf.\n",
    "            num_seg_a = sep_index + 1\n",
    "\n",
    "            # The remainder are segment B.\n",
    "            num_seg_b = len(input_ids) - num_seg_a\n",
    "\n",
    "            # Construct the list of 0s and 1s.\n",
    "            segment_ids = [0]*num_seg_a + [1]*num_seg_b\n",
    "\n",
    "            # There should be a segment_id for every input token.\n",
    "            assert len(segment_ids) == len(input_ids)\n",
    "\n",
    "            # ======== Evaluate ========\n",
    "            # Run our example question through the model.\n",
    "            start_scores, end_scores = model(torch.tensor([input_ids]), # The tokens representing our input text.\n",
    "                                            token_type_ids=torch.tensor([segment_ids])) # The segment IDs to differentiate question from answer_text\n",
    "\n",
    "            # ======== Reconstruct Answer ========\n",
    "            # Find the tokens with the highest `start` and `end` scores.\n",
    "            answer_start = torch.argmax(start_scores)\n",
    "            answer_end = torch.argmax(end_scores)\n",
    "\n",
    "\n",
    "            # Get the string versions of the input tokens.\n",
    "            tokens = tokenizer.convert_ids_to_tokens(input_ids)\n",
    "\n",
    "            # Start with the first token.\n",
    "            answer = tokens[answer_start]\n",
    "\n",
    "            # Select the remaining answer tokens and join them with whitespace.\n",
    "            for i in range(answer_start + 1, answer_end + 1):\n",
    "\n",
    "                # If it's a subword token, then recombine it with the previous token.\n",
    "                if tokens[i][0:2] == '##':\n",
    "                    answer += tokens[i][2:]\n",
    "\n",
    "                # Otherwise, add a space then the token.\n",
    "                else:\n",
    "                    answer += ' ' + tokens[i]\n",
    "\n",
    "            s_scores = start_scores.detach().numpy().flatten()\n",
    "            e_scores = end_scores.detach().numpy().flatten()  \n",
    "            print(com_id)\n",
    "            if (answer!=\"[CLS]\") & (float(max(s_scores))>0)& (len(answer)>0)&(answer!=non_answer):\n",
    "                data_output.append([paper_id,key,answer,max(s_scores)])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['0ced1f946cce007aa319a0ba38aef2c4b14dab0e',\n",
       " '0_Background',\n",
       " 'neutralizing antibodies',\n",
       " 1.7667923]"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data_output[3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "# load additional module\n",
    "import pickle\n",
    "\n",
    "# define a list of places\n",
    "with open('output_sample.data', 'wb') as filehandle:\n",
    "    # store the data as binary data stream\n",
    "    pickle.dump(data_output, filehandle)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('output_sample.data', 'rb') as filehandle:\n",
    "    # read the data as binary data stream\n",
    "    placesList = pickle.load(filehandle)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "for i in data_output:\n",
    "    print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2284"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(data_output)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "paper_id_list=[i[0] for i in data_output]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "441"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(set(paper_id_list))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "simulation\n",
      "educate\n",
      "video recording and sharing\n",
      "neutralizing antibodies\n",
      "im\n",
      "initiatives and response mechanisms\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] rinderpest is german for \" cattle plague \" . it is a highly infectious viral disease that can affect domesticated and wild , cloven - hoofed mammals . african cattle and buffalo are extremely susceptible to the disease while sheep and goats experience a mild form that is not as acute , resulting in lower fatalities . in susceptible animal , rinderpest infection has a fatality rate greater than 90 % and a mortality rate of 100 % . in the 1890 ' s , an outbreak of rinderpest south of the river zambezi killed about 5 . 2 million cattle , sheep , goats and oxen , and an unknown number of wild giraffe , buffalo and wildebeest . this rinderpest epidemic , happening at a time of much historical tumult , was the most devastating epidemic to hit southern africa in the late nineteenth century . there is no conclusive evidence on how rinderpest was brought to africa . it is thought to have been brought through indian cattle by italian colonial masters who introduced the cattle to the horn of africa . the disease is spread through ingested contaminated matter and / or through direct contact . endemic areas have caused animals to develop immunity through exposure or vaccinations\n",
      "bites of infected insects and contact with blood of infected animals\n",
      "global eradication\n",
      "multidisciplinary collaboration\n",
      "good governance and political / economic stability\n",
      "looking for a practical and cost - effective solution\n",
      "vaccine development\n",
      "internet of things methodology\n",
      "lesser expenses and mistakes\n",
      "iot\n",
      "iot\n",
      "smartphone application\n",
      "iot\n",
      "internet of things\n",
      "iot\n",
      "vaccination\n",
      "mhc - i cross - linking\n",
      "immunoelectrophoresis\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] die mortalitat der tuberkulose liegt weltweit bei 24 % , in den industrienationen bei 5 - 7 % . diese ist bei patienten mit notwendigkeit einer intensivmedizinischen behandlung mit 25 - 67 % deutlich erhoht . risikofaktoren , die mit erhohter mortalitat assoziiert werden , sind ein verzogerter therapiebeginn , akutes nierenversagen , sepsis , ards , beatmungspflicht sowie begleitende nosokomiale pneumonie [ 3 ] . je nach ursache der erkrankung ergibt sich eine unterschiedliche prognose sowohl bezuglich des uberlebens als auch der nierenfunktion bzw . weiterer organmanifestationen . das typische hus weist eine bessere prognose als die atypischen formen auf . bei kindern mit typischem hus ist zunachst bei bis zu 2 / 3 der falle mit einer zumindest temporaren dialysepflichtigkeit zu rechnen . bezuglich einer bleibenden terminalen niereninsuffizienz wird das risiko in studien bei 12 % angegeben , mit zusatzlich bis zu 25 % fortbestehender nierenfunktionseinschrankung [ 6 ] . patienten mit atypischen hus und z . b . angeborenem mangel der adam - ts13 - metalloprotease haben ein hohes rezidivrisiko . experimentelle therapien wie die durchfuhrung einer nierenoder auch lebertransplantation konnten bisher ihre effektivitat nicht endgultig beweisen . der wichtigste die prognose bestimmende faktor ist die zeit bis zur diagnosestellung und dem beginn einer chirurgischen intervention\n",
      "immunitat . fur den intensivmediziner sind die zerebralen beteiligungen mit enzephalitis\n",
      "vaccines\n",
      "biological warfare\n",
      "vaccination\n",
      "vaccination\n",
      "streptomycin or doxycycline\n",
      "antibiotics\n",
      "vaccine\n",
      "antitoxin and support therapies\n",
      "multiple antimicrobial drugs\n",
      "strict isolation and quarantine measures\n",
      "universal\n",
      "massive vaccine preparations\n",
      "laboratory evaluation\n",
      "antibiotics\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] pneumonia develops in stages , starting with hemorrhage . the lung is dark red , consistency is fi rm , and on the cut surface , there is some granularity seen , corresponding to fi brin cloths out of the alveoli ( fig . 8 . 1 ) . in the next stage , the color of the lung changes to gray and grayish yellow . this is induced by the infl ux of leukocytes , dying of leukocytes , and release of lipid substances ( fig . 8 . 2 ) . the consistency of the lung is comparable to liver tissue , hence the old name \" hepatization . \" finally in the best scenario , the exudate is reabsorbed , the alveoli are fi lled with air , and the lung changes back to normal ( lysis ) . most often these classical stages are not anymore seen , because pneumonia is immediately treated with antibiotics\n",
      "mechanical ventilation and exposure to supplemental oxygen\n",
      "bronchoalveolar lavage\n",
      "good functioning immune system and slowly growing mycobacteria will result in healing or scar\n",
      "stains\n",
      "airborne spores are inhaled\n",
      "inhalation of airborne spores\n",
      "it is important to rule out neutrophilic , eosinophilic , and mixed granulocytic and lymphocytic vasculitis\n",
      "immunohistochemical stains\n",
      "fibrosing pneumonias\n",
      "ct scans\n",
      "diagnostic\n",
      "high - resolution computed tomography\n",
      "cryobiopsy\n",
      "corticosteroid treatment\n",
      "randomized controlled trials\n",
      "non - invasive ventilation\n",
      "reduce surgical volumes\n",
      "surgical\n",
      "preoperatve screening\n",
      "alternatve treatment strategies\n",
      "organiied recommendatons\n",
      "tmes when the right decision becomes easier - as the impact of the decision evaporates\n",
      "real - time policy decisions\n",
      "reduce\n",
      "[SEP]\n",
      "natural selection\n",
      "modern technology , transportation , and trade\n",
      "deploy their armies\n",
      "high taxes levied by colonial governments\n",
      "technological and political steps we take to mitigate our impacts often aggravate them . too many of us simply take too much from the natural world and ask it to absorb too much waste\n",
      "[SEP] from the appearance of h . sapiens about 200 , 000 years ago , it took the human population until 1804 to reach its first billion , 123 years to double to 2 billion , and 33 years to achieve 3 billion . human population doubled again from 3 billion to 6 billion in about 40 yearsbefore most post - world war ii baby boomers reached retirement age . even with fertility rates declining in developed countries , china , and some developing countries where women are gaining education and economic power , and with pandemics like aids claiming more lives , the us census bureau predicts that world population will reach 9 billion by 2044 . people appropriate about 40 % of global plant production , 54 % of earth ' s freshwater runoff , and enough of the ocean ' s bounty to have depleted 63 % of assessed marine fish stocks . in energy terms , one person ' s food consumption amounts to 2500 - 3000 cal a day , about the same as that of a common dolphin . but with all the other energy and materials humans use , global per capita energy and material consumption has soared even faster than population growth over the past 50 years . now , instead of coevolving with a natural economy\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] a resource - accounting\n",
      "direct biological assessment\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] early in the 20th century , two sciences of \" home maintenance \" began to flourish : the young science of ecology ( from the greek oikos , meaning home ) and a maturing neoclassical economics ( also from oikos ) . ecology arose to document and understand the interactions between organisms and their living and nonliving surroundingsin essence , how organisms make a living in the natural economy . in fact , ernst haeckel , who coined the term in the 1860s , defined ecology in an 1870 article as the body of knowledge concerning the economy of nature . neoclassical economics , in contrast , reinforced humans ' self - appointed dominion over nature ' s wealth . it brought unparalleled gains in societal welfare in some places , but it also divorced the human economy from the natural one on which it stands ( see fig . 1 ) . in his short history of progress , wright ( 2004 , p . 8 ) recounts tales of \" progress traps \" that humanity has fallen into ; each time history repeats itself , he reminds us , the price goes up . by now it is clear to economists and ecologists alike that human progress has reached scales unprecedented in the history of life . we have altered earth ' s physical and chemical environments , changed the planet ' s water and nutrient cycles , and perturbed its climate . we have unleashed the greatest mass extinction in 65 my and distorted the structure and function of nonhuman and human communities worldwide . in trying to make our own living , we have jeopardized earth ' s capacity to sustain other species and our own species as well . we are losing life on earththe bio in biosphere . confronted with these unprecedented losses , we need to understandnot denythe ecological consequences of what we do . we urgently need a new craft of home maintenance\n",
      "vaccination campaign\n",
      "bidirectional transmission\n",
      "a public health approach\n",
      "immunization\n",
      "cry\n",
      "antibodies\n",
      "intranasal administration of protein m epitopes\n",
      "anti - basal ganglia antibodies\n",
      "real time rt - pcr\n",
      "similarity search using blast and phylogenetic analysis\n",
      "multiplex pcr kits\n",
      "rt - pcr\n",
      "real - time rt - pcr\n",
      "salvage chemotherapy\n",
      "conditioning regimen of i . v . cy 50 mg / kg / day from day a5 to a3 , a single fraction of 7 gy thymic irradiation\n",
      "donor leukocyte infusion\n",
      "gvhd prophylaxis\n",
      "wilson method\n",
      "chemotherapy\n",
      "treatment or isolation\n",
      "pontryagin ' s minimum principle\n",
      "optimal control\n",
      "construction of optimal controls\n",
      "vaccination\n",
      "optimal control\n",
      "rabbit anti - human polyclonal - hrp conjugate\n",
      "euthanized by cervical dislocation\n",
      "mice\n",
      "detection of chikv specific igm antibodies using an elisa\n",
      "follow up samples blood samples could be collected from these three patients at 12 weeks\n",
      "polymerase chain reaction\n",
      "real - time reverse transcription polymerase chain reaction\n",
      "supplementary materials\n",
      "thai monoclonal antibodies\n",
      "gttitaraldehyde\n",
      "ang\n",
      "decrease ang ii while increasing ang - ( 1 - 7 ) actions . this may be of particular interest when complete suppression of ang ii in response to therapy with ace1 or at1 receptor antagonist\n",
      "informed consent\n",
      "nitric oxide synthase inhibition\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] a 65 - year - old man experienced worsening dyspnea , cough with clear sputum and fever for 7 days before admission in our department in june 2010 . the patient underwent cardiac surgery ( coronary artery bypass grafts\n",
      "seir model\n",
      "intuition\n",
      "screening\n",
      "migrations\n",
      "contact tracing\n",
      "piece wise linearity\n",
      "contact tracing and random testing\n",
      "intramuscular inoculation\n",
      "post - mortem examinations\n",
      "reverse\n",
      "[SEP]\n",
      "upregulating the expression of slc39a14\n",
      "q\n",
      "upregulating ifn - induced genes and increasing intracellular zinc ion concentration\n",
      "hi test with antisera from rabbits\n",
      "kaolin\n",
      "antibodies were conjugated with horseradish peroxidase ( hrp ) as described by avrameas and ternynck ( 1971 ) . free peroxidase was separated by gel chromatography with sephacryl s - 300 ( pharmacia , freiburg ) , non - coupled globulins by affinity chromatography on con a - sepharose ( lann ~ r et al . , 1978 ) . antibodies were biotinylated\n",
      "serial dilutions of mabs ( ascitic fluids ) were first reacted with optimal working dilutions of conjugated competitive mabs . the mixtures were then transferred to elisa plates\n",
      "silver staining\n",
      "multiple test concepts\n",
      "electroconvulsive therapy\n",
      "psychiatrists to carefully review the treatment needs in consultation with patients and their families\n",
      "electroconvulsive therapy\n",
      "well - engineered wastewater treatment plant\n",
      "log\n",
      "turbidity is also taken as a crude parameter for pathogen removal\n",
      "sand filter for drinking water treatment\n",
      "sz can be prepared by connecting a pipe to the drainage exit and rising the pipe opening to the transition level\n",
      "biofilm\n",
      "plantation\n",
      "polymod data collection\n",
      "data fusion\n",
      "bayesian hierarchical modelling\n",
      "school closure and social distancing of younger individuals\n",
      "estimate the effective reproduction number\n",
      "infectiousness\n",
      "active surveillance system\n",
      "prescription\n",
      "swabs\n",
      "emergency admission diagnoses between cases and controls ; with the exception of heart failure\n",
      "[SEP]\n",
      "vaccine\n",
      "[SEP]\n",
      "case - case comparison\n",
      "pharyngeal ( throat ) and nasopharyngeal swabbing\n",
      "broad confidence intervals\n",
      "future\n",
      "control hospitals\n",
      "local first responders\n",
      "discretionary rescue - related decisions and actions , which oftentimes can be more effective than \" just \" following orders issued from above\n",
      "rescue operations\n",
      "rescue operations\n",
      "shifting related responsibilities onto non - governmental entities\n",
      "centralized national disaster or safety management system\n",
      "antibodies\n",
      "modified eagle medium ( dmem ) supplemented with 10 % fetal bovine serum\n",
      "fixed with methanol on ice for 5 - 7 min and allowed to dry before treatment for 15 min with giemsa stain\n",
      "β - galactosidase complementation\n",
      "soybean trypsin inhibitor\n",
      "broad - spectrum antibiotics\n",
      "oxidase - positive\n",
      "complement - and neutrophil - mediated killing\n",
      "epidemiology of viral - bacterial co - infections\n",
      "modulation of innate and adaptive immune responses\n",
      "prevention and treatment strategies\n",
      "generation of dna template by polymerase chain reaction\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the arabidopsis hy5 gene ( genbank accession no . ab005436 ) was previously cloned [ 5 ] and was inserted into a peu - based vector ( peu - dbtag ) . the open reading frames of the glycogen synthase 1 ( gs , muscle , nm _ 002103 ) and the following 11 human protein kinases were amplified by pcr from their respective commercially available cdna templates ( biochain institute , inc . , ca , usa and takara bio inc . , otsu , japan ) : mst3 ( accession no . nm _ 001032296 ) , mst2 ( nm _ 006281 ) , srpk2 ( nm _ 182692 ) , ck2a1 ( nm _ 001895 ) , pkr ( nm _ 002759 ) , mark3 ( nm _ 002376 ) , pak2 ( nm _ 002577 ) , pak3 ( nm _ 002578 ) , camk2d ( nm _ 001221 ) , dapk3 ( nm _ 001348 ) , mark3 ( nm _ 002376 ) , ck1g3 ( nm _ 004384 ) , and ttk ( nm _ 003318 ) ] . the amplified clones were inserted into the vector pt7blue ( novagen , merck biosciences , inc . , darmstadt , germany ) , and their sequences were confirmed by dna sequencing\n",
      "purify , 50 ll of the translational mixture was loaded onto 20 ll of dna - conjugated column ( ge healthcare ) . the column was first washed three times with 100 ll of wash buffer ( 20 mm tris - hcl , ph 7 . 8 , 200 mm nacl , 2 mm mgcl 2 , and 1 mm dtt ) , and then the proteins ( dbtag or dbtag - fusion protein ) were eluted with an elution buffer\n",
      "staurosporine in a dmso solution ( at the indicated final concentration ) was added to the kinase solution\n",
      "immobilized on the microplate\n",
      "ictus isquemico e infeccion por sars\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] introduccion : se ha comunicado la asociacion de ictus isquemico y covid - 19 , con mayor frecuencia en aquellos pacientes mas graves . sin embargo , se desconoce en que medida podria estar en relacion con la inflamacion sistemica e hipercoagulabilidad producidas en el contexto de la infeccion . metodos : descripcion de cuatro pacientes atendidos en nuestro centro por ictus isquemico y diagnostico de covid - 19 , clasificandolos segun el grado de probabilidad causal\n",
      "una\n",
      "via telefonica , tras la aprobacion por el comite etico de investigacion clinica de granada . se recogieron los siguientes grupos de variables : demograficas / basales ; relacionadas con la clinica al ingreso y con la enfermedad covid - 19 ; relacionadas con el ictus isquemico ; parametros de laboratorio en el momento del ictus y evolucion clinica . la etiologia del ictus se estimo siguiendo los criterios del sistema de clasificacion toast ( 6 ) . los pacientes se clasificaron segun el \" grado de causalidad\n",
      "grado de causalidad\n",
      "balance\n",
      "sneezing\n",
      "vaccinated\n",
      "vaccination\n",
      "vaccination\n",
      "cell - mediated immunity\n",
      "killed vaccines\n",
      "the vaccine could be shed from the wild animals\n",
      "vaccinated with a cdv vaccine\n",
      "mlv vaccines\n",
      "multiple\n",
      "killed ( not mlv ) vaccines\n",
      "adopting\n",
      "nutritional supplementation\n",
      "artificial colostrum can be fed if the puppy or kitten is less than 1 day old . artificial colostrum is 50 % milk replacer ( e . g . esbilac tm or other similar product ) and 50 % immune serum ( preferably from the dam or other well vaccinated animal living in the same environment as the dam ) . if pups or kittens are older and 1 day of age , serum from a well immunized adult animal ( free of infectious disease ) can be given subcutaneously or intraperitoneally or citrated plasma can be given intravenously\n",
      "serological testing\n",
      "core vaccination\n",
      "two doses of vaccine\n",
      "rev\n",
      "serological tests\n",
      "booster vaccination\n",
      "international rabies vaccines\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] infectious diseases are caused by pathogenic microorganisms , such as bacteria , viruses , parasites or fungi , and can spread , directly or indirectly , from one person ( or animal ) to another . a serious infectious disease might cause mass deaths , social panics , or even a national crisis . some examples of infectious diseases are the black death during the middle fourteenth century , the spanish flu pandemic in 1918 , the severe acute respiratory syndrome ( sars ) in 2002 , and more recently , the highly pathogenic avian influenza ( hpai ) [ 1 ] . in order to prevent and control infectious diseases , the study of mathematical models for the spread of infectious diseases is an important issue in epidemiology . through scientifically modeling the spread of an infectious dis - ease , some key factors that disclose the mechanism of the spread of the disease can be found out and the effect of some interventions ( e . g . , therapy , isolation , immunization\n",
      "phase plane method\n",
      "local transition rule\n",
      "weighting functions based on global contagion patterns\n",
      "merged populations with similar hla allele compositions\n",
      "surveillance\n",
      "passive\n",
      "collection of convalescent - phase sera\n",
      "if we limit analysis to the population of suspect and probable cases with definitive laboratory results\n",
      "serologic or pcr testing\n",
      "vaccination\n",
      "social\n",
      "pandemic vaccine prioritization\n",
      "pursue preparedness activities\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] over the last decades , many host - pathogen interactions have been characterized using genetics , biochemical , and microscopy approaches . these discoveries relied on mutants , pharmacological reagents , immunoprecipitations , immunofluorescence , electron microscopy , cell fractionation , and western blotting to name a few of the methods employed . these approaches provided much precious information but , given the typical focus of these approaches on individual molecules , likely only revealed a small portion of the proteins involved . other methods such as high throughput two - hybrid and genetic screens , nucleic acid arrays , rna interference , and proteomics\n",
      "rna interference\n",
      "produce the virus on cells that lack these proteins\n",
      "proteomics\n",
      "short - interfering rnas and new vaccine strategies that use plasmid - based genetic systems\n",
      "hpai\n",
      "intubation\n",
      "reverse transcriptase polymerase chain reaction\n",
      "new\n",
      "agriculture\n",
      "widal ' s agglutination test\n",
      "paper questionnaire\n",
      "immunization\n",
      "qualitative interview\n",
      "outbreak preparedness and response plan with necessary investigation tools\n",
      "ur\n",
      "blood tests included reticulocyte count , total bilirubin , direct bilirubin , hemoglobin ( hb ) level , coombs test , abo incompatibility , c - reactive protein ( crp ) , and blood culture\n",
      "patient isolation\n",
      "work with their local health departments to develop individualized plans\n",
      "surveillance\n",
      "community survey\n",
      "[SEP] at admission , 411 ( 53 % ) had leukocytosis ( wbc > 11 a 10 9 / l ) and 23 ( 3 % ) had leukopenia ( wbc < 3 a 10 9 / l ) . sixty - five ( 8 % ) patients had a sputum culture\n",
      "dipeptidyl peptidase 4\n",
      "fitc - conjugated rabbit - anti - guinea pig igg\n",
      "statistical comparison\n",
      "anti\n",
      "cardiaca\n",
      "antibioticos\n",
      "el diagnostico acostumbra a ser clinico en nuestro pais\n",
      "dicha derivacion\n",
      "manipulaciones instrumentales inmediatas\n",
      "torticolis de gran intensidad\n",
      "tromboflebilits de la vena yugular interna ( empeoramiento con escalofrios , fiebre alta , dolor y tumefaccion cervical\n",
      "amigdalectomia\n",
      "cult\n",
      "coe\n",
      "criterios de derivacion al medico desde la farmacia comunitaria\n",
      "reverse real - time reverse transcription polymerase chain reaction ( rt - pcr ) assay\n",
      "rt - pcr assay of sars - cov - 2 rna\n",
      "in\n",
      "chest ct\n",
      "serious\n",
      "virion assembly and release\n",
      "exploit the host cell machinery for their own replication and spread\n",
      "good hand hygiene and coughing etiquette and avoiding close contact with infected individuals\n",
      "rt - pcr\n",
      "incorporation of high titer hyperimmune antisera\n",
      "immunosuppressive therapy\n",
      "antiviral treatment\n",
      "antiviral treatment\n",
      "transbronchial lung biopsies\n",
      "metagenomics and transcriptomics\n",
      "protein alignments were visualized\n",
      "peer - reviewed\n",
      "carefully cover the nose and mouth completely with the sleeve\n",
      "understanding\n",
      "calculation\n",
      "richer communities or nations\n",
      "full genome sequences\n",
      "temporal\n",
      "selective sweeps\n",
      "molecular biology and evolution online\n",
      "treatment strategies\n",
      "literature search\n",
      "full - text review\n",
      "tcz\n",
      "tcz dosing\n",
      "a latent tb test\n",
      "tcz\n",
      "tocilizumab monotherapy\n",
      "public health interventions\n",
      "competing - risk parametric survival\n",
      "hospitalization\n",
      "[SEP]\n",
      "generalized linear models with a poisson link function\n",
      "retrospective reviews\n",
      "data collection , data analysis , data interpretation , or the writing of the report . the corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication\n",
      "laboratory confirmation\n",
      "censoring of recent hospitalizations\n",
      "dates of confirmatory diagnosis\n",
      "ethical approval and written consent from patients\n",
      "time - dependent logit model\n",
      "enhanced infection control practices\n",
      "chemotherapy\n",
      "gene therapy\n",
      "formulating plasmid dna with a cationic lipid\n",
      "monocional antibody\n",
      "peripheral blood mononuclear cell\n",
      "trypan blue dye exclusion\n",
      "various dilutions of dialysed mab preparations\n",
      "a standard porcine ifna\n",
      "antibodies\n",
      "[SEP]\n",
      "sds - polyacrylamide gel electrophoresis\n",
      "serum antibodies\n",
      "multiplex pcr reactions\n",
      "strand displacement\n",
      "nu\n",
      "lamp amplification\n",
      "agarose gel electrophoresis\n",
      "electrophoresis\n",
      "lamp\n",
      "pcr\n",
      "pcr\n",
      "toxin genotyping\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] mabs were diluted geometrically ( from 10 pg / well total protein ) and added to each well . after 2 hr at 25 \" , the plates were washed and further incubated with a 1 : 500 dilution of goat antimouse alkaline phosphatase conjugate . bound antibody was detected by addition of sigma 104 substrate , and absorbance was measured at 405 nm after 5 min . although each antibody was tested in a dilution series , only the results with 1 . 25 gg antibody are reported . analysis of the mab reactivities with reduced and nonreduced mve virus page sample buffer ( laemmli , 1970 ) with or without the reducing agent , 2 - mercaptoethanol , was added to 10 pg of purified mve virus . samples were boiled for 3 min at 100 \" and separated on 12 . 5 % sds gels . proteins were then transferred to nitrocellulose sheet ( towbin et a / . , 1979 ) and blocked with 3 % goat serum\n",
      "mass immunization or eradication of animal reservoirs\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the goal of lipidomic analysis is the quantitative characterization of all lipids in a biological system , including the dynamic changes that occur in response to stimuli and the physiological consequences of these changes . this is technically challenging due to the structural diversity of lipid molecules and the inability to predict or infer lipid structure based on genomic , transcriptomic , or proteomic data . lipidomic analysis is also challenging because the abundance of individual species can vary over a wide range . phospholipids are so abundant that they constitute up to 50 % of the total mass of lipids in the cell , whereas prostaglandins and other bioactive signaling lipids may be present at only picomolar concentrations . no single analytical method is sufficient to capture the full lipidome of a biological system , and as with other \" omics \" approaches , the methods used for quantitative analysis of large lipidomic data sets affect interpretation of the data . strategies currently being used to examine the interaction of viruses with host lipids generally fall into one of three categories . first , there are classical reductionist approaches using metabolic labeling and biochemical reconstitution experiments to examine the potential function of a limited set of specific lipids in viral processes . second , it is possible to infer roles for different classes of lipids through transcriptomic and proteomic studies that detect changes in the expression of host enzymes responsible for the synthesis , metabolism , and trafficking of these lipid classes . third , global analytical chemistry\n",
      "high - throughput analysis\n",
      "viral replication\n",
      "fusion of the viral membrane with a cellular membrane\n",
      "spatial restriction of genome replication\n",
      "scission of the neck to sever the viral particle from the budding membrane\n",
      "yeast double - hybrid and co - immunoprecipitation\n",
      "rt - pcr from the genome of sars - cov frankfurt - 1 ( accession number ay291315 ) as previously described [ 16 ] . the nsp10 and nsp16 genes ( encoding residues 4231 - 4369 , 5903 - 6429 , and 6776 - 7073 of replicase pp1ab ) were cloned into a gateway modified dual - promotor expression plasmid and in the gateway pdest 14 expression vector . in this backbone , sars cov nsp10 can be expressed under a tet promoter and encodes a protein in fusion with a n - terminal strep tag , whereas nsp16 is expressed under a t7 promoter and encodes a protein in fusion with a n - terminal hexahistidine tag . the mutants were generated by pcr using the quickchange site - directed mutagenesis kit\n",
      "high - performance liquid chromatography\n",
      "alanine mutations\n",
      "linear regression analysis\n",
      "antimicrobial agent\n",
      "qrt - pcr\n",
      "crystal violet staining\n",
      "qualitative\n",
      "qualitative methodik\n",
      "e - mail\n",
      "informationsbedarf\n",
      "pandemic · epidemic · ehec · influenza · primary care · health services research\n",
      "activation in vitro\n",
      "injection\n",
      "tlrs\n",
      "damp\n",
      "implementation of systematic methods\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] blood safety and availability in china has significantly improved since the blood donation law came into effect in october 1998 . the central health authority expects to reach a donor / population rate of 1 . 5 % by 2020 , an ambitious increase of 50 % over the next 5 years . challenges are likely to be encountered , particularly related to meeting ever - increasing clinical demands for blood products while maintaining the safety , integrity , and sustainability of the service . most of these challenges are already being addressed , including but not limited to inappropriate blood utilization [ 29 ] , the high prevalence of transfusion - transmitted infections [ 30 ] , restrictions on eligible donation ages and intervals , regional differences in development , and isolated information management systems . there are other challenges , however , that are not linked directly to any specific issues , but that are of more strategic significance and have greater long - term implications . identifying and resolving these challenges will lay the groundwork for an effective and reliable blood service system . this article has identified a number of concerns facing the blood services industry in china that have thus far received inadequate attention . first , the amount of blood donated annually has not kept pace with demand . second , blood services are being impaired by cost - assessment standards that were inadequate from the very beginning . third and finally , there is not enough performance measurement in the blood collection and processing system . a number of questions on these issues remain : shall the current mode of donation motivation remain driven by personal incentives , or would it be appropriate to embrace a major change and reaffirm the original principle of vnrbd ? shall blood establishments remain fiscally squeezed , or will cost recovery and government subsides be reassessed and revised regularly ? is it time to implement hemovigilance programs\n",
      "pre - exposure or postexposure prophylaxis\n",
      "good\n",
      "self - limited\n",
      "ivermectin\n",
      "removal of the intact larvae\n",
      "removal of the flea\n",
      "chemoprophylaxis\n",
      "obtain thin and thick smears\n",
      "prompt recognition and initiation of therapy\n",
      "vaccines against serotype typhi , but not paratyphi . this gram - negative organism is ingested , survives gastric acidity , and invades gut epithelium . from there , it invades lymphatic tissue\n",
      "parental vaccination\n",
      "antirejection drugs\n",
      "live vaccines\n",
      "antibiotic was associated with increased odds of death , nec , and the composite measure of nec or death . these investigators concluded that prolonged initial empiric antibiotic therapy may be associated with increased risk of nec or death and should be used with caution . extreme caution should then be exerted at the moment of deciding to start antibiotics in preterm infants . long - lasting consequences and life - threatening situations could result from the indiscriminate use of antibiotics\n",
      "b - ultrasound\n",
      "paired serology\n",
      "paired serologic assays ( micro - immunofluorescence\n",
      "pcr , polymerase chain reaction\n",
      "routine\n",
      "aspiration pneumonia\n",
      "bioterrorism\n",
      "exposure\n",
      "rabbit exposure\n",
      "rodent flea exposure\n",
      "bioterrorism\n",
      "exposure to urine\n",
      "exposure to soil contaminated with bird droppings\n",
      "bronchoalveolar lavage\n",
      "high - quality paired sera\n",
      "diagnostic methods on the horizon include genomic and proteomic analyses . host gene expression analyses using blood microarray\n",
      "treatment studies of both old and new antimicrobials and adjunctive therapies\n",
      "hematoxylin and eosin ( h & e ) stain\n",
      "reverse transcriptase - polymerase chain reaction\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] to evaluate the cellular distribution of sars - cov in the lungs , in situ hybridization was performed based on the protocol of zhang and colleagues . 14 in brief , before hybridization incubation , all solutions were prepared with diethyl pyrocarbonate - treated water . after deparaffinization and rehydration , tissue sections were treated by proteinase k digestion or microwave heating and were then incubated with hybridization cocktail containing 50 g / ml sars probe at 45°c for 16 hours . after blocking with normal horse serum\n",
      "double\n",
      "vimentin immunostaining\n",
      "in situ hybridization\n",
      "in situ hybridization\n",
      "in situ hybridization\n",
      "in\n",
      "therapeutic interventions aiming at controlling the inflammatory response associated with infection . hence the suggestions that new definitions were needed , that would allow a quicker and simpler identification of septic patients for accrual into randomised trials\n",
      "hemodialysis and mechanical ventilation\n",
      "immunodepression\n",
      "corticosteroids\n",
      "[SEP]\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] most studies and clinical trials have focused on 28 - day or hospital mortality , a relatively short - term view , which does not provide a complete picture of the impact of sepsis on life expectancy , an important consideration for cost - benefit studies of the impact of new therapies . admittedly , most deaths usually occur early in severe sepsis . for example , 77 % and 71 % of all deaths had occurred by day 14 and by day 21 , respectively , in the french multicenter study [ 13 ] and in the study by pittet et al . [ 17 ] . however , 16 % of patients remained in the hospital for more than 30 days in the former study , and the median hospital stay of survivors was 34 days , with lengths of stay ranging from 1 to 87 days [ 13 ] . these data suggest that it would be advisable to assess the outcome of sepsis at least after 3 rather than 1 months after sepsis . similarly , sands et al . reported that the crude mortality of patients with severe sepsis was 34 % at 28 days and 45 % at five months post - discharge [ 8 ] . sasse et al . [ 30 ] reported a crude 28 - day and hospital mortality rate of 40 % and 51 % , respectively , in 153 icu patients with bacteraemic sepsis , and of 65 % and 72 % respectively at 6 months and 1 year after admission ; it should be emphasised that in this particular study , 25 % of patients each had hiv infection or malignancy . finally , rangel - frausto et al . , reported a 28 - day crude mortality of 9 % in the cohort of 2527 patients meeting at least sirs criteria ; an additional 111 patients died during the ensuing 3 months , and 113 more between 3 and 6 months follow - up [ 6 ] . the overall crude mortality rate at 6 months was therefore of 17 % in patients meeting at least sirs criteria . however , the relative part of sepsis and other host factors in the overall mortality is unknown . perl et al . , have addressed part of the problem by examining factors associated with late mortality after sepsis in a cohort of 100 patients with severe sepsis entered in one clinical trial of anti - endotoxin antibodies\n",
      "including\n",
      "organ dysfunction score\n",
      "hemagglutination inhibition\n",
      "elisa\n",
      "inoculation with any viruses\n",
      "reducing visits to hospital by asking patients to stay at home\n",
      "multivariate permutation testing\n",
      "general\n",
      "hierarchical clustering\n",
      "any use of trade , product , or firm names in this publication is for descriptive purposes only and does not imply endorsement by the u . s . government . the experiment described here complies with all rules and regulations pertaining to the land and resources where they were performed\n",
      "proteininduced fluorescence emission\n",
      "probability\n",
      "dichotomous variables were compared using the chisquare test and fisher ' s exact test . quantitative data were expressed as medians [ interquartile range ( iqr ) ] and compared using the mann - whitney u test\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] thirty - one patients were enrolled : 16 in the 1 g / 8 h group and 15 in the 2 g / 8 h group . a subject in the 1 g / 8 h group was excluded due to problems with bal sample processing . to compensate , an additional patient was recruited and randomized\n",
      "eradication\n",
      "administration of meropenem by continuous infusion\n",
      "prognostics\n",
      "reporting of observational studies in epidemiology\n",
      "standardized investigation forms\n",
      "elisa kits\n",
      "transmission electron microscopy\n",
      "fitting a log - normal , gamma , weibull , or a normal distribution by one - sample kolmogorov - smirnov test . for continuous variables we used one - sample or paired - sample t - test . for categorical variables we used mann - whitney u test , chi - square test , or fisher ' s exact test . we also performed univariable and multivariable logistic regression analysis\n",
      "structural changes in institutional organization\n",
      "en\n",
      "texto\n",
      "the breeders ' consent was obtained prior to enrollment of dogs and fecal sample collection\n",
      "viral pathogen analysis\n",
      "wilcoxon ranksum test\n",
      "halocur o and rehydration therapy\n",
      "weighed\n",
      "oneway anova and post - hoc tukey test\n",
      "genotyped\n",
      "professional codes of ethics\n",
      "expertise\n",
      "publicly - funded health care systems , such as those found in many western societies , there is a strong claim for a social contract between the hcp and society . it is a reasonable and legitimate expectation by the public that hcps will respond in an infectious disease emergency . society has granted and permits professions to be self - regulating\n",
      "codes of ethics remain current , practical , and concordant with public expectations\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] there is presently a need to address the professional duties of hcps to their patients with the risks to the well - being of society , which may include family , friends , co - workers , and other patients , in addition to the population at large . this is a matter of balance . the content of current professional codes of ethics offers little guidance or reflection of consensus in the health care community . in the wake of sars and with the current threat of avian influenza , it is clearly time for medicine , nursing , and other self - regulating health care professions to address the issue head on . a number of options are open to the professions . one option , which we have already argued is unacceptable , would be to remain silent . on the other extreme , codes of ethics could be revised with a strong emphasis on the professional obligation and duty to provide care during infectious disease emergencies ; that is , assume a position leaning towards supererogation , or performing acts that are ' above the call ' of duty [ 7 ] . several other options exist between these two extremes . for instance , the codes could reflect a strong but limited duty to care , with the limits clearly specified . alternatively , there could be a weak emphasis on duty to care - an option more sympathetic to the self - regarding concerns of hcps [ 8 ] - although this may run the risk of dissolution of the generally high regard for the health care professions that exists in society today . we maintain that , with respect to the duty to care , it is not acceptable for codes of ethics to be vague , ambiguous , or otherwise avoid explicit statements of position . this is particularly true in light of calls for additional protections for hcps during infectious disease outbreaks , including a position statement to that effect issued by the ontario medical association [ 25 ] . such calls for danger pay and / or enhanced disability insurance could be justified if the professions expressed a strong commitment to the ethical duty to provide care during public health emergencies . in the absence of such commitment , however , any additional measures to protect and safeguard the well - being of hcps would appear self - serving and misplaced . in the current context of pandemic influenza planning , as with other public health emergencies , there is an acute need for strategies to encourage greater discussion and dialogue among all interested parties and stakeholders\n",
      "either the mfe or the enforced mode\n",
      "folds arbitrary long sequences and reports as many suboptimal solutions as the user requests . the windows version contains a basic graphical user interface , the other versions provide a powerful interactive command line tool\n",
      "enhanced health education\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] in order to minimize staff exposure , and therefore infection , only essential staff should be present in the delivery room / theatre\n",
      "online resource portal\n",
      "clear protocols and communication of the protocols\n",
      "surveys\n",
      "external restriction or compression of the lungs\n",
      "identification of pulmonary pathology at autopsy\n",
      "antiviral strategies\n",
      "presence of two or more of the following features : fever\n",
      "temperature > 100 . 4°f ( > 38°c ) , andone or more clinical findings of lower respiratory illness\n",
      "radiographic evidence of pneumonia , or acute respiratory distress syndrome , or autopsy\n",
      "one or more of the following exposures\n",
      "one or more of the following exposures\n",
      "detection of serum antibody to sars - cov by a test validated by cdc ( e . g . enzyme immunoassay\n",
      "interferon - α , glycyrrhizin , and protease inhibitors\n",
      "investigation of 8 covariates\n",
      "polymerase chain reaction - restriction fragment length polymorphism\n",
      "blood samples\n",
      "univariable analysis\n",
      "multivariable modelling\n",
      "negative binomial regression\n",
      "calf scour prophylaxis\n",
      "radiation\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the medical literature contains little about the immediate response to the chernobyl disaster . even so , lessons can be learned about the gaps in reporting and communication and the secrecy of the authorities at the time . this failure to inform generated fear , rumors , and uncertainty . 39 there could be very high rates of posttraumatic stress disorder after a major radiation exposure . groups particularly at risk include children , pregnant women , mothers of young children , and emergency workers . prevention is essential through openness and communication\n",
      "st . vincent ' s hospital was one of the main receiving hospitals and performed well to avoid over - triage\n",
      "two - way radios\n",
      "commercial air travel\n",
      "field hospitals\n",
      "traditional battlefield medicine has focused on providing ' ' definitive ' ' trauma casualty care\n",
      "interagency collaboration and communication\n",
      "disaster preparation\n",
      "developing\n",
      "regularization method\n",
      "location and velocity initialization . the initial location and velocity of each robot are randomly assigned according to real conditions and features of each robot . 2 ) plume finding\n",
      "source localization\n",
      "using data from local and mainland china\n",
      "better biosecurity\n",
      "education for physicians in private care\n",
      "antibiotic therapy\n",
      "audit\n",
      "surveillance of sewage discharge\n",
      "educate\n",
      "a burn - in period\n",
      "a sensitivity analysis\n",
      "case numbers predicted by the parameter estimates of the idea model\n",
      "logistic regression\n",
      "intravenously per tail vain in 100 μl phosphate - buffered saline or by i . c . injection in 30 μl phosphate - buffered saline\n",
      "bisulfite treatment\n",
      "animation through a z - series of 1 - nm - thick digital slices ( total depth 200 nm ) of a dual - axis electron tomogram\n",
      "delphi method\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] our process to recruit individuals involved in snomed ct implementation was via email\n",
      "doodle was used to schedule individual interviews\n",
      "interviews\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] four interviewees felt that clinicians were generally in favour of using snomed ct\n",
      "challenges indentified by the interviewees\n",
      "ct\n",
      "snomed ct\n",
      "post - coordination\n",
      "requiring\n",
      "the ihtsdo should provide more guidance . interviewees who have had experience developing subsets suggested starting from a domain as restricted as possible and working towards more complex ones . 3 . 3 . 2 . 3 . data retrieval\n",
      "snomed ct\n",
      "snomed ct\n",
      "consult or referral letters\n",
      "policies\n",
      "training\n",
      "keep the user interface simple for clinicians by hiding the complexities of snomed ct\n",
      "migrating to snomed ct\n",
      "snomed ct\n",
      "snomed ct\n",
      "training\n",
      "snomed ct\n",
      "post - coding\n",
      "snomed ct\n",
      "snomed ct\n",
      "snomed ct\n",
      "interviews\n",
      "snomed ct\n",
      "snomed ct\n",
      "allowing clinicians to use an interface terminology\n",
      "extensions\n",
      "developing search algorithms\n",
      "auto - complete\n",
      "interface terminology codes and snomed ct ids\n",
      "cross maps\n",
      "data retrieval functions should be included to harness the rich semantics in snomed ct and enable clinicians to run patient case queries and to facilitate decision support . organisations that do not have the capacity to develop advanced retrieval functionality can consider using third party terminology services or application programming interfaces ( apis )\n",
      "training sessions\n",
      "unencoded terms should be routinely extracted for review to determine if they can be coded\n",
      "post - coordination\n",
      "implementing post - coordination continues to be a challenge both from a graphical user interface design and clinical terminology point of view ( e . g . , creating clinically nonsensical concepts , concept duplication and inefficiency of concept composition ) . in some cases there are some alternatives to post - coordination , such as using an information model\n",
      "test if the concept used in the mapping subsumes the post - coordinated expression\n",
      "submitting extensions\n",
      "snomed ct\n",
      "informed consent\n",
      "extraction\n",
      "real - time reverse transcription - pcr ( rrt - pcr ) assay\n",
      "the chi - square test\n",
      "a decrease in population fitness\n",
      "in the lowest ecological regions ( such as the sediment surface ) of a body of water\n",
      "a benign tumour of the intrahepatic bile ducts\n",
      "tumour\n",
      "an organochlorine insecticide\n",
      "marginal and long - term changes in birth , death , immigration\n",
      "improvements\n",
      "immunofluorescence with monoclonal antibodies\n",
      "pcr\n",
      "type specific primers\n",
      "rna - pcr\n",
      "rna\n",
      "reverse - transcription polymerase - chain - reaction\n",
      "sputum suctioning\n",
      "treatment\n",
      "improved systematic serial collection and testing of an increased number of urine samples\n",
      "use\n",
      "a medical mask\n",
      "wore\n",
      "bonferroni stepdown method\n",
      "standardized comparison\n",
      "combined ward rounds\n",
      "patient education\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] type i ifn is produced and secreted rapidly following viral infection ( 1 , 2 ) . it subsequently signals to surrounding cells\n",
      "induction of interferon\n",
      "ifn\n",
      "neutralizing , serotype - specific , and haemagglutinationinhibiting antibodies\n",
      "rt - pcr\n",
      "return to play ( rtp ) decisions after illness but also to prepare the athlete to act in a more preventive manner\n",
      "exercise\n",
      "[SEP]\n",
      "[SEP]\n",
      "training in a dehydrated state and excessive use of nutritional supplements\n",
      "antipyretics\n",
      "antipyretics\n",
      "[SEP]\n",
      "exercise\n",
      "oral antibiotic treatment\n",
      "non - infectious conditions\n",
      "fluid replacement\n",
      "prevention of illness\n",
      "frequent handwashing\n",
      "educating athletes , coaches and support staff in proactive stress management\n",
      "eating a well - balanced diet\n",
      "daily supplementation with 600 mg vitamin c\n",
      "saliva secretory immunoglobulin a\n",
      "glutamine supplementation\n",
      "ingestion of cystine and theanine\n",
      "ing\n",
      "probiotic supplementation\n",
      "individual preventive measures\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] canine coronavirus ( ccov ) is an enveloped virus of dogs associated with moderate to severe enteritis in young pups . ccov is included in the group i of coronaviridae family with transmissible gastroenteritis virus ( tgev ) of swine , porcine epidemic diarrhoea virus ( pedv ) , porcine respiratory coronavirus ( prcov ) , feline coronaviruses ( fcovs ) and human coronavirus 229e ( hcov 229e ) . coronavirus virions contain a single molecule of linear , positive sense rna ranging from 27 . 6 to 31 kb . the genome has a 5 - terminal cap followed by a leader sequence of 65 - 98 nucleotides ( nt ) and an untranslated region of 200 - 400 nt . at the 3 end of the genome there is an untranslated region of 200 - 500 nt followed by a poly ( a ) tail . the virion rna functions as an mrna and is infectious . it contains approximately 7 - 10 functional genes , 4 or 5 of which encode structural proteins . the genes are arranged in the order 5 - replicase - ( he ) - s - e - m - n - 3 , with a variable number of other genes that are believed to be non - structural and largely non - essential ( lai and holmes , 2001 ) . the s protein , a large surface glycoprotein ranging from 1160 to 1452 amino acids ( aa ) , is responsible for attachment to cells , haemagglutination , membrane fusion and induction of neutralizing antibodies\n",
      "highest serum dilution\n",
      "immunoblotting\n",
      "radiographic\n",
      "chest computed tomographic ( ct ) scans\n",
      "descriptive statistics\n",
      "expectoration\n",
      "oxygen inhalation supportive therapy\n",
      "early\n",
      "chemotherapeutic drug\n",
      "immunoblot analysis\n",
      "low speed centrifugation\n",
      "negative staining\n",
      "total antibody detection\n",
      "real - time quantitative pcr\n",
      "hem\n",
      "mechanischen einwirkungen konnen blutungen\n",
      "sonderfall ist das hws - « schleudertrauma « ( whiplash\n",
      "embolisation\n",
      "stopping\n",
      "radio\n",
      "reflexbedingte asystolie\n",
      "verbruhungen pflegebedurftiger patienten\n",
      "rauchgasinhalation\n",
      "abort\n",
      "nidation\n",
      "spezialfragen bei der begutachtung nichtnaturlicher todesfalle\n",
      "sonderfall der wundaltersbestimmung\n",
      "todesursachliche bedeutung\n",
      "mehrfachverletzungen\n",
      "blutaustrittspforte\n",
      "preventive medicine\n",
      "leukopheresis\n",
      "vaccination and antiviral treatment\n",
      "hospitalization ward , the length of hospital stay and outcome ( occurrence of complication , intensive care unit admission and death ) . data were retrieved from the medical charts , interviews with the patients and families , and laboratory databases\n",
      "respiratory virus testing\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the median age of the 53 patients with rsv infection alone was 74 years ( iqr , 61e84 ) ( table 2 ) . chronic underlying diseases were present in 45 cases ( 45 / 53 , 85 % ) , and consisted mainly of chronic respiratory diseases ( 29 / 53 , 55 % ) , chronic heart disease ( 24 / 53 , 45 % ) and cancer ( 18 / 53 , 34 % ; 12 solid tumours , 6 haematological malignancies ) . fifteen patients ( 15 / 53 , 28 % ) were on immunosuppressive therapy\n",
      "clinical trials\n",
      "fluvac\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] using ili symptoms to predict culture or rt - pcr positivity for influenza is difficult : \" symptoms do not occur in 30 - 50 % of influenza infections . asymptomatically infected persons can shed detectable influenza virus and may transmit influenza to others , although data supporting the frequency of transmission prior to symptoms is limited \" and \" in most instances , individual cases of influenza are difficult to identify reliably by clinical examination and routine clinical laboratory findings alone , and the appropriate use of influenza diagnostic tests\n",
      "detecting which pathogens are circulating and using proven barrier and hygiene methods\n",
      "renaming\n",
      "development of a \" core outcome set\n",
      "consensus meeting\n",
      "snow\n",
      "evidence - based medicine\n",
      "search\n",
      "delphi survey\n",
      "the questionnaire for professionals and the public was sent by smartphone\n",
      "the questionnaire\n",
      "voting\n",
      "questionnaire\n",
      "delphi survey\n",
      "incentive measures\n",
      "sars - cov - 2 nucleic acid tests\n",
      "systematically\n",
      "initial assessment was based on review of title and abstract of all studies\n",
      "diagnostic testing\n",
      "openly available maps\n",
      "thorough planning\n",
      "randomized controlled trials\n",
      "surveys\n",
      "simulated client technique\n",
      "discrete choice experiments\n",
      "qualitative research\n",
      "data collection\n",
      "reflexivity\n",
      "enhance trust with participants\n",
      "combination of more than one research method\n",
      "practice - based research\n",
      "pharmacy practice research\n",
      "statistical testing\n",
      "real - time rt - pcr\n",
      "virus isolation\n",
      "fplv dna\n",
      "urine\n",
      "electrophoresis apparatus . 7 . uv transilluminator . 8 . qiaxcel ® capillary electrophoresis system\n",
      "optimization\n",
      "briefl y centrifuge each reagent\n",
      "pcr products may be analyzed by agarose gel electrophoresis or by capillary electrophoresis\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] severe acute respiratory syndrome ( sars ) is a newly emerged disease caused by sars coronavirus ( scov ) . sars originated in southern china in 2002 and spread to five different continents causing > 8000 infection and > 700 deaths before its apparent eradication as a human infection in 2004 [ 1 ] . healthcare systems in affected areas were severely stressed and additional economic costs in trade and travel were very high . it is not known if the virus will be reintroduced into the human population but ancestral coronaviruses are widely distributed in bats and are thought to have adapted to civets and then to humans in recent time periods [ 2 , 3 ] . because emerging viruses tend to reemerge as conditions change [ 4 ] , it is highly desirable to develop safe and efficacious vaccines and / or antivirals to prevent scov infections . all coronaviruses , including scov , carry four structural proteins : nucleocapsid ( n ) protein and three envelope proteins , namely spike ( s ) protein , a type i transmembrane glycoprotein ; envelope ( e ) protein ; and membrane ( m ) protein , which has three membrane - spanning domains . coronavirus s protein is responsible for virus adsorption to susceptible cells through a specific virus - receptor interaction and induces membrane fusion between viral envelope and host cell membrane [ 5 ] . s protein is a main player for determining coronavirus tissue tropism , host specificity and viral pathogenicity [ 6 ] [ 7 ] [ 8 ] [ 9 ] [ 10 ] [ 11 ] [ 12 ] . because most coronavirus neutralizing antibodies recognize s protein [ 1 , 13 ] , it is not surprising that most of the current scov vaccine candidates are either the s protein subunit itself or those carrying s protein [ 14 ] [ 15 ] [ 16 ] [ 17 ] [ 18 ] [ 19 ] . furthermore , prophylactic administration of monoclonal antibodies\n",
      "low - speed centrifugation\n",
      "bio - rad dc protein assay\n",
      "western blotting\n",
      "soaking the gel with bio - safe coomassie stain\n",
      "negative staining\n",
      "kruskal - wallis non - parametric analysis of variance\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] histopathological examination of the groups of mice that neither produced neutralizing antibodies\n",
      "development\n",
      "extraction and purification\n",
      "sialidase inhibitory assay\n",
      "kinetic inhibition assay\n",
      "prompt recognition combined with appropriate therapy\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] laboratory service consolidations have to answer the following : \" how can the consolidation make the laboratory operations more advantageous both financially and clinically , given available resources ? \" from a clinical laboratory perspective , a centralized laboratory network enables addressing different levels of complexity in analytical processes , while concurrently servicing increased volumes of routine tests . the challenge is to simultaneously address the demand for detection and characterization of unusual or exotic pathogens , drug resistance , or virulence traits as appropriate , and meeting the requirement for health - care cost containment and financial efficiency . in this perspective , a number of high profile microbiology services consolidations have already taken place in the private sector over the last decade : an effective approach includes the creation of task - specific teams representing multiple skills built around infectious diseases specialists and cms . the need for an increase in professional diversity sometimes contradicts the established specialty training and certification pathways and creates complexities with regard to the required staffing structure and laboratory organization . in general , the utilization of cross - disciplinary teams forced the move in the direction of a flatter hierarchical structure within healthcare organizations ( 16 ) ( 17 ) ( 18 ) . even though cms play a pivotal role in the management of infected patients ( 19 ) ; the technological advances and laboratory consolidation process have clearly changed the landscape of the interaction between clinicians and cms . increasingly , such interactions are based on video conferencing\n",
      "repurpose commercially available drugs\n",
      "natural\n",
      "surface - sterilized with 95 % ethanol and rinsed twice in water before nucleic acid extraction\n",
      "first strand cdna synthesis\n",
      "blast searches\n",
      "rapid amplification of cdna ends\n",
      "multiple sequence alignment\n",
      "orcid\n",
      "biotechnology\n",
      "synthesizing a wide plethora of organic compounds\n",
      "plants\n",
      "prove a product unsafe\n",
      "medicinal plants\n",
      "develop techniques to enhance the active ingredient from its usual quantity present in the plant , and to enhance the biomass and better growth of medicinally important herbs\n",
      "molecular docking simulation\n",
      "represent the drug - nr pair sample\n",
      "2d\n",
      "pseudo amino acid composition\n",
      "combining the two equations as given by ( 19 ) where g represents the drug - nr pair , a the orthogonal sum , and the 256 + 500 = 756 components are defined by equations ( 2 ) and ( 18 ) . for the sake of convenience , let us use x i ( i = 1 , 2 , , 756 ) to represent the 756 components in equation ( 19 ) ; i . e . , ( 20 ) to optimize the prediction quality with a time - saving approach\n",
      "jackknife test\n",
      "progressive respiratory failure due to alveolar damage and even death\n",
      "multiple sequence alignment\n",
      "hospitalized\n",
      "shedding analyses\n",
      "posted\n",
      "augmented dickey - fuller ( adf ) test 19\n",
      "distributed lag model\n",
      "more lags\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] can comparison of mortality rates across hospitals provide information on the quality of care provided ? this question remains highly contentious . clearly mortality may be affected by the mix of cases included in the population in which mortality is measured ( case - mix ) and a range of other , potential risk factors such as a patient ' s age or stage of disease ( case - severity ) [ 41 ] [ 42 ] [ 43 ] . to correct for these factors that vary at the individual patient level some high - income countries employ sophisticated adjustment approaches . a number of hospital mortality measures are used in high - income countries and are recommended by organisation for economic co - operation and development ( oecd ) and national governments as part of portfolios of quality indicators and there is little doubt such measures ( and the debate around them ) have directed nations ' attention to improving quality and outcomes . examples include the uk ' s summary hospital mortality index or medicare ' s more disease specific acute myocardial infarction 30 - day mortality rate that are both used as indicators of hospital performance . so , could specific hospital mortality data be useful in gauging the quality of health care and health systems in lmic ? two such measures are already part of who ' s 100 core indicators for global tracking and comparison , peri - operative mortality and institutional maternal mortality rates . these , and other measures may be useful for three reasons : a ) for benchmarking particularly in conditions where case - specific mortality may be informative , b ) box 2 - the use of simple funnel plots to illustrate variability in hospital mortality funnel plots\n",
      "benchmarking against peers\n",
      "obtain timely and accurate information from other places\n",
      "improve health services\n",
      "multi - media communication\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] from 2006 , in anticipation of an outbreak of pandemic influenza , malawi drafted a preparedness plan that would assist in reducing its threat and intensity . although there was substantial preparedness planning and progress in its cycle of development , many planning tasks and responses remained unmet . the 2009 hin1 pandemic influenza arrived sooner than was expected , and the plan was activated in april 2009 with inadequate time for influenza drills , exercises and simulations to test the plan . surveillance at the time , however , included only screening for possible influenza cases at country borders . activities were incomplete prior to and during the pandemic , and were characterised by poor reporting , lack of surveillance systems and infrastructure . adequate reporting would have required building the capacity of the virology reference laboratory to conduct appropriate tests and collect appropriate and timely data to characterise the epidemic by person , place and time . this can be done through influenza web - based reporting systems and where possible , the use of rapid test technology in rural areas to capture real time surveillance data . there were inevitable tensions between global policy and its local operationalisation . the adoption of decisions without consideration of malawi - specific situations , needs , priorities and actions created confusion and communication difficulties . insufficient epidemiological evidence at the national and local level raised questions about the science behind prpi , echoing schuchat ' s and colleagues ' argument about decision - making with imperfect science , and the challenges of generalising patterns of transmission or risk factors in seasonal and pandemic influenza [ 19 ] . in this study , we found a weak scientific advisory committee unable to bridge the gap between the epidemiology of the disease and operational responses . this reflects in part the role of simulation exercises\n",
      "interviews and data analysis\n",
      "ethics\n",
      "a well - functioning health and surveillance system\n",
      "disinfection of the sewage is by chlorine\n",
      "dried\n",
      "ch\n",
      "seeded with sars - cov and f 2 to a final concentration of approximately 10 2 - 10 3 pfu or tcid 50 per milliliter . after mixing , samples were taken for an initial virus assay\n",
      "ten milliliters of na 2 s 2 o 3 ( 10 % , w / v ) were added to the disinfected sewage collected from the hospitals to neutralize the residual chlorine\n",
      "virus rna extracting kit\n",
      "a pair of consensus primers of enteroviruses\n",
      "rt - pcr assay\n",
      "pcr products were analyzed by electrophoresis\n",
      "pcr products from four different samples were purified with the qiaquick pcr purification\n",
      "semi\n",
      "[SEP]\n",
      "pcr\n",
      "druggability , all campaigns towards clinically relevant protease inhibitors\n",
      "peptide - based inhibitors\n",
      "zika virus protease\n",
      "mitigation and prevention strategies\n",
      "sequencing the virus\n",
      "evaluation of host genetics\n",
      "imaging\n",
      "chest computed tomography\n",
      "telemedicine\n",
      "estimating such parameters from in - practice data\n",
      "machine\n",
      "reuse those that have been approved for other purposes\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] presently , there is much to be learned regarding how best to treat covid - 19 patients when sufficient resources are available , as well as how to optimize operational decisions such as the triage of patient testing and care when they are not . as accessible , cleaned , and structured ehr data become available for covid - 19 patients at both the institutional and multi - site consortium levels , there will be increased opportunity to apply machine learning to better understand and make risk predictions on a variety of clinically and operationally relevant outcomes . the accessibility of data science and ml packages ( e . g . pandas , scikit - learn , and tensorflow python libraries ) , paired with widely available high - powered computational hardware offers significant opportunity for researchers to get involved in data analysis and modeling . however , many caveats need to be taken into consideration in order to develop and apply effective , rigorous ml analysis pipelines for replicable covid - 19 investigation . some key considerations and targets of research include : ( 1 ) feature engineering , transforming raw data into features ( i . e . variables ) that ml can better utilize to represent the problem / target outcome , ( 2 ) feature selection , applying expert domain knowledge , statistical methods , and / or ml methods to remove ' irrelevant ' features from consideration and improve downstream modeling , ( 3 ) data harmonization , allowing for the integration of data collected at different sites / institutions , ( 4 ) handling different outcomes and related challenges , e . g . binary classification , multi - class , quantitative phenotypes , class imbalance , temporal data , multi - labeled data , censored data , and the use of appropriate evaluation metrics , ( 5 ) ml algorithm selection for a given problem can be a challenge in itself , thus strategies to integrate the predictions of multiple machine learners as an ensemble are likely to be important , ( 6 ) ml modeling pipeline assembly , including critical considerations such as hyper - parameter optimization\n",
      "smartphones and other technology for educating the public about the pandemic and ways to avoid infection as well as monitoring , and the second explores the use of sensors\n",
      "smartphones and other wearable smart devices contain research - grade sensors that are capable of shedding light on at least a subset of covid - 19 symptoms which include fever , fatigue , dry - cough , and shortness of breath . for example , the temperature recorded by fingerprint sensors , which are now standard on most modern smartphones , has previously been used to successfully predict fever [ 19 ] . in addition , activity sensors such as the accelerometer have been used to detect fatigue . while high resolution computed tomography\n",
      "information systems for the monitoring and dissemination of accurate information to the public\n",
      "adequate disease monitoring\n",
      "prior\n",
      "real - time monitoring capability\n",
      "biomedical\n",
      "cross - validation\n",
      "svrmhc\n",
      "additive method\n",
      "step - wise outlier determination and exclusion scheme\n",
      "drastic measures are being taken that affect large populations of youth to slow the rate of infection . young people adapt daily as schools , colleges , movie theaters , restaurants , and bars close ; sports games , music concerts , dance recitals , graduations , and proms are cancelled ; and shelter - in - place orders are becoming a way of life . these public health measures are critically important to protect individuals ' health , reduce the burden on our healthcare system , and limit the number of people whose lives are cut short by covid - 19 . at the same time , questions have emerged about whether costs to young people associated with the aggressive disease prevention measures such as school closures\n",
      "diagnostic pathway\n",
      "respiratory and droplet - isolation precautions\n",
      "close attention to regional risk and the incubation period is essential , and can help to rule out several of the aforementioned conditions . patients with fever and jaundice should be admitted to hospital with appropriate contact precautions , pending diagnostic confirmation , for observation and appropriate therapy\n",
      "empiric treatment based on the clinical presentation\n",
      "cytotoxic and anti - rv\n",
      "[SEP]\n",
      "cultured\n",
      "regression analysis\n",
      "nr assay\n",
      "mtt reduction assay\n",
      "trypan blue exclusion method\n",
      "limit - dilution method\n",
      "crystal violet method\n",
      "therapeutic\n",
      "sampling strategy , we report the clinical and biological features of the first five cases of confirmed covid - 19 in europe , which occurred in france , and their dynamics in parallel with changes in their viral load , based on severe acute respiratory syndrome coronavirus 2 ( sars - cov - 2 ) rna detection\n",
      "sampling strategy\n",
      "immediate isolation of cases after symptom onset together with a rapid screening and monitoring of the contacts of infected patients\n",
      "data analysis , data interpretation , and writing of the report . the corresponding author had full access to study data and final responsibility for the decision to submit for publication\n",
      "immediate isolation\n",
      "iron supplement therapy\n",
      "use adult sources of stem cells such as the haematopoietic stem cells\n",
      "retrospective registration of unwanted events that has happened\n",
      "blood transfusion\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] patients treated with high dose chemotherapy\n",
      "combined detection of hepatitis c virus core antigen and antibody\n",
      "plt transfusion\n",
      "division of responsibilities between blood establishments and hospital based transfusion services\n",
      "completing\n",
      "recruiters should developed methods for reaching and motivating them to donate blood\n",
      "blood donation\n",
      "temporary deferral\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] questionnaire on 2700 subjects - students , their knowledge and motivation on blood donation f vladareanu , a bugner and s sirian national institute of heamatology transf , bucharest , romaniathe research theme of this questionnaire is as follows : ' what is the level of knowledge and of motivation in the non - remunerated and voluntary blood donation at students ? ' we also tried to see the practical implications that this study will have and how it will influence the knowledge in this area . the purpose of this questionnaire was not dissimulated . the general theme of the knowledge and motivation on blood donation had been studied before through two big questionnaires applied in 1987 and 1992 , but the general population was their target . students had never been an investigated lot up to now . the hypothesis referring to this problem is as follows : students are not informed either on the act of donation , or on the crisis of blood . 1 . the lack of information is a first cause of the indifference of the studied lot towards the idea of donation . 2 . the lack of motivation of the studied lot is another cause . the questionnaire was applied on a 2700 lot of students from seven different cities : bucharest , iasi , constanta , cluj , sibiu , brasov , timisoara . the number of the questions was limited to 22 , which we consider best for a questionnaire applied on the street or at college\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] background : in life - threatening exacerbations of sle a satisfying efficient therapy is lacking . despite intensive immunosuppressive therapy some patients are resistant or contraindicated to conventional treatment . in particular circulating antibodies and immune complexes play an important role in the pathogenesis of sle and mctd . an extracorporeal removal of these pathological substances may be effective in the treatment of active disease . methods : five patients with severe therapy - resistant sle / mctd underwent immunoadsorption onto protein a . blood was drawn from patients by using a jugular catheter or a peripheral intravenous catheter . anticoagulation was performed with acd - a and heparine or acd - a and r - hirudine\n",
      "blood transfusion\n",
      "developing our own model\n",
      "flow cytometry\n",
      "web - based outcome review\n",
      "blood transfusion\n",
      "blood\n",
      "preventative maintenance\n",
      "transfusions\n",
      "blood transfusion\n",
      "measurement system analysis\n",
      "technical standards for safe storage and transport of blood components and blood samples\n",
      "two cell separators\n",
      "retrospectively analysed\n",
      "registration\n",
      "collecting and displaying the information on hemovigilance this way , creates a transparent and more easy - to - manage process . it establishes a basis , which incorporates all resources , responsibilities , actions , and internal controls to all participants and enables the organisation to operate both efficiently and effectively . it allows us to show auditors ( both internal and external ) which processes are related to which guidelines as well as the results in daily . in addition , it reveals which factors determine the genuine application of the guidelines in clinical practice . conclusion : by outlining the process , followed by defining , analysing , securing , on the ' w6 ' method\n",
      "transfusion medicine\n",
      "transplantation\n",
      "establish countrywide effective blood transfusion practice\n",
      "blood transfusion\n",
      "quality\n",
      "antibodies\n",
      "high dose iv immunoglobulin\n",
      "antibody screening\n",
      "early detection of hepatitis b surface antigen\n",
      "percentage oxygen as a surrogate marker for bacterial growth\n",
      "earlier detection of human immunodeficiency type 1 , hepatitis c and hepatitis b viruses using the procleix® ultrio tm assay\n",
      "organ transplantation or from blood transfusion\n",
      "transfusion of erythrocyte concentrates as the only possible treatment for many years . objective : to show the prevalence of hepatitis b ( hbsag ) and hepatitis c ( anti hcv antibodies\n",
      "mandatory tests for each blood donations\n",
      "blood donor screening\n",
      "abbott prism assays\n",
      "industry - sponsored clinical trials\n",
      "blood donation\n",
      "blood is a national resource , it is the responsibility of governments through it ' s communities\n",
      "efforts to recruit young people as blood donors\n",
      "dna based assays\n",
      "blood transfusion\n",
      "transfused\n",
      "transfusion and iron chelation\n",
      "transfusion\n",
      "regular blood transfusion therapy\n",
      "viral inactivation / elimination of plasma derived medicinal products\n",
      "sodium citrate\n",
      "photochemical treatment\n",
      "flow cytometry\n",
      "cell salvage autotransfusion\n",
      "ventilation with pure o2 ( hyperoxic ventilation\n",
      "colloid solutions\n",
      "recombinant human erythropoietin therapy in critically ill patients - a dose response study * objective : the aim of our study was to assess the efficacy of two dosing schedules of recombinant human erythropoietin ( rhuepo ) in increasing hemoglobin ( hb ) level and reducing the exposure to red blood cells ( rbc ) transfusion\n",
      "irradiation\n",
      "improved skin antisepsis\n",
      "cost - effectiveness and sensitivity analyses\n",
      "dcb collection\n",
      "increased yield of mature platelets\n",
      "hematopoiesis\n",
      "tissue banking\n",
      "intravenous immunoglobulin\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] introduction : the bombay phenotype is extremely rare and characterized by complete absence of abh activity both on erythrocytes and in secretions . those individuals can produce anti - h , which is active over a wide thermal range . method : using liss indirect antiglobulin technique\n",
      "computerized system\n",
      "frozen\n",
      "anti - j k3\n",
      "evaluation of validity of the expired enzymetreated 0 . 8 % red cells in antibody identification gel tests using nacl cards p chalkia , s intzepeli , v avgoloupi , a tsoukala , e ntinopoulou and p didoudi ahepa hospital , thssaloniki , greecebackground : expired red blood cells of required phenotypic profile is often used to identify antibody specificities in patients with multiple anti - erythrocytes antibodies . accurate results depend on the integrity of the antigens . purpose : to validate the expired enzyme - treated 0 . 8 % red cells for use in antibody identification gel tests using nacl cards\n",
      "worldwide\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] unusual ab0 grouping discrepancy - inhibition of anti - b reagent by isolated increase of plasmatic b substance in a patient with group ab and pancreatic cancer m pisacka * , k petrtylova † , m kralova * and h flidrova * * uhkt , prague 2 , † blood bank , faculty hospital m , prague 5 , czech republic introduction : in rare pathological conditions excess amount of blood - group specific substances can be observed and can cause neutralization of grouping reagents . changes in abh and related histo - blood group antigens in malignant tissues were described but there are few information about similar changes in secreted bloodgroup specific substances . aim of the study : we describe a case of isolated increase of b group substance in plasma of a group ab patient with pancreatic cancer . methods : ab0 grouping was performed with registered immucor reagents ( immuclone : anti - a birma 1 , anti - b lb2 ) by slide and tube tests . neutralizing effect was quantified by ( i ) inhibition od anti - b reaction by titrated patient ' s serum\n",
      "antibody\n",
      "lateral\n",
      "autovuetm system\n",
      "regular rbc transfusions\n",
      "flow cytometric analysis\n",
      "multiple isoforms\n",
      "genomic dna analysis\n",
      "flow cytometry with three - color fluorescence . in this study , the third generation bags and filters\n",
      "pre - and post - storage filtration\n",
      "platelet compatibility testing and alloimunization\n",
      "disseminated intravascular coagulation\n",
      "maternal platelet transfusion therapy\n",
      "inheritance of a rhd cat vi type ii in a twin pregnancy : a case report\n",
      "human anti - d immunoglobulin\n",
      "chimeric primed donor cells\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] background : incompatibility with many blood units is a major problem in transfusion therapy . in selective operations , preoperative autologous blood donation\n",
      "use of darbepoetin - alpha in preoperative autologous blood donation\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] background : preoperative autologous blood donation\n",
      "autologous blood transfusion ) through preoperative blood donation\n",
      "autologous blood donation\n",
      "cytokine release\n",
      "high - resolution dna\n",
      "improvement of the system and nil for plasma\n",
      "plasma fractionation\n",
      "provision of safe and sufficient plasma derivatives\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] ( light cycler , roche diagnostic systems , nj ) was used for the identification of the c282y , h63d and the s65c point mutations of the hemochromatosis gene , and were based on protocols developed , for c282y by the unidad de medicina molecular ( ingo , santiago de compostela , espanha ) , and for the other two mutations by bolhalder m et al . the primers and probes were designed by tib molbiol ( berlin , germany ) . results : the analysis of the percentages of genotypes and allele frequencies of the hemochromatosis gene mutations are described in the table . no differences were found between the patients and the controls . when we compared subgroups of patients based on their hepatitis c genotypes , a higher value for the c282y allele was obtained ( 9 . 0 % ) in individuals with genotype 1 , however without statistical significance . discussion : hereditary hemochromatosis is a common disorder and is associated , in some studies , with a worst prognosis in patients with viral hepatitis . follow - up studies are necessary in order to evaluate if the presence of these mutations can cause a more severe course of the illness ( greater risk to develop fibrosis or cirrhosis ) and a different outcome when treated with antiviral drugs . also , it will be important to evaluate if aggressive phlebotomies\n",
      "a combination of techniques\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] who cares about the quality of life of the chronic patients treated with blood products ? d ilcenco * , e hanganu - turtureanu † , c burcoveanu † , c vartolomei ‡ and d azoicai § * blood transfusion center , † hospital ' sfantul spiridon ' , ‡ institute of hygiene , § university of medicine , iasi , romaniaquality of life\n",
      "hemolytic medium time ) techniques in 23 sera of patients with ascariasis . results : the ai and hk tests showed : b epithopes in 4 ae from b patients and in 3 ae from ab patients ; a epithopes in 1 ae from ab patient and in 3 ae from a patients ; p and p1 epithopes in 18 ae and only p1 epithopes in 3 ae . these 21 patients had both epithopes in their erythrocytes . the hemolytic techniques showed : anti b immune antibodies\n",
      "electroforesis\n",
      "passing\n",
      "education of all staff handling blood components , to reduce human error . - the implementation of and access to , proactive blood safety technologies\n",
      "gene therapy\n",
      "immune hemolytic anemias\n",
      "frozen plasma\n",
      "avoidance of using plasma containing blood components\n",
      "maximising the blood supply chain\n",
      "reducing the current usage of blood through appropriate use programmes\n",
      "updating of the russian law ' concerning the donation of blood and blood components\n",
      "funding for blood donations\n",
      "regular whole blood removal\n",
      "preoperative autologous blood donation\n",
      "statistical analysis\n",
      "hemagglutination inhibition assay\n",
      "the hi test\n",
      "[SEP]\n",
      "statistics\n",
      "public health interventions\n",
      "policy options\n",
      "coordinated policy action\n",
      "moderate social distancing\n",
      "social distancing\n",
      "closing schools , working from home , household quarantine and city lockdown\n",
      "sustained policy intervention\n",
      "general social distancing intervention\n",
      "applying the seir - hqd model , we designed two sets of scenarios to explore : 1 ) the age - specific effects of policy interventions\n",
      "working from home\n",
      "quarantine rate table 2 scenario design for age - specific effects analysis\n",
      "data collection , data analysis , data interpretation , or writing of the report . the corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication\n",
      "no intervention\n",
      "maintain the interventions\n",
      "declare no competing interests\n",
      "modeling code and estimation\n",
      "preprint\n",
      "early identification of populations in the first stages of psychological crisis will allow for the efficient implementation of interventional strategies\n",
      "reverse transcription\n",
      "restriction digest\n",
      "pcr products were cloned into the pgem - t - easy vector ( promega ) . plasmid dna ( 600 ng ) was sent to the sequencing service ( university of dundee , uk ) for sequencing\n",
      "bootstrap and maximum parsimony analyses\n",
      "partial spike protein gene\n",
      "type - specific antisera\n",
      "pcr\n",
      "rt - pcr\n",
      "after removal of medium , slides were fixed with 100 % methanol and allowed to dry in air\n",
      "centrifugation\n",
      "inc\n",
      "incorporation of an alkoxyphenyl side chain\n",
      "synthesis and characterization\n",
      "short - column flash chromatography\n",
      "short - column flash chromatography\n",
      "short - column flash chromatography\n",
      "chloroacetyl chloride\n",
      "inhibition of hiv - 1 ( iii b ) - and hiv - 2 ( rod ) - induced cytopathicity in cem cell cultures\n",
      "cytotoxicity measurements\n",
      "animal experimentation\n",
      "ultrasound treatment\n",
      "freeze / thaw\n",
      "inc\n",
      "isolated co - culture cell system\n",
      "phosphate buffered saline\n",
      "the cells were washed by pbs and 1 . 5 ml maintenance medium\n",
      "immunofluorescence assay\n",
      "whole - genome analysis\n",
      "gel electrophoresis\n",
      "triaging\n",
      "advance care planning\n",
      "bepaling van de bloedgroepen van het ab0 - systeem en het resussysteem en bepaling van eventuele irregulaire antistoffen zijn daartoe noodzakelijk\n",
      "type en screenmethode\n",
      "traten van erytrocyten en trombocyten en geisoleerd plasma\n",
      "zoals plasma\n",
      "acuut longoedeem door acuut hartfalen\n",
      "shock\n",
      "immunoglobuline\n",
      "anti\n",
      "transplant\n",
      "chronische anemie\n",
      "anesthesie\n",
      "damage control\n",
      "pooling van trombocyten , verdunning en een verminderde productie . bij trombocytopenie door een verhoogde afbraak , zoals de auto - immuuntrombocytopenie en bij pooling\n",
      "fresh - frozen plasma\n",
      "chirurgische bloeding\n",
      "tranexaminezuur en ffp of fibrinogeenconcentraat\n",
      "intraveneus heparine\n",
      "anesthesiol\n",
      "dosis\n",
      "recombinantfactor ( rf ) viia\n",
      "supplementation of parenteral or enteral feeding with ω - 3 fatty acids\n",
      "counseling\n",
      "psychophysical examination\n",
      "topical steroids\n",
      "res\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the unique concept of the proposed ventilator is depicted in figs . 1 and 2 . it comprises a plastic air tank , two wooden or plastic circles ( fixed and mobile discs ) , a bendable wire , two check valves , a dc motor , and a support box ( guide cylinder ) . as shown in fig . 1 , the motor is fixed to the center of the upper circle . in the on state ( fig . 3a ) , the motor is activated , causing the upper circle to rotate in one direction . the movement of the motor causes the wire to bend . this pulls the bottom circle upwards , which pressurizes the air inside the tank . this pressurized air is consequently directed into pipes through the check valve . this state corresponds to the inspiration phase . in the off state ( fig . 3b ) , the motor is released . the bottom circle then moves downwards under the influence of its own weight and the release of the tension in the wire , which is restored to its initial position . since the pressure in the lungs is higher than the pressure in the air tank , the device will draw air from the patient ' s lungs . thus , the off state corresponds to the expiration phase . the cycling of on and off states induces respiration . on the other hand , the movement of the bendable wire towards its initial position causes the motor to rotate in the opposite direction , so the motor can be used as a dynamo to generate electricity , thus recharging the battery\n",
      "ventilator design is proposed . the concept is still under development . future iterations will include changes induced by the results of our prototype testing . it will incorporate an adjustable inspiratory / expiratory ratio\n",
      "controlled interrupted time series\n",
      "randomized controlled trial\n",
      "maintenance and continuous adaptation and improvement of public health measures\n",
      "search\n",
      "plaque assay\n",
      "adding 1 mm pmsf and 200 µm ne inhibitor\n",
      "σ3 removal , the proteins from 5 . 0 × 10 10 particles were separated on sds - 12 % polyacrylamide gels and visualized with coomassie brilliant blue staining\n",
      "public health measures\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the copyright holder for this preprint this version posted may 11 , 2020 . . https : / / doi . org / 10 . 1101 / 2020 the copyright holder for this preprint this version posted may 11 , 2020 . . https : / / doi . org / 10 . 1101 / 2020 the copyright holder for this preprint this version posted may 11 , 2020 . , and mood disorder ( orr 0 . 859 - 0 . 896 ) showed a decreased risk of covid - 19 in multivariable analysis . the copyright holder for this preprint this version posted may 11 , 2020 . . https : / / doi . org / 10 . 1101 / 2020 . 05 . 08 . 20095174 doi : medrxiv preprint associated with an increased risk of covid - 19 only in multivariable analysis ( figure 3 , table s8 ) . the patients who had non - insulin dependent diabetes with complication ( or 1 . 267 - 1 . 290 ) was associated with an increased risk of presence of covid - 19 in multivariable model 1 . chronic lower respiratory disease ( orr 0 . 670 - 0 . 798 ) , non - b & non - c hepatitis ( orr 0 . 703 - 0 . 765 ) , lower digestive system diseases ( orr 0 . 698 - 0 . 820 ) , dementia ( orr 0 . 573 - 0 . 656 , and neurosis ( orr 0 . 642 - 0 . 807 ) showed a decreased risk of covid - 19 in multivariable analysis . this pattern was consistent in the subgroup which excluded long term health care utilizers ( table s9 ) . the copyright holder for this preprint this version posted may 11 , 2020 . . https : / / doi . org / 10 . 1101 / 2020 . 05 . 08 . 20095174 doi : medrxiv preprint severe covid - 19 in all multivariable analysis . isolated hypertension ( or 1 . 378 , 95 % ci 1 . 008 - 1 . 883 ) , rheumatoid arthritis ( orr 1 . 865 - 1 . 908 ) , and substance use\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the novel coronavirus disease caused by sars - cov - 2 , has rapidly emerged since december 2019 . as of april 18 , 2020 , a total of 2 , 160 , 207 confirmed cases , including 146 , 088 deaths , have been reported worldwide [ 1 ] . despite the introduction of social distancing\n",
      "reverse transcription polymerase chain reaction\n",
      "multivariable analysis\n",
      "laboratory tests\n",
      "subgroup analysis of multivariable analysis with whole disease category\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] this subpopulation analysis was conducted to identify the risk factors for high regional outbreak . hypertensive renal disease ( orr 1 . 501 - 2 . 602 ) , glomerular disease ( orr 1 . 783 - 2 . 380 ) , crf and esrd ( orr 2 . 105 - 3 . 237 ) , and anemia ( orr 1 . 259 - 1 . 539 ) were associated with an increased risk of covid - 19 outbreak in univariate and multivariable analysis\n",
      "multivariate analysis\n",
      "intra\n",
      "rt - pcr\n",
      "ultrafiltration\n",
      "subcutaneously injected with sars - psv , mers - psv or pbs for the first prime immunization\n",
      "detection of relative light units using a firefly luciferase assay kit\n",
      "lumbar puncture on admission\n",
      "serotype identification\n",
      "a standard reference virus strain\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] we leveraged molecular dynamic simulations and automated fast - flow peptide synthesis\n",
      "bio\n",
      "122blocking\n",
      "peptide\n",
      "disruption\n",
      "[SEP]\n",
      "cleavage solution\n",
      "therapien\n",
      "prospektive analysen\n",
      "monitoring\n",
      "g\n",
      "the method of baltimore et al . ( 1970 ) for determining primary transcription in vivo , the method of bean and simpson\n",
      "measuring the association of radiolabeled input viral genomic rna with rnase resistant complexes\n",
      "statistical analysis\n",
      "respiratory samples of a total of 3 , 505 patients , viruses\n",
      "mini\n",
      "broad npis and without a vaccine\n",
      "computing approximate solutions\n",
      "intervention is more impactful when there is a larger infected population\n",
      "dividing\n",
      "standard application of pontryagin ' s maximum principle\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] in this section only , we consider controls that reach the optimal value x ∞ = 1 / σ 0 . this is achieved only at ( x , y ) = ( 1 / σ 0 , 0 ) , a state that cannot be reached from any other state without imposing some control\n",
      "bang\n",
      "setting\n",
      "hamiltion - jacobi - bellman ( hjb ) equation for this problem and apply an upwind numerical method\n",
      "first - order upwind finite difference method\n",
      "keep the number of infected below some threshold\n",
      "peer review\n",
      "apply no control until a certain switching time , and then apply maximum control\n",
      "subcellular fractionation\n",
      "hff cells were propagated\n",
      "recombinant human integrin α9β1\n",
      "her\n",
      "western blotting\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the burden of influenza has been estimated by statistical models using population - based administrative databases or those from surveillance systems coupled with laboratory surveillance data [ 1 ] [ 2 ] [ 3 ] [ 4 ] . laboratory surveillance systems collect data on influenza testing but provide less detail related to noninfluenza viruses . these other respiratory viruses ( orvs ) such as respiratory syncytial virus ( rsv ) , human metapneumovirus ( hmpv ) , human parainfluenza viruses ( hpivs ) , and coronaviruses ( covs ) co - circulate with influenza viruses during winter , and have been increasingly recognized as significant pathogens not only in pediatric [ 5 ] [ 6 ] [ 7 ] but also in adult populations , particularly the elderly [ 8 ] [ 9 ] [ 10 ] [ 11 ] [ 12 ] . when different statistical methods are compared , they may produce consistent age and temporal patterns [ 13 , 14 ] . however , depending on what endpoints are extracted from administrative databases and introduced in the model ( eg , pneumonia and influenza , respiratory and / or circulatory hospitalizations or mortality , or all - cause mortality ) , up to 3 - fold variation in the absolute magnitude of influenza - associated hospitalization and up to 6 - fold variation for influenzaassociated mortality is found [ 1 , 2 ] . validation studies that have attempted to directly compare model - based estimates to values measured through epidemiologic study have shown substantial variation in their correlation by model , by virus , and by outcome [ 15 , 16 ] . furthermore , estimates of burden attributable to influenza may also vary when additional covariates ( such as climate / weather effects or orvs ) are included in the model [ 17 ] . the paucity of data on orvs and their limited use in statistical models may have resulted in an overestimation of the disease burden of influenza . in addition , in the absence of systematic testing for orvs in hospitalized adults , it is difficult to disentangle their contribution from that of influenza . despite increasing awareness of the role of orvs , most surveillance programs continue to focus on the burden of influenza by collecting and reporting data on influenza - tailored indicators such as influenza - like illness ( ili ) , or respiratory disease confirmed by an influenza laboratory test\n",
      "provincial sentinel laboratory surveillance system\n",
      "reverse transcription polymerase chain reaction\n",
      "χ 2 test or the fisher exact test\n",
      "institutional review board\n",
      "swabbed\n",
      "[SEP]\n",
      "vaccinated\n",
      "passing the virus through an animal system\n",
      "prevention of transmission , which is best done in humans by conscientious hand and food washing\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] public ' s behavioral responses to an infectious disease could greatly affect the transmission patterns of the disease , and it has been proved that information about transmissibility and severity of the disease conveyed through the mass media plays the central role in raising the awareness and influencing individuals ' decision making on whether or not to take self - protections [ 1 , 2 , 3 , 4 , 5 , 6 ] . many studies [ 7 , 8 , 9 , 10 , 11 , 12 ] have used mathematical models to investigate how the awareness of diseases affects the outbreak of diseases . most approaches [ 13 , 14 , 15 ] explored this problem by modifying the parameters in standard epidemic models . funk et al . first incorporated the impact of awareness into classic epidemic models and found that the spread of awareness could significantly reduce the epidemic size [ 16 ] . wu et al . modeled the effect of three forms of awareness : global awareness , local awareness , and contact awareness [ 17 ] . the model studied by chen focuses on the quality of information in an agent - based model [ 18 ] . multiplex ( also named as multilayer ) networks\n",
      "mean\n",
      "logistic regression models\n",
      "clinical\n",
      "coordinated , multi - institutional infection control initiative\n",
      "use\n",
      "financial incentive\n",
      "implementation , and coordination\n",
      "establishment of project management center , the establishment of model hospitals in different regions , and the assessment of participating hospitals in different regions . the four major promotional strategies include engagement , education , execution , and evaluation\n",
      "medical personnel training , the implementation and monitoring of care bundle measures , process and outcome indicators reporting\n",
      "encourage hospitals in the actual implementation of hai control\n",
      "all contributing authors declare no conflicts of interest\n",
      "preventing and responding to disease epidemics\n",
      "fetps\n",
      "surveillance and response\n",
      "collaboration with key regional and global public health partners\n",
      "feedback from the reviewers\n",
      "cell\n",
      "reverse transfected\n",
      "standard\n",
      "western blot analysis\n",
      "gfp filter\n",
      "trees\n",
      "monoclonal antibodies\n",
      "no vaccine\n",
      "keeping in contact with patients\n",
      "digital technology\n",
      "hypertonic saline inhalation\n",
      "vacuum pump\n",
      "hypertonic saline\n",
      "forced expiratory volume in 1 s ( fev 1 ) and forced vital capacity ( fvc ) were obtained according to standard guidelines prior to the cough study . 15 respiratory muscle strength was assessed using maximum inspiratory pressure ( mip ) and maximum expiratory pressure ( mep ) ( morgan pmax ) at the paediatric centre and using a micro medical respiratory pressure meter\n",
      "age , gender , presence of current exacerbation of disease , height , weight and body mass index were recorded\n",
      "standard quantitative culture methods\n",
      "voluntary coughing\n",
      "chest computed tomography\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] dad commonly shows a bilateral , diffused , and rapidly deteriorating clinical pattern . however , in the case of our patient , a localized and slowly progressing pattern of dad was observed . first , the patient was asymptomatic despite the organizing stage dad shown in the chest radiographs . second , a localized lesion was present in the lul of the patient , an uncommon clinical pattern for which the rather new term \" regional alveolar damage ( rad ) \" was coined 3 , 4 . third , the etiology of the dad in the case of this patient was unclear . aip and aeiip were known to be the common causes of idiopathic dad . however , the clinical and radiological findings of this patient were not suggestive of either of the 2 diseases . aip normally occurs as ards , and the most common type of aeiip is acute exacerbation idiopathic pulmonary fibrosis ( aeipf ) . the diagnostic criteria for aeipf include : a previous history or diagnosis of ipf , occurrence and / or aggravation of dyspnea for a 30 - day period before aeipf can be diagnosed , newly occurring bilateral ground - glass opacity in the lungs confirmed by high - resolution ct of the chest , absence of pulmonary infection confirmed by bal , and the absence of pulmonary thromboembolism and causes of acute lung injury 1 , 5 , 6 . high dose corticosteroid therapy\n",
      "strain genbank acc . no . jx869059 . 2 ) to the lumazine synthase encoding gene in pcaggs vector encoding a cd5 signal peptide and strep tag . s1 a - np were expressed in hek - 293s cells and purified using strep - tactin sepharose beads\n",
      "ha assay\n",
      "hemagglutination inhibition assay\n",
      "pr\n",
      "staining\n",
      "mann\n",
      "cellular\n",
      "emergency medical teams\n",
      ".\n",
      "laboratory\n",
      "obtain 80 % power at 2 - sided 5 % significant level for detecting a significant difference of attack rate between the intervention arms\n",
      "accurately estimating the prevalence of covid - 19\n",
      "guide a trend line\n",
      "peer review\n",
      "confirmed\n",
      "estimate point prevalence from daily deaths of covid - 19\n",
      "peer review\n",
      "peer review\n",
      "hematopoietic stem cell transplantation\n",
      "chemotherapy\n",
      "communication\n",
      "quantitative\n",
      "broad - spectrum antibiotics and corticosteroids\n",
      "mechanically ventilated\n",
      "broad spectrum antibiotics\n",
      "finding ways to support individual and community mental health\n",
      "virus release\n",
      "reducing\n",
      "the mapping\n",
      "a hl ( i ) = 1 indicates that there is a relationship r i between them\n",
      "clustering coefficient\n",
      "if two subnets are compounded\n",
      "medical history of vomiting\n",
      "numbers of nodes and edges in the six channel subnets\n",
      "augmented immune suppression\n",
      "we only included genes with at least 1 read per million mapped reads in at least 30 samples\n",
      "differential gene expression analysis\n",
      "allograft rejection\n",
      "accurate diagnosis\n",
      "hemodialysis\n",
      "statistical analysis\n",
      "empiric or presumptive therapy\n",
      "platelet transfusions\n",
      "antibiotic therapy\n",
      "chemotherapy\n",
      "adrenocorticosteroid therapy\n",
      "surgical procedure . septicemia is most likely to occur in patients with impaired host defenses . the frequency of infection has been determined in several autopsy\n",
      "mechanical ventilation\n",
      "broad - spectrum antibiotics\n",
      "natural ventilation\n",
      "modulation of rh and temperature in buildings or care facilities\n",
      "air decontamination\n",
      "multiplex polymerase chain reaction\n",
      "descriptive analyses\n",
      "upper airway microbiology in urban - based indigenous children should be interpreted with caution\n",
      "scientific data and analysis\n",
      "direct person - to - person contact or via a contaminated environment\n",
      "low temperature\n",
      "multiple\n",
      "[SEP]\n",
      "planned intervention\n",
      "regular\n",
      "ingestion by the cattle\n",
      "anti - pa tag affinity chromatography\n",
      "western blotting\n",
      "two - stage least squares ( tsls ) method\n",
      "ordinary least squares ( ols )\n",
      "research\n",
      "intravenous benzodiazepines\n",
      "ethical approval\n",
      "early detection and containment\n",
      "myocardial perfusion imaging\n",
      "strict personal and institutional infection control practices\n",
      "screening\n",
      "segregation\n",
      "social distancing\n",
      "pharmacologic stress testing\n",
      "expand\n",
      "injected plasmids intradermally\n",
      "transfection efficacy is dependent on both the efficiency of dna delivery into the nucleus and dna expression , as well [ 35 ] . although a higher expression can usually be achieved with strong promoters and enhancers ( e . g . , human cytomegalovirus : hcmv ) [ 4 , 36 ] , improvements in the efficiency of dna delivery per second have been difficult to achieve . therefore , most dna delivery systems operate at three general levels : dna condensation , endocytosis and nuclear targeting\n",
      "revaccinated\n",
      "vaccination\n",
      "inoculated on its own\n",
      "adoptive transfer of ibvinfection - induced ab t cells\n",
      "deviation of exponential function\n",
      "early diagnosis\n",
      "normalized mean squared error\n",
      "learn subject - specific regression models and therefore recommend an individualized approach\n",
      "beat\n",
      "forward primer sequence\n",
      "molecular epidemiology study\n",
      "3d pol nucleotide sequences of the hrv - c strains have been lodged within the genbank sequence database under accession no . jn896368 - jn896372 . ( table 2 ) . vp4 and 3d pol sequence analysis\n",
      "laboratory surveillance\n",
      "incubated in medium containing gentamicin\n",
      "covers\n",
      "development of new anti - sarc - cov - 2 m pro compounds\n",
      "development of new compounds\n",
      "approval for clinical trials\n",
      "in\n",
      "inhibitors\n",
      "docking\n",
      "stress response\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] currently , the hajj pilgrimage to mecca is an exceptional event , mixing populations from various countries and viruses . several outbreaks have been linked to this trip in the past , including meningococcal meningitis and pneumonia [ 1 ] . this year , the fear was that the new middle east coronavirus could cause a massive outbreak [ 2 ] . this is because of hubris that overtook the scientific press , the who and governments about this disease , which is very rare and has low transmissibility [ 3 ] . the attention focused on this rare disease deflected attention from real infectious disease epidemics that are well known . among them is influenza . the meeting in mecca of pilgrims from regions where seasonal influenza has not started , such as the maghreb and europe ( 250 000 pilgrims on average from europe go to mecca ) , and regions where influenza is now particularly common , such as tropical africa , means that pilgrims are exposed to a very high risk of acquiring this disease . this is what is happening now , and pilgrims returning to marseille are very commonly infected with , h3n2 , h1n1 and b influenza viruses ( unpublished ) . thus , as often in recent years , the false epidemics take precedence over real epidemics , and prevent the establishment of true studies on the surveillance and prevention of true epidemics . the recommendation for early vaccination\n",
      "hospital admission\n",
      "personal protective equipment\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] elements of therapeutics were also captured spanning ventilatory support including fio2 ( as above ) , . cc - by - nc - nd 4 . 0 international license it is made available under a is the author / funder , who has granted medrxiv a license to display the preprint in perpetuity . ( which was not certified by peer review ) the copyright holder for this preprint this version posted may 11 , 2020 . these patients underwent a computerised tomographic pulmonary angiogram ( ctpa ) to screen for an overt pulmonary embolus ( pe ) and a non - contrast computerised tomogram of the brain ( ctb ) using established institutional protocols , to exclude intracranial haemorrhage or an acute cerebral infarct , priorto initiating systemic anticoagulation\n",
      "intubated\n",
      "calculation\n",
      "no age - relationship with the core critical markers of crp or ferritin\n",
      "evaluating all cases\n",
      "imaging , trial of continuous positive pressure ventilation\n",
      "anticoagulation\n",
      "real - time reverse transcriptase - polymerase chain reaction\n",
      "review\n",
      "handwashing\n",
      "endoscopy\n",
      "rrt - pcr\n",
      "the index of suspicion\n",
      "viral gastrointestinal infection and potential fecal - oral transmission can last even after viral clearance from the respiratory tract\n",
      "blood\n",
      "ficoll density gradient centrifugation\n",
      "multiplex cytokine assay\n",
      "purified pdcs from six aged and six young subjects were pooled , and rna was extracted using tri reagent kit ( molecular research center inc . , cincinnati , oh , usa ) , following the manufacturer \" s protocol . real time pcr\n",
      "statistical analysis\n",
      "direct - acting antiviral ( daa ) and vaccinations\n",
      "antiviral therapy\n",
      "nanotechnology\n",
      "nanomaterials ( recent data ) for antiviral therapy\n",
      "antiretroviral drugs\n",
      "treating or improving treatment success rate for viral diseases are fundamental responsibilities . the established potential and boosted progress of nanotechnology in antiviral therapy development generates great expectations for new therapeutic innovative strategies for attacking or eradicating viral disorders . at present , studies explored numerous and diverse nano - platforms including nanoparticles , liposomes , micelles , with different compositions , size , with single or combined entrapped drugs that may serve as potential antiviral drug delivery transporters . these nano - based systems have exhibited versatile features to improve the identified current therapy drawback . however , the clinical use of a nano - based antiviral formulation to date based on our knowledge has turned out just a few approved or under clinical trials nanoformulations , mainly vaccines\n",
      "statistical analysis\n",
      "virus titration\n",
      "plaque reduction neutralization titers ( prnts ) were determined using a conventional serum neutralization assay\n",
      "rrt - pcr\n",
      "iga antibodies\n",
      "[SEP]\n",
      "direct therapeutic maneuvers\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] between january 1989 and december 1999 , 8 , 085 patients underwent total colonoscopy at our institution , a tertiary referral center in southern taiwan . medical records and colonoscopic files were then carefully reviewed . those patients who fulfilled all of the following criteria were considered to have ahrus and included into this study : 1 ) sudden onset of painless , massive rectal bleeding , which was defined as : hemoglobin < 10 g / dl with shock ( systolic blood pressure < 90 mmhg and / or pulse rate > 110 / min ) or hemoglobin < 7 g / dl ; 2 ) serious underlying disorders ; 3 ) presence of ulcerations with ongoing bleeding or stigmata of recent bleeding in the rectum , as confirmed by colonoscopy ; 4 ) sources of bleeding from the upper gastrointestinal tract were excluded by esophagogastroduodenoscopy ; 5 ) stool cultures and cultures of biopsy specimens from the margins of these ulcers were negative ; and 6 ) no history of nonsteroidal anti - inflammatory drug ( nsaid ) administration within one month before the bleeding episode . we analyzed clinical features , colonoscopic findings , treatment , and outcome of the patients . the histologic slides of biopsy specimens were reviewed by one of the authors ( k - bt ) , an independent and experienced pathologist . table 1 . time elapsed from hospitalization for underlying disorders to the onset of massive bleeding ranged from 3 to 14 ( mean , 9 ± 3 . 3 ) days . all patients were admitted to the intensive care unit and required massive amounts of blood transfusion\n",
      "endoscopic biopsy\n",
      "blood cultures\n",
      "cauterization\n",
      "therapy\n",
      "global emergency fund has been proposed to support accelerated vaccine development\n",
      "neutered\n",
      "frozen\n",
      "cells lysed by pipetting up and down multiple times\n",
      "nonparametric analysis\n",
      "pcr\n",
      "differential\n",
      "rna was extracted from allantoic fluid using trizol o reagent ( ambion , life technologies , carlsbad , usa ) according to the manufacturer ' s protocol . the genome was transcribed to cdna and amplified using a transplex o whole transcriptome amplification kit\n",
      "de novo assembly\n",
      "coding sequence and orf prediction was carried out in vigor ( wang et al . , 2010 ) . trimmed paired - end reads were re - mapped against the 3665 / 11 consensus sequence for snp detection\n",
      "secondary structure ( ssm ) superposition method\n",
      "interferon induction\n",
      "inhibition of interferon promotor activation and irf - 3 function\n",
      "assays\n",
      "inter\n",
      "inter\n",
      "automated\n",
      "indirect immunofluorescence assay\n",
      "total rna\n",
      "student ' s ttest\n",
      "sins3 - 2\n",
      "sequence - specific mechanism\n",
      "multiple sirna expression\n",
      "multiple sirnas\n",
      "multiple sirna expression\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] patients were categorized according to their comorbidity status ( i . e . , patients without comorbidity , with chronic respiratory disease , or with other comorbidities ) and compared using chi - squared tests\n",
      "anonymized data\n",
      "antiviral drugs and vaccines\n",
      "infection\n",
      "alcohol\n",
      "isolation\n",
      "online training\n",
      "association\n",
      "excision\n",
      "injection\n",
      "literature search\n",
      "case - control\n",
      "two authors perused the papers and extracted the data according to the above inclusion and exclusion criteria\n",
      "sensitivity analysis\n",
      "stimulation with isotonic saline\n",
      "meta - analysis\n",
      "angiotensin - converting enzyme gene\n",
      "published in a peer - reviewed journal\n",
      "discussion\n",
      "meta - analysis\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] initially , we conducted a meta - analysis of ali / ards risk using healthy control subjects\n",
      "case - control association investigations\n",
      "gen\n",
      "analysis\n",
      "pcr - kit\n",
      "weeding\n",
      "mixed planting of vegetables and ornamental flowers\n",
      "inhibitors identified here could also represent lead compounds for the development of new candidate antiviral agents\n",
      "cutting - edge proteomic approaches\n",
      "developing specific diagnostic methods for its early diagnosis\n",
      "surgery , chemotherapy , and radiotherapy\n",
      "successful production of reliable diagnostic kits and targeted drugs\n",
      "psychological crisis intervention\n",
      "no funding sources\n",
      "not required\n",
      "late respiratory infections\n",
      "high - dose corticosteroid therapy\n",
      "t - test or variance analysis\n",
      "viral respiratory investigation\n",
      "hospitalizations\n",
      "multivariate analysis\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] traditional and complementary medicine ( t & cm ) can be defined as a set of healthcare modalities ( local or imported products and practices ) that are historically located outside the dominant model of healthcare [ 1 , 2 ] . in africa , t & cm may include traditional healthcare products and practices ( herbal medicine or products and traditional bone setting ) and imported complementary medicine ( acupuncture and massage therapy , yoga naturopathy ) [ 3 ] [ 4 ] [ 5 ] . t & cm use in africa is considered a public health issue primarily due to its widespread use alone or alongside conventional medicine , with most studies showing more than half the population using t & cm [ 4 ] . in sierra leone , high use of t & cm , especially herbal medicines use , has been observed among pregnant women [ 6 ] , lactating mothers [ 7 ] , hypertensive patients [ 8 ] , infertile women [ 9 ] , healthcare students [ 10 ] and for the treatment of malaria in children [ 11 ] and adults [ 12 ] . the 2014 - 2016 ebola virus disease ( evd ) outbreak in west africa was considered to be the most significant outbreak in history with evd infecting 28 , 616 people and resulting in 11 , 310 deaths [ 13 ] . the outbreak also produced the highest number of survivors in the three most affected countries of sierra leone , liberia and guinea . as of the 12 may 2016 , the global estimate of evd survivors was approximately 10 , 000 [ 14 ] . this number will increase as evd outbreaks continue in other countries such in the democratic republic of congo ( dr congo ) [ 15 ] . survivors of evd outbreaks experience a myriad of post - ebola physical and psychological complications , which include musculoskeletal pain , ocular and auditory problems , depression , anxiety , fatigue , insomnia , as well as stigma and discrimination from the community [ 16 ] [ 17 ] [ 18 ] . ebola survivors are known to seek conventional care\n",
      "descriptive nationwide questionnaire survey\n",
      "herbal medicine , traditional medicine practice ( traditional bone - setting ) , prayer / faith healing and massage\n",
      "t & cm boosts my immune system / resistance ; t & cm gives me more control over my health / body ; knowledge about the evidence of t & cm is important to me as a patient ; my personal experience of the effectiveness of t & cm is more important than clinical evidence ; cam needs to be tested for safety and side - effects ; and t & cm\n",
      "backward stepwise binary logistic model\n",
      "self - reported\n",
      "boost the body ' s immunity\n",
      "post - marketing surveillance after substantial vaccine use has occurred . for settings where highquality administrative health records\n",
      "consensus document\n",
      "likelihood mapping\n",
      "molecular\n",
      "nonparametric mann - whitney u test\n",
      "quantitative proteomics\n",
      "plated on collagen\n",
      "one - step immunoprecipitations\n",
      "collision - induced dissociation\n",
      "trans\n",
      "post sirna silencing\n",
      "multimerization of the bait protein\n",
      "characterization\n",
      "virus mutation\n",
      "air re - circulation in enclosed spaces\n",
      "food and water\n",
      "construction of \" generations\n",
      "work , aging , and retirement\n",
      "understand\n",
      "work together\n",
      "medical countermeasures\n",
      "microbiologic testing\n",
      "oral antibiotic\n",
      "providing support for prevention\n",
      "antibiotics\n",
      "total rna\n",
      "poly ( i : c ) high molecular weight and poly ( da : dt ) were purchased from invivogen . cells were stimulated with either poly ( i : c ) or poly ( da : dt ) using lipofectamine 2000\n",
      "sirna\n",
      "one - way anova\n",
      "confocal microscopy\n",
      "canine\n",
      "host interferon - induced transmembrane proteins\n",
      "reduced viral restriction\n",
      "metabolic labelling\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] experts predict that an influenza pandemic is likely to occur , and , as a result , the federal government has instituted a number of initiatives to enhance pandemic influenza planning efforts . to minimize and delay the spread of an influenza pandemic , a number of nonpharmaceutical interventions that would be readily available at the onset of a pandemic are recommended by government agencies and nongovernment organizations . the use of respiratory protective devices\n",
      "ni\n",
      "ms\n",
      "loading level control coupons\n",
      "plaque assay\n",
      "log\n",
      "k\n",
      "find a set of k centers\n",
      "update for k - means at node n i with centroids from n j local centroids c\n",
      "weighted averaging\n",
      "hyperloglog ( hll ) counters\n",
      "applying k - means\n",
      "cent merge\n",
      "bfr algorithm\n",
      "p2p k - means algorithms\n",
      "agml\n",
      "machine learning\n",
      "cluster\n",
      "hyperloglog counters\n",
      "electrophoretic gel mobility shift assay\n",
      "nmr spectroscopy\n",
      "putative g4 prediction\n",
      "diagnosis\n",
      "logistic regression analysis\n",
      "clinical severity scores\n",
      "psi and the curb - 65 score\n",
      "lymphocyte counts less than 1 . 045 x 10 9 / l\n",
      "predict\n",
      "superoxide dismutase\n",
      "constant humidity\n",
      "intraperitoneal injection of sodium pentobarbital\n",
      "intraperitoneal injection of sodium pentobarbital\n",
      "centrifuged\n",
      "centrifugation\n",
      "comparisons between 2 groups were made by using a 2 - tailed mann - whitney test\n",
      "administration period , the symptoms of the treatment groups alleviated without dose - response dependence\n",
      "lungs were lavaged\n",
      "superoxide dismutase\n",
      "the production of mda in serum and homogenate after treatment ( nmol / ml )\n",
      "oxidation and anti - oxidation\n",
      "neurosurgery\n",
      "identify and inhibit the molecular mechanisms by which viruses replicate in cells\n",
      "studying human viruses\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] more than 30 million individuals are infected with the human immunodeficiency virus ( hiv ) worldwide , resulting in about 2 million fig . 1 . the gal4 / uas system can be used to express foreign viral proteins in vivo in drosophila melanogaster . a gene of interest is placed next to the upstream activating sequence ( uas ) , which allows activation of gene expression by the gal4 transcription factor . flies with a uas - responsive transgene are crossed with other flies with a specific gal4 driver gene . in this illustrated example , the offspring has a gal4 gene under control of the actin promoter , which expresses gal4 ubiquitously throughout development . gal4 then binds to uas and turns on the viral gene in all cells that express gal4 . if expression had to be targeted to a specific subset of cells , then a different gal4 line would be used to restrict viral gene expression to specific tissues . for example , gal4 expression could be targeted to the eye where the viral gene would only be expressed in those cells but not in the other tissues of the organism . deaths annually ( kilmarx , 2009 ) . hiv - 1 is an enveloped retrovirus that uses its own reverse transcriptase to replicate its genomic single - stranded rna through a dna intermediate . during its life cycle , this viral dna can become permanently integrated into the host cell dna where its genes are expressed ( cherepanov et al . , 2011 ) . the virus is generally spread through sexual contact or contact with blood products . although antiviral drugs\n",
      "standardized high - temperature indices\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] 30 covid - 19 , the disease caused by the 2019 novel coronavirus , has placed an unprecedented 31 strain on global health care systems . while the disease is known predominantly for its respiratory 32 manifestations , a subset of critically ill patients demonstrates clinically significant 33 hypercoagulability . [ 1 ] [ 2 ] [ 3 ] this phenomenon has been noted by multiple intensive care unit ( icu ) 34 physicians and has been further described at the tongji hospital in wuhan , china . 1 , 2 thrombotic 35 events range from acute pulmonary embolism in patients with covid - 19 pneumonia to 36 extremity ischemia , and the precise incidence of thrombotic events has yet to be determined . 3 - 6 37as our understanding of this disease grows , it is crucial to investigate this trend further because 38 hypercoagulability may worsen disease prognosis in critically ill covid - 19 patients . 3 , 7 39 40 few studies to date have focused exclusively on patients with signs of hypercoagulability . an 41 early analysis from wuhan , china described seven cases of extremity ischemia in critically ill 42 patients with covid pneumonia . 1 all 7 of these patients , who did not meet criteria for shock 43 and were not undergoing active therapy with vasopressors\n",
      "intubated\n",
      "prophylactic anticoagulation\n",
      "coronary bypass surgery\n",
      "policies and guidelines\n",
      "all countries can still act to change its course\n",
      "close proxy events\n",
      "machine learning\n",
      "gradient boosted trees\n",
      "logistic regression\n",
      "free of charge\n",
      "information\n",
      "adoptive transfer\n",
      "isolation\n",
      "total body irradiation\n",
      "adoptive\n",
      "medicated drinking water\n",
      "csa\n",
      "ear and skin biopsies\n",
      "ox\n",
      "transplant medicine\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] varicella - zoster virus ( vzv ) is one of the most common opportunistic infections among hematopoietic stem cell transplant\n",
      "intralesional injections\n",
      "licensed influenza vaccines\n",
      "live , attenuated vaccines administered via the mucosal route\n",
      "maternal immunization together with pediatric vaccination\n",
      "rapid self - quarantine\n",
      "real - time reverse transcriptase polymerase chain reaction ( pcr ) assay\n",
      "discharged after viral clearance\n",
      "rrt - pcr\n",
      "modification of location where testing for triclosan will be performed . modification of frequency of sampling ( stool , urine , saliva , skin swabs ) from the mother ( every 4 months ) , and the method of urine collection from the baby\n",
      "electronic data collection\n",
      "height - for - weight z - score\n",
      "exposure to the antimicrobial triclosan\n",
      "randomized removal of triclosancontaining cleaning products from the household\n",
      "prolonged treatment\n",
      "weekly health status reports\n",
      "email\n",
      "telephone survey\n",
      "better knowledge of how infection and host immune responses affect body habitus may lead to more effective prevention and treatment strategies\n",
      "intervention arm\n",
      "to assess the association between triclosan exposure and microbial diversity . to assess the association between triclosan exposure and the breadth of the developing immune system response\n",
      "cumulative sick - days\n",
      "all subjects will undergo an assessment\n",
      "high risk pregnancy\n",
      "concurrently enrolled in another research study\n",
      "termination\n",
      "participants\n",
      "formulated , packaged and labeled by the original manufacturer\n",
      "the product will be replaced\n",
      "products containing triclosan\n",
      "the study coordinator will assess whether this use is justified\n",
      "products\n",
      "randomization to triclosan or nontriclosan containing cleaning products\n",
      "randomized to the non - triclosan arm to remove any triclosan - containing toothpaste from the home\n",
      "triclosan is not administered or dosed in this study , but is simply present in each participant ' s individual environment at work and at home in unknown amounts , no adverse events due to triclosan exposure will be identified . no prophylactic medications or procedures\n",
      "rescue medications\n",
      "information will be collected and recorded by trained study personnel using standardized , pre - tested forms\n",
      "antibodies\n",
      "blood samples will be collected by a qualified phlebotomist according to standard procedures and precautions . the blood draw\n",
      "frozen\n",
      "place a sterile swab in her mouth for a short time until the swab becomes soaked in saliva\n",
      "the armpit will be swabbed\n",
      "assessments\n",
      "study screening\n",
      "a test of comprehension will be administered and informed consent for study participation will be obtained . subjects will be given contact information for the study and a copy of their informed consent . blood [ a tablespoon ] , urine and saliva samples will be taken and a structured interview\n",
      "cord blood\n",
      "structured phone - based questionnaire\n",
      "stool samples\n",
      "a questionnaire\n",
      "vaccinations\n",
      "indirect calorimetry\n",
      "early termination\n",
      "phlebotomy\n",
      "pregnancy\n",
      "collection of laboratory data\n",
      "medical\n",
      "all attempts will be made to complete the termination visit for the mother / infant pair\n",
      "if a participating mother drops out while the study is still enrolling participants , or prior to the birth of her child then she will be replaced\n",
      "identifying appropriate medical resources\n",
      "randomized intervention\n",
      "assessment of the association between triclosan exposure and microbial diversity . assessment of the association between triclosan exposure and the breadth of the developing immune system response\n",
      "non - parametric testing\n",
      "randomization of pregnant women to the two arms of cleaning products\n",
      "international conference for harmonisation good clinical practice\n",
      "institutional review board\n",
      "the\n",
      "communicate effectively in english or spanish\n",
      "participants are free to discontinue participation in the study at any time . all efforts will be made to understand why the participant has chosen to discontinue participation\n",
      "residual specimens\n",
      "copies of all datasets\n",
      "weekly\n",
      "indirect calorimetry\n",
      "all testing can be performed in a batched fashion\n",
      "study files , except for future use consent forms\n",
      "intent to treat analysis as initially randomized\n",
      "study design\n",
      "either the arthropod or mosquito acquires the virus through a blood meal\n",
      "introduction of sterile male mosquitoes\n",
      "convalescent serum therapy\n",
      "ribavirin\n",
      "convalescent serum therapy\n",
      "convalescent serum therapy\n",
      "increase the replication error rate\n",
      "supportive therapy and ribavirin\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the clinical presentation of marburg virus infection is similar to that of ebola virus . the incubation period is 3 to 10 days after which there is a sudden onset of fever , chills , headache , and myalgia . after 6 to 8 days the illness may progress to severe hemorrhagic fever . on the fifth day of illness , some patients develop a maculopapular rash followed by nausea , vomiting , chest pain , sore throat , abdominal pain , and diarrhea . as patients become worse , jaundice , pancreatitis , weight loss , delirium , shock , liver failure , massive bleeding , and multiorgan failure develops [ 158 ] . although the mortality has been recorded as 25 % to 90 % , it is closer to 25 % to 30 % . virus may be isolated from survivors ' semen as long as 3 months after recovery . uveitis with viral isolation from the anterior chamber has been reported [ 16 , 17 ] . diagnosis is made by isolating the virus in biosafety level 4 laboratory . antigen may be detected by pcr and antigen - capture elisa . igm and igg antibodies may persist for long periods [ 16 ] . an effective public health response ( as seen during the outbreak in angola , 2005 ) involves ( 1 ) accurate diagnosis , ( 2 ) isolation of patients and contacts , and ( 3 ) proper infection control procedures at health care facilities . strict isolation precautions for patients are absolutely necessary . there is no vaccine or specific antiviral therapy\n",
      "treatment of cows for tick infestations and the use of insect repellents\n",
      "bio\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] dear editor - in - chief : during these times when the world is occupied with the peril of the covid - 19 pandemic , and while society is endeavoring to stop the spread of coronavirus disease , contact lens patients are seeking wearing guidance from eye care professionals . hundreds of millions of people around the world use contact lenses each day and , in many cases , these prescribed medical devices are essential for their jobs . this includes frontline healthcare professionals and emergency responders who are working day and night fighting the outbreak . in recent days and weeks , there have been considerable media reports speculating that contact lens wear is unsafe , that wearers of contact lenses are more at risk of contracting covid - 19 , and therefore contact lens wearers should stop wearing lenses and revert to spectacle wear to protect themselves . an egregious example has been guidance issued and actively promoted by the american academy of ophthalmology ( 1 ) , which was carried by leading news outlets ( 2 ) that led to at least almost 600 stories in the past month ( 3 ) . a social media video in italy conveyed that contact lenses are not safe to wear and that certain contact lens materials are \" riskier \" than others . the guidance to stop contact lens wear has even extended into an article on do - it - yourself ( diy ) injuries during the coronavirus lockdown ( 4 ) . the dissemination of this speculation has been particularly unfortunate in that almost none seem to be evidence - based . an evidence - based approach\n",
      "anticoagulants\n",
      "hydrolysis of feedstocks\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] we have shown that with high - sequencing depth , short sequences can be used for de novo assembly of small dna targets ( e . g . viral genomes ) that are up to 10 ' s of kb in length . for larger and more complex sequencing targets , such as bacterial genomes , short reads can be rapidly and stringently assembled into contigs that accurately represent the non - repetitive portion of the genome . it is clear that the best approach for de novo sequencing of targets more complex than viral genomes will likely involve some combination of sanger reads and assembled short reads\n",
      "trained immunity\n",
      "trained immunity\n",
      "del\n",
      "targeting il - 6\n",
      "quarantine measures\n",
      "coip\n",
      "deletion mutant\n",
      "subclone all individual orfs predicted , and not to use the precursor polyproteins\n",
      "nested polymerase chain reaction\n",
      "better understanding how they infect host cells and release viral particles\n",
      "personal\n",
      "angiotensin - converting enzyme 2\n",
      "written informed consent\n",
      "random\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] stratified sampling\n",
      "sample size estimation\n",
      "a self - administered questionnaire\n",
      "lower serum mbl level\n",
      "developing appropriate population - specific prevention measures\n",
      "contact precautions\n",
      "droplet precautions are used on entry into a patient ' s room for conservative measures\n",
      "contact precautions should be placed in a single - patient room , with strict adherence to hand hygiene and donning of isolation gowns and gloves to box 7 multidrug - resistant organisms requiring use of contact precautions\n",
      "extension of the duration of precaution use\n",
      "petechial rash\n",
      "droplet precautions\n",
      "airborne precautions\n",
      "transmission - based precautions must be implemented based on clinical suspicion , and immediately on presentation to a health care facility . certain clinical syndromes warrant suspicion of airborne pathogens , and necessitate initiation of airborne precautions\n",
      "2\n",
      "rapid identification and diagnosis\n",
      "extended - spectrum b - lactamase\n",
      "use of contact precautions\n",
      "timely discontinuation of precautions\n",
      "well - organized infection control program\n",
      "a chest radiograph\n",
      "outcomes were compared between the rti and non - rti groups using a v 2 or fisher ' s exact test\n",
      "high - dose methylprednisolone bolus therapy\n",
      "accurate diagnosis and excellent owner compliance\n",
      "housing on nonslick surfaces\n",
      "supplemental feeding\n",
      "polymer\n",
      "lateral ear canal resection , ostectomy , and total ear canal ablation\n",
      "dil\n",
      "surgery and radiation\n",
      "eu\n",
      "dialysis\n",
      "kinetic trap\n",
      "assembly in vivo\n",
      "real - time pcr\n",
      "pcrs\n",
      "serotyping\n",
      "hemagglutination inhibition ( hi ) test , or enzyme - linked immunosorbent assay ( elisa )\n",
      "antimicrobial chemotherapy\n",
      "statistical analysis of the difference in clinical fi ndings in relation to the causative pathogens was performed using the fisher ' s exact test\n",
      "infection process\n",
      "humanitarian assistance\n",
      "specific drugs or vaccines\n",
      "tcm can cure covid - 19 pneumonia\n",
      "the application can only be adjusted within the local scope\n",
      "clearing away heat and toxic materials , dispelling wind and penetrating the exterior , invigorating qi and nourishing yin\n",
      "early\n",
      "qualitative approach\n",
      "bottom - up approach\n",
      "a thematic approach\n",
      "consensus\n",
      "technical exchange\n",
      "restructuring process of the public health organizations ( table 5 ) . this restructuring process reflected the continuous health sector reform under the context of financial decentralization in china , including the establishment of the cdcs in early 2000 . this whole process had witnessed the weakening of the clinical functions of the cdcs and redeployment of the tb control staff to the designated hospitals . since then , tb services were integrated into the designated hospital\n",
      "allocate the tb control budget to the hospital\n",
      "personal relationships : \" only for the bigger issues , we would invite the health bureau to coordinate\n",
      "resource allocation\n",
      "the relationship between the cdc and designated hospital\n",
      "effective inter - organizational collaboration\n",
      "primers\n",
      "multiplex rt - pcr\n",
      "antiviral therapy , prophylactic and vaccination\n",
      "social distancing regulations\n",
      "video conferencing\n",
      "rehydrate and eat regularly\n",
      "placing a mirror close to the computer\n",
      "headset when attending videoconferencing\n",
      "seek contradictory opinion / evidence\n",
      "ensure that the aims of the session have been achieved ( this may contrast with the agenda items ) and to summarise key findings\n",
      "setting the agenda and timings note taker\n",
      "virtual meetings\n",
      "immunosuppression\n",
      "observational prospective analysis\n",
      "reverse transcriptase polymerase chain reaction\n",
      "modified\n",
      "data were expressed as mean or median ± standard deviation as well as a percentage . as it is a case series with only seven patients included , further statistical analysis\n",
      "incubation period of 4 and 9 days , respectively , the source of infection was a close contact with their relatives\n",
      "tracheostomy\n",
      "oxygen therapy\n",
      "tracheostomy\n",
      "rt\n",
      "close active supervision\n",
      "all documents were handled after removing their filiation data\n",
      "enhanced green fluorescence protein\n",
      "negative cd11b staining\n",
      "immunolabeled\n",
      "immunofluorescence\n",
      "double fluorescence / immunofluorescence staining\n",
      "neuronal staining\n",
      "phylogenetic tree\n",
      "structural mapping\n",
      "preparation of ors in milk\n",
      "experiments\n",
      "feeding timemorning ( 0700 ) midmorning ( 0900 ) afternoon ( 1600 ) evening ( 1800 ) night ( 2200 ) midnight ( 2400 ) milk - ors a 2 l milkþ ors - 2 l milk þors - 2 l milkþ ors - water - ors 2 l milk ors in 2 l water 2 l milk ors in 2 l water 2 l milk ors in 2 l water milk a . l . b þwater - ors milk ad libitum ors in 2 l water ors in 2 l water ors in 2 l water a oral rehydration solution\n",
      "availability of water\n",
      "none\n",
      "chemical synthesis\n",
      "production of chimeric antibodies\n",
      "humanized antibodies with the murine hypervariable regions spliced into a human antibody\n",
      "antimicrobial therapy\n",
      "antimicrobial therapy\n",
      "replacement of normal donor plasma\n",
      "antibiotics\n",
      "son\n",
      "irradiation\n",
      "examen biologique n ' est utile au diagnostic\n",
      "reflux\n",
      "repetition au mieux apres un avis specialise\n",
      "biopsies nasales\n",
      "tabagisme passif\n",
      "ozone\n",
      "immersion\n",
      "examen precis de la cavite nasale est necessaire pour confirmer le diagnostic\n",
      "diagnostic bacteriologique\n",
      "hemocultures ( espacees idealement d ' une heure ) dans le but de mettre en evidence\n",
      "transillumination\n",
      "radiographie standard\n",
      "exploration\n",
      "injection de produit de contraste\n",
      "irradiation du cristallin\n",
      "forfait technique\n",
      "tomodensitometrie\n",
      "le dosage ponderal des immunoglobulines\n",
      "exploration\n",
      "systematiquement en urgence d ' un avis specialise\n",
      "injection de produit de contraste\n",
      "prescription\n",
      "pristinamycine a partir de six ans , notamment en cas de contre - indication aux betalactamines\n",
      "association avec lui . le groupe d ' experts a liste tous les traitements retrouves dans la litterature afin d ' en faire l ' evaluation\n",
      "paracetamol\n",
      "envisager specifiquement\n",
      "le lavage nasal avec une solution saline isotonique ou hypertonique permet le drainage du mucus\n",
      "indication\n",
      "prescription\n",
      "aucune etude\n",
      "pathologie\n",
      "aerosol\n",
      "mouchage\n",
      "pression\n",
      "coordination\n",
      "drainage\n",
      "une reduction ou une suppression du tabagisme\n",
      "symptomatologie recidive rapidement ou si une symptomatologie chronique s ' installe , un avis spe - cialise est utile pour verifier precisement de dysfonctionnement nasal et l ' etat endonasal\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] les infections rhinosinusiennes de l ' enfant sont un frequent motif de consultation\n",
      "antibiotherapie\n",
      "stained\n",
      "inoculated intraperitoneally ( i . p . ) , intradermally ( i . d . ) or intranasally with 10 4 pfu zh548 , rzhdnss - hrluc or rzhdnss - gfp rvfv in dmem supplemented with 2 % fcs , and antibiotics\n",
      "eu\n",
      "non\n",
      "countries have strictly restricted the movement of people and transportation\n",
      "quarantine measures\n",
      "travel restriction order\n",
      "uses the concentration of no 2 in the air as an evaluation indicator\n",
      "ozone monitoring instrument\n",
      "lockdown\n",
      "covid - 19 effectively suppressed the ghg emissions such as co 2 . however , the observed data indicate that this beneficial effect only occurs during quarantine\n",
      "multiple antioxidant assay method\n",
      "scoping review\n",
      "by including a third researcher\n",
      "data were extracted and recorded in an excel spreadsheet\n",
      "collected 585 environmental samples from the huanan seafood market in wuhan , hubei province , china on 1 january and 12 january 2020 . they detected 33 samples containing sars - cov - 2 and indicated that it originated from wild animals sold in the market [ 39 ] . then , researchers used the lung fluid , blood , and throat swab samples of 15 patients to conduct laboratory tests\n",
      "antibiotics treatment\n",
      "systematic and rigorous search\n",
      "conduct further research\n",
      "co 2 inhalation or cervical dislocation\n",
      "inhalation\n",
      "grip strength monitor\n",
      "inhalation\n",
      "onetailed t - test\n",
      "supplementary material is available at hmg online\n",
      "presence of pets\n",
      "transmission\n",
      "canine respiratory coronaviruses\n",
      "re - occurring contact with dogs ' coronaviruses\n",
      "transgenic insect cell line\n",
      "gene therapy\n",
      "packet delivery process and the epidemic spreading\n",
      "recovered\n",
      "real\n",
      "randomly selecting a node to become infected\n",
      "network density\n",
      "efficient routing protocol\n",
      "traffic - driven sir epidemic model and study the impacts of several factors on our model . we find that the epidemic spreading is greatly affected by the load distribution , and homogeneous load distribution facilitates the epidemic spreading . increasing the network density or network homogeneity will enhance the epidemic spreading . large - degree nodes have dual effects on the epidemic spreading , since large - degree infected nodes facilitate the epidemic spreading , while large - degree recovered nodes greatly inhibit the epidemic spreading . to realize an intense and wide epidemic spreading , the paths for the delivery of packets are generally biased towards including small - degree nodes . increasing packet generation rate generally favors the epidemic spreading . however , when the amount of generated packets is larger than the delivery capacity of the network , there will exit traffic congestion , which blocks the epidemic spreading . also , we find similar impacts of different static routing protocols on the traffic - driven sir epidemic spreading . our work helps understanding the interplay between traffic dynamics and epidemic spreading , and provides some clues for network immunization\n",
      "dna sequencing\n",
      "vaccines\n",
      "decreasing vaccine price\n",
      "adequate vaccine manufacturing\n",
      "involvement of vaccine companies\n",
      "improving health is the way of fighting poverty [ 8 ] . a specific line of research will be funded , entitled \" confronting the major communicable diseases linked to poverty \" . the strategic objective for this action is to develop new vaccines , drugs and other innovative interventions to fight the three major infectious diseases linked to poverty : hiv / aids , malaria and tuberculosis . these three diseases are both the cause and consequence of poverty in many developing countries , in particular in sub - saharan africa . in its programme for action \" accelerated action on hiv / aids , malaria and tuberculosis in the context of poverty reduction \" [ 9 ] , the eu commission provided a broad policy framework for a comprehensive global and multidisciplinary approach against the three poverty - linked diseases . concerning research , the overall strategy is to develop new effective interventions against these three diseases . in order to realise this goal , the action is organised in two major components : ( i ) developing new promising candidates up to the pre - clinical and early human testing\n",
      "translating\n",
      "clinical trials\n",
      "innate mechanisms used by host cells\n",
      "by interfering with uptake or by inhibition of phagolysosome formation\n",
      "mu\n",
      "vaccination\n",
      "vs\n",
      "constructed chimeras\n",
      "specific\n",
      "transfection\n",
      "deciphering each step in the different processes by which microbes adapt to new hosts is critical to developing effective countermeasures\n",
      "cell viability and proliferation assay\n",
      "centrifugation\n",
      "endpoint dilution assays\n",
      "q\n",
      "measuring the percentage of ev71 rna from the untreated control cells\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] since the 1950 ' s , scientific interest has been increasingly shifting to molecular biology leading to the accomplishment of gene sequencing in the human genome project ( hgp ) . proteomics has been the focus due to the role of executor of the life function . proteomics refers to the analysis of all the proteins expressed in a cell or tissue . 2 - d page is the most universal method for proteomics and possesses high resolving power for proteins . some problems in 2 - d page , however , are still difficult to overcome , such as limited ph range , time - consumption , and inefficient sensitivity for low abundance proteins . this reality has unleashed considerable effort in developing new proteomics techniques as alternatives to 2 - d page . in contrast to 2 - d page , multi - dimensional liquid chromatography\n",
      "specifi c antiviral therapy\n",
      "antivirals\n",
      "antibiotic use\n",
      "tracheotomies and the use of indwelling devices\n",
      "choice of antibiotic\n",
      "[SEP]\n",
      "blood transfusions\n",
      "phagocytosis\n",
      "antibiotics\n",
      "surgery\n",
      "treatment\n",
      "surgical treatment such as incision and drainage or puncture and drainage\n",
      "intestinal barrier\n",
      "the intestinal barrier\n",
      "intestinal bacterial translocation\n",
      "bacterial translocation\n",
      "systemic cytokine responses\n",
      "culture - positive blood cultures\n",
      "mods\n",
      "novel prevention strategies\n",
      "post - surgical\n",
      "antibiotic therapies\n",
      "euthanized\n",
      "euthanized\n",
      "statistical analyses\n",
      "infection\n",
      "x - ray diffraction analysis\n",
      "symbols\n",
      "statistics\n",
      "declare no conflicts of interest\n",
      "tobramycin / dexamethasone\n",
      "orally\n",
      "a viscoelastic solution of 1 . 4 % sodium hyaluronate\n",
      "dna extraction\n",
      "antiparasitic treatment\n",
      "bayesian analysis\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] rk13 cells were infected with rvv - s or lc16m8 at moi 10 . after 24 h infection , cells were lysed with ripa buffer\n",
      "polyclonal antibodies\n",
      "in\n",
      "serial dilutions of heat - inactivated sera\n",
      "serial dilutions of heat - inactivated sera\n",
      "oneway anova followed by turkey test\n",
      "diagnostic algorithm that delineates evaluation and treatment indications for patients who range from minimally symptomatic to critically ill after potential cyanide exposure via smoke inhalation\n",
      "weight loss medication qsymia\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] connors nc , nelson ls new york university school of medicine , new york , ny , usa background : opioid intoxication is an increasingly common reason for an emergency department visit . naloxone , a competitive mu - opioid receptor antagonist , can be used judiciously to reverse hypoventilation , but in excess , can precipitate opioid withdrawal syndrome ( ows ) in opioiddependent patients . the optimal dose of naloxone remains controversial , particularly in this latter group . research question : what naloxone dose do authoritative sources recommend to treat opioid - induced hypoventilation ? methods : a convenience sample of textbooks , study guides , and internet resources published within the last 10 years in the fields of emergency medicine ( em ; four ) , anesthesiology ( four ) , medical toxicology ( mt ; four ) , pediatrics ( two ) , internal medicine ( im ; two ) , and general medicine ( acls , pharmacology reference , and internet resources ; six ) were reviewed for their recommended naloxone initial dosing , dose range , and titration protocol for opioid toxicity . results : twenty - two resources were identified that provided a naloxone dose recommendation . of these , 12 / 22 ( 55 % ) recommended an initial dose of 0 . 04 or 0 . 05 mg iv and 9 / 22 ( 41 % ) suggested 0 . 4 or 0 . 5 mg iv . the maximum dose by titration recommended by source was 2 mg in six , 10 mg in eight , and 20 mg in two . no trend towards lower recommended dosage was noted based on year of publication ( r 2 = 0 . 012 ) . an initial dosage less than 0 . 1 mg recommended by source was 3 / 4 mt , 3 / 4 anesthesia , 4 / 6 general medicine , and 2 / 4 em . no im or pediatric sources recommended an initial dose less than 0 . 4 mg . discussion : low - dose naloxone\n",
      "topical capsaicin cream\n",
      "a baclofen taper\n",
      "[SEP]\n",
      "single - patient chart review\n",
      "single - patient chart review\n",
      "suspended tio 2\n",
      "ionic chromatography\n",
      "photocatalytic buxair reactor\n",
      "photo\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] an understanding of cftr function , and cftr mutations impacting on channel activity , is required prior to the description of animal models of cf - related disease . under normal conditions the cftr protein functions as a cl − channel pumping cl − ions out of the cell . cftr also functions as a regulator of other ions , including na + , by negatively regulating the epithelial na + channel ( enac ) [ 21 , 22 ] . enac , also known as sodium channel nonneuronal 1 ( scnn1 ) , is an amiloride - sensitive ion channel responsible for the transepithelial transport of na + ions . structurally , the enac protein comprises three distinct , , and subunits encoded by the scnn1a , scnn1b , and scnn1c genes , respectively [ 23 ] . each subunit contains two transmembrane domains , an extracellular loop , and short n and c termini . a fourth ( ) subunit of enac has been described but remains comparably underexplored [ 24 , 25 ] . dysfunctional cftr combined with increased enac activity in cf results in the inhibition of normal cl − secretion to the apical surface of airway epithelium and significant na + hyperabsorption , followed by an osmotically driven efflux of water to the basolateral membrane\n",
      "pancreatic enzyme replacement therapy\n",
      "ivacaftor therapy\n",
      "administration of antibiotics\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the pancreas of the cftr − / − ferret demonstrates a similar histopathology to that of human neonates where lesions and dilation of acini and ductules occur [ 18 , 116 ] . cf ferrets that survived mi demonstrated increased pancreatic inflammation with exocrine tissue loss similar to that observed in humans with cf . sun and colleagues administered a protonpump inhibitor\n",
      "bedside ultrasound and abdominal ct\n",
      "grouped the articles into subcategories\n",
      "prolonged mechanical ventilation\n",
      "prone positioning\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] in sepsis and ards a cascade of inflammatory responses leads to production of proinflammatory cytokines . this cascade might be inhibited by eliminating the pathogenic toxins using haemoperfusion\n",
      "shorter duration of rebreathing\n",
      "invasive arterial catheter\n",
      "simulation\n",
      "a multifaceted retention strategy\n",
      "vaccination\n",
      "adoptive transfer of antibody\n",
      "[SEP]\n",
      "reverse genetic technology\n",
      "mention of trade names or commercial products\n",
      "communication with and education of all personnel on infectious disease control measures\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] biosecuity for the technician at a veterinary practice and for the horse owner or caretaker is critical to managing the introduction of an infectious agent . the most common means of spread is through the introduction of a new horse , particularly a horse that is returned from a hospital to a property . new horses should be isolated from the resident population for a minimum of 14 days , ideally for 30 days . clinical condition and temperature should be monitored daily . supplies should be separated . the recent arrival should be attended to last . manure and bedding should not be spread on the fields . hand washing in running water with soap after handling horses ( waterless hand foams or gels if no running water ) should be mandatory even if gloves have been worn . vaccination\n",
      "cellular\n",
      "supportive therapy\n",
      "recumbent\n",
      "quarantine of affected and in - contact horses\n",
      "vaccination\n",
      "prevention\n",
      "pcr\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] infection occurs primarily in horses 1 - 5 years of age and in geriatric and immune - compromised horses . in susceptible populations , morbidity is high ( up to 100 % ) and mortality low ( 10 % ) with appropriate treatment\n",
      "enzyme - linked immunosorbent assay\n",
      "penicillin\n",
      "stained\n",
      "phagocytosis\n",
      "chest radiographs\n",
      "autopsy\n",
      "lysis of cardiac muscle fibres\n",
      "localized necrosis was present and there was apoptosis of lymphocytes\n",
      "massive central necrosis\n",
      "vasculitis\n",
      "infiltration of the vascular walls by monocytes and lymphocytes\n",
      "localized proliferation of polychromatophilic erythroblasts\n",
      "chest radiography\n",
      "beauti 1 . 8 . 3 29 with default options to generate an xml file with the metadata of spatial and temporal coordinates\n",
      "bay\n",
      "maximum likelihood estimate\n",
      "gravity\n",
      "analysis\n",
      "district ( admin - 2 ) localization\n",
      "partially observed transmission network ( potn ) algorithm\n",
      "include\n",
      "gravity model\n",
      "prescription of active antibiotic therapy has a salutary impact on outcome . the situation often is sufficiently urgent that antibiotic therapy only should be administered based on suspicion of diagnosis\n",
      "im\n",
      "induction of crossreactive antibodies\n",
      "cross - reactive antibody or t cell reactions\n",
      "substrate - binding subsite\n",
      "gel filtration\n",
      "electron density map\n",
      "immunisation with dendritic cells\n",
      "low\n",
      "activate cd8 + t cell\n",
      "over activation of t cells\n",
      "viral replication\n",
      "phagocytic markers and facilitates viral replication\n",
      "0\n",
      "pcr assays\n",
      "ifa was used to detect the infection rate\n",
      "student ' s t test\n",
      "rt - pcr\n",
      "specific immunofluorescence\n",
      "sub - cloning with limited serial dilutions\n",
      "eradication strategy\n",
      "solid organ and hematopoietic stem cell transplantation\n",
      "ampicillin\n",
      "developing policies on control measures\n",
      "dialysis\n",
      "single nasal swab culture\n",
      "active surveillance\n",
      "terminal cleaning of the consultation rooms\n",
      "electronic tagging\n",
      "cleaning\n",
      "hand hygiene\n",
      "active screening\n",
      "temporarily displacing an adjacent colorectal ward\n",
      "active screening\n",
      "radiographic and ct imaging\n",
      "radiography and ct scanners\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] from december 2019 , a novel coronavirus named covid - 19 was reported in china . 1 , 2 human - tohuman transmission was subsequently confirmed , 3 , 4 and the global number of confirmed cases of covid - 19 has surpassed 1 , 500 , 000 across 184 countries ; covid - 19 caused more than 90 , 000 deaths 5 within 3 months ( date april 09 th , 2020 ) . the world health organization ( who ) recognised covid - 19 as pandemic on the march 11 th , 2020 . 6 a precise estimate of the mean incubation period for covid - 19 infection is still debated , however the who reported an official estimate ranging from 2 to 10 days . 7 while , a study by qun et al . 8 described an average incubation period of 5 . 2 days , before the onset of the first symptoms . covid - 19 has proven highly contagious 9 , 10 and it mostly spreads through respiratory droplets , but may also be transmitted by touching a surface that is contaminated with the virus . 11 given the high infectivity , it is vital to identify and promptly isolate subjects with covid - 19 . positive real - time reverse transcriptase polymerase chain reaction ( rt - pcr ) for viral nucleic acid is the reference standard for covid - 19 diagnosis , while sensitivity and specificity of computed tomography ( ct ) are reported to range from 80 - 90 % and 60 - 70 % , respectively . 12 , 13 diagnostic imaging exams , such as chest radiography and ct , are crucial in understanding the severity and disease progression in covid - 19 infection . 14 in this context , radiologists , radiographers , nurses , and other healthcare professionals or technical support personnel are among the first - line healthcare workers who might be exposed to covid - 19 . 15 therefore , it is vital to adopt the necessary precautions in order to avoid further spread of the virus . the shortage of personal protective equipment ( ppe ) and other protection devices is leaving radiologists , radiographers , nurses and other frontline workers dangerously ill - equipped to care for covid - 19 patients and themselves . 16 thus , it is very important to optimise the use of supplies\n",
      "deep sanitization\n",
      "laboratory confirmation\n",
      "all\n",
      "schedule cohorts of patients of the same type together\n",
      "high - resolution ct\n",
      "early\n",
      "views of the solvent face of the 80s pk - trna - ef2 , 80s pk - trna and 80s sl reconstructions\n",
      "a superposition\n",
      "western blot analysis of 80s pk , 80 sl and 80s apo complexes purified from rabbit reticulocyte lysates . samples were loaded onto a 20 % sodium dodecyl sulfate - polyacrylamide gel ( sds - page ) and a western blot performed according to standard procedures using an anti - rack1 monoclonal antibody ( bd biosciences pharmingen ) . blots were imaged using infrared fluorescence of appropriately tagged secondary antibodies and a licor odyssey scanner and software . ( b ) control 20 % sds - page showing total protein content of each sample loaded onto the western blot of panel a . proteins were stained with the coomasie blue - based imperial protein stain\n",
      "map display using the atomic model for a mammalian ribosome built on the basis of a canine ribosome reconstruction\n",
      "thermal b factors\n",
      "new\n",
      "authorship contributions\n",
      "the author has completed the icmje form\n",
      "a\n",
      "cumulative fatalities as a function of time and the maximum required number of respiratory equipment\n",
      "gm could for example be used to apply it to such countries as soon as sufficient data is available\n",
      "testing instruments : the dhp - 9052 electro - heating standing - temperature cultivator ; the kq - 100e ultraviolet ray disinfecting device ; the ca - 920 - 3 perpendicular layer flowing cleaning\n",
      "ultrasonic backflow method\n",
      "water polyurethane with high - speed stirring\n",
      "sterilized\n",
      "calculation of the ratio of anti - bacteria\n",
      "influenza a virus strain pr8 ( a / pr8 / 34 / n1h1 ) was purchased from the peking virus institute of the chinese academy of preventive medicine\n",
      "preparation method of anti - virus filter sample\n",
      "ultrasonic backflow method\n",
      "anti - bacteria\n",
      "anti - virus rate of the finished filters\n",
      "[SEP]\n",
      "hematoxylin - eosin stain\n",
      "early detection of infected individuals\n",
      "supportive medical care\n",
      "sars vaccine\n",
      "binding\n",
      "whole - genome sequencing\n",
      "sitting - drop method\n",
      "binding studies\n",
      "hotlines and psychiatric services , remain able to respond appropriately\n",
      "mental health\n",
      "psychology\n",
      "immunosuppression\n",
      "intravenous administration of immunoglobulin\n",
      "annual vaccination\n",
      "administration of immunoglobulin\n",
      "identification of potential therapeutic targets\n",
      "renal replacement therapy\n",
      "semi - quantitative reverse - transcriptase polymerase chain reaction\n",
      "rna extraction and real - time rt - pcr\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] pbmcs and serum samples were collected on days 14 - 16 , 20 , 22 , and 24 after illness onset for evaluation of the various immunogenicity endpoints . all tests were performed at the all rights reserved . no reuse allowed without permission . ( which was not certified by peer review\n",
      "peer review\n",
      "conducting genetic research on its own\n",
      "[SEP]\n",
      "contacts\n",
      "diabetes\n",
      "cent\n",
      "diluted tenfold with sodium thiosulfate\n",
      "tcid 50 method\n",
      "chemical reagents\n",
      "tcid 50 method\n",
      "facemasks\n",
      "test - negative case - control design\n",
      "cluster - randomised controlled trial\n",
      "participation in another clinical trial investigating a medical intervention that may interfere with the study outcome measures , like laboratory - confirmed viral rti . • any known contraindication to mask use\n",
      "telephone , mail , email ) in their country of residence to collect their post - hajj health diaries\n",
      "mask use makes a significant difference in reducing the frequency of laboratoryconfirmed respiratory viral infection ( including influenza , coronavirus or other respiratory viruses ) or syndromic rti . the primary endpoints ( efficacy of facemasks against rti and laboratory - confirmed viruses respectively ) will be analysed by intentionto - treat . the self - reported uptake rates of influenza vaccination\n",
      "using a strategy similar to the design of fq , the quinuclidinyl and the piperidinyl side chains of quinine 21 and mefloquine ( mf ) 21 were respectively substituted with a ferrocene moiety while maintaining a basic amino group 23 , 24\n",
      "fq\n",
      "artemisinin - based combination therapy\n",
      "nested pcr\n",
      "rna polymerase\n",
      "multiplex rt - pcr\n",
      "unbiased metagenomic approach for viral pathogen discovery\n",
      "base quality and filter\n",
      "degree\n",
      "external input toggles a nanoswitch\n",
      "self - sorting\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] due to the limited material and the lack of explicit mechanistic scenarios the interpretation of the kinetic data cannot be conclusive . if we screen the various kinetically analyzed processes the most defined ones are those ignited either by oxidation / reduction or pure thermal exchange reactions\n",
      "progressive resumption of medical care\n",
      "regional or local anesthesia\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] while the goal of pediatric urologists must be to maintain a high as possible standard of care , the number of patients attending the outpatient clinic must be reduced in order to minimize the chance of infecting patients or health care providers , as well as preserving personal protection equipment . each individual case should be screened for the possibility of replacing an outpatient visit by consultation via telephone or video - call , when available . post - operative follow - up for genito - scrotal procedures may be aided by photographic documentation by caregivers and uploaded into patient files when possible ( following the general data protection regulation gdpr ) . a telephone consultation may also be used to screen for the need for physical consultation . if a physical outpatient clinic visit is necessary , the child should be accompanied by only a single caregiver . prior to the outpatient clinic visit it is also necessary to assess if either child or caregiver have symptoms that may be covid - related . if there are covid - 19 symptoms , child or caregiver has been tested positive for covid - 19 or are in quarantine , they should be seen in a covid - dedicated area of the hospital without interaction with other patients . for details on these procedures we refer to local guidelines . suggested reduction in outpatient clinic visits during various stages of severity of the covid - 19 pandemic stage 1 : start to reduce outpatient cases such as benign scrotal and penile pathology or well as incontinence . stage 2 : see only cases that are at least semi - urgent , such as initial postoperative ultrasound\n",
      "ultrasound and voiding cystography\n",
      "simulation exercises and e - learning\n",
      "reverse back through the aforementioned stages . during this process we will need to confer with our fellow surgical ( sub ) specialties to prioritize the available surgical time and resources among all surgical patients . while it is wise to postpone surgery\n",
      "androgen - armediated changes\n",
      "immune modulation\n",
      "snap\n",
      "forward : 5 ' - gacctccttcttccaggctttg - 3 ' reverse : 5 ' - ctcccaccttgtctccagtcttta - 3 '\n",
      "isolation of viral rna and dna\n",
      "statistical analysis\n",
      "[SEP]\n",
      "pancorona primers ' sequence\n",
      "postpone the lockdown\n",
      "sustainable control techniques\n",
      "low mortality rate\n",
      "selective containment measures\n",
      "short time horizon strategies which permits to derive suitable feedback controlled models\n",
      "stat\n",
      "identifying the deterministic parameters of the model through a suitable fitting procedure\n",
      "reno\n",
      "linear interpolation\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] in order to highlight the differences in the behaviour of the infection according to the choices related to specific activities , such as school and work , we have considered the effects of a specific lockdown relaxation\n",
      "relax\n",
      "how gradually to reopen the various social and economic activities without creating a new wave of infected and therefore deaths . in order to analyze possible future scenarios , it is essential to have models capable of describing the impact of the epidemic according to the specific social characteristics of the country and the containment actions implemented . in this work , aware of the complexity of the problem , we have tried to provide a suitable modeling context to describe possible future scenarios\n",
      "taxonomy classification\n",
      "next generation sequencing ( ngs ) technology\n",
      "application of the ngs technique on biosafety monitoring\n",
      "ngs\n",
      "ngs method\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] a previously healthy 20 - year old male college student had 5 days of non - productive cough , rhinorrhea , myalgias , and fever but no headaches or neck stiffness . on the 6th illness day , he presented to the emergency department of a community hospital with lethargy and confusion . he was electively intubated for airway protection . his chest x - ray ( cxr ) was normal . routine admission laboratory tests including hepatic transaminases were within normal range . a non - contrast head computed tomography ( ct ) did not reveal any abnormalities ( fig . 1 , top row ) , and he underwent lumbar puncture\n",
      "assessing patients clinically , it is important to determine if the patient has active or recent symptoms ( within days ) of influenza or if the neurologic symptoms have appeared in a subacute manner . we will first discuss neurologic complications in the setting of recent influenza virus infection and then proceed to complications that present in a delayed manner\n",
      "csf analysis\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] one of the most devastating complications of seasonal and pandemic influenza is ane [ 37 ] [ 38 ] [ 39 ] . patients develop rapid neurologic deterioration to coma . seizures are often present . initial brain ct\n",
      "isothermal titration calorimetry ( itc ; fig . 1 ) and zone - interference gel electrophoresis\n",
      "adpribose binding\n",
      "cl\n",
      "lymphatic filariasis elimination programme\n",
      "steatorroe\n",
      "incubatietijd van enkele weken tot maanden\n",
      "de volwassen worm\n",
      "indeling\n",
      "manual correction\n",
      "viral metagenomic analysis\n",
      "pcr\n",
      "convalescent plasma\n",
      "convalescent plasma\n",
      "empathy and best medical care\n",
      "passive immunization\n",
      "passive immunization\n",
      "isolation , expansion and cloning\n",
      "cea pool d\n",
      "antibody titration\n",
      "staphylococcus enterotoxin b ( seb ) at 10 g / ml and dmso were used as positive and background control . cells were then washed and stained with surface antibodies\n",
      "student ' s t - test or log - rank test\n",
      "online meetings\n",
      "a\n",
      "oral presentations\n",
      "creation and registration of local viewing sites at various institutions\n",
      "twitter poster session\n",
      "brief the presenters on the software , to check the quality of the video and sound , and to generally minimize it issues\n",
      "continuing onto the next talk and moving that speaker to the next session\n",
      "testing the connection at all of the hubs in advance and using external microphones\n",
      "online meetups\n",
      "online meetups\n",
      "ras blockade\n",
      "prospective identification of a community - based cohort of patients infected with sars - cov - 2\n",
      "iv\n",
      "se\n",
      "cent\n",
      "elisa\n",
      "washing the strips in a solution of acetic acid and methanol\n",
      "non - parametric kruskal - wallis test\n",
      "cytostatic activity of the tested compounds\n",
      "50\n",
      "maintaining organ transplantation care\n",
      "guidelines were made public through internet communications and newsletters\n",
      "a centrally coordinated national effort was made to double icu capacity to a total of 2400 in early april 2020\n",
      "chest ct - scan\n",
      "transplant\n",
      "simulations\n",
      "generation\n",
      "simple estimator d / n\n",
      "simulations\n",
      "refrigerated overnight\n",
      "a solution of 3 ( 0 . 02 mol ) in concd hcl ( 20 ml ) was heated under reflux\n",
      "heated under reflux\n",
      "sequestration\n",
      "empirically\n",
      "brisk diuresis\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the first pandemic of the 21st century was caused by the sars - cov , which emerged in southern china in november 2002 and spread to 29 countries in five continents with 8096 confirmed cases and 774 deaths in 3 months . 12 rt - pcr , cloning , and sequencing contributed to identification of the novel coronavirus . 13 - 16 sars - cov spreads by respiratory secretions and airborne transmission . although market animals are believed to have been the source of human transmission , 17 bats are suspected to be the sylvatic reservoir of the virus . early in the illness , sars cannot be distinguished from common respiratory infections based on clinical symptoms . 18 sars - cov causes high mortality ; thus , timely , sensitive , and specific diagnosis\n",
      "hypovolemic shock\n",
      "molecular assays\n",
      "molecular assays\n",
      "molecular testing\n",
      "single pulses of tms over the right motor cortex\n",
      "spearman rank order correlation tests\n",
      "group\n",
      "teps\n",
      "electromyography\n",
      "single - trial analyses of tms - evoked response variability by pooling data across participants\n",
      "[SEP]\n",
      "spearman rank order correlation test\n",
      "screened for contraindications to tms ( rossi et al . , 2009 ) , which included having no history of hearing impairment or injury , and no neurological or psychiatric disorders . all participants were right handed , as assessed using the edinburgh handedness scale ( oldfield , 1971 ) . the mean handedness index was 0 . 79 ( sd = 0 . 19 ; range 0 . 3 to 1 ) . potential participants were also screened with the epworth sleepiness scale\n",
      "participants were prompted to relax\n",
      "eeg\n",
      "stable isotope labeled proteomics strategy\n",
      "machine learning\n",
      "normalization\n",
      "run 728 water samples\n",
      "peer - reviewed\n",
      "drug target identification\n",
      "drug targets\n",
      "blast search\n",
      "computational comparative and subtractive genomics analysis of different metabolic pathways from e . coli o157 : h7 , for the identification of potential drug targets . a systematic workflow was defined involving several bioinformatics tools , databases , and drug target prioritization parameters ( figure 1 ) , with the goal of obtaining information about proteins that were involved in various metabolic pathways of e . coli o157 : h7 , but absent in its host\n",
      "drug target identification\n",
      "drug target identification\n",
      "correspondence\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] clostridium difficile is a gram - positive , spore forming , and anaerobic bacillus that has been relatively recently identified as a human pathogen ( dawson et al . , 2009 ; gibbs , 2009 ) . the first confirmed case of cl . difficile infection ( cdi ) was reported in 1977 ( larson et al . , 1978 ) , when the use of clindamycin was introduced and resulted in a rapid increase in the number of pseudomembranous colitis cases ( dawson et al . , 2009 ) . cl . difficile grows optimally at 35 - 40 1c , ferments amino acids in order to create adenosine triphosphate as an energy source , and can also utilize sugars ( gibbs , 2009 ) . extensive research on the genome of this bacterium has been carried out aiming at elucidating its mechanisms of infection and pathogenicity . pathogenic strains of the organism produce two distinct toxins , both of which are high - molecular weight proteins capable of binding to specific receptors on the intestinal mucosal cells : ( 1 ) toxin a , an enterotoxin and ( 2 ) toxin b , a cytotoxin ( gibbs , 2009 ) . colonization of the gut by cl . difficile and toxin production results in an acute inflammatory response and severe damage to the intestinal epithelium , particularly following treatment with broad - spectrum antibiotics\n",
      "freezing\n",
      "use of new risk assessment tools , the development and utilization of new monitoring technologies ( both serological and molecular ) , as well as health education\n",
      "none or mild symptomatology\n",
      "surveillance programs\n",
      "nucleotide synthesis\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] further details and an outline of resources used in this work can be found in supplemental experimental procedures . dsrna tethers each ( predominantly ) dsrna molecule consists of a template strand for pv rdrp hybridized to a complementary tethering strand that is linked at its two extremities to the flow chamber and the beads , respectively ( dulin et al . , 2015c ) . apart from a small hairpin that terminates the 3 0 end of the template strand ( sequence of the initial 24 bases of the template strand : 3 0 - ggggagcuccccuuuuuuuuuuuu . - 5 0 , where the hairpin sequence is underlined ) , the dsrna construct used in this study is identical to that employed in our preceding studies of f6 p2 rdrp ( dulin et al . , 2015c ( dulin et al . , , 2015d ) ( figure 1a ) . this hairpin forms an efficient way to mimic a primer hybridized to the template strand and promotes primer - dependent initiation\n",
      "magnetic tweezers\n",
      "boots\n",
      "cells were then washed\n",
      "anti - retroviral therapy\n",
      "metronidazole , tinidazole or nitazoxanide\n",
      "prophylaxis\n",
      "intravenous ganciclovir\n",
      "anti - cd20 monoclonal antibody rituximab , chemotherapy or radiotherapy\n",
      "intravenous ganciclovir or foscarnet\n",
      "intravenous aciclovir\n",
      "antigen testing\n",
      "amphotericin b , caspofugin or an azole , such as voriconazole\n",
      "amphotericin b , voriconazole or caspofungin\n",
      "prophylaxis\n",
      "management of potential casualties\n",
      "negative pressure isolation room\n",
      "modelling analyses\n",
      "yellow fever vaccine\n",
      "immunization of pregnant women\n",
      "maternal immunization\n",
      "literature search\n",
      "serologic methods\n",
      "[SEP]\n",
      "chest x - ray\n",
      "real - time pcr\n",
      "enzyme - linked immunosorbent assay\n",
      "neutralization assay\n",
      "microneutralization assay\n",
      "a standardized questionnaire was administered to the cases and controls by face - to - face interview\n",
      "pharyngeal swabs\n",
      "frequent hand - washing , egg consumption and milk consumption . ( shown in tab 3 ) stratification of data analysis\n",
      "anti - adenovirus igm antibody\n",
      "multi - premier pcr\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the trudeau institute ( saranac lake , ny ) , in partnership with the state university of new york upstate medical university ( syracuse , ny ) , hosted a summit entitled , ' ' translational immunology supporting biomedical countermeasure development for emerging vector - borne viral diseases . \" the attendees included basic scientists , physician - scientists , science support professionals and organizations and institutions with experience and expertise in identifying and working to solve major global health problems . the mission was to define today 0 s most pressing global health problems , identify critical obstacles which challenge the develop - ment of solutions to these problems , and prospect how both may be overcome . summit sessions focused on disease preparedness and vaccine development . summit organizers desired to catalyze the formation and sustainment of productive and strategic interdisciplinary partnerships and collaborative research networks with a focus on the rapid development of countermeasures against our most pressing global health threats . three keynote speakers representing the international vaccine institute ( ivi ) , coalition for epidemic preparedness innovations ( cepi ) , and the u . s . national institutes of health ( nih ) framed four concept areas which were then discussed during two individual sessions per topic ; each session was defined by a specific topic and led by a pre - selected session leader . the overall organization is presented in box 1 . the first concept discussed was , ' ' how do we identify and prepare for disease x , \" referring to the next major infectious disease epidemic or pandemic . dr . melanie saville , director of vaccine development from cepi , introduced the concept by discussing possible disease x pathogens stressing they may be currently known or unknown . this may include known threats such as ebola , known viruses with unrecognized impacts such as zika , and unknown threats not previously identified . current global trends indicate that a new disease emerges every four months , and more likely than not , disease x will emerge as zoonotic in origin , as nearly 60 % of all pandemics fit that model . the need to identify a burgeoning outbreak and initiate development of countermeasures\n",
      "effective collaboration\n",
      "clinical trials infrastructure . the group concluded that the major limitation to rapid advancement of vaccines was the inability to plan and execute a full product development plan from start to finish , including the necessary end to end funding\n",
      "developing countermeasures\n",
      "recall ' and ' withdrawal\n",
      "interview\n",
      "vaccination\n",
      "grown in cv - 1 cells\n",
      "blood collections were performed for serology , and the animals were euthanized\n",
      "endogenous peroxidase blocking\n",
      "tukey ' s test\n",
      "coccidiostat agents\n",
      "pcr amplified dna\n",
      "pcr\n",
      "sound research\n",
      "similarity analysis of dna sequences\n",
      "international health regulations\n",
      "barrier nursing techniques\n",
      "timeliness\n",
      "dilution series\n",
      "[SEP]\n",
      "apobec3g\n",
      "subtilisin protease protection assay\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the host cytoskeletal network is involved in the transport of viral components in the cell and particularly during the stages of virus entry and exit [ 46 , 47 ] . several studies on rna viruses have also indicated that cytoskeletal proteins such as tubulin and actin are required for viral gene expression [ 48 ] [ 49 ] [ 50 ] [ 51 ] . for influenza virus , it has been shown that the virus requires an intact actin cytoskeleton for entry , specifically into polarized cells [ 52 ] and interactions between the cytoskeleton and lipid rafts has been proposed to facilitate budding of filamentous virus particles [ 53 ] . furthermore , an association of m1 and np with cytoskeletal elements has been reported [ 54 , 55 ] , and actin and tubulin were both identified as proteins that interact with influenza rnps [ 21 ] . in the present study , protease treatment\n",
      "complement - mediated lysis\n",
      "pngase f\n",
      "western blot analysis\n",
      "fluorescence - activated cell sorting\n",
      "klinische erfahrung in der interpretation der testresultate und auswahl der therapiestrategie\n",
      "reifungsparameter\n",
      "hit ) ist eine immunologisch mediierte erkrankung\n",
      "differential diagnosis\n",
      "simplified workflow for molecular detection\n",
      "real - time rt - pcr ( rt - qpcr ) analysis could be performed with minimal pretreatment on patients ( n = 89 ) oropharyngeal swaps\n",
      "computerised tomography\n",
      "qiacube purification system\n",
      "instantly quarantine the infected people\n",
      "multi - objective differential evolution ( mode ) - based convolutional neural networks\n",
      "max pooling layer\n",
      "greedy selection\n",
      "20 . 80 cross - validation\n",
      "specificity\n",
      "20 - fold cross - validation\n",
      "ethical approval\n",
      "immunostaining\n",
      "solution chemistry\n",
      "vaccines\n",
      "singleplex xmap assay\n",
      "xmap duplex assay\n",
      "multiplex xmap assay\n",
      "antibodies\n",
      "ibv elisa kit\n",
      "smoking\n",
      "collect data\n",
      "declare that the work was supported as described in the funding statement above\n",
      "smoking\n",
      "vaccines and antibiotics\n",
      "binding ligands\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] although the active targeted strategy using nano - carriers has been solved many concerns from the conventional drug strategy , there is still a challenge reported by some researches [ 117 ] . active targeted strategy\n",
      "specific targeted ligands\n",
      "prevention\n",
      "community and healthcare facility - based infection control and prevention activities , surveillance , outbreak response\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the id workforce plays a critical role in managing infections such as human immunodeficiency virus ( hiv ) , tuberculosis , and viral hepatitis , which can cause community outbreaks if not promptly diagnosed and treated . the public health workforce , including id physicians , has been shrinking over the last decade [ 10 , 11 ] . these workforce losses pose a significant barrier to carrying out routine public health activities and responding to public health threats . id physicians employed by federal agencies and state health departments have the community as their patient . along with id physicians in other practice settings , they provide leadership and subject matter expertise to enable a wide variety of community - based interventions . for example , id management and prevention . public health strategies to contain the spread of hiv rely on ensuring that people living with hiv - aids have access to id - driven clinical care . by achieving sustained virologic suppression\n",
      "developing policies to respond to novel infections , and ensuring that the healthcare environment and medical devices are properly cleaned and maintained\n",
      "greater use of diagnostic tests\n",
      "establish\n",
      "methylprednisolone\n",
      "hi may alter the immunodominance , induce changes in polarisation or result in loss of speci c t m cells\n",
      "intranasal vaccination\n",
      "molecular mimicry of antibodies\n",
      "hem\n",
      "experimental\n",
      "antibodies directed against cancer antigens\n",
      "computationally optimized broadly reactive antigen ( cobra ) ha : e ha amino acid compositions from many isolated iv a strains is analysed\n",
      "respiratory failure or autonomic instability . axonal forms of gbs , namely aman and amsan are associated with anti - gm1 and / or anti gd1a antibodies\n",
      "u\n",
      "heterologous innate immune stimulation\n",
      "e immune response\n",
      "autoimmune mediated loss of insulin - producing β cells in the pancreas , while glucagon - producing α cells and somatostatin producing δ cells are spared . disease is thought to be t cell mediated\n",
      "e - mail\n",
      "quantitative polymerase chain reaction assay ( qpcr )\n",
      "qpcr analysis\n",
      "the mann - whitney u test was used to compare continuous variables , while the chi - square test\n",
      "laboratory tests\n",
      "ct imaging\n",
      "oxygen therapy\n",
      "ct imaging\n",
      "dialysis\n",
      "sterile saline\n",
      "elisa\n",
      "flow cytometry and microscopy\n",
      "flow cytometry\n",
      "confocal microscopy\n",
      "plaque assay\n",
      "plaque assay\n",
      "the paired t - test\n",
      "immunostained immediately using anti - pedv polyclonal antisera and dab\n",
      "plaque assay\n",
      "hepa - filtered air\n",
      "hem\n",
      "rt\n",
      "multiple group analysis\n",
      "random screening\n",
      "attachment\n",
      "linking the electrophilic building blocks to appropriate amino acids\n",
      "aza - peptide epoxide\n",
      "intramuscular injection\n",
      "active - site - directed inhibitors\n",
      "virtual screening\n",
      "virtual screening and 3d - qsar studies , tsai et al . discovered a group of sars - cov 3cl pro inhibitors\n",
      "computer modelling\n",
      "molecular docking\n",
      "inhibit\n",
      "notified to the region ' s public health department were reported to the research team . because the notified cases were recruited only after august 2005 and the recruitment of the hospitalized patients\n",
      "notified to the public health department with a laboratory diagnosis of gastroenteritis for one of the microbial enteric pathogens of interest\n",
      "standardized questionnaire by telephone\n",
      "the questionnaire\n",
      "analysed for bacteria\n",
      "microscopy with iron - haematoxylin stain\n",
      "negative - staining electron microscopy\n",
      "water samples from each household were collected from the kitchen tap in sterile bacteriological containers\n",
      "[SEP]\n",
      "systematic evaluation\n",
      "livestock density\n",
      "informed written consent was obtained in the hospitals from the caretakers of the children enrolled in the study , before collecting stool specimens\n",
      "contact tracing , adequate testing and isolation , onward referral for treatment\n",
      "aggressive electrolyte replacement\n",
      "early case identification and testing , effective isolation and contact tracing\n",
      "the development of an international response group\n",
      "a wide variety of information sources from all life science disciplines need to be considered in research\n",
      "plug - ins\n",
      "a\n",
      "liv\n",
      "enzymatic shedding\n",
      "r\n",
      "transfer patients to designated hospitals for intensive care\n",
      "traditional chinese medicines\n",
      "pharmacists provide drugs to the outside of the buffer zone , and coordinate hospital and ward staff to transfer medications inside wards\n",
      "rna isolation\n",
      "field\n",
      "bernfeld ( 1955 )\n",
      "lingual lipase assay\n",
      "student t - test\n",
      "photomicrographs\n",
      "vaccines\n",
      "stop the viral replication at the initial phase of the disease\n",
      "vaccines\n",
      "antiviral therapeutics and efficacious vaccines\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] evere acute respiratory syndrome ( sars ) first emerged in southern china in late 2002 . it spread suddenly and quickly with a high mortality rate and resulted in a global outbreak in the year that followed . first - line treatment protocols that were used clinically , for instance , ribavirin and steroid , were fairly limited in terms of effectiveness . 1 , 2 a preliminary study suggests that interferon - a plus steroids may be of value in the treatment of sars . 3 treatment with convalescent plasma [ 4 ] [ 5 ] [ 6 ] suggested that passive immunity is an effective approach specific for sars , as observed in other deadly infectious diseases including ebola . 7 superiorly , preparation of virus - inactivated , purified , and concentrated hyperimmune globulins from pooled convalescent plasma minimizes the risk of transmission of blood - borne viruses , enhances the polyvalency of neutralizing antibodies , and increases product consistency . 8 , 9 to develop such sars hyperimmune globulins for intravenous ( iv ) injection , a combination of cohn fractionation 10 and ion - exchange chromatography\n",
      "plasmapheresis\n",
      "cold ethanol precipitation\n",
      "intraperitoneal injection\n",
      "if\n",
      "simulation\n",
      "anesthetization by i . p . injection with ketamine\n",
      "intraperitoneal ( i . p . ) injection\n",
      "immunoperoxidase staining\n",
      "assessment of cxcl9 in the supernatants of mhv - cxcl9 - and mhv - ccxcl9 - infected cells was determined with mouse mig ( cxcl9 ) elisa kit\n",
      "direct pcr sequencing\n",
      "peg treatment\n",
      "pc\n",
      "sweep nets\n",
      "increasing the awareness of end - users and local enforcement of best management practices\n",
      "high - throughput screening\n",
      "non\n",
      "pooled sequencing\n",
      "stratifying the infected population into high ( h ) and low ( l ) symptom populations\n",
      "testing\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the amount of surveillance testing\n",
      "tested\n",
      "once an individual has tested positive , they are a confirmed case , and any further testing\n",
      "testing results\n",
      "sampling\n",
      "no data is collected\n",
      "china imposed travel restrictions on its own residents , denying travel visas to those wanting to leave , and 3 stopping all overseas toursa self - imposed control measure intended to prevent the virus from spreading abroad . though the virus that causes covid - 19 seems to be highly contagious , as of february 24 , the epidemic had been largely contained within hubei province . in addition to hubei , only 4 out of 32 provincial - level administrative divisions in mainland china had a cumulative confirmed case count over 1 , 000 , ranging from 1 , 016 ( hunan ) to 1 , 342 ( guangdong ) ; 2 all had laboratory - confirmed deaths of fewer than 20 . 2 within hubei province , cases and deaths have been mostly concentrated in wuhan and a handful of neighbouring cities ( figure 1 ) . 2 these epidemic control efforts bought life - saving time for the rest of the country and the international community , allowing for more research on covid - 19 for treatment strategies , development and production of diagnostic testing and vaccines\n",
      "driving\n",
      "protecting high - risk elderly individuals\n",
      "estimate\n",
      "approximation\n",
      "data sharing\n",
      "data normalization and de analysis\n",
      "euthanized\n",
      "animal experimental design\n",
      "virus isolation\n",
      "air - dried\n",
      "conventional reverse transcription - polymerase chain reaction\n",
      "rapid detection kit\n",
      "phylogenetic analysis\n",
      "hemagglutination inhibition\n",
      "nose - throat specimens were collected for culture\n",
      "examination\n",
      "antibody rises\n",
      "concurrent significant antibody\n",
      "elisa\n",
      "isopcynic banding by centrifugation\n",
      "[CLS] what is the best method to combat the hypercoagulable state seen in covid - 19 ? [SEP] the ideal tracer would be radiolabelled virus\n",
      "use of an antifoam\n",
      "aerosolized\n",
      "passage of dry air through a dyecontaining spray fluid\n",
      "a fluorescent dye\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " None,\n",
       " ...]"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[print(i[2]) for i in data_output]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'3ae24898796b7972372f6ed11be3d07c44e8cfd5'"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "paper_id_list[-1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "520\n"
     ]
    }
   ],
   "source": [
    "data_paper_id=[]\n",
    "n=0\n",
    "with open(file_name, 'r') as f:\n",
    "    for line in f:\n",
    "        con=json.loads(line)\n",
    "        n=n+1\n",
    "        paper_id=con[\"paper_id\"]\n",
    "        data_paper_id.append(paper_id)\n",
    "        if paper_id == '3ae24898796b7972372f6ed11be3d07c44e8cfd5':\n",
    "            print(n)\n",
    "            break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "520"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(data_paper_id)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "520"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(set(data_paper_id))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "colab": {
   "collapsed_sections": [],
   "name": "Question Answering with a Fine-Tuned BERT.ipynb",
   "provenance": [],
   "toc_visible": true
  },
  "kernelspec": {
   "display_name": "Environment (conda_pytorch_p36)",
   "language": "python",
   "name": "conda_pytorch_p36"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.10"
  },
  "widgets": {
   "application/vnd.jupyter.widget-state+json": {
    "0619db0363894129880d090367b4194a": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "DescriptionStyleModel",
     "state": {
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "DescriptionStyleModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/base",
      "_view_module_version": "1.2.0",
      "_view_name": "StyleView",
      "description_width": ""
     }
    },
    "0c5547ffbd4143609051b231a14853e1": {
     "model_module": "@jupyter-widgets/base",
     "model_name": "LayoutModel",
     "state": {
      "_model_module": "@jupyter-widgets/base",
      "_model_module_version": "1.2.0",
      "_model_name": "LayoutModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/base",
      "_view_module_version": "1.2.0",
      "_view_name": "LayoutView",
      "align_content": null,
      "align_items": null,
      "align_self": null,
      "border": null,
      "bottom": null,
      "display": null,
      "flex": null,
      "flex_flow": null,
      "grid_area": null,
      "grid_auto_columns": null,
      "grid_auto_flow": null,
      "grid_auto_rows": null,
      "grid_column": null,
      "grid_gap": null,
      "grid_row": null,
      "grid_template_areas": null,
      "grid_template_columns": null,
      "grid_template_rows": null,
      "height": null,
      "justify_content": null,
      "justify_items": null,
      "left": null,
      "margin": null,
      "max_height": null,
      "max_width": null,
      "min_height": null,
      "min_width": null,
      "object_fit": null,
      "object_position": null,
      "order": null,
      "overflow": null,
      "overflow_x": null,
      "overflow_y": null,
      "padding": null,
      "right": null,
      "top": null,
      "visibility": null,
      "width": null
     }
    },
    "0e044677b4fc4ffe809b318e8963e08a": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "ProgressStyleModel",
     "state": {
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "ProgressStyleModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/base",
      "_view_module_version": "1.2.0",
      "_view_name": "StyleView",
      "bar_color": null,
      "description_width": "initial"
     }
    },
    "1e6e46c1520d4a309d77a4ff7cc07900": {
     "model_module": "@jupyter-widgets/base",
     "model_name": "LayoutModel",
     "state": {
      "_model_module": "@jupyter-widgets/base",
      "_model_module_version": "1.2.0",
      "_model_name": "LayoutModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/base",
      "_view_module_version": "1.2.0",
      "_view_name": "LayoutView",
      "align_content": null,
      "align_items": null,
      "align_self": null,
      "border": null,
      "bottom": null,
      "display": null,
      "flex": null,
      "flex_flow": null,
      "grid_area": null,
      "grid_auto_columns": null,
      "grid_auto_flow": null,
      "grid_auto_rows": null,
      "grid_column": null,
      "grid_gap": null,
      "grid_row": null,
      "grid_template_areas": null,
      "grid_template_columns": null,
      "grid_template_rows": null,
      "height": null,
      "justify_content": null,
      "justify_items": null,
      "left": null,
      "margin": null,
      "max_height": null,
      "max_width": null,
      "min_height": null,
      "min_width": null,
      "object_fit": null,
      "object_position": null,
      "order": null,
      "overflow": null,
      "overflow_x": null,
      "overflow_y": null,
      "padding": null,
      "right": null,
      "top": null,
      "visibility": null,
      "width": null
     }
    },
    "2b6be0f1b89044c3a934f3eccf29cf54": {
     "model_module": "@jupyter-widgets/base",
     "model_name": "LayoutModel",
     "state": {
      "_model_module": "@jupyter-widgets/base",
      "_model_module_version": "1.2.0",
      "_model_name": "LayoutModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/base",
      "_view_module_version": "1.2.0",
      "_view_name": "LayoutView",
      "align_content": null,
      "align_items": null,
      "align_self": null,
      "border": null,
      "bottom": null,
      "display": null,
      "flex": null,
      "flex_flow": null,
      "grid_area": null,
      "grid_auto_columns": null,
      "grid_auto_flow": null,
      "grid_auto_rows": null,
      "grid_column": null,
      "grid_gap": null,
      "grid_row": null,
      "grid_template_areas": null,
      "grid_template_columns": null,
      "grid_template_rows": null,
      "height": null,
      "justify_content": null,
      "justify_items": null,
      "left": null,
      "margin": null,
      "max_height": null,
      "max_width": null,
      "min_height": null,
      "min_width": null,
      "object_fit": null,
      "object_position": null,
      "order": null,
      "overflow": null,
      "overflow_x": null,
      "overflow_y": null,
      "padding": null,
      "right": null,
      "top": null,
      "visibility": null,
      "width": null
     }
    },
    "461b9936e0864bc1aac73925b730ef7f": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HTMLModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HTMLModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HTMLView",
      "description": "",
      "description_tooltip": null,
      "layout": "IPY_MODEL_2b6be0f1b89044c3a934f3eccf29cf54",
      "placeholder": "​",
      "style": "IPY_MODEL_bd8a1fa1079448f585e87dafcd856bfc",
      "value": "100% 398/398 [00:00&lt;00:00, 11.2kB/s]"
     }
    },
    "49263ffffaee42438fc699c57fab7814": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "ProgressStyleModel",
     "state": {
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "ProgressStyleModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/base",
      "_view_module_version": "1.2.0",
      "_view_name": "StyleView",
      "bar_color": null,
      "description_width": "initial"
     }
    },
    "549ca681c27743aa8c28af40d2185900": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HBoxModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HBoxModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HBoxView",
      "box_style": "",
      "children": [
       "IPY_MODEL_8665ab6d11084a6e980121c5475d8170",
       "IPY_MODEL_461b9936e0864bc1aac73925b730ef7f"
      ],
      "layout": "IPY_MODEL_0c5547ffbd4143609051b231a14853e1"
     }
    },
    "632ff7bd64cf4b2c92acee6f0f17d6db": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HBoxModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HBoxModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HBoxView",
      "box_style": "",
      "children": [
       "IPY_MODEL_f6590ea2e9c14d3099b9999ce1a4602a",
       "IPY_MODEL_b3e5f72146e0406d9977465e9549419f"
      ],
      "layout": "IPY_MODEL_87719f2515a34ba49761e7f18772a90d"
     }
    },
    "6f9df97c25e84e7d8efccce6cde22fbc": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HBoxModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HBoxModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HBoxView",
      "box_style": "",
      "children": [
       "IPY_MODEL_94daf90c961945cdafc12178c3e357e4",
       "IPY_MODEL_82461e6ee22b44918d424f24245bdf0e"
      ],
      "layout": "IPY_MODEL_f3d792809e234442b6c888b56421479d"
     }
    },
    "82461e6ee22b44918d424f24245bdf0e": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HTMLModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HTMLModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HTMLView",
      "description": "",
      "description_tooltip": null,
      "layout": "IPY_MODEL_8892ad9564d84ff190062d0a9d5d9f6f",
      "placeholder": "​",
      "style": "IPY_MODEL_e86b7da45ef6466ebf25f28c10df61b8",
      "value": "100% 1.34G/1.34G [00:33&lt;00:00, 40.4MB/s]"
     }
    },
    "8665ab6d11084a6e980121c5475d8170": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "IntProgressModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "IntProgressModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "ProgressView",
      "bar_style": "success",
      "description": "Downloading",
      "description_tooltip": null,
      "layout": "IPY_MODEL_1e6e46c1520d4a309d77a4ff7cc07900",
      "max": 398,
      "min": 0,
      "orientation": "horizontal",
      "style": "IPY_MODEL_49263ffffaee42438fc699c57fab7814",
      "value": 398
     }
    },
    "87719f2515a34ba49761e7f18772a90d": {
     "model_module": "@jupyter-widgets/base",
     "model_name": "LayoutModel",
     "state": {
      "_model_module": "@jupyter-widgets/base",
      "_model_module_version": "1.2.0",
      "_model_name": "LayoutModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/base",
      "_view_module_version": "1.2.0",
      "_view_name": "LayoutView",
      "align_content": null,
      "align_items": null,
      "align_self": null,
      "border": null,
      "bottom": null,
      "display": null,
      "flex": null,
      "flex_flow": null,
      "grid_area": null,
      "grid_auto_columns": null,
      "grid_auto_flow": null,
      "grid_auto_rows": null,
      "grid_column": null,
      "grid_gap": null,
      "grid_row": null,
      "grid_template_areas": null,
      "grid_template_columns": null,
      "grid_template_rows": null,
      "height": null,
      "justify_content": null,
      "justify_items": null,
      "left": null,
      "margin": null,
      "max_height": null,
      "max_width": null,
      "min_height": null,
      "min_width": null,
      "object_fit": null,
      "object_position": null,
      "order": null,
      "overflow": null,
      "overflow_x": null,
      "overflow_y": null,
      "padding": null,
      "right": null,
      "top": null,
      "visibility": null,
      "width": null
     }
    },
    "8892ad9564d84ff190062d0a9d5d9f6f": {
     "model_module": "@jupyter-widgets/base",
     "model_name": "LayoutModel",
     "state": {
      "_model_module": "@jupyter-widgets/base",
      "_model_module_version": "1.2.0",
      "_model_name": "LayoutModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/base",
      "_view_module_version": "1.2.0",
      "_view_name": "LayoutView",
      "align_content": null,
      "align_items": null,
      "align_self": null,
      "border": null,
      "bottom": null,
      "display": null,
      "flex": null,
      "flex_flow": null,
      "grid_area": null,
      "grid_auto_columns": null,
      "grid_auto_flow": null,
      "grid_auto_rows": null,
      "grid_column": null,
      "grid_gap": null,
      "grid_row": null,
      "grid_template_areas": null,
      "grid_template_columns": null,
      "grid_template_rows": null,
      "height": null,
      "justify_content": null,
      "justify_items": null,
      "left": null,
      "margin": null,
      "max_height": null,
      "max_width": null,
      "min_height": null,
      "min_width": null,
      "object_fit": null,
      "object_position": null,
      "order": null,
      "overflow": null,
      "overflow_x": null,
      "overflow_y": null,
      "padding": null,
      "right": null,
      "top": null,
      "visibility": null,
      "width": null
     }
    },
    "930457a02cbe469181b0dbaf1eb9fac0": {
     "model_module": "@jupyter-widgets/base",
     "model_name": "LayoutModel",
     "state": {
      "_model_module": "@jupyter-widgets/base",
      "_model_module_version": "1.2.0",
      "_model_name": "LayoutModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/base",
      "_view_module_version": "1.2.0",
      "_view_name": "LayoutView",
      "align_content": null,
      "align_items": null,
      "align_self": null,
      "border": null,
      "bottom": null,
      "display": null,
      "flex": null,
      "flex_flow": null,
      "grid_area": null,
      "grid_auto_columns": null,
      "grid_auto_flow": null,
      "grid_auto_rows": null,
      "grid_column": null,
      "grid_gap": null,
      "grid_row": null,
      "grid_template_areas": null,
      "grid_template_columns": null,
      "grid_template_rows": null,
      "height": null,
      "justify_content": null,
      "justify_items": null,
      "left": null,
      "margin": null,
      "max_height": null,
      "max_width": null,
      "min_height": null,
      "min_width": null,
      "object_fit": null,
      "object_position": null,
      "order": null,
      "overflow": null,
      "overflow_x": null,
      "overflow_y": null,
      "padding": null,
      "right": null,
      "top": null,
      "visibility": null,
      "width": null
     }
    },
    "94daf90c961945cdafc12178c3e357e4": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "IntProgressModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "IntProgressModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "ProgressView",
      "bar_style": "success",
      "description": "Downloading",
      "description_tooltip": null,
      "layout": "IPY_MODEL_930457a02cbe469181b0dbaf1eb9fac0",
      "max": 1340675298,
      "min": 0,
      "orientation": "horizontal",
      "style": "IPY_MODEL_0e044677b4fc4ffe809b318e8963e08a",
      "value": 1340675298
     }
    },
    "b3e5f72146e0406d9977465e9549419f": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HTMLModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HTMLModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HTMLView",
      "description": "",
      "description_tooltip": null,
      "layout": "IPY_MODEL_c17dfd9c89694880a04d07942db3e426",
      "placeholder": "​",
      "style": "IPY_MODEL_0619db0363894129880d090367b4194a",
      "value": "100% 232k/232k [00:00&lt;00:00, 1.18MB/s]"
     }
    },
    "bd8a1fa1079448f585e87dafcd856bfc": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "DescriptionStyleModel",
     "state": {
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "DescriptionStyleModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/base",
      "_view_module_version": "1.2.0",
      "_view_name": "StyleView",
      "description_width": ""
     }
    },
    "bf4308a7859f4bfd9356215bbd9ef5e4": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "ProgressStyleModel",
     "state": {
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "ProgressStyleModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/base",
      "_view_module_version": "1.2.0",
      "_view_name": "StyleView",
      "bar_color": null,
      "description_width": "initial"
     }
    },
    "c17dfd9c89694880a04d07942db3e426": {
     "model_module": "@jupyter-widgets/base",
     "model_name": "LayoutModel",
     "state": {
      "_model_module": "@jupyter-widgets/base",
      "_model_module_version": "1.2.0",
      "_model_name": "LayoutModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/base",
      "_view_module_version": "1.2.0",
      "_view_name": "LayoutView",
      "align_content": null,
      "align_items": null,
      "align_self": null,
      "border": null,
      "bottom": null,
      "display": null,
      "flex": null,
      "flex_flow": null,
      "grid_area": null,
      "grid_auto_columns": null,
      "grid_auto_flow": null,
      "grid_auto_rows": null,
      "grid_column": null,
      "grid_gap": null,
      "grid_row": null,
      "grid_template_areas": null,
      "grid_template_columns": null,
      "grid_template_rows": null,
      "height": null,
      "justify_content": null,
      "justify_items": null,
      "left": null,
      "margin": null,
      "max_height": null,
      "max_width": null,
      "min_height": null,
      "min_width": null,
      "object_fit": null,
      "object_position": null,
      "order": null,
      "overflow": null,
      "overflow_x": null,
      "overflow_y": null,
      "padding": null,
      "right": null,
      "top": null,
      "visibility": null,
      "width": null
     }
    },
    "d0989443c5e84d6b8eeee08879c07db6": {
     "model_module": "@jupyter-widgets/base",
     "model_name": "LayoutModel",
     "state": {
      "_model_module": "@jupyter-widgets/base",
      "_model_module_version": "1.2.0",
      "_model_name": "LayoutModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/base",
      "_view_module_version": "1.2.0",
      "_view_name": "LayoutView",
      "align_content": null,
      "align_items": null,
      "align_self": null,
      "border": null,
      "bottom": null,
      "display": null,
      "flex": null,
      "flex_flow": null,
      "grid_area": null,
      "grid_auto_columns": null,
      "grid_auto_flow": null,
      "grid_auto_rows": null,
      "grid_column": null,
      "grid_gap": null,
      "grid_row": null,
      "grid_template_areas": null,
      "grid_template_columns": null,
      "grid_template_rows": null,
      "height": null,
      "justify_content": null,
      "justify_items": null,
      "left": null,
      "margin": null,
      "max_height": null,
      "max_width": null,
      "min_height": null,
      "min_width": null,
      "object_fit": null,
      "object_position": null,
      "order": null,
      "overflow": null,
      "overflow_x": null,
      "overflow_y": null,
      "padding": null,
      "right": null,
      "top": null,
      "visibility": null,
      "width": null
     }
    },
    "e86b7da45ef6466ebf25f28c10df61b8": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "DescriptionStyleModel",
     "state": {
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "DescriptionStyleModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/base",
      "_view_module_version": "1.2.0",
      "_view_name": "StyleView",
      "description_width": ""
     }
    },
    "f3d792809e234442b6c888b56421479d": {
     "model_module": "@jupyter-widgets/base",
     "model_name": "LayoutModel",
     "state": {
      "_model_module": "@jupyter-widgets/base",
      "_model_module_version": "1.2.0",
      "_model_name": "LayoutModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/base",
      "_view_module_version": "1.2.0",
      "_view_name": "LayoutView",
      "align_content": null,
      "align_items": null,
      "align_self": null,
      "border": null,
      "bottom": null,
      "display": null,
      "flex": null,
      "flex_flow": null,
      "grid_area": null,
      "grid_auto_columns": null,
      "grid_auto_flow": null,
      "grid_auto_rows": null,
      "grid_column": null,
      "grid_gap": null,
      "grid_row": null,
      "grid_template_areas": null,
      "grid_template_columns": null,
      "grid_template_rows": null,
      "height": null,
      "justify_content": null,
      "justify_items": null,
      "left": null,
      "margin": null,
      "max_height": null,
      "max_width": null,
      "min_height": null,
      "min_width": null,
      "object_fit": null,
      "object_position": null,
      "order": null,
      "overflow": null,
      "overflow_x": null,
      "overflow_y": null,
      "padding": null,
      "right": null,
      "top": null,
      "visibility": null,
      "width": null
     }
    },
    "f6590ea2e9c14d3099b9999ce1a4602a": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "IntProgressModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "IntProgressModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "ProgressView",
      "bar_style": "success",
      "description": "Downloading",
      "description_tooltip": null,
      "layout": "IPY_MODEL_d0989443c5e84d6b8eeee08879c07db6",
      "max": 231508,
      "min": 0,
      "orientation": "horizontal",
      "style": "IPY_MODEL_bf4308a7859f4bfd9356215bbd9ef5e4",
      "value": 231508
     }
    }
   }
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
